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Abstract 
The research presented herein describes four separate projects, focusing on 
synthetic methodology development, discovery of novel cytotoxic agents, and natural 
product isolation.   
Catalysis of Intra- and Intermolecular Schmidt Reactions. A method for carrying 
out the intramolecular Schmidt reaction of alkyl azides and ketones using a 
substoichiometric amount of catalyst is described. Following extensive screening, the use 
of the strong hydrogen-bond-donating solvent hexafluoro-2-propanol (HFIP) was found to 
be consistent with low catalyst loadings, which ranged from 2.5 mol % for favorable 
substrates to 25 mol % for more difficult cases. Reaction optimization, broad substrate 
scope, and preliminary mechanistic studies of this improved version of the reaction are 
discussed. The use of HFIP as the solvent also allowed for the extension of this 
methodology to intermolecular variants of Schmidt reaction favoring the development of 
mild, operationally simple, and more efficient protocols, requiring considerably less 
amounts of acid catalysts for these variants.  
Copper-Catalyzed Oxaziridine-Mediated C–H Bond Oxidation. The highly regio- 
and chemoselective oxidation of an activated C−H bond via a copper-catalyzed reaction of 
oxaziridine is described. The oxidation proceeded with a variety of substrates, primarily 
comprising of allylic and benzylic examples, as well as one example of an otherwise 
unactivated tertiary C−H bond. The mechanism of the reaction is proposed to involve 
single-electron transfer (SET) to the oxaziridines to generate a copper-bound radical anion, 
followed by hydrogen atom abstraction and collapse to products, with regeneration of the 
catalyst by a final SET event. The involvement of allylic radical intermediates en route to 
the product was supported by a radical-trapping experiment with TEMPO. 
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Synthesis and Cytotoxic Evaluation of Withalongolide A Analogues. The natural 
product withaferin A exhibits potent antitumor activity and other diverse pharmacological 
activities. The recently discovered withalongolide A, a C-19 hydroxylated congener of 
withaferin A, was reported to possess cytotoxic activity against head and neck squamous 
cell carcinoma (HNSCC). Interestingly, semisynthetic acetylated analogues of 
withalongolide A were shown to be considerably more cytotoxic than the parent compound. 
To further explore the structure–activity relationship (SAR), 20 new semisynthetic 
analogues of this highly oxygenated withalongolide A were designed, synthesized, and 
evaluated for cytotoxic activity against four different cancer cell lines. A number of 
derivatives were found to be more potent than the parent compound and withaferin A. 
Isolation of Withalongolide O from Physalis longifolia. The SAR analysis of 
reported bioactive withanolides revealed certain crucial structural requisites for possessing 
a potent cytotoxic activity. The semisynthesis of a putative unnatural withanolide 
incorporating all the basic and essential structural features to boost the antiproliferative 
activity was contemplated. Withaferin A was considered as an appropriate starting material 
for this purpose. Although the semisynthetic efforts met with failure, it was during the 
isolation of withaferin A from the crude plant extract that we discovered a novel 
withanolide, withalongolide O. The structure of withalongolide O was determined using 
various spectroscopic techniques and subsequently confirmed by X-ray crystallographic 
analysis. Both withalongolide O and its diacetate exhibited potent cytotoxicity against four 
different cancer cell lines. 
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Chapter 1 
Catalysis of Intra- and Intermolecular Schmidt Reactions 
 
1.1   Introduction 
Amide and Lactam  
The amide bond is one of the most important functional groups in chemistry and 
biology.
1
 The hydrogen bonding of amide groups defines the structural features of proteins, 
the key building blocks of life.
2
 Apart from the prevalence of amide functionality in 
biological systems, the vast majority of molecules including natural products and major 
marketed drugs contain amide and lactam functionalities (Figure 1).
3
 The ubiquity of amide 
and lactam skeletons in nature, pharmaceuticals, and technology as structural materials has 
continued to inspire the discovery of new reaction methodologies for their synthesis.  
Amides are traditionally synthesized by the condensation of amine and carboxylic 
acids via an activated ester. Many new approaches have been developed over the past few 
decades including catalytic methods for amide formation.
4
 Nitrogen-insertion reactions 
offer alternative routes to the formation of amides and lactams. The Beckmann 
rearrangement of ketoximes
5
 and the Schmidt reaction of ketones
6
 are the two most 
common rearrangement approaches to form amides or lactams (Scheme 1). The Beckmann 
rearrangement is a two-step transformation, where a ketone is first converted to an oxime, 
followed by an acid-catalyzed rearrangement to an amide or a lactam. The Beckmann 
rearrangement of cyclohexanone is commonly applied for the large-scale production of 
caprolactam, which is used in the manufacturing of Nylon-6, a synthetic polymer.
7
 In 
contrast, the Schmidt reaction of a ketone with hydrazoic acid (HN3) in the presence of an 
acid catalyst can lead to an amide or a lactam in a single step. 
2 
 
 
Figure 1. Natural products and drugs with amide and lactam functionalities. 
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Scheme 1. Beckmann and Schmidt Reactions 
 
 
Schmidt Reaction  
The Schmidt family comprises related reactions of carbonyl compounds with HN3 
(normally generated in situ from sodium azide, NaN3) or alkyl azides to give a variety of 
nitrogen-insertion products.
6c
 The mechanism for the Schmidt reaction of a ketone with 
HN3 is shown in Scheme 2. Acid-catalyzed activation of the carbonyl followed by addition 
of the azide leads to the formation of an azidohydrin. This intermediate can directly 
collapse through concomitant migration of the R group and the loss of nitrogen, which is a 
powerful driving force through an entropic gain, to provide amide regioisomers (path a). 
Alternate pathway (path b) involves the initial dehydration step to form diazoiminium ions 
(A and B) followed by rearrangement to give iminocarbonium ions (C and D) or nitrilium 
ions (C' and D'). The iminocarbonium ions can either undergo hydration to provide same 
amide regioisomers or excess HN3 can add to iminocarbonium ions via path c to form 
tetrazole isomers. Similar to the Beckmann reaction mechanism, the substituents (mostly 
alkyl groups) antiperiplanar to the nitrogen leaving group migrates from carbon to nitrogen 
leading to iminocarbonium or nitrilium ion intermediates. The group migrates with the 
4 
 
retention of configuration about the migrating carbon and generally the bulkier of the two 
carbonyl substituents migrates preferentially.
8
 
 
Scheme 2. Mechanism for the Schmidt Reaction of a Ketone with HN3 
 
 
In the case of an aldehyde, the diazoiminium ion E formed after dehydration of an 
azidohydrin intermediate can undergo two pathways (Scheme 3). The elimination pathway 
(path a) via proton loss provides a nitrile and the rearrangement pathway (path b) through 
R
1
 group migration generates a iminocarbonium ion F or nitrilium ion F', which upon 
hydration affords a formamide.  
 
 
 
5 
 
Scheme 3. Mechanism for the Schmidt Reaction of an Aldehyde with HN3 
 
 
Boyer Reaction 
The use of alkyl azides in place of hydrazoic acid would provide a direct access to N-
substituted lactams, which would further extend the scope of the Schmidt reaction. During 
its initial explorations, Briggs
9
 and Smith
10
 found that alkyl azides did not react with 
ketones to yield any Schmidt products under standard conditions such as the use of 
concentrated sulfuric acid (H2SO4). In the 1950’s, Boyer reported a limited success for the 
Schmidt reaction of aromatic aldehydes with alkyl azides in the presence of concentrated 
H2SO4.
11
 Though the reaction with alkyl azides afforded poor yields (10–25%) of 
corresponding amides, the reaction of aromatic aldehydes with hydroxyalkyl azides 
proceeded with much greater efficiency affording oxazolines and dihydrooxazines, 
respectively (Scheme 4). Unfortunately, this Boyer reaction was severely limited in scope 
and the reactions failed with aliphatic or electron-rich aromatic aldehydes and ketones. 
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Scheme 4. Reaction of Aromatic Aldehydes with Alkyl Azides and Hydroxyalkyl 
Azides 
 
 
Intramolecular Schmidt Reaction  
In 1991, Aubé and Milligan discovered an intramolecular variant of the Schmidt 
reaction.
12
 The tethered alkyl azide reacts with the ketone under Lewis or Brønsted acid 
activation in an intramolecular fashion to provide an amide or a lactam in high yield and in 
one step under straightforward reaction conditions (Scheme 5).
12-13
 Formal insertion of the 
azide into the activated carbonyl provides an azidohydrin intermediate, which in theory 
could lead to two regiochemical outcomes. A fused lactam would arise from bond a 
migration whereas the migration of bond b would give a bridged system.
13-14
 The reaction 
proceeds with retention of configuration at the migrating carbon.
13
 
 
Scheme 5. Typical Example of an Intramolecular Schmidt Reaction 
 
7 
 
The intramolecular Schmidt reaction (also known as the Schmidt–Aubé reaction15) is 
an effective and useful method for generating fused lactams with varied ring sizes and 
substitution patterns.
6c,12-13,16
 The typical fused lactam product with the nitrogen atom at a 
ring fusion (highlighted in red, Scheme 5) is a prominent structural motif found in a wide 
variety of alkaloids. This strategy has thus been applied to the syntheses of many 
biologically important alkaloids as well as natural product-inspired libraries (Figure 2).
17
 
 
Figure 2. Applications of the intramolecular Schmidt reaction (ref. 17). 
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1.2   Catalysis of the Intramolecular Schmidt Reaction  
Despite the broad utility, the main limitation of the intramolecular Schmidt reaction 
has been the requirement of excess Lewis or Brønsted acid
6c,13,18
 in order to achieve 
complete conversion, which often renders it unsuitable for strongly acid-sensitive substrates 
and limits scalability. Two representative examples are shown in Schemes 6a,b. Indeed, we 
are unaware of any examples that proceed to high conversion with less than a full equiv of 
acid promoter. This can be attributed to strong product inhibition, which is intrinsic to any 
reaction that converts a ketone to an amide.  
 
Scheme 6. Examples of Intramolecular Schmidt Reactions Requiring >1 Equiv 
Catalyst 
  
 
The first step in a hypothetical catalytic cycle for the intramolecular Schmidt reaction 
is the activation of a substrate S with a Lewis or Brønsted acid LA to form complex SLA 
(Figure 3).
14
 The tethered azide then attacks the activated carbonyl, forming the 
azidohydrin intermediate AH, which upon antiperiplanar bond migration and nitrogen 
extrusion results in the formation of a product P. The lactam produced is strongly Lewis 
9 
 
basic and sequesters the catalyst in an unproductive manner. We propose that this 
unfavorable catalyst–product interaction results in product inhibition deterring the progress 
of reaction and necessitating the use of superstoichiometric amounts of catalyst.
13,18a,19
   
 
 
Figure 3. Hypothetical catalytic cycle showing product inhibition through catalyst 
sequestration by the product. 
 
Catalytic reaction development could be considered as an effective strategy for 
streamlining many challenges that still lie in organic synthesis. In addition, a version of this 
reaction that employs vastly smaller amounts of metal may well be cleaner and more 
efficient, even as it minimizes the generation of metal waste.
20
 Hard Lewis acids such as 
titanium(IV) chloride (TiCl4) and boron trifluoride diethyl etherate (BF3∙OEt2) and strong 
Brønsted acids such as triflic acid (TfOH, CF3SO3H) and trifluroacetic acid (TFA, 
CF3CO2H) are typically required to promote this reaction. A fundamental challenge in 
designing a catalytic variant for this reaction lies in the inherent strength of the complex 
formed between the catalyst and the product, which is a hard acid-hard base interaction. 
Related reactions that generate amide or lactam products, such as the Beckmann 
10 
 
rearrangement and Ritter reaction, have also suffered in the past from the requirement of a 
stoichiometric amount of strong acids and harsh reaction conditions.
21-22
 The role of the 
lactam in product inhibition has been showcased for Beckmann rearrangement using a 
microchemical system.
23
 However, recent catalytic developments for these reactions have 
allowed for the use of substoichiometric amounts of Lewis or Brønsted acid, improving 
efficiency and expanding scope of those processes.
21-22
 The use of ionic liquids
24
 and 
extensive screening of catalysts and solvents led to the realization of these catalytic 
reactions. We envisioned that catalysis in the intramolecular Schmidt reaction might be 
more efficient if conditions were identified wherein a ligand, solvent, or additive is capable 
of competing with the catalyst in forming a complex with the Lewis basic lactam, thus 
allowing catalyst turnover. Our long standing efforts in this direction led us to the 
development of a catalytic intramolecular Schmidt reaction
25
 that is superior in essentially 
every way to the version that we and others have been exploring since 1991.
6c,12-13,18
  
 
Screening and Optimization of Reaction Conditions  
A long-standing goal of this laboratory has been to replace the stoichiometric 
Schmidt reaction by identifying conditions that would (1) require low, substoichiometric 
amounts of catalyst, (2) be mild, efficient, and proceed at room temperature, and (3) would 
have broad substrate scope. We initially focused on catalyst and additive screening. An 
initial survey of Lewis acids for the conversion of 1c to 2c was carried out by Sze-Wan Li 
(this laboratory; unpublished). After examining several conditions, she found that 5 mol % 
of scandium(III) triflate (Sc(OTf)3) could efficiently promote the reaction of 1c to 2c, but 
only at high temperatures (Scheme 7; see Table S1 in the Experimental Section for details). 
However, for a more demanding five-membered cyclic azido ketone 1a, only 42% 
conversion to lactam 2a was observed, even when 10 mol % Sc(OTf)3 was used. 
11 
 
Scheme 7. Preliminary Screening by Sze-Wan Li 
 
 
Erin Hirt followed up on the results obtained by Sze-Wan Li and she found that 10 
mol % of Sc(OTf)3 was required for the similar transformation of 1c to 2c (Scheme 8; see 
Table S2 in the Experimental Section for details).
26
 She further investigated various 
lanthanide triflates as Lewis acids to promote the reaction, however, all lanthanide Lewis 
acids examined were found to be less effective than Sc(OTf)3 (see Table S2). Upon 
screening of additives, she found that the use of a phase-transfer catalyst, 
tetrabutylammonium hydroxide (TBAH, n-Bu4NOH) under microwave irradiation 
conditions along with 25 mol % Sc(OTf)3 helped achieve complete conversion of 1a to 2a. 
Unfortunately, these reaction conditions were plagued with extremely limited substrate 
scope (cf. 1c and 1d in Scheme 8). Furthermore, the use of a phase-transfer catalyst made 
the aqueous work-up and purification more cumbersome and less efficient resulting in 
lower yields of desired lactams. 
 
 
12 
 
 Scheme 8. Preliminary Screening by Erin Hirt 
 
 
After Erin Hirt, Charlie Fehl further advanced the development by identifying 
acetonitrile (ACN, CH3CN) as a better solvent than H2O for this reaction, either alone or 
with a phase-transfer catalyst; albeit on a different substrate 1e (unpublished; Scheme 9, see 
Table S3 in the Experimental Section for details). A short screening of different Lewis and 
Brønsted acids in ACN once again revealed Sc(OTf)3 as an optimal catalyst. However, 
higher catalyst loadings up to 25 mol % and unacceptably high temperature of 200 C were 
generally necessary (Scheme 9). Although the reaction of cyclopentanone 1a in ACN gave 
slightly better yield of lactam 2a, the reaction of 1d under the same conditions failed as 
before (cf. Schemes 8 and 9). Reactions of substrates like 1a or 1d require longer reaction 
times than 1c in the stoichiometric reaction and are often poorer yielding as well.
13,27
 
Several additives were also screened with or without Sc(OTf)3 in ACN, H2O, or DCE at 
different temperatures, but all of them delivered either similar or inferior conversion 
13 
 
compared to Sc(OTf)3 alone (see Table S3, entry 4 in the Experimental Section; for the list 
of additives, see below Table S3). 
 
Scheme 9. Preliminary Screening by Charlie Fehl 
 
 
On the basis of these preliminary results, we decided to expand our search by 
focusing on three screening parameters: solvent, catalyst, and temperature. trans-4-Phenyl-
2-(3-azidopropyl)cyclohexanone 1f was chosen as a test example to probe several issues 
known to arise in the intramolecular Schmidt reaction (Scheme 10). The trans isomer was 
primarily chosen to probe for epimerization (known to be a problem in some 
applications),
28
 which could lead to the thermodynamically more stable cis ketone 1e; the 
read-out for this process would be the detection of lactam 2e following ring expansion. In 
addition, the trans ketone 1f is capable of generating either a fused lactam 2f or a bridged 
isomer 3f by migration of one -carbon over the other (bond a vs bond b migration).13 
Finally, the phenyl chromophore in 1f allowed faster analyses and quantification of reaction 
mixtures by UPLC (see the Experimental Section).  
14 
 
Scheme 10. Model Reaction 
 
 
Figure 4 depicts the results of more detailed screening of reaction conditions (see the 
Experimental Section for details). Examination of 23 different solvents was first carried out 
using 20 mol % Sc(OTf)3 at 150 C. Only five solvents [nitromethane, benzonitrile, acetic 
acid, trifluoroethanol (TFE, CF3CH2OH), and the ionic liquid 1-butyl-3-methylimidazolium 
tetrafluoroborate (BMIMBF4)] gave the product in high yield. When the Sc(OTf)3 loading 
was reduced to 10 mol %, only TFE resulted in complete conversion. We then focused our 
attention on catalyst screening using 10 mol % catalyst with TFE as the solvent at 80 C. In 
total, 51 catalysts were screened, including 44 Lewis acids representing 31 different 
elements and 7 Brønsted acids. Of these, a number of transition metal salts such as TiCl4, 
ZrCl4, and Fe(OTf)3, some post-transition metal salts such as In(OTf)3 and Bi(OTf)3, and 
metalloid-containing compounds such as SiCl4 and SbCl5 gave results that were good 
enough for further screening. Further evaluation of these selected catalysts at 10 mol % 
loading in TFE at lower temperatures (50 and 25 C) revealed TiCl4 and SiCl4 to be most 
effective. The identification of TiCl4 was notable as it has been a catalyst of choice for 
many stoichiometric intramolecular Schmidt reactions.
13,18a,29
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Figure 4. Screening flow chart. Transition metals are depicted in deep red, post-transition 
metals in green, and metalloids in blue. 
 
Identification of TFE as nearly unique in permitting catalyst turnover prompted us to 
more rigorously examine the effect of solvents using 1f as the substrate and 10 mol % TiCl4 
as the catalyst (Table 1). Again, TFE was observed to give the best results with respect to 
both conversion and stereochemical retention (cf. entry 7 with entries 1–6). The results with 
TFE prompted us to consider other fluorinated alcohols, specifically hexafluoro-2-propanol 
(HFIP, (CF3)2CHOH). Compared to their non-fluorinated alcohol analogues, TFE and HFIP 
have low nucleophilicity, low pKa, high ionizing power, high polarity, ability to solvate 
anions, and are strong hydrogen-bond donors (Table 2).
30
 Accordingly, they are often used 
as a solvent, co-solvent, or a Lewis acid substitute
30j,31
 in oxidations
32
 and in ring-opening 
reactions of oxiranes, cycloadditions, and deprotection reactions.
30g,i,k
 Their utility has been 
attributed to the strong hydrogen-bond donor ability of these solvents.
30g,h,32b,33
 Moreover, 
16 
 
the use of these solvents to denature proteins and induce -helical secondary structures 
provided some ancillary expectation that they might prove useful in modifying the ability 
of our product lactams to coordinate with acid promoters.
34
 Because of the stronger 
hydrogen-bond donor ability and higher ionizing power of HFIP compared to TFE, HFIP 
often provides superior results both in reaction rate enhancement
30g,j,31,35
 and as a helix-
inducing co-solvent.
34a
  
 
Table 1. Optimization of Conditions for Intramolecular Schmidt Reaction of 1f
a,b 
 
entry catalyst 
catalyst 
(mol %) 
solvent additive 
temp 
(C) 
time 
(h) 
% yield 
(2f:2e)
c
 
% recovery 
(1f:1e)
d
 
1 TiCl4 10 CH2Cl2 – 25 18 6% (40:60) 84% (10:90) 
2 TiCl4 10 CH3NO2 – 25 18 35% (37:63) 61% (3:97) 
3 TiCl4 10 BMIMBF4 – 25 18 12% (30:70) 80% (12:88) 
4 TiCl4 10 C6F5CN – 25 18 30% (32:68) 58% (10:90) 
5 TiCl4 10 i-PrOH – 37 18 trace 86% (3:97) 
6 TiCl4 10 CH3CN – 37 18 41% (15:85) 47% (1:99) 
7 TiCl4 10 CF3CH2OH – 25 18 79% (82:18)
d
 trace 
8 none – (CF3)2CHOH – 37 18 ND 93% (98:2) 
9 TiCl4 10 CH3CN (CF3)2CHOH
e
 25 18 34% (10:90) 61% (5:95) 
10 TiCl4
g
 10 (CF3)2CHOH – 25 12 88% (90:10)
f
 ND 
11 TiCl4 10 (CF3)2CHOH – 25 12 91% (98:2)
f
 ND 
12 TiCl4 7 (CF3)2CHOH – 25 24 88% (98:2)
f
 ND 
13 TiCl4 5 (CF3)2CHOH – 25 38 89% (99:1)
f
 trace 
14 TiCl4
h
 5 (CF3)2CHOH – 25 38 86% (98:2) trace 
15 TiCl4
i
 5 (CF3)2CHOH – 25 38 89% (98:2) ND 
16 TiCl4 5 (CF3)2CHOH DTBMP
j
 25 38 52% (98:2) 19% (98:2) 
17 TiCl4 5 (CF3)2CHOH DTBMP
k
 25 38 21% (99:1) 50% (96:4)
c
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entry catalyst 
catalyst 
(mol %) 
solvent additive 
temp 
(C) 
time 
(h) 
% yield 
(2f:2e)
c
 
% recovery 
(1f:1e)
d
 
18 TiCl4 5 (CF3)2CHOH MS (4Å) 25 38 11% (97:3) 86% (98:2) 
19 SiCl4 5 (CF3)2CHOH – 25 38 86% (98:2)
f
 ND 
20 SbCl5 5 (CF3)2CHOH – 25 38 86% (98:2)
f
 ND 
21 NbCl5 5 (CF3)2CHOH – 25 38 82% (98:2) ND 
22 WCl6 5 (CF3)2CHOH – 25 38 86% (98:2)
f
 ND 
23 HfCl4 5 (CF3)2CHOH – 25 38 77% (99:1)
f
 15% (98:2) 
24 
Hf(OTf)4 
hydrate 
5 (CF3)2CHOH – 25 38 76% (98:2) 14% (98:2) 
25 Bi(OTf)3 5 (CF3)2CHOH – 25 38 60% (98:2) 25% (98:2) 
26 Fe(OTf)3 5 (CF3)2CHOH – 25 38 83% (98:2)
f
 trace 
27 Sc(OTf)3 5 (CF3)2CHOH – 25 38 28% (97:3) 61% (98:2) 
28 HCl 10 (CF3)2CHOH – 25 38 40% (96:4)
f
 46% (98:2) 
29 HCl 20 (CF3)2CHOH – 25 38 78% (97:3)
f
 trace 
30 CF3CO2H 10 (CF3)2CHOH – 25 38 62% (97:3) 34% (98:2) 
31 
Armstrong’s 
acid 
5 (CF3)2CHOH – 25 38 65% (98:2) 13% (98:2) 
32 ClSO3H 10 (CF3)2CHOH – 25 20 80% (98:2)
f
 ND 
33 (S)-BNDHP 5 (CF3)2CHOH – 25 38 32% (96:4)
l
 62% (98:2) 
34 Ti(O
i
Pr)4 10 (CF3)2CHOH – 25 38 trace 93% (95:5) 
a
To a solution of substrate 1f (0.10 mmol) in solvent (0.50 mL) at rt was added a catalyst under 
nitrogen or argon atmosphere, unless otherwise mentioned. For TiCl4, SiCl4, or SbCl5, a 1.0 M 
solution in CH2Cl2 was used. A 2.0 M solution of hydrogen chloride (HCl) in diethyl ether was 
used. ND = Not detected. 
b
Concn of substrate was ca. 0.20 M, unless otherwise mentioned.
 c
Isolated 
yield after preparative TLC purification; ratios were determined by 
1
H NMR analysis. 
d
Isolated 
yield after preparative TLC purification; ratios were determined by UPLC of the crude reaction 
mixtures. 
e
1 equiv of (CF3)2CHOH was added. 
f
Bridged lactam 3f was also isolated in 1–4% yield. 
g
A 1.0 M solution of TiCl4 in CH2Cl2 was added to substrate 1f followed by the addition of 
(CF3)2CHOH. 
h
Concn of substrate was ca. 0.40 M. 
i
Concn of substrate was ca. 0.10 M. 
j
10 mol % 
DTBMP was used as a Brønsted acid scavenger. 
k
20 mol % DTBMP was used. 
l
No kinetic 
resolution was observed. MS (4Å) = Molecular sieves activated (4Å). Armstrong’s acid = 1,5-
Naphthalenedisulfonic acid tetrahydrate. (S)-BNDHP = (S)-()-1,1-Binaphthyl-2,2-diyl hydrogen 
phosphate. 
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Table 2. Properties of Fluorinated and their Corresponding Non-Fluorinated Alcohols 
properties 
CH3CH2OH 
(EtOH) 
CF3CH2OH 
(TFE) 
(CH3)2CHOH 
(i-PrOH) 
(CF3)2CHOH 
(HFIP) 
bp (°C) 78 73.8 82.5 58.6 
mp (°C) –114 –43.5 –89.5 –4 
Density () 0.789 1.373 0.781 1.605 
pKa 15.9 12.4 17.1 9.3 
Dielectric constant () 24.5 26.7 19.4 16.7 
Polarity (Ps) – 10.20 – 11.08 
Polarity (  
 ) 0.654 0.898 0.546 1.068 
Nucleophilicity (N) 0.09 –2.78 0.09 –3.93 
Ionizing power (Y) –2.03 1.045 –2.73 2.46 
Polarizability (*) 0.54 0.73 0.48 0.65 
Dipole moment () 1.69 2.03 1.68 2.05 
Hydrogen-bond donor acidity ()30c 0.83 1.51 0.76 1.96 
Hydrogen-bond acidity (  
 )
30d 0.328 0.567 0.324 0.771 
Hydrogen-bond acceptor basicity () 0.77 0.00 0.95 0.00 
Self-association constant (dm
3
/mol) 0.89 0.65 – 0.13 
 
Using HFIP as a substitute for TiCl4 in a control experiment did not afford any 
product and substrate 1f was recovered almost quantitatively (Table 1, entry 8). Using 1 
equiv of HFIP as an additive with ACN as a solvent did not improve the yield (entry 9). 
However, when HFIP was used as solvent in combination with 10 mol % TiCl4, complete 
conversion was observed with increased catalyst turnover compared to TFE (cf. entries 10 
and 11 with 7). It was noted that the sequence of addition for the TiCl4 was important. 
Slight epimerization was observed when TiCl4 was added to substrate 1f before the addition 
of HFIP (entry 10). However, when TiCl4 was added to a solution of 1f in HFIP, negligible 
epimerization was observed suggesting a buffering action of HFIP (entry 11; vide infra). 
Lowering the catalyst loading to 7 and 5 mol % TiCl4 produced similar results as with 10 
19 
 
mol % TiCl4 but at the expense of longer reaction times (entries 12 and 13). Changing the 
concentration of reaction mixture had minimal effect on yield (entries 14 and 15).  
We speculated that reaction of HFIP with TiCl4 might generate HCl in situ along with 
Ti[OCH(CF3)2]4. If so, then 5 mol % TiCl4 should be capable of generating 20 mol % HCl 
in situ. To test this hypothesis, we ran the reaction in the presence of 10 and 20 mol % 2,6-
di-tert-butyl-4-methylpyridine (DTBMP) as a proton scavenger (Table 1, entries 16 and 
17). Significant catalyst inhibition resulting in lower yields was observed, but reaction to 
some extent was still observed when 20 mol % DTBMP was used. This could mean that the 
catalytically active species is HCl generated in situ or that DTBMP, being a base, has some 
other deleterious effect on the reaction.
36
 The reaction in HFIP with other Lewis acids 
provided the lactam in good yields (entries 19–26), but Sc(OTf)3 provided the product in 
only 28% yield (entry 27). The reaction with Brønsted acids (520 mol %) delivered 
comparatively lower yield of the product than the reaction with 5 mol % TiCl4 (entries 28–
32). Interestingly, reaction with 20 mol % HCl in ether (entry 29) gave a lower yield than 
that with 5 mol % TiCl4 (entry 13). The use of a chiral phosphoric acid
18b
 neither provided 
good yield nor led to any degree of kinetic resolution (entry 33). The reaction with 
Ti(O
i
Pr)4 resulted in only a trace amount of product with quantitative recovery of substrate 
1f (entry 34). Although this supported our supposition that in situ-generated HCl could be 
the active catalyst, it was hard to reconcile with the reduced yield obtained when HCl in 
ether solution was used, possibly as a result of concentration errors in the commercial 
product (see Table 5 and associated discussion for more on this point). 
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Substrate Scope  
Having identified conditions that satisfied our goals (5 mol % TiCl4 in HFIP), we 
sought to determine the scope of this substoichiometric, catalytic Schmidt reaction. We 
began with cyclohexanone-derived azido ketones, as previous experience had taught us that 
these are in general the most facile substrates (Table 3).
12-13
 Indeed, the results obtained 
were in general as good as or better than those obtained using stoichiometric catalysts. 
Thus, the transformations of 1c and cis ketone 1e required only 2.5 mol % TiCl4 (entries 1 
and 2), whereas trans ketone 1f required 5 mol % TiCl4 and a longer reaction time to obtain 
slightly lower yield of the product (entry 3). The reaction of 1,3-diketone 1b proceeded in 
higher yield than reported in the literature (entry 4; cf. Scheme 6b),
18a
 while -ester-
substituted 1d, which failed in the preliminary screening (Schemes 8 and 9), afforded an 
excellent yield of 2d using the optimized protocol (entry 5). Other functionalized 
cyclohexanones such as -tetralone 1g (entry 6) and allylic azide 1h17m (entry 7) also 
provided good yields of the corresponding lactams 2g and 2h. 
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Table 3. Initial Substrate Scope for the Catalytic Intramolecular Schmidt Reaction on 
Cyclohexanone-Derived Azido Ketones
a,b
 
 
entry
 substrate 
1 
catalyst 
(mol %) 
time  
(h) 
product 
2 
yield  
(%)
c 
1
 
 
2.5 20 
 
94
 
 1c   2c  
2
 
 
2.5 20 
 
98
 
 1e   2e  
3
 
 
5 38 
 
87
d 
 1f   2f  
4
 
 
5 24 
 
94 
 1b   2b  
5 
 
5 40 
 
94 
10 18 95 
 1d   2d  
6 
 
5 24 
 
89
 
 1g   2g  
7 
 
5 24 
 
84 
 1h   2h  
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a
To a solution of substrate (0.40 mmol) in (CF3)2CHOH (2.0 mL) at rt was added a 1.0 M 
solution of TiCl4 in CH2Cl2 under nitrogen atmosphere, and the reaction mixture was 
stirred at 25 C for the designated period. 
b
Concn of substrate was ca. 0.20 M. 
c
Isolated 
yields. 
d
Bridged lactam 3f was also isolated in ca. 2% yield. 
 
We next examined a broader range of ketone types, including some that we have 
found challenging under previously established reaction conditions (Table 4). Although the 
substrate scope was broad, some recalcitrant substrates generally required higher catalyst 
loadings compared to cyclohexanone-derived azides. For example, cyclopentanone 1a with 
20 mol % TiCl4 afforded a superior yield of indolizidinone 2a, a structural motif found in 
many pharmacologically relevant alkaloids (entry 1). The reaction of seven- and eight-
membered cyclic azido ketones afforded lactams of medium ring sizes in high yields 
(entries 2 and 3), and norcamphor-derived 1k provided a good yield of tricyclic lactam 2k 
with 25 mol % TiCl4 (entry 4). N-Substituted pyrrolidinones 2l and 2m were obtained in 
good yields from acyclic azido ketones (entries 5 and 6), whereas benzylic azide 1n 
provided a mixture of two regioisomers 2n and 3n in 4:1 ratio in modest yield with 15 mol 
% TiCl4 (entry 7).  
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Table 4. Additional Evaluation of the Reaction Scope
a,b 
 
entry
 substrate 
1 
catalyst 
(mol %) 
time 
(h) 
product 
2 
yield  
(%)
c 
1
 
 
10 44 
 
60 (78)
d 
15 44 79 
20 24 87 
 1a   2a  
2
 
 
5 62 
 
34 (85)
d 
20 48 86
e 
 1i   2i  
3
 
 
25 62 
 
90
 
 1j   2j  
4
 
 
10 62 
 
43 (78)
d 
25 62 87 (90)
d
 
 1k   2k  
5 
 
20 24 
 
79 (96)
d,f
 
25 32 94
f
 
 1l   2l  
6
 
 
10 36 
 
73
g 
15 24 77 (81)
d,g
 
20 24 86
g
 
 1m   2m  
7 
 
15 24 
 
64 
 1n   2n 3n  
    2n:3n = 4:1  
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entry
 substrate 
1 
catalyst 
(mol %) 
time 
(h) 
product 
2 
yield 
(%)
c 
8 
 
25 48 
 
87
h
 
 1o   2o  
9 
 
35 20 
 
90 
 1p   2p  
10 
 
5 24 
 
86 
 1q   2q  
11 
 
20 60 
 
11 (20)
d
 
 1r   2r  
a
To a solution of substrate (0.40 mmol) in (CF3)2CHOH (2.0 mL) at rt was added a 1.0 M solution 
of TiCl4 in CH2Cl2 under nitrogen atmosphere and the reaction mixture was stirred at 25 C for the 
designated period. 
b
Concn of substrate was ca. 0.20 M. 
c
Isolated yields. 
d
Yields in parentheses are 
based on recovered starting material. 
e
Bridged lactam 3i was also isolated in 2% yield (see the 
Experimental Section). 
f
The product contained 7% 1-phenethylpiperidin-2-one 3l (see the 
Experimental Section). 
g
The product contained 3% N-methyl-2-piperidone 3m (see the 
Experimental Section). 
h
Bridged lactam 3o was also isolated in 5% yield (see the Experimental 
Section). 
 
One of the most recalcitrant substrate in the series of cyclohexanone-derived azido 
ketones was -phenyl-substituted 1o (Table 4, entry 8; cf. Table 3, entries 2, 3, and 5). The 
transformation of 1o required 25 mol % TiCl4 and a longer reaction time to afford the 
corresponding fused lactam 2o along with a small amount of bridged lactam 3o. Previously, 
it was shown that the reaction of substrate 1o with 1 equiv of methylaluminum dichloride 
(MeAlCl2) in dichloromethane (DCM, CH2Cl2) preferentially afforded the fused lactam 
25 
 
2o.
37
 Substrate 1p containing a tertiary amine (a possible additional source of catalyst 
inactivation) required 35 mol % TiCl4 to provide pyrrolodiazepinone 2p (Table 4, entry 
9).
38
 Typically, for the intramolecular Schmidt reaction, nitrogen gas evolution is observed 
immediately upon addition of the catalyst. However, when TiCl4 was added slowly to a 
solution of substrate 1p in HFIP, a yellow precipitate was initially observed, with 
effervescence commencing only upon the addition of 25 mol % TiCl4.
39
 This observation 
suggests that the initial 25 mol % TiCl4, which was capable of generating 100 mol % HCl, 
formed a salt with the basic amine, with the remaining 10 mol % TiCl4 being responsible 
for the desired transformation into lactam 2p. Azido aldehyde 1q required only 5 mol % 
TiCl4 to provide 3-benzylpyrrolidinone 2q in good yield (entry 10). Unfortunately, 
extending the tether length between the carbonyl and the azide moiety from the usual four 
to five carbons resulted in a sluggish reaction that afforded only an 11% yield of lactam 2r, 
even when 20 mol % TiCl4 was employed (entry 11). This is consistent with the stringent 
dependence of the intramolecular Schmidt reaction on tether length observed since the 
initial discovery of the reaction.
6c,12-13
  
Given the requirement of relatively high catalyst loading for these less reactive 
substrates, we sought to optimize our reaction conditions further using substrate 1a (Table 
5). After evaluation of a series of Lewis and Brønsted acids, TiCl4 was still found to be the 
most effective catalyst for this substrate (entries 1–14). However, the combination of TiCl4 
with other Lewis or Brønsted acids, while not initially promising (entries 15–20 and 28) 
ultimately revealed acetyl chloride (AcCl, CH3COCl) as an effective promoter of this 
reaction even in the absence of TiCl4 (entries 21–25). Thus, the reaction with 80 mol % 
AcCl (entry 25) gave results comparable to those with 20 mol % TiCl4 (entry 1). We 
realized that this would support the case that HCl is the active catalytic species, provided 
that we could show HFIP to be capable of generating HCl from AcCl (an ironic notion in 
26 
 
view of the low nucleophilicity of HFIP
30g
).
40
 To address this, we combined 1 equiv of 
AcCl and 2 equiv of HFIP in CDCl3 and monitored the reaction by 
1
H NMR spectroscopy 
(Figure 5; see the Experimental Section for details). Within 6 min, ca. 50% conversion to 
HFIP acetate was observed. The rate decreased after 20 min, and the reaction took 4 h to 
reach >95% conversion. Conversely, we were not able to obtain any evidence for the in situ 
generation of HCl from TiCl4.  
 
Table 5. Further Optimization of the Reaction Conditions for 1a
a,b
 
 
entry catalyst 
catalyst 
(mol %) 
additive 
additive 
(mol %) 
2a:1a
c
 
1 TiCl4 20 – – 95:5 
2 TiCl4 10 – – 59:41 
3 TiF4 10 – – 26:74 
4 TiBr4 10 – – 46:54 
5 Ti(O
i
Pr)4 10 – – <2:98
d
 
6 SiCl4 10 – – 58:42 
7 SbCl5 10 – – 45:55 
8 NbCl5 10 – – 44:56 
9 WCl6 10 – – 54:46 
10 HCl in ether
e
 40 – – 45:55 
11 Aqueous HCl
f
 40 – – 59:41 
12 HCl in HFIP
g
 40 – – 
57:43–75:25 
(variable) 
13 H2SO4 40 – – 76:24 
14 TiCl4 5 CF3SO3H 5 42:58 
15 – – CF3SO3H 20 49:51 
16 TiCl4 5 ClSO3H 5 49:51 
17 TiCl4 10 AgOTf
h
 20 56:44 
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entry catalyst 
catalyst 
(mol %) 
additive 
additive 
(mol %) 
2a:1a
c
 
18 TiCl4 10 Al(O
i
Pr)3 20 50:50 
19 TiCl4 10 Silica gel
i
 – 47:53 
20 TiCl4 10 CH3COCl
j
 40 95:5 
21 – – CH3COCl
j
 40 58:42 
22 – – CH3COCl
k
 40 70:30 
23 – – CH3COCl
k
 70 90:10 
24 – – CH3COCl
j
 80 94:6 
25 – – CH3COCl
k
 80 97:3
l
 
26 – – CH3COBr
m
 40 72:28 
27 – – CH3COBr
m
 80 98:2
n
 
28 TiCl4 10 (CH3)3SiCl 40 89:11 
29 – – (CH3)3SiCl 80 92:8 
30 – – (CH3)3SiI 80 13:87
o
 
a
To a solution of substrate 1a (0.10 mmol) in (CF3)2CHOH (0.50 mL) at rt was added a 
catalyst and/or an additive under nitrogen atmosphere, unless otherwise mentioned. For 
TiCl4, SiCl4, and SbCl5, a 1.0 M solution in CH2Cl2 was used. 
b
Concn of substrate was ca. 
0.20 M. 
c1
H NMR ratios were determined after a brief work-up (see the Experimental Section 
for details). 
d
Only unreacted 1a was observed. 
e
A 1.0 M solution of HCl in ether 
(commercial) was used. 
f
Aqueous HCl (37%) was used. 
g
A 0.105–0.116 M solution of HCl in 
HFIP was prepared and used immediately. 
h
TiCl2(OTf)2 was generated in situ from TiCl4 and 
AgOTf.
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i
Silica gel (50mg) was used. 
j
An old container of AcCl (>5 years since initial 
opening) was used. 
k
A new container of AcCl was used. 
l
The 2a:1a ratio did not change 
between 18 and 24 h. 
m
A new container of AcBr was used. 
n
The 2a:1a ratio did not change 
between 18 and 24 h. 
o
Several other unidentified byproducts/impurities were also observed.  
28 
 
 
Figure 5. Results of 
1
H NMR monitoring of the reaction of AcCl with HFIP to generate 
HCl in situ. 
 
Additional experiments were carried out to gather further detail about the effect of 
various sources of H
+
 on these Schmidt reactions. In our initial survey, we had first tried 
adding commercially prepared solution of HCl in ether to the HFIP solvent (Table 1, entries 
28 and 29, and Table 5, entry 10). Neither that method nor the addition of aqueous HCl
30k
 
(Table 5, entry 11) gave good results in our hands. On the other hand, when HCl gas was 
separately generated and infused into the HFIP (entry 12), a range of results were obtained. 
The nonreproducibility of these experiments can be blamed on the ease with which the HCl 
gas escaped the solution, making it difficult to gauge accurately the amount of acid present 
in a particular experiment. For example, markedly reduced yields (on the low end noted in 
entry 12) were obtained when HCl/HFIP solutions were aged for even a few minutes. We 
also examined whether HBr generated by the addition of acetyl bromide (AcBr, CH3COBr) 
29 
 
to HFIP was a suitable substitute for HCl, and the initial evidence suggested that it is (cf. 
entries 26 and 27 with 22 and 25). We still prefer to use AcCl-generated HCl because AcCl 
is generally easier to handle and more resistant to hydrolysis in air. Moreover, we observed 
very little difference when different sources of AcCl were used in the reaction (i.e., freshly 
opened vs older bottles of reagent; cf. entries 25 and 24). Taking into account both 
efficiency and practicality, we prefer using TiCl4 or AcCl as the HCl source among all of 
the methods tested to date. 
We decided to explore the substrate scope further under these new reaction conditions 
utilizing AcCl as a procatalyst. The substrate scope was comparable to that described for 
TiCl4, and lactams were obtained in good to excellent yields (Table 6). Although higher 
amounts of AcCl than TiCl4 were required to achieve complete conversion, the use of AcCl 
was convenient. In addition, both HFIP and its acetate ester byproduct are volatile, easing 
the work-up. Finally, no metal waste was produced. 
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Table 6. Scope under the Conditions Employing Acetyl Chloride
a,b
 
 
entry
 substrate 
1 
catalyst 
(mol %) 
time 
(h) 
product 
2 
yield 
(%)
c 
1
 
 
10 20 
 
95 
 1c   2c  
2
 
 
10 20 
 
98 
 1e   2e  
3
 
 
20 38 
 
90
d,e 
 1f   2f  
4
 
 
20 24 
 
95 
 1b   2b  
5 
 
20 24 
 
77 
 1h   2h  
6 
 
60 24 
 
68 
 1n   2n 3n  
    2n:3n = 65:35 (ca. 2:1)  
7 
 
80 24 
 
90 
 1a   2a  
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entry
 substrate 
1 
catalyst 
(mol %) 
time 
(h) 
product 
2 
yield 
(%)
c 
8 
 
80 48 
 
87
f
 
 1i   2i  
9 
 
100 62 
 
92 
 1k   2k  
10 
 
100 32 
 
96
g
 
 1l   2l  
a
To a solution of substrate (0.40 mmol) in (CF3)2CHOH (2.0 mL) at rt was added CH3COCl under 
nitrogen atmosphere, and the reaction mixture was stirred at 25 C for the designated period, unless 
otherwise noted. 
b
Concn of substrate was ca. 0.20 M. 
c
Isolated yields. 
d
Bridged lactam 3f was also 
isolated in ca. 3% yield. 
e
The reaction was run on a 0.10 mmol scale. 
f
Bridged lactam 3i was also 
isolated in 3% yield (see the Experimental Section). 
g
The product contained 7% 1-
phenethylpiperidin-2-one 3l (see the Experimental Section).  
 
We then applied this protocol to stereochemically and structurally challenging 
steroidal ketones. Structurally modified steroids, in particular steroidal lactams, have been 
shown to possess favorable biological activities relative to their ketone precursors.
42
 For 
example, fused (modified E-ring steroids) and C-16 substituted analogues of estrone have 
potential therapeutic applications as inhibitors of 17-hydroxysteroid dehydrogenase type 1 
(17-HSD).43 Thus, we applied our current methodology to the synthesis of a D-homo 
fused lactam analogue of estrone 8 (Scheme 11). Estrone 3-methyl ether 4 was alkylated 
under standard LDA conditions to provide a chloroalkyl substituted C16-isomer 5 as the 
major product.
44
 The chloro derivative 5 was converted to its corresponding azide 6 by 
treating with NaN3. The azidoalkyl ketone 6 serves as a potential substrate to test the 
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current substoichiometric variant of the intramolecular Schmidt reaction. The low reactivity 
of 6 was anticipated due to the presence of a cyclic five-membered neopentyl ketone. 
Hence, the reaction of 6 in HFIP required 25 mol % TiCl4 to achieve good conversion of 
the corresponding D-homo fused lactam 7 (Scheme 11). Further deprotection of the methyl 
ether with BBr3 gave the 17-azaestrone analogue 8. However, when the reaction of 6 was 
carried out in DCM for comparison purpose, 2 equiv (200 mol %) of TiCl4 was required to 
obtain 7 in excellent yield (Scheme 12). 
 
Scheme 11. Synthesis of 17-Azaestrone Analogue 8 using a Substoichiometric Variant 
of the Intramolecular Schmidt Reaction 
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Scheme 12. Synthesis of 7 using a Conventional Intramolecular Schmidt Reaction  
 
 
We and others have explored the combination of the intramolecular Schmidt reaction 
with other C–C bond forming processes to expediently access diverse heterocyclic ring 
systems with a variety of substitution patterns (for selected examples, see Figure 2).
17d,f,j,k,45
 
In particular, our group has developed different subtypes of Lewis acid-promoted domino 
intramolecular Schmidt reaction coupled with intramolecular
46
 and intermolecular
17d,45a
 
Diels–Alder reactions. This one-pot domino process involves the initial Lewis acid-
promoted Diels–Alder reaction, which reveals the ketone for the subsequent intramolecular 
Schmidt reaction.
45a
 Since enones rarely undergo intramolecular Schmidt reactions,
47
 they 
have been commonly utilized for the domino reaction with the Diels–Alder reaction 
(Scheme 13).  
 
Scheme 13. Domino Intermolecular Diels–Alder/Intramolecular Schmidt Reactions 
 
 
In the typical domino reaction as exemplified in Scheme 13, an excess of MeAlCl2 
was employed as a Lewis acid to bring about the desired transformation into tricyclic 
lactam 11. The literature precedent for the catalytic Diels–Alder reaction
48
 and our own 
34 
 
work towards the development of a catalytic intramolecular Schmidt reaction in HFIP
25
 
prompted us to attempt the domino reaction in a catalytic fashion. Moreover, HFIP has 
been shown to promote the Diels–Alder reaction without the aid of Lewis acids.
35
 
However, our initial efforts to render this domino reaction catalytically turned out to be 
unsuccessful (Scheme 14). Formation of lactam 11 was not observed when a reaction of a 
cyclic azido enone 9 and silyloxydiene 10 in HFIP was performed in the presence of 10 mol 
% TiCl4. Unidentified byproducts and decomposition of 10 was observed by TLC and 
1
H 
NMR analysis. Increasing the catalyst loading to 25 mol % TiCl4 and using a mixed solvent 
system, HFIP/DCM, resulted in the formation of a complex mixture.  
 
Scheme 14. Unsuccessful Catalytic Approach towards a Domino Intermolecular 
Diels–Alder/Intramolecular Schmidt Reaction 
 
 
Mechanistic Studies  
On the basis of precedent,
30g-j,33
 we propose the involvement of HFIP as a strong 
hydrogen-bond donor to the lactam carbonyl (Figure 6). As proposed above, we believe 
that association of a Lewis or Brønsted acid with the Lewis basic lactam product inhibits 
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the catalytic reaction carried out in DCM. Hexafluoro-2-propanol as the solvent can 
potentially form complexes with the substrate, intermediates, and product. Critically, 
hydrogen bonding of HFIP with the lactam carbonyl by displacement of the Lewis or 
Brønsted acid allows for regeneration of the catalyst (most likely a proton). In addition, one 
cannot rule out coordination between HFIP and the catalyst to produce a catalytically more 
reactive species such as [HFIPH]
+
.
49
 We note that a cursory measurement of the pH of the 
reaction mixture using pH indicator strips (nonbleeding) gave a reading of pH 4.0 for the 
present version, as opposed to pH 1.0 for an intramolecular Schmidt reaction carried out 
with TiCl4 in CH2Cl2 (the pH of pure HFIP was measured to be 5.0 by this method), 
suggesting an overall buffering effect of the solvent. Various experiments were designed 
and executed to further explore different mechanistic aspects of this substoichiometric 
intramolecular Schmidt reaction, such as the product inhibition by lactams and the 
hydrogen bonding interactions of HFIP with lactams. 
 
 
Figure 6. Proposed catalytic cycle for the intramolecular Schmidt reaction employing HFIP 
as solvent. 
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Competition and Product Inhibition Experiments. To gain more insight into the 
different behaviors of different classes of azidoalkyl ketones, a competition experiment 
between cyclohexanone-derived 1e and cyclopentanone-derived 1a was performed 
(Scheme 15a and Figure 7). Treating an equimolar mixture of 1e and 1a in HFIP with 20 
mol % AcCl resulted in complete conversion of substrate 1e to lactam 2e within 3 h (also 
see Table 6, entry 2). In sharp contrast, the conversion of 1a to lactam 2a was only 13% 
complete after 12 h (also see Table 6, entry 7). These results could be explained by an 
innate kinetic difference between the substrates, a difference in the degree of product 
inhibition, or a combination of the two. 
 
Scheme 15. Competition and Product Inhibition Experiments 
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Figure 7. Relative reaction rates for 1e and 1a (see Scheme 15a above), 1e with 1 equiv of 
2e added at the outset of the reaction (Scheme 15b), and 1e with 1 equiv of 2a added at the 
outset of the reaction (Scheme 15c).  
 
With respect to the latter point, we made note of the requirement of different catalyst 
loadings for different substrate classes. This could probably be attributed to the difference 
in basicity of different lactam products, with a more basic lactam requiring higher catalyst 
loadings.
50
 In order to demonstrate different degrees of product inhibition with different 
lactams, 
1
H NMR experiments were carried out to determine the effect of adding two 
different product lactams at the outset of a single relatively fast reaction. For this, we chose 
the product of the quicker reaction leading to 2e (and a case that succeeds with 10 mol % 
AcCl procatalyst) and 2a, the product of a much slower reaction (and one that requires 80 
mol % AcCl to reach completion). In the first case, the facile azido ketone substrate 1e was 
combined with an equimolar amount of its lactam product 2e and then treated with 20 mol 
% AcCl in HFIP (Scheme 15b and Figure 7). The time needed for quantitative conversion 
of 1e to 2e was ca. 6 h. In contrast, the reaction of a 1:1 mixture of 1e and 2a with 20 mol 
% AcCl in HFIP required >24 h to attain completion (Scheme 15c and Figure 7). These 
results would be consistent with significantly more product inhibition by lactam 2a than 2e, 
38 
 
which is in turn consistent with the need for higher catalyst loadings with relatively 
recalcitrant substrates.
19a
  
The reaction rate for the conversion of 1e to 2e was also studied in deuterated HFIP 
(HFIP-d2) with 20 mol % AcCl using 
1
H NMR. Data collection at different time points 
revealed >55% conversion in 10 min, slowly reaching up to 75% in 30 min. Then the 
reaction further slows down requiring ca. 4 h to achieve complete conversion (Figure 8). 
While the initial reaction rate seems faster, the actual conversion of 1e to 2e correlates with 
the amount of time requires for the in situ generation of HCl from AcCl upon reaction with 
HFIP-d2 (cf. Figures 8 and S3 in the Experimental Section). The reaction rate for 1e in 
HFIP-d2 seems slightly slower compared to HFIP (cf. Figures 7 and 8). Such difference 
could be simply due to experimental errors or from the use of different curve fitting 
softwares (see the caption for Figure 7 in the Experimental Section).  
 
 
  
Figure 8. Reaction rate for 1e in HFIP-d2 (blue line represents the % conversion to 2e and 
red line represents the % remaining of 1e). 
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Despite the importance of the Schmidt reaction, very few kinetic studies focusing on 
the intermolecular reaction of ketones with azides using 
1
H NMR and azotometry 
(determination of the rate of N2 evolution) have been published.
51
 This has been attributed 
to the considerable difficulties encountered for a quantitative study of such complex 
processes.
51
 As shown above, reaction rate and competition experiment studies have clearly 
revealed that the initial rate for the intramolecular Schmidt reaction in HFIP is much faster 
and most of the conversion to product occurs during the first few minutes of the reaction. 
Toward this end, we endeavored to perform a detailed kinetic investigation to address fully 
the relative roles of kinetics versus product inhibition in the intramolecular Schmidt 
reaction. 
Initial kinetic experiments were attempted on two substrates 1a and 1b and 
conversions to their corresponding products 2a and 2b were monitored over time using 
three different techniques, 
1
H NMR, GC, and UV–visible spectrophotometry. 
Unfortunately, we were not able to determine the rate of the reaction using these 
techniques. During this trial, a cursory analysis showed that ca. 40% conversion occurred 
within 1 min. Since we were trying to determine the kinetic behavior at early conversion 
(initial rate of a reaction), manual sampling to aliquot enough number of samples in 1 min 
for reasonable data analysis turned out to be challenging. Moreover, different methods 
(such as the use of different bases and filtration through Celite) tested to quench the 
reaction for later analysis by GC and 
1
H NMR proved to be ineffective and unreliable. With 
UV–visible study, an immediate increased in the absorbance was observed upon catalyst 
addition (a stock solution of TiCl4 in HFIP was used) for 3–4 seconds, after which it 
plateaued till the end of the experiment (120 seconds). This abnormal observation during 
the time course of the absorbance did not allow for measurement of the rate constants. 
Future kinetic studies might take advantage of advanced NMR techniques and azotometric 
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determination to overcome various problems encountered during our initial attempt. To this 
point, it remained a challenge to understand the details of this mechanistically complicated 
reaction using kinetics.  
 
Characterization of Protonated Lactams. In general, O-protonation is significantly 
favored over N-protonation for amides and lactams.
1,50e
 To the best of our knowledge, X-
ray crystal structures of a bicyclic lactam protonated on oxygen is not known. On the other 
hand, structural characterizations of the highly sought N-protonated species are limited to 
twisted or bridged amides and lactams.
52
 Thus, we attempted to isolate and characterize 
examples of a bicyclic lactam–catalyst complex. This would not only provide the first 
example of such complex but will also serve the purpose of verifying product inhibition 
through catalyst sequestration, which we and others have proposed in the intramolecular 
Schmidt reaction.
13,18a
  
In order to have a successful outcome, it was necessary to carry out the experiments 
under conditions, which does not affect the lactam–catalyst complex. Running the 
experiments under AcCl and HFIP conditions seemed promising as volatile components 
such as HFIP and its in situ-generated acetate ester were easy to remove under vacuum, 
once the reaction was complete. This will apparently leave nothing but lactam product 
bound to HCl in the reaction vessel. Accordingly, complete conversion of 1a to 2a was 
achieved with 0.90 equiv of AcCl in HFIP (Scheme 16a). Following concentration and 
drying of the reaction mixture under vacuum, we were excited to see the deposition of solid 
particles in the vial. Several recrystallization attempts eventually afforded small diffractable 
crystals of protonated 2a (2aHCl) in twinned bundles. Dr. Victor W. Day was able to get a 
single-crystal X-ray structure of lactam 2a bound to HCl from these poor quality crystals 
(Scheme 16a). Similarly, the reaction of 1k with 1.25 equiv of AcCl in HFIP resulted in the 
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isolation and characterization of the protonated lactam 2k (2kHCl) by a single-crystal X-
ray analysis (Scheme 16b). In this case also, twinned crystals were obtained.  
 
Scheme 16. Single-Crystal X-Ray Structures of Lactams Bound to HCl 
 
 
Crude 
1
H NMR analysis of 2aHCl in CDCl3 displayed a broad signal corresponding 
to one proton at  10.67, indicating the presence of HCl. Also, protons attached to the -
carbon of the carbonyl shifted downfield by 0.36 (from  2.11 to 2.47) and 0.41 (from  
2.27 to 2.68) ppm compared to 2a. In a similar way, HCl signal was observed at  10.11 
and the -proton of the carbonyl shifted downfield by 0.34 ppm (from  2.71 to 3.05) for 
2kHCl compared to 2k. A downfield shift of 2.6 ppm (from C 175.2 to 177.8) was also 
observed for the carbonyl carbon in the 
13
C NMR of 2kHCl. 
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In both cases, O-protonation caused a significant lengthening of the C1 to O1 bond 
(1.300 and 1.301 Å for 2aHCl and 2kHCl) with C–O single bond character and shortening 
of the C1 to N1 bond (1.288 and 1.255 Å for 2aHCl and 2kHCl) with enhanced C=N 
double bond character (see Table 7 for details). The short O–H bonds (1.013 and 0.9309 Å 
for 2aHCl and 2kHCl), typical of a covalent character in a hydroxyl group (0.967 Å) were 
also observed, indicating a stronger acceptor strength (basicity) of the amide oxygen. The 
preferred O-protonation results from the stabilization of the positive charge on the O-
protonated species by partial charge delocalization from the nitrogen atom through 
enhanced resonance phenomenon (Scheme 16). This charge delocalization is favored 
because the less electronegative nitrogen can bear the positive charge more readily than the 
amide oxygen.
53
 On the other hand, the presence of long (O–)H···Cl bonds (1.85 and 1.93 
Å for 2aHCl and 2kHCl) compared to HCl (1.274 Å) suggested a short hydrogen bond 
with a relatively strong intermolecular hydrogen bonding, characteristic of a O–H donor 
and chloride (Cl
–
) acceptor (Table 7).
53-54
 The bond angles (O–H···Cl) of 176.0 and 164.3 
for 2aHCl and 2kHCl were indicative of nearly linear hydrogen bonds.
54c
 
 
Table 7. Geometric Details of the LactamHCl Complex 
lactam 
bond length (Å) bond angle () 
C=O (C–OH) C–N (C=N) O–H H···Cl O–H···Cl 
typical bond 
length
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1.233
a
 (1.333)
b
 1.352
c
 (1.279)
d
 0.967
e
 1.274 (for H–Cl) – 
2aHCl 1.300(18) 1.288(19) 1.013 1.85 176.0 
2kHCl 1.301(6) 1.255(7) 0.9309 1.93 164.3 
a
(C*)2–N–C=O (in -lactams). 
b
C=C–OH (in enols). 
c
(C*)2–N–C=O (in -lactams). 
d
Car–C=N–C 
(in general for Csp
2
=N). 
e
C*–O–H (in alcohols). ar = aromatic. 
a–e
 The values for bond lengths were 
taken from ref. 55. 
 
43 
 
 Undoubtedly, we were able to provide a clear proof of evidence for the Lewis basic 
lactam based catalyst sequestration through characterizations of protonated forms of 
lactams as HCl salts by single-crystal X-ray analysis.  
 
Determination of Association Constants for HFIP–Lactam Complexes using 
NMR Titration. HFIP has been shown to form aggregates, such as trimers, having 
potential hydrogen bonds with strengths comparable to those of covalent linkages.
30h
 Such 
strong hydrogen bonding could well explain the role of HFIP in the catalysis of the 
intramolecular Schmidt reaction. NMR technique could provide a useful means to 
investigate this exceptional hydrogen-bond donor ability of HFIP with different lactams. A 
study has been reported for the determination of association constants (Ka) for the 
hydrogen-bonded complexes of HFIP with ethers.
30h
 Determination of Ka using the NMR 
technique might offer further insight into the relative basicities of various lactams, which 
evoke different degrees of product inhibition. 
When a host (H) and a guest (G) species interacts to form a host–guest complex 
(HG), which is held together via weak intermolecular forces such as hydrogen bonding, the 
equilibrium constant is often referred to as a binding constant (K) or an association constant 
(Ka) (equation (1)).
56
 NMR spectroscopy is the most widely used technique for studying 
intermolecular binding or reversible complexation between a host (H) and a guest (G) 
species and determining Ka in host–guest complexes.
56-57
 Besides being an important 
method in supramolecular chemistry,
56b,c
 the NMR technique has also been used in the 
determination of protein–ligand dissociation constants.
58
 The most common NMR 
experiment for quantifying interactions is a titration of the guest to a solution of the host, 
noting a change in the chemical shift. NMR titration methods are mostly useful to study Ka 
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in the range 10–10
4
 M
–1
. To get reliable Ka, it is necessary to design the experiment in a 
way so that the complexation ratio for a binding curve ranges from 20 to 80%.
56a,b
  
 
        H + G  HG  
   
[  ]
[ ][ ]
 
(1) 
[H] = Concentration of Host, [G] = Concentration of Guest, 
and [HG] = Concentration of Host–Guest Complex. 
 
Despite the apparent simplicity of the NMR titration approach, several issues need to 
be addressed carefully in order to obtain reliable results.
56,57b
 Some of the common issues 
involve: (1) different type of approximations such as determining the value for c or max 
(the difference between the chemical shift of the free host and the theoretical signal shift in 
the host–guest complex at 100% complexation), (2) careful choice of graphical methods 
(e.g., NMR vs UV–visible) such as Benesi–Hildebrand, Rose–Drago, etc. as each method 
has limitations in different applications, (3) finding a right concentration of host/guest for a 
particular system as carrying out titrations at concentrations unsuitable for the equilibrium 
often lead to systematic errors, (4) ensuring a constant host concentration during the course 
of the experiment; it is best to prepare a guest solution in the host solution with the same 
concentration of the host for the titration, (5) it is always necessary to determine the 
stoichiometry of binding before any determination of Ka for the host–guest complex as 
different graphical methods required for the determination of Ka depend on the ratio of 
binding, and (6) use of a reliable non-linear regression or curve-fitting methods.
56,57b
 
Commercial software packages for fitting data to binding models such as GraphPad
 
Prism
59
 
are relatively user-friendly compared to custom written programs that often run along with 
generic data and mathematical programs such as Microsoft Excel or Matlab.
56c
 Advantages 
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of using GraphPad
 
Prism involve no requirement for approximations, accounts for 
estimation of uncertainties, and allows for unrestricted distribution of experimental data 
points (concentrations).
56a,c
 Results obtained are more reliable and provides more accurate 
measurements of Ka. Equilibrium binding or dissociation constant (Kd), which is defined as 
the guest concentration needed to achieve a half-maximum binding at equilibrium is 
generally obtained in the GraphPad Prism upon data processing and Ka could be easily 
determined from Kd using the following equation, Ka = 1/Kd. 
Equation (2) describes the complexation-induced shift of an NMR signal for a fast 
equilibrium and the change in a chemical shift with a change in the concentration forms the 
basis of NMR titration for the determination of Ka.
56,57b,60
 All of the graphical methods and 
curve fitting programs designed to find solutions for this general equation (2) for the 
archetypical 1:1 binding system (two parameters fit) produce a hyperbolic binding curve 
(titration curve). [H]0 and [G]0 are two known parameters and the two unknown parameters, 
Kaand max could be obtained by non-linear curve fitting of the titration data.  
 
        
     
 [ ] 
[
 
  
 [ ]  [ ]  √(
 
  
 [ ]  [ ] )
 
  [ ] [ ] ] (2) 
obs = an experimentally measured chemical shift, 0 = the chemical shift of the free host,  = 
measured change in chemical shift (upon addition of guest species) referenced to that of the 
uncomplexed host, max = the difference between 0 and the theoretical signal shift at 100% 
complexation, Ka = the association constant, [H]0 = the initial concentration of host, and [G]0 = the 
initial concentration of guest. Equation taken from refs. 56, 57b, and 60. 
 
Job′s method of continuous variation was used to first determine the stoichiometry of 
binding for HFIP–product and HFIP–substrate complexes (Figure 9).
30h,61
 The Job plots 
based on the 
1
H NMR data provide good evidence that HFIP forms a 1:1 complex with both 
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product 2a and substrate 1a, as can be observed from the peak abscissa values of 0.52 for 
2a and 0.50 for 1a. Although the stoichiometries of binding were similar, the complexation 
shift () of the HFIP hydroxyl resonance upon complexation of lactam 2a was 
significantly higher than for azido ketone 1a, consistent with the expected stronger 
complexation of HFIP with the lactam than with the ketone. 
 
 
Figure 9. Job plots for the complexation of lactam 2a and azido ketone 1a with HFIP. 
 
With this information in hand about the stoichiometry of binding for HFIP with the 
lactam and the azido ketone, a simple 1:1 binding model could be employed to treat the 
NMR data for finding out the Ka in order to study the strength of the hydrogen bonding 
interaction. Initial NMR titration experiments were carried out following a slight 
modification of the reported procedure used for studying hydrogen bonding complexes of 
HFIP with ethers.
30h
 Initial experiments, which involved measuring a change in the 
chemical shift of the carbonyl carbon using 
13
C NMR in CDCl3 were erroneous, thus 
unsuccessful (Figure 10). In these attempts, azido ketones 1a and 1e, and lactam 2e were 
treated as host and HFIP was treated as guest. Several problems were encountered. First, 
the high concentrations initially used were unsuitable for the equilibriums being measured. 
Second, we learned that concentration errors were introduced upon successive additions of 
the guest to the NMR tube, in which the titration experiment was being performed. Since 
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we did not have any custom-written curve-fitting programs for the determination of Ka, we 
sought help of Dr. Justin Douglas to develop a process for fitting the NMR titration data to 
a 1:1 binding model based on equation (2) using Microsoft Excel. Unfortunately, 
processing the NMR data using Microsoft Excel was unreliable as correct approximations 
for max could not be made.
30h,56,57b,60,61b
 Due to errors in the experimental design, reliable 
values for Ka were not obtained. Moreover, saturation plots obtained were erroneous as 
concentration ratios for HFIP (guest) to 1e and 2e (hosts) were inaccurate because 
concentrations of hosts did not remain constant during the titration experiments (Figure 10).  
 
             
Figure 10. Saturation plots for unsuccessful NMR titration experiments of 1e and 2e with 
HFIP. 
 
Given these issues, we approached Dr. Blake R. Peterson for his help and insights in 
to designing the experiment, since his laboratory routinely determines Kd in biological 
settings. He guided us on how to run the NMR titration and helped to process the titration 
data using GraphPad
 
Prism software. Here, the NMR titration experiment was performed 
with HFIP as a host and azido ketone 1a as a guest and the change in the chemical shift of 
the hydroxyl proton of HFIP was monitored using 
1
H NMR. Since sufficient quantity of 
azido ketone 1a was available compared to lactam 2a, 1a was used for preliminary titration 
experiments to find the concentration range for the host and the guest.  
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Trial titration experiments were run at 20 and 2 mM concentrations of HFIP. To 
avoid the concentration error, individual NMR tubes were used for each dilution step. The 
titration at 20 mM concentration of HFIP was accomplished by preparing a series of 11 
different concentrations (titration points), where increasing amounts of 1a was added up to 
15 equiv in to individual NMR tubes. The stock solution of 1a was prepared with a stock 
solution of HFIP in CDCl3 and the final volume in the NMR tube was kept constant at 0.60 
mL. The change in the chemical shift () of the hydroxyl proton of HFIP was determined 
by 
1
H NMR. A significant downfield shift of the hydroxyl proton was observed with 
increasing concentrations of 1a. The presence of only one hydroxyl proton signal was 
indicative of a hydrogen-bonded complex with a fast equilibrium on a NMR time scale. A 
titration curve was obtained by plotting the absolute value of the observed chemical shift 
change (Δ) against the concentration of 1a (Figure 11). Non-linear regression analysis 
with one site specific binding model using GraphPad Prism gave a Kd of 151 mM for 1a, 
from which Ka was calculated to be 0.00662 mM
–1
. NMR titration at 2 mM concentration 
of HFIP failed to give reliable data points because the concentration of HFIP was too low to 
detect the hydroxyl proton signal accurately at increasing concentrations of 1a by 
1
H NMR. 
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Figure 11. Titration curve of HFIP at 20 mM concentration with up to 15 equiv of 1a (11 
titration points). 
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In practice, the experiments are generally designed to set the constant host 
concentration much lower than the Kd and that was the case observed here (Figure 11). In 
addition, 20 mM concentration gave an appropriate signal to noise ratio for measuring the 
chemical shift of the hydroxyl proton of HFIP by 
1
H NMR, so other concentrations of HFIP 
were not explored further. To validate the consistency of the result obtained in the first 
experiment, NMR titration at 20 mM concentration of HFIP was repeated, but with a series 
of 10 different concentrations up to 20 equiv of 1a. Processing the data in a similar way 
using GraphPad Prism gave a Kd of 130 mM and Ka of 0.00769 mM
–1
 for 1a (Figure 12).  
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Figure 12. Titration curve of HFIP at 20 mM concentration with up to 20 equiv of 1a (10 
titration points). 
 
Since good results were obtained for 1a, a titration experiment was run with the 
corresponding lactam 2a in a similar way as per our initial goal of determining the Ka for 
different lactams in order to assess their hydrogen-bond acceptor abilities with HFIP. When 
HFIP was titrated with up to 20 equiv of 2a (10 titration points), GraphPad Prism based 
treatment of the titration data provided a Kd of 16.8 mM and Ka of 0.0595 mM
–1
 for 2a 
(Figure 13a).  
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(b) Plot at 20 mM concentration of HFIP
with up to 10 equivalents of 2a
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Figure 13. NMR titration curves of HFIP with 2a. 
 
The carbonyl oxygen of lactam 2a, being strongly Lewis basic is a much better 
hydrogen-bond acceptor compared to the ketone 1a. Hence, a higher affinity of 2a towards 
a hydrogen-bond donor such as HFIP was expected. A lower Kd for lactam 2a is indicative 
of a stronger complexation of 2a with HFIP compared to a weaker interaction observed for 
1a (cf. Figures 12 and 13a). Because of the stronger hydrogen bonding interaction between 
HFIP and lactam, a lower concentration of lactam should be sufficient to achieve a half-
saturation point, where 50% of the HFIP is bound to the lactam. Hence, titration was 
repeated at 20 mM concentration of HFIP with up to 10 equiv of 2a (11 titration points) 
(Figure 13b). GraphPad Prism based data treatment provided a titration curve with a Kd of 
18.8 mM and Ka of 0.0532 mM
–1
 for 2a (Figure 13b). Since the lower concentration of the 
lactam 2a gave a value of Kd within the range of an experimental error than that carried out 
at the higher concentration, NMR titration studies for other lactams were carried out at 
lower concentrations. The main advantage lies in the requirement of a lesser amount of a 
given lactam for carrying out the experiment. With the optimized experimental procedure, 
NMR titrations for lactams 2e, 2f, and 2k were carried out at 20 mM concentration of 
HFIP. Dissociation constants, Kd (association constants, Ka) were ascertained to be 21.3 
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mM (0.0469 mM
–1
), 19.6 mM (0.0510 mM
–1
), and 20.5 mM (0.0488 mM
–1
) for lactams 2e, 
2f, and 2k, respectively (Figure 14).  
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(b) Plot at 20 mM concentration of HFIP
with up to 10 equivalents of 2f
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 (c) Plot at 20 mM concentration of HFIP
with up to 10 quivalents of 2k
0 50 100 150 200
0.0
1.0
2.0
3.0
4.0
5.0
6.0
N
H
O O
F3C
CF3
H
2k
Kd = 20.5 mM
Ka = 0.0488 mM
1
Concentration of 2k (mM)
C
h
a
n
g
e
 in
 c
h
e
m
ic
a
l s
h
ift
 (


) 
o
f
h
y
d
ro
x
y
l p
ro
to
n
 o
f 
H
F
IP
 
Figure 14. NMR titration curves of HFIP with lactams 2e, 2f, and 2k. 
 
The complexation or association constants (KC or Ka) for hydrogen-bonded 
complexes of HFIP with THF and 1,4-dioxane have been reported to be 0.065 and 0.033 
mM
–1
 respectively.
30h
 These authors also showed that the pKC (pKC = log10KC) of these 
ethers correlate well to the hydrogen-bond basicity pKHB data available in the literature
62
 
(pKC for THF and 1,4-dioxane were reported to be 1.81 and 1.52).
30h
 The pKHB scale, which 
utilizes p-fluorophenol (pKa = 9.91 and hydrogen-bond acidity (  
 ) = 0.629)30d as the 
reference hydrogen-bond donor is a well-established thermodynamic hydrogen-bond 
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basicity scale for organic bases, which serve as corresponding acceptors (pKHB, pKC, and 
pKa are all similar terms except determined in different ways).
30h,50f,62
 Increasing efforts 
have been made to build a pKHB scale for the quantitative measurement of the strength of 
organic Lewis bases such as ketones, ethers, amides, and lactams.
62c
 The basicity of various 
lactams as pKHB or pKa (pKa = log10Ka; not to be confused with the logarithm of the acid 
dissociation constant) have also been determined by titration with phenols using IR 
spectroscopy.
50a,f
 In one of this study, the basicities of unsubstituted lactams followed the 
following trend based on the ring size: 6-membered > 7-membered > 5-membered (pKa of 
piperidone, caprolactam, and pyrrolidone was found to be 0.75, 0.36, and –0.30).
50a
 The 
presence of N-substituents had a significant influence on the basicity of these lactams.  
In an analogous way as reported in the literature,
30h
 we calculated the pKa value for 
the lactam from their corresponding Ka (Table 8). All four lactams (2a, 2e, 2f, and 2k) 
under study showed very close hydrogen-bond basicities (pKa or pKHB). Thus, no clear 
correlation was observed between the basicity of different lactams and the amount of 
catalyst loading required for their conversion. This conflicts with the hypothesis set forth in 
the discussion with respect to Figure 7 and Scheme 15. Likewise, the chemical shift () of 
the lactam carbonyl carbon did not compare well both with Kd and pKa values and the need 
for a specific amount of catalyst loading for a particular azidoalkyl ketone substrate for 
their conversion to the corresponding lactam (Table 8).  
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Table 8. Correlation of Kd, Ka, and pKa Values Obtained from NMR Titration 
Experiments with the Observed Catalyst Loading Requirements
a
 
lactam 
2 
Kd  
(mM) 
Kd  
(M) 
Ka  
(mM
–1
) 
Ka  
(M
–1
) 
pKa 
 of carbonyl 
carbon (ppm) 
TiCl4 catalyst 
loading (mol %)
b
 
2a 18.8 0.0188 0.0532 53.2 1.73 168.9 20 
2f 19.6 0.0196 0.0510 51.0 1.71 172.3 5 
2k 20.5 0.0205 0.0488 48.8 1.69 175.2 25 
2e 21.3 0.0213 0.0469 46.9 1.67 173.4 2.5 
a
pKa = log10Ka. pKa has been compared to pKHB (hydrogen-bond basicity).
30h
 
b
See Tables 3 and 4. 
 
As noted above, we have proposed that product inhibition due to lactam–catalyst 
interaction is responsible for the need of superstoichiometric amounts of catalysts under 
most conditions (i.e., those using solvents other than HFIP). Since it was difficult to 
determine the pKHB value for the lactam using HCl as a hydrogen-bond donor, we sought to 
measure the inherent hydrogen-bond interactions of lactams with HFIP. However, the 
strength of the hydrogen-bonded complexes between HFIP and lactams determined using 
NMR titration experiments did not reflect the different degrees of product inhibition 
observed in the intramolecular Schmidt reaction. One explanation would be that the 
lactam–catalyst interaction does not correlate the hydrogen bonding interaction observed 
between lactam and HFIP. Because HFIP is a better hydrogen-bond donor than p-
fluorophenol (cf. pKa and   
  values; see discussion above and Table 2), it is less likely that 
using p-fluorophenol as the reference hydrogen-bond donor will provide a better 
determination of pKHB value for the lactam and in turn correlate with the different catalyst 
loading requirement. Moreover, we cannot rule out the dependance of product inhibition on 
unknown and unanticipated factors other than basicity, such as fused ring strain.
63
 Future 
elaborative studies might reveal comprehensive understandings in to the complex scenario 
of product inhibition, informing future synthetic efforts. 
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Conclusions 
We have demonstrated a catalytic intramolecular Schmidt reaction with broad 
substrate scope and utility. Two versions of the reaction, one using TiCl4 and the other with 
AcCl, have been identified as having strong synthetic utility that is as good or better than 
all previous versions of this process. In either case, the strong hydrogen bonding ability of 
HFIP was critical to the development of these substoichiometric reactions. The discovery of 
conditions employing AcCl as a procatalyst in the presence of HFIP provided evidence that 
HCl is an active catalytic species as well as providing a metal-free catalytic reaction. Prior 
to this discovery, the primary metal-free variations of the intramolecular Schmidt reaction 
used either TFA as the solvent or TfOH or ClSO3H as a stoichiometric reagent. 
The most favorable examples utilized attractively low loadings of catalyst, as low as 
2.5 mol % for the TiCl4-promoted version or 10 mol % AcCl. Although some of the least 
cooperative substrates needed as much as 100 mol % of "H

" catalyst added (via either the 
addition of 25 mol % TiCl4 or the straight-ahead addition of 100 mol % AcCl), we note that 
these conditions still measure up very favorably to those previously reported for analogous 
substrates. For example, the reaction of 1a in CH2Cl2 needed 4.5 equiv of TiCl4 to afford a 
67% yield,
13
 while the same reaction carried out with 20 mol % TiCl4 or 80 mol % AcCl 
gave a product yield of 87% or 90%, respectively. Although we did not quantitatively 
compare the purities of the products obtained in these various reactions, we note informally 
that the presently reported procedures tended to provide products requiring little additional 
purification. 
Catalyst sequestration by the lactam resulting in product inhibition was evidently 
proved by the single-crystal X-ray analysis of the lactam bound to catalyst.
 
In addition, 
1
H 
NMR experiments were performed to exhibit different degrees of product inhibition with 
different lactams. That such structurally similar lactams have substantially different effects 
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on the rate of a given reaction is provocative and might lead to increased understanding of 
the role of product inhibition in this and other reactions that afford lactam or amide 
products. Our effort to correlate the basicity and the extent of product inhibition exhibited 
by various lactams using NMR titration was unsuccessful. Elucidation of further 
mechanistic details such as the determination of initial reaction rate will be a part of 
prospective study. Extensions of this reaction methodology to other variants of the Schmidt 
reaction in terms of scope, applications, and limitations are subjects of the following 
sections in this chapter.  
A chiral BINOL-derived N-triflylphosphoramides has been used to promote the 
enantioselective desymmetrization in the intramolecular Schmidt reaction of 2-substituted-
2-azidopropylcyclohexane-1,3-dione.
18b
 However, 1.5 equiv of a chiral Brønsted acid was 
required to promote the reaction with acceptable yields and modest enantioselectivities. The 
chiral Lewis or Brønsted acid catalysts and ligands are often expensive and thus, their use 
in stoichiometric amounts will have limited applications, especially on an industrial scale. 
This substoichiometric variant sets up an avenue for the further development of asymmetric 
version of this chemistry utilizing a substoichiometric amount of chiral acid catalysts.  
Our laboratory has also recently reported the in situ conversion of halo ketones to 
azido ketones and their corresponding conversion to lactams via the intramolecular Schmidt 
reaction in a microwave-assisted continuous flow format.
64
 The main limitations of this 
continuous flow reaction system were the requirement of high temperature, limited 
substrate scope, and laborious isolation procedure. Suitable reaction conditions, such as the 
use of AcCl and HFIP could be instrumental in enabling a safe and efficient continuous 
flow Schmidt chemistry, which is currently under development in our laboratory. 
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1.3   Catalysis of the Intermolecular Schmidt Reaction of Ketones with TMSN3 
The Schmidt reaction represents one of the most powerful tools in organic chemistry 
for the conversion of carbonyl-containing compounds into their nitrogenous products.
6b,c
 
Since its discovery,
6a,65
 the Schmidt reaction has been widely used for the synthesis of 
amides or lactams from ketones (Scheme 15). This formal nitrogen-insertion process has 
received considerable attention in the past few decades and has evolved to include variants 
expanding its scope and utility.
6c,12-13,16b,17g,m,45a,b,47,66
 Although widely useful, a major 
limitation for the Schmidt reaction and its variants in general as discussed in the previous 
Section 1.2 is the necessity of superstoichiometric amounts of acid catalysts, often as a 
solvent, for the reaction to reach completion.
6b,c
 This limitation particularly hinders its 
application to large scale processes and to acid-sensitive substrates, and contributes to acid 
and metal waste impacting the environment. We discovered that a strong hydrogen-bond-
donating solvent, HFIP, promotes catalysis in the intramolecular Schmidt reaction (see 
Section 1.2).
25
 This result sparked our interest to revisit other variants of the Schmidt 
family in order to identify milder reaction conditions that utilize significantly less amounts 
of preferably metal-free acid catalyst, in the presence of HFIP. 
To achieve this objective, we primarily targeted the intermolecular Schmidt reaction 
of ketones with TMSN3. The Schmidt reaction of ketones with an azide (HN3, NaN3, or 
TMSN3) typically yields amides or lactams as the major product and tetrazoles as a minor 
byproduct. The formation of tetrazoles can generally be increased by using larger amounts 
of azides (Scheme 17), but the success of this strategy is highly dependent on the reaction 
conditions and the structure of ketones.
6c,67
 Hence, exploratory efforts were concentrated 
toward the optimization of reaction conditions in HFIP for the synthesis of tetrazoles. 
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Scheme 17. Schmidt Reaction of Ketones with Azides 
 
 
Tetrazoles have found widespread applications as organocatalysts,
68
 ligands,
69
 
precursors for other nitrogen-containing heterocycles,
70
 and in material science.
71
 From a 
medicinal chemistry perspective, tetrazoles have become increasingly relevant, especially 
5-substituted 1H-tetrazoles as carboxylic acid bioisosteres and 1,5-disubstituted tetrazoles 
as conformational mimics of cis amide bonds.
72
 In addition, tetrazole-based compounds 
possess numerous pharmacological activities such as anticancer
73
 and human growth 
hormone secretagogue (GHS).
72b,e,74
 Noteworthy examples include Losartan

, an 
angiotensin-II receptor antagonist for the treatment of hypertension
75
 and Cardiazole (PTZ, 
13a), a GABAA receptor antagonist and a prototypical anxiogenic drug
76
 (Figure 15).
72f
  
 
 
Figure 15. Representative examples of pharmacologically active tetrazoles. 
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Besides the Schmidt reaction of ketones with azides,
67,77
 numerous methods for the 
synthesis of substituted tetrazoles are known.
72b,c,78
 Some common strategies to prepare 1,5-
disubstituted tetrazoles entail intramolecular cycloaddition reaction of nitriles and 
azides,
72f,79
 reaction of in situ-generated nitrilium ion with TMSN3,
72d,78b
 reactions of 
amides with NaN3 in the presence of PCl5 or triflic anhydride through the intermediacy of 
imidoyl chlorides
80
 or triflates,
81
 and reaction of amides with TMSN3 in the presence of 
triphenylphosphine and diethyl azodicarboxylate.
80a,82
 Despite such advancements, most 
methods either require more than one step and/or high reaction temperatures (>100 °C) to 
obtain the tetrazole.
72b,78a,b,79c
 High reaction temperatures often pose a safety concern due to 
explosion hazards of azides and tetrazoles, especially on a large scale.
6c,78a,83
 As well, 
tedious work-ups due to the use of polar aprotic solvents such as DMF, long reaction times, 
and the requirement of the pre-designed starting materials often limits their applications as 
a general method for the synthesis of tetrazoles.  
On the contrary, the synthesis of 1,5-disubstituted tetrazoles (mostly fused) using the 
Schmidt reaction have received considerably less attention; the main limitations being the 
use of excess acid and long reaction times, often rendering it unsuitable for functionalized 
substrates.
67
 In addition, due to the instability and hazardous nature of HN3, its in situ 
generation from NaN3 in the presence of excess acid catalyst often presents a safety 
concern.
6c,83b,84
 The use of surplus acid catalyst also necessitates basic work-up to remove 
leftover acid components.
6c
 Trimethylsilyl azide (TMSN3) has emerged as a safer and 
convenient alternative to HN3 and NaN3 as an organic solvent soluble azide source for 
various synthetic transformations.
84b,85
 Our efforts to overcome some of these limitations by 
developing conditons that employ TMSN3 and substoichiometric catalyst for the synthesis 
of 1,5-disubstituted tetrazoles is described here. 
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Optimization of Reaction Conditions 
Prior to this work, the only report of a Schmidt reaction being carried out under 
substoichiometric catalysis was reported by Nishiyama, who described the synthesis of 
tetrazoles using 10 mol % SnCl2∙2H2O under solvent-free conditions.
77b
 Though attractive 
in terms of catalyst loading, the reaction only proceeded at higher temperature of 55 C 
over an extended period of 16 h. In our hands, following the procedure described by 
Nishiyama, the neat reaction of cyclohexanone 12a and TMSN3 with 10 mol % SnCl2∙2H2O 
at 55 C afforded tetrazole 13a in 87% yield compared to the reported yield of 71%
77b
 
(Table 9, entry 1). However, the reaction of 12a and TMSN3 with 5 mol % SnCl2∙2H2O in 
HFIP at 55 C turned out to be slightly less effective (entry 2). For the ease of reaction 
monitoring by TLC, we decided to carry out the optimization studies on 4-
phenylcyclohexanone 12b. Screening of different Lewis and Brønsted acids in HFIP 
identified TfOH as the optimal acid catalyst for this transformation; 25 mol % TfOH 
provided the maximum yield of 84% for tetrazole 13b and 7% of aminotetrazole 15b in just 
1 h (entries 3–9). The use of TfOH over other strong acids such as H2SO4 (commonly 
employed in the Schmidt reaction) offers an additional advantage in that it resists oxidation, 
minimizing side reactions in few cases.
86
 The reaction of 12b with 1.5 equiv of TMSN3 in 
HFIP afforded 13b as the major product, which was contrary to previous reports, where two 
or more equivalents of the azide nucleophile were generally needed to obtain a tetrazole as 
the major product (entry 3).
6b,67,77a
 HFIP seemed to play a role in promoting the formation 
of tetrazole over lactam, and the modest yield of 13b in this reaction was due to incomplete 
conversion. The reaction with iron(III) chloride in HFIP also delivered tetrazole 13b (entry 
7), which was interesting since the reaction of a ketone with 1.5 equiv of TMSN3 in DCE 
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has been reported to provide lactam.
84b
 Nevertheless, the reaction with 2.5 equiv of TMSN3 
in the presence of 50 L of water afforded lactam 14b as a major product (entry 10).  
 
Table 9. Optimization of Reaction Conditions for Tetrazole Synthesis
a,b
 
 
entry 
R 
12 
TMSN3 
(equiv) 
catalyst  
catalyst 
(mol %) 
solvent temp, time 
yield (%)
c
 
13 14 15 
1 H 3.0 SnCl2∙2H2O 10 neat 55 C, 16 h 87 (71)
d
 ND ND 
2 H 3.0 SnCl2∙2H2O 5 (CF3)2CHOH 55 C, 16 h 66 ND ND 
3 Ph 1.5 CF3SO3H 10 (CF3)2CHOH rt, 20 h 49 ca. 7
e
 ca. 6
e
 
4 Ph 2.5 CF3SO3H 20 (CF3)2CHOH rt, 2 h 75 ND ND 
5 Ph 2.5 CH3COCl
f
 20 (CF3)2CHOH rt, 18 h 31 ND ND 
6 Ph 2.5 BF3∙OEt2 20 (CF3)2CHOH rt, 22 h 16 ND ND 
7 Ph 2.5 FeCl3∙6H2O 20 (CF3)2CHOH rt, 22 h 60 ND ND 
8 Ph 3.0 ClSO3H
g
 20 (CF3)2CHOH rt, 2 h 51 ND ND 
9 Ph 2.5 CF3SO3H 25 (CF3)2CHOH rt, 1 h 84 ND 7 
10 Ph 2.5 CF3SO3H 25 (CF3)2CHOH
h
 rt, 5 h 13 53 ND 
11 H 3.0 CF3SO3H 5 (CF3)2CHOH 55 C, 16 h 85 ND ND 
12 Ph 2.5 SnCl2∙2H2O 25 neat rt, 2 h trace – – 
13 Ph 2.5 CF3SO3H 25 neat rt, 2 h 34 ca. 12
e
 ca. 3
e
 
a
To a solution or a suspension of ketone 12a (0.40 mmol) or 12b (0.20 mmol) and TMSN3 in 
(CF3)2CHOH (1.0 or 0.50 mL) or under neat conditions was added a catalyst and the reaction was 
allowed to stir at a specified temperature for a designated period of time unless otherwise 
mentioned (see the Experimental Section for details). 
b
Concn of ketone was ca. 0.40 M. 
c
Isolated 
yields. 
d
Yield in parentheses refers to the reported yield in ref. 77b. 
e
Corrected yield for 14b and 
15b from a slightly impure inseparable mixture as determined by 
1
H NMR. 
f
Could generate 20 mol 
% of HCl in situ (ref. 25). 
g
The reaction was carried out under argon atmosphere. 
h
50 L of 
deionized water was added before the addition of TfOH. ND = Not determined. 
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The reaction of 12a with 5 mol % TfOH in HFIP at 55 C provided comparable yield 
as with 10 mol % SnCl2∙2H2O without solvent (Table 9, cf. entries 11 and 1). Conversely, 
when the neat reaction of 12b was carried out with 25 mol % SnCl2∙2H2O at room 
temperature, only a trace amount of tetrazole 13b, in addition to unidentified byproducts 
and some unreacted 12b, were observed by crude 
1
H NMR (entry 12). Very poor 
conversion could be due to the heterogeneity of the reaction mixture as the catalyst 
(SnCl2∙2H2O) was insoluble. As per the report by Nishiyama, the reaction of ketones and 
TMSN3 with SnCl2∙2H2O at room temperature provided only trace amounts of tetrazoles for 
cyclic ketones and diazido intermediates for acyclic ketones.
77b
 As diazido compounds are 
high-energetic materials and explosive in nature, their build-up in a reaction should be 
avoided.
6c,87
 Moreover, it is best to avoid tin due to toxicity concerns.
88
 Still, the neat 
reaction of 12b and TMSN3 with 25 mol % TfOH at room temperature was somewhat 
effective and 13b was obtained in 34% yield along with a small amount of 14b and 15b as 
a mixture and unreacted 12b (entry 13). 
Mechanistically, the formation of aminotetrazole 15b is intriguing since likely 
migrations of both the carbonyl substituents occur via two consecutive Schmidt reactions to 
afford an amidinocarbonium ion I or aminonitrilium ion I' (Scheme 18). Subsequent 
addition of the third molecule of azide to either resonance structures of the reactive 
intermediate I leads to the formation of aminotetrazole 15b, the structure of which was 
confirmed by single-crystal X-ray diffraction analysis. Although substituted 5-
aminotetrazoles are known in the literature,
78a,89
 they are rarely prepared from the Schmidt 
reaction.
6b
 The formation of iminodihydrotetrazole (tautomer of aminotetrazole)
78b,90
 from 
benzophenone was the only example of such a Schmidt reaction.
6a,67
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Scheme 18. Proposed Mechanism for the Formation of Aminotetrazole 15b 
 
 
Substrate Scope and Limitations  
The scope and limitations of various cyclic and acyclic ketones were investigated 
under the optimized reaction conditions (Table 10). Unsubstituted and substituted 
cyclohexanones worked well, with 25 mol % TfOH delivering good yields of tetrazoles and 
<15% combined yields of aminotetrazoles and lactams (entries 1–4). Functionalized and 
sterically hindered cyclohexanones required 45–65 mol % TfOH to afford the desired 
transformation in good yields (entries 5–7). Given the possibility for the isomerization of an 
-center under the strong acidic conditions, the formation of a single tetrazole product 13f 
from L-menthone 12f with a high level of regio- and diastereoselectivity was remarkable 
(entry 6). On the other hand, both methyl and isopropyl substituents in 12f are equatorial. A 
similar buffering effect of HFIP was also observed in our previous work on the catalytic 
intramolecular Schmidt reaction (see Table 1 and the associated discussion in Section 
1.2).
25
 The requirement of 65 mol % TfOH for piperidone substrate 12g was in agreement 
with the decreased catalytic turnover due to an additional site (amide) of catalyst 
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deactivation (entry 7). Reactions of smaller and medium ring ketones provided moderate to 
excellent yields of tetrazoles (entries 8–10). In contrast, the reaction of aliphatic ketones 
required close to a stoichiometric amount of acid catalyst to afford the corresponding 
tetrazoles in moderate to good yields (entry 11–13). 
 
Table 10. Substrate Scope of Ketones for the Synthesis of Tetrazoles 
a,b
  
 
entry 
ketone 
1 
catalyst 
(mol %) 
time  
(h) 
yield (%)
c
 
2 3 4 
1 
 
25 2 
 
– 
 
 12a   13a (91%) ND 15a (4%) 
2 
 
25 2 
   
 12b   13b (84%) 14b (3%) 15b (9%) 
3 
 
25 2 
 
– 
 
 12c   13c (83%) ND 15c (9%) 
4 
 
25 1.5 
 
– 
 
 12d
d
   13d (83%)
e
 ND 15d (3%)
e
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entry 
ketone 
1 
catalyst 
(mol %) 
time  
(h) 
yield (%)
c
 
2 3 4 
5 
 
45 2.5 
  
 12e   13e (53%) 14e (3%)
f
 15e (7%)
f
 
6 
 
50 6 
 
– – 
 12f   13f (87%) ND ND 
7 
 
65 2.5 
 
 
– 
 12g   13g (50%)
g
 14g (14%)
g
 ND 
8 
 
50 6 
 
– 
 
 12h   13h (51%) ND 15h (7%) 
9 
 
60 2 
 
– 
 
 12i   13i (93%) ND 15i (ca. 2%) 
10 
 
60 2 
 
– – 
 12j   13j (86%) ND ND 
11 
 
80 3 
 
 
– 
 12k   13k (40%)
h
 14k (19%)
h
 ND 
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entry 
ketone 
1 
catalyst 
(mol %) 
time  
(h) 
yield (%)
c
 
2 3 4 
12 
 
90 6 
 
– – 
 12l   13l (74%)
i
 ND ND 
13 
 
90 6 
 
– – 
 12m   13m (66%) ND ND 
a
To a solution of ketone (0.40 mmol) and TMSN3 (1.0 mmol) in (CF3)2CHOH (1.0 mL) was 
added TfOH and the reaction was allowed to stir at room temperature for a specified period. 
b
Concn of ketone was ca. 0.40 M. 
c
Isolated yields. 
d
Mixture of isomers (ca. 95% major isomer). 
e
Corrected yield of the major isomer from a mixture of isomers (see the Experimental Section for 
details). 
f
Corrected yield for 14e and 15e from an inseparable mixture as determined by 
1
H NMR. 
g
Mixture of rotamers (see the Experimental Section for details). 
h
Corrected yield for 13k and 14k 
from an inseparable mixture as determined by 
1
H NMR (see the Experimental Section for 
details). 
i
Corrected yield of 13l, contains a small amount of byproduct (probably amide) as 
determined by 
1
H NMR and HRMS (See the Experimental Section). ND = Not determined.  
 
The Schmidt reaction of aromatic ketones, in particular chromanones and flavanones, 
has been extensively studied with respect to the synthesis of benzoheterazepine analogues 
as potential psychotropic agents.
77a,d,h,91
 The reaction of less reactive aromatic ketones 
requires excess acid catalysts, often as solvents, and long reaction times to provide lactam 
isomers as major products in most cases.
77a,h
 Although the reaction of flavanone 12n using 
our HFIP methodology required a full equiv of TfOH, the reaction time was much shorter 
and tetrazole 13n was furnished in moderate yield along with only a small amount of 
lactam regioisomers 14na and 14nb (Scheme 19). Moreover, three unusual products 16, 17, 
and 18 were obtained through intra- and intermolecular trapping of carbonium ion 
intermediates with different nucleophiles en route to the tetrazole and aminotetrazole 
products.  
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Scheme 19. Unusual Products Formation from Flavanone 12n 
 
 
Iminoether 16 was obtained through the trapping of iminocarbonium ion with HFIP. 
The formation of iminoesters as major products upon treatment of flavanone with NaN3 in 
TFA and trichloroacetic acid has been documented (see Scheme 33b; Section 1.7.2).
77a
 A 
cis-isomer J'' of an eight-membered amidinocarbonium ion formed after two sequential 
Schmidt reactions was intermolecularly trapped with TMSN3 leading to the formation of 
guanyl azide 17, which in theory could cyclize into the aminotetrazole. However, the 
corresponding aminotetrazole product was not observed (Scheme 20). This result was 
counterintuitive since cyclization into the aminotetrazole is generally the 
thermodynamically more favored process.
89a,92
 The thermal isomerization of 
aminotetrazoles is believed to proceed via a transient guanyl azide intermediates.
89a,92a
 
However, in our system, guanyl azide is favored, presumably due to stabilization of 17 by 
the aromatic ring or due to internal hydrogen bonding between the oxygen and guanidino 
"–NH–" group, which made its isolation possible.
78b,92a
 Moreover, the isolation of guanyl 
azide 17 provides strong evidence for the involvement of intermediate J (also see 
amidinocarbonium ion I and aminonitrilium ion I' in Scheme 18). Guanyl azide 17 was 
67 
 
subsequently subjected to copper-promoted click reaction with phenyl acetylene to provide 
a unique guanidino triazole 19 that further confirmed the structure of 17 (Scheme 21).  
 
Scheme 20. Proposed Mechanism for the Formation of Guanyl Azide 17 and 
Aminobenzoxazole 18 
  
 
Mechanistically fascinating was the formation of a small amount of 
aminobenzoxazole 18 (Schemes 19 and 20). Presumably, isomerization of cis-J to trans-J, 
followed by its intramolecular trapping by the oxygen atom present in the ring would 
generate an oxonium ion K. Bicyclic ring-opening of K affords a benzylic carbocation L, 
which upon hydration leads to 18. Formation of aminobenzoxazoles have also been 
reported by Misiti in few instances from the Schmidt reaction of substituted flavanones 
with NaN3.
91b
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Scheme 21. Copper-Catalyzed Alkyne-Azide Cycloaddition (CuAAC) of 17 to 
Guanidino Triazole 19 
 
 
The scope of this methodology was further extended to more challenging substrates 
such as benzylic and steroidal ketones (Schemes 22 and 23). Low yields of tetrazoles have 
been reported for the Schmidt reaction of -tetralone 12o with HN3.
77d
 The reaction of 12o 
in HFIP using the optimized conditions provided tetrazoles 13oa and 13ob in modest yield 
in addition to small amounts of lactams 14oa and 14ob, and aminotetrazoles 15oa and 15ob 
(Scheme 22). On the other hand, the reaction of 2-indanone 12p afforded a complex 
mixture, from which tetrazole 13p and aminotetrazole 15p were isolated in low yields 
(Scheme 22). Similarly, the reaction of adamantanone 12q gave the desired tetrazole 
product 13q in low yield; however, it was obtained in twice the yield than the reported 
procedure using NaN3 and methanesulfonic acid (MeSO3H; Scheme 23).
93
 Carbonitrile 20 
was obtained as a major product in this reaction, which was in consistent with the literature 
report and resulted likely from either diazoiminium or nitrilium ion intermediates via 
fragmentation.
93
 In addition, a small amount of an inseparable mixture of lactam 14q and 
aminotetrazole 15q was obtained along with some unreacted 12q. The reaction of trans-
androsterone 12r with 1 equiv of TfOH gave a mixture of several unidentified and 
inseparable byproducts from which it was possible to isolate a single tetrazole isomer 13r 
in ca. 48% corrected yield and ca. 94% purity (Scheme 23). 
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Scheme 22. Schmidt Reaction of Benzylic Ketones 
 
 
Scheme 23. Schmidt Reaction of Adamantanone 12q and trans-Androsterone 12r 
 
 
The methodology was found to be substrate dependent (Scheme 24). The reaction of 
cyclobutanone 12s showed a trace amount of tetrazole in an isolated mixture. An initial 
effervescene indicative of a nitrogen gas evolution suggests divergence to a non-productive 
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reaction pathway such as fragmentation (similar to that observed for 12q). This might have 
led to the formation of volatile byproducts as no tractable product was observed in this 
reaction. The reaction of bicycloheptenone 12t resulted in a complex mixture. In a similar 
way as 12s, the reaction of norcamphor 12u gave an impure sample of a small amount of 
what is believed to be a single tetrazole isomer 13u. Additionally, a mixture of several 
byproducts was obtained. The reaction of 1-phenylisatin 12v gave a mixture of several 
unidentified byproducts of which the non-polar byproduct was the major component. 
 
Scheme 24. Unsuccessful Examples Attempted 
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Conclusions 
The current protocol for the synthesis of tetrazoles has addressed many limitations of 
the older methods such as high temperatures, making it superior in terms of operational 
practice. The use of a considerably less amount of the acid catalyst and short reaction times 
for most cases were the key highlights of this methodology. A relatively broad substrate 
scope was also demonstrated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
1.4   Catalysis of the Intermolecular Schmidt Reaction of Aldehydes with TMSN3 
The importance of nitriles as a versatile functional group not only lies in their 
synthetic utility as building blocks or precursors to other functionalities such as acids, 
amines, amides, aldehydes, and tetrazoles but also because they are important structural 
motifs in many natural products,
94
 pharmaceuticals,
95
 agrochemicals, dyes, etc.
96
 In 
pharmaceuticals, aryl nitriles contributes heavily to the total number of nitrile-containing 
drugs, for examples, letrozole, pericyazine, escitalopram, dapivirine, and the list goes on 
(Figure 16).
95
 Nitrile groups on the aromatic ring can serve many functions such as ketone 
bioisosteres and increased resistance of aromatic system to the oxidative metabolism.
95
 
 
 
Figure 16. Drugs containing aryl nitriles. 
 
General strategies for the synthesis of aryl nitriles involve the Sandmeyer reaction of 
aryldiazonium salts,
96d,97
 Rosenmund–von Braun reaction from aryl halides,
97c,98
 transition 
metal-catalyzed cyanation of aryl halides
99
 or direct cyanation through C–H bond 
functionalization of arenes,
100
 and ammoxidation of methyl arenes, which is a preferred 
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industrial process.
101
 Major drawbacks for most of these processes are the use of 
stoichiometric to excess amounts of toxic cyanide source, generation of heavy metal waste, 
requirement of relatively high temperatures (>100 °C), long reaction times, requirement of 
a reactive aryl halide source (aryl iodides and bromides are generally preferred), and the 
scarcity of the commercially available substrates such as methyl arenes.
99c,102
  
Given the limitations for these existing protocols, development of a mild and 
practically simple process for the synthesis of aryl nitriles would be attractive. In a similar 
sense as described in Section 1.3 for the outcome of the Schmidt reaction of ketones with 
an azide, the Schmidt reaction of aromatic aldehydes is known to provide a mixture of 
nitriles and formanilides (Scheme 25a).
103
 Due to such non-selective transformations, the 
utility of the Schmidt reaction for the synthesis of aromatic nitriles has been limited. 
Recently, Prabhu and co-workers demonstrated that the Schmidt reaction of aldehydes with 
NaN3 in the presence of TfOH as a catalyst and ACN as solvent, exclusively affords 
corresponding nitriles (Scheme 25b).
66j
 In order to achieve this chemoselective reaction, 3 
equiv of TfOH was minimally required for an instantaneous reaction to obtain a high yield 
of the aromatic nitrile. A conversion of mere 6% was observed when 1.5 equiv of TfOH 
was used during the optimization studies. The utility of this chemoselective Schmidt 
process would improve if substoichiometric amount of acid catalyst could be used. In order 
to further expand the scope of the methodology developed for the Schmidt reaction in HFIP 
(see Sections 1.2 and 1.3), we sought to test those reaction conditions on aromatic 
aldehydes. 
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Scheme 25. Intermolecular Schmidt Reaction of Aromatic Aldehydes 
 
 
Optimization of Reaction Conditions 
As reported by Prabhu,
66j
 we also began our optimization on 4-nitrobenzaldehyde 21a 
with NaN3 and TfOH, however with HFIP as a solvent instead of ACN (Table 11, entry 1). 
Low conversion to 22a with 50 mol % TfOH (entry 1) and 80 mol % AcCl (entry 2) 
indicated a solubility issue with NaN3 in HFIP, resulting in low reactivity. Changing to a 
soluble azide source such as TMSN3 drastically improved the yield with 25 mol % of 
catalysts (entries 3 and 4). However, reactions did not go to completion even after longer 
periods and few polar byproducts were observed by TLC during reaction monitoring. Even 
though the reaction with 30 mol % TfOH offered complete conversion in 2 h, only a 
modest yield was obtained due to the formation of polar unidentified byproducts (entry 5). 
Gratifyingly, a 1:1 combination of HFIP and ACN as a solvent significantly increased the 
yield, but complete conversion was not observed even after 4 h (entry 6). Finally, the 
reaction of 21a with 40 mol % TfOH proved to be optimal, providing a slightly better yield 
of 22a along with a much shorter reaction time (entry 7). 
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Table 11. Optimization of the Schmidt Reaction of 4-Nitrobenzaldehyde 21a
a,b
  
 
entry 
azide 
source 
azide 
(equiv) 
catalyst 
catalyst 
(mol %) 
solvent 
time  
(h) 
NMR ratio 
(22a:21a)
c
 
yield (%)
d 
22a  
1 NaN3 1.5 CF3SO3H 50 (CF3)2CHOH 16 30:70
e
 ND 
2 NaN3 1.5 CH3COCl
f
 80 (CF3)2CHOH 8 19:81 ND 
3 TMSN3 1.5 TiCl4
g 
25 (CF3)2CHOH 24 ND 75 
4 TMSN3 1.5 CF3SO3H 25 (CF3)2CHOH 8 ND 68 
5 TMSN3 2.0 CF3SO3H 30 (CF3)2CHOH 2 ND 65
h
 
6 TMSN3 2.0 CF3SO3H 30 
(CF3)2CHOH/ 
CH3CN (1:1) 
4 ND 81 
7 TMSN3 2.0 CF3SO3H 40 
(CF3)2CHOH/ 
CH3CN (1:1) 
45 min ND 83 
a
To a solution of 4-nitrobenzaldehyde 21a (0.25 or 0.50 mmol) and azide in a solvent (0.50, 1.0, or 
2.0 mL) was added a catalyst and the reaction was allowed to stir at rt (23 or 25 °C) for a 
designated period of time, unless otherwise mentioned. 
b
Concn of 21a was ca. 0.25 or 0.50 M. 
c1
H 
NMR ratio determined on a crude reaction mixture. 
d
Corrected isolated yields of 22a (22a was 
contaminated with a small amount (ca. 3–6%) of 21a). 
e
Other byproducts were also observed. 
f
Capable of generating 80 mol % HCl in situ. 
g
A 1.0 M solution of TiCl4 in CH2Cl2 was used. 
h1
H 
NMR only showed peaks of 22a. ND = Not determined 
 
Substrate Scope 
Various aromatic aldehydes were subjected to the optimized reaction conditions 
(Table 12). In general, a variety of aldehydes containing different functional groups were 
well tolerated and their corresponding nitriles were obtained in good to excellent yields. 
Benzaldehydes containing electron-withdrawing (entries 1 and 2) and electron-donating 
groups (entries 3–5) underwent a facile reaction to furnish the corresponding nitriles. Even 
cinnamaldehyde 21h reacted smoothly to afford cinnamonitrile 22h in excellent yield 
(entry 8).  
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Table 12. Scope of Aromatic Aldehydes
a,b
  
 
entry 
aldehydes 
21 
time  
(min) 
nitriles 
22 
yield  
(%)
c
 
1 
 
45 
 
83
d
 
 21a  22a  
2 
 
30 
 
78 
 21b  22b  
3 
 
30 
 
95 
 21c  22c  
4 
 
30 
 
82 
 21d  22d  
5 
 
20 
 
86 
 21e  22e  
6 
 
20 
 
71 
 21f  22f  
7 
 
30 
 
68 
 21g  22g  
8 
 
45 
 
90 
 21h  22h  
a
To a solution of aldehyde 21 (0.50 mmol) and TMSN3 (1.0 mmol) in a 
premixed (CF3)2CHOH/CH3CN solvent mixture (2.0 mL, 1:1) was added TfOH 
(0.20 mmol) and the reaction was allowed to stir at rt for a designated period. 
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b
Concn of aldehyde was ca. 0.25 M. 
c
Isolated yields. 
d
Contains ca. 4% of 
unreacted 21a (same as entry 7 in Table 3; see the Experimental Section for 
details). 
 
After successfully demonstrating the utility of this methodology for the synthesis of 
aromatic nitriles, we then focused on preparing tetrazoles from aliphatic aldehydes and 
TMSN3.
104
 The reaction of hydrocinnamaldehyde 21i with 3 equiv of TMSN3 in the 
presence of 25 mol % TfOH resulted in a complex mixture from which 3-
phenylpropionitrile 22i was isolated in low yield (Scheme 26). The formation of the 
complex mixture could be possibly due to the use of excess TMSN3 and impure 21i, which 
was realized later. Moreover, the presence of tetrazole 23 in the mixture could not be 
determined. 
 
Scheme 26. Intermolecular Schmidt Reaction of Aliphatic Aldehyde 21i with TMSN3 
 
 
Conclusions 
We have clearly shown that HFIP promotes this acid-catalyzed intermolecular 
Schmidt reaction, allowing for the use of only 40 mol % TfOH for the conversion of 
aromatic aldehydes to aromatic nitriles. A wide range of functional group compatibility was 
observed. Additional optimization of the reaction conditions might facilitate the extension 
of the scope to aliphatic aldehydes.  
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1.5  Improved Protocol for the Intermolecular Schmidt Reaction with Hydroxyalkyl 
Azides 
Boyer was the first to utilize hydroxyalkyl azides in the intermolecular Schmidt 
reaction with aromatic aldehydes to afford oxazolines and dihydrooxazines (see Section 
1.1; Boyer reaction).
11a,b
 Professor Aubé further exploited this in situ tethering of 
hydroxyalkyl azides (azido alcohols) to ketones for the synthesis of N-hydroxyalkyl 
lactams (also known as the Boyer–Aubé reaction;
83b
 Scheme 27a).
66c,105
 Mechanistically, 
the hydroxyl group of a hydroxyalkyl azide 24a attacks the activated carbonyl group of 12a 
promoting the formation of a hemiketal M, which upon dehydration generates an oxonium 
ion intermediate N (Scheme 27b).
66c,g,105a
 Subsequent intramolecular attack by the azido 
group results in a hemiaminal species O. Antiperiplanar migration of one of the alkyl 
groups with concomitant loss of N2 then yields an iminium ether intermediate P that upon 
hydrolysis with aqueous base affords N-hydroxyalkyl lactam 25a, which could be seen as 
the formal product of direct insertion of the azide end of 24a into the ketone 12a. This 
intermolecular Schmidt variant has been utilized for nitrogen asymmetric ring-expansion 
reactions,
66g,106
 construction of -turn-like peptidomimetic libraries,107 and syntheses of 
functionalized lactams
108
 and N-alkyl heterocycles
66i,109
 via nucleophilic additions to 
iminium ethers. The increased reactivity and stability of hydroxyalkyl azides compared to 
alkyl azides under acidic conditions has considerably expanded the scope and utility of this 
variant. 
 
 
 
 
79 
 
Scheme 27. Intermolecular Schmidt Reaction of Ketones with Hydroxyalkyl Azides 
 
 
Typically, the reaction of ketones with hydroxyalkyl azides requires 2–5 equiv of 
BF3∙OEt2 in DCM to achieve successful iminium ether formations over extended periods 
(Scheme 27a).
66c,105,110
 However, in principle, only 1 equiv of acid catalyst should be 
sufficient to promote the reaction to completion as only 1 equiv of the counter ion (X

) is 
required to stabilize the isolable iminium ether intermediate (Scheme 27b).
66c,105a
 Thus, 
carrying out this transformation with 1 equiv of Brønsted acid catalyst in a short period is 
attractive, both in terms of metal-free transformation and acid waste minimization. It would 
also provide an easy access to the isolation of iminium ethers for further functionalization 
when necessary; in this case, its hydrolysis to afford N-hydroxyalkyl lactam. 
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Optimization of Reaction Conditions on Ketones 
We initially utilized the substoichiometric amount of BF3∙OEt2 and TiCl4 to promote 
the reaction of cyclohexanone 12a with 2-azidoethan-1-ol 24a in the presence of HFIP 
(Table 13, entries 1 and 2). However, low to partial conversion to the desired lactam 25a 
was observed suggesting the necessity for a full equiv of the acid catalyst. Reaction with 25 
mol % TiCl4 (capable of generating a full equiv of HCl) resulted in a satisfactory yield of 
25a (entry 3). Employing 1 equiv of TfOH for the reaction of 12b with 24a in HFIP turned 
out to be preferable, affording a quantitative yield of the corresponding lactam 25b. 
Substrate scope of diverse ketones with these conditions has been further investigated by 
Manwika Charaschanya. 
 
Table 13. Preliminary Optimization Studies for the Intermolecular Schmidt Reaction 
of Ketones with 2-Azidoethanol 24a in HFIP
a,b
  
 
entry 
R 
12 
catalyst 
catalyst 
(mol %) 
solvent temp, time 
yield (%)
c
 
25 
1 H BF3∙OEt2 25 (CF3)2CHOH rt, 30 min 20 
2 H TiCl4
d
 10 (CF3)2CHOH 25 °C, 24 h 40 
3 H TiCl4
d 
25 (CF3)2CHOH rt, 30 min 76 
4 Ph CF3SO3H 100 (CF3)2CHOH rt, 1 h 99 
a
To a solution of ketone 12 (1.0 equiv) and 2-azidoethanol 24a (1.3 or 1.5 equiv) in 
HFIP (1.6 or 2.5 mL) was added a catalyst (0.10–1.0 equiv) and the reaction mixture 
was stirred at a specified temperature for a designated period of time. Further 
hydrolysis with a saturated aqueous NaHCO3 solution for 6–20 h followed by 
purification afforded 25. 
b
Concn of 12 was ca. 0.25 or 0.40 M. 
c
Isolated yields. 
d
10 and 
25 mol % TiCl4 could generate 40 and 100 mol % HCl in situ, respectively. 
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Limitations with Aromatic Aldehydes 
Boyer′s initial work for the synthesis of oxazolines and dihydrooxazines from 
aromatic aldehydes and hydroxyalkyl azides in H2SO4 have met several limitations.
11a,b
 
Professor Aubé showed that the modification of the original reaction conditions by 
employing Lewis acid such as BF3∙OEt2 substantially extended the scope of the process.
66e
 
The modified reaction conditions required 2 equiv of BF3∙OEt2 to provide good to 
quantitative yields of oxazolines and dihydrooxazines from a variety of aldehydes. We 
sought to optimize the modified reaction conditions by employing HFIP with a hope to 
utilize a substoichiometric amount of an acid catalyst. In general, aldehydes are more 
reactive than ketones and the reaction of aldehydes with hydroxyalkyl azides does not 
involve the formation of iminium ether. Thus, one could envision that less than 1 equiv of 
the acid catalyst should be capable of promoting the desired reaction. 
 
Table 14. Initial Screening of Conditions for the Intermolecular Schmidt Reaction of 
Aldehydes with 3-Azidopropanol 24b in HFIP
a,b
 
 
entry 
R 
21 
catalyst 
catalyst 
(mol %) 
solvent temp, time 
yield (%) 
26 
1 NO2 BF3∙OEt2 25 (CF3)2CHOH rt, 6 h ca. 9
c
 
2 NO2 TiCl4
d
 25 (CF3)2CHOH rt, 6 h ca. 5
e
 
3 NO2 CF3SO3H
 
25 (CF3)2CHOH rt, 6 h ca. 12
c
 
4 H CF3SO3H 10 (CF3)2CHOH rt, 24 h ca. 10
f
 
a
To a solution of aldehyde 21 (0.20 mmol) and 3-azidopropanol 24b (0.30 mmol) in 
HFIP (0.50 mL) was added a catalyst (0.020–0.050 mmol) and the reaction mixture 
was allowed to stir at rt for a designated period. 
b
Concn of 21 was ca. 0.40 M. 
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c
Isolated yield (contains trace amounts of unidentified impurities). 
d
Could generate 
100 mol % HCl in situ. 
e
Corrected isolated yield (contains ca. 50% of unidentified 
impurities). 
f
Corrected isolated yield (contains ca. 10% of unidentified impurities). 
 
Scheme 28. Competitive Hemiacetal Formation of Aldehydes 21 
 
 
Given our success on the reaction of ketones with 24a in HFIP (see Table 13 above), 
we carried out a similar optimization study on aromatic aldehydes 21 with 3-azidopropan-
1-ol 24b for the synthesis of dihydrooxazines 26 (Table 14). Unfortunately, screening of 
few acid catalysts in HFIP only resulted in very low yields of 26 (entries 1–4). A potential 
reason for the low reactivity of the aromatic aldehydes under these conditions could be 
attributed to facile formation of a relatively stable hemiacetal 27 with HFIP compared to 
the formation of hemiacetal 28 with 24b (Scheme 28). Hence, the intermolecular Schmidt 
reaction with hydroxyalkyl azides in HFIP has so far been limited to ketone substrates. 
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Conclusions 
We have identified an improved protocol for the synthesis of N-hydroxyalkyl lactams 
from ketones. The protocol is attractive even with its use of a full equiv of TfOH. High 
yields and short reaction times were additional main features of this HFIP-promoted 
reaction. We found that this reaction methodology was limited to ketone substrates and its 
utilization for the synthesis of dihydrooxazines from aldehydes was unfruitful.             
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1.6   Intermolecular Schmidt Reaction with Alkyl Azides 
As discussed previously (see Section 1.1; Boyer reaction), alkyl azides are known not 
to react with ketones under standard Schmidt conditions.
9-10
 Severe limitations were also 
observed for the intermolecular Schmidt reaction of aromatic aldehydes with alkyl azides.
11
 
Professor Aubé reported for the first time the TiCl4-catalyzed Schmidt reaction of n-hexyl 
azide and benzyl azide on facile cyclic ketones to give N-substituted lactams.
66a
 Although 
useful, the reaction suffered from a very limited substrate scope. Similarly, for the Schmidt 
reaction of alkyl azides with aliphatic aldehydes, some improvements were achieved; 
however, with a very narrow substrate scope to access useful quantities of amides.
111
 Given 
our success in the development of mild and efficient reaction conditions employing HFIP 
for the different variants of Schmidt family (see Sections 1.2–1.5), we decided to explore 
those conditions for the intermolecular Schmidt reaction with alkyl azides. 
 
Table 15. Exploration of Reaction Conditions for the Intermolecular Schmidt 
Reaction of Benzaldehydes 21 with Alkyl Azide 29
a,b
  
 
entry 
R 
21 
catalyst 
catalyst 
(mol %) 
solvent temp, time 
reaction 
outcome
c,d
 
1 H TiCl4 10 (CF3)2CHOH 
25 °C, 16 h to 
50 °C, 7 h 
no reaction 
2 OH CF3SO3H 50 (CF3)2CHOH rt, 5 h no reaction 
3 OH CF3SO3H
 
50 
(CF3)2CHOH/ 
CH3CN (1:1) 
rt, 5 h no reaction 
4 OH CF3SO3H 50 
(CF3)2CHOH/ 
CH3CN (1:4) 
rt, 5 h no reaction 
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a
To a solution of benzaldehyde 21 (0.17 mmol) and (3-azidopropyl)benzene 29 (0.33 
mmol) in solvent (0.83 mL) was added a catalyst and the reaction was allowed to stir at 
a specified temperature for a designated period of time. 
b
Concn of 21 was ca. 0.20 M. 
c1
H NMR of a crude reaction mixture was used to determine the reaction outcome. 
d
Trace amounts of unidentified byproducts were observed. 
 
Scheme 29. Unsuccessful Attempts towards the Intermolecular Schmidt Reaction of 
Ketones with Alkyl Azide 29 
 
 
Initial exploration using substoichiometric amounts of acid catalysts in HFIP were 
disappointing as no amide products 30 were obtained when benzaldehydes 21 were reacted 
with (3-azidopropyl)benzene 29 (Table 15). Replacing the aldehydes with cyclic ketones 
12b and 12q also resulted in similar failure (Scheme 29). The 
1
H NMR of a crude reaction 
mixture of 12b with 29 apparently showed the presence of a trace amount of product 31 
along with other byproducts. Since initial results were discouraging, no further efforts were 
made in these regards. 
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1.7   Development of New Variants in the Schmidt Family  
1.7.1 Decarboxylative Condensation of Azides and -Keto Carboxylic Acids  
As discussed in the introduction of this chapter (Section 1.1), the conventional 
approach for the synthesis of amides involves the condensation of amines and carboxylic 
acids. Although various methods for amide formation have been introduced, the discovery 
of the native chemical ligation of C-terminal peptide thioesters and N-terminal cysteines 
has revolutionized the field of protein synthesis.
4,112
 In 2006, Bode and co-workers 
discovered a chemoselective approach to amide synthesis by the decarboxylative 
condensation of N-alkylhydroxylamines and -keto carboxylic acids (Scheme 30a).113 The 
efficiency of this process was reflected in the mild reaction conditions, which requires no 
reagents or catalysts, and the fact that only water and carbon dioxide were generated as 
byproducts. Furthermore, this strategy was applied to the chemoselective ligation of 
unprotected-peptide fragments. Alternatively, Fang and co-workers reported the 
decarboxylative amidation of -keto carboxylic acids and alkylamines using iodine as an 
oxidant (Scheme 30b).
114
 This methodology was successfully applied for the amidation of 
monosaccharides containing -keto carboxylic acids such as sialic acid with simple 
alkylamines.  
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Scheme 30. Decarboxylative Amidation of -Keto Acids 
 
 
In N-alkylhydroxylamines (R
2
NHOH), N-iodinated alkylamines (R
2
NHI), and alkyl 
azides (R
2
N3), the nitrogen has a same oxidation state of –1. Hence, it should be possible to 
employ alkyl azides for the decarboxylative amidation reaction of -keto carboxylic acids 
in the presence of an acid catalyst (Scheme 30c). To this hypothesis, we began our initial 
optimization study on pyruvic acids 33 with n-hexyl azide 34 (Scheme 31). Running the 
amidation reaction of 33 and 34 under Bode′s conditions (DMF, 40 °C) did not afford any 
amide product 35. While working with phenylpyruvic acid 33b, it was observed that 33b 
predominantly exists in enol form 33ba (Scheme 31). The combination of enolization of -
keto acids 33 and decreased nucleophilicity and volatile nature of 34 resulted in an 
unproductive reaction outcome. Even under strong Lewis acid conditions by employing 3 
equiv of TiCl4, no product formation was observed.   
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Scheme 31. Initial Failed Optimization towards the Decarboxylative Amidation 
Reaction of -Keto Acids 33 and n-Hexyl Azide 34 
 
 
In order to avoid the enolization process, phenylglyoxylic acid 36 was used in the 
decarboxylative amidation reaction along with 29, a non-volatile source of alkyl azide. A 
short screening of different acid catalysts in stoichiometric to excess amount under various 
conditions showed that the desired amidation reaction was very sluggish (Table 16). The 
desired amide product, N-(3-phenylpropyl)benzamide 30j was only obtained in a very low 
yield upon reaction of 36 and 29 in the presence of excess BF3∙OEt2 (entry 1). Running the 
reaction with other acid catalysts, at higher temperature or both in order to drive the 
reaction to completion either resulted in no reaction or the formation of a complex mixture 
(entries 2–7). 
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Table 16. Optimization Studies for the Decarboxylative Amidation Reaction
a
 
 
entry catalyst 
catalyst 
(equiv) 
solvent temp, time 
yield (%) 
30j 
1 BF3∙OEt2 3.5 CD2Cl2 rt, 52 h 16
b
 
2 BF3∙OEt2 3.5 CD2Cl2 100 °C (W), 0.5 h mixture
c
 
3 CF3SO3H 3.5 CD2Cl2 rt, 2 h mixture
c
 
4 Sc(OTf)3
 
0.95 CH3CN rt to 160 °C (W), 6.7 h complex mixture 
5 CF3CO2H 2.0 CH2Cl2 rt, 24 h to 40 °C, 48 h no reaction
d
 
6 none – H2O/THF 100 °C (W), 1.7 h no reaction
d
 
7 SnCl4 4.0 CH2Cl2 rt, 24 h no reaction
d
 
a
To a solution of phenylglyoxylic acid 36 (0.20–0.33 mmol) and (3-azidopropyl)benzene 29 
(0.40–0.45 mmol) in solvent (1.0–2.5 mL) was added a catalyst and the reaction mixture was 
allowed to stir at a specified temperature for a designated period of time. 
b
Isolated yield. 
c
Mixture of unidentified byproducts/impurities along with unreacted starting materials. 
d
Mostly 
unreacted starting materials were observed by TLC analysis.  
 
Scheme 32. Failed Decarboxylative Amidation Reaction of 36 and TMSN3 
 
 
A reaction of 36 and TMSN3, a stronger nucleophilic azide source with a 
substoichiometric amount of TfOH in HFIP did not yield any desired benzamide 37 
(Scheme 32). Mostly unreacted 36 in addition to trace amounts of unidentified 
byproducts/impurities were observed upon crude 
1
H NMR analysis. So far we have been 
unable to find suitable conditions for the decarboxylative amidation reaction of -keto 
acids and azides. 
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1.7.2 Intercepted Schmidt Reaction 
The Schmidt reaction of a ketone with an azide involves the formation of a 
iminocarbonium ion intermediate (Schemes 2 and 33a).
6c
 In a typical example, cyclic 
ketone such as cyclohexanone reacts with HN3 under acidic conditions to generate 
diazoiminium ion Q. The concurrent migration of one of the alkyl substituent and the loss 
of nitrogen gas yields a iminocarbonium species R, which can also exist as a nitrilium ion 
R' (although strained in case of cycloheptyne
115
). The iminocarbonium ion could be 
trapped either with water to afford a lactam (caprolactam in this case) or with another 
molecule of the azide to yield a tetrazole (Scheme 33a). Traditionally, in the Schmidt 
reaction, iminocarbonium ions have only been intercepted with water and azide 
nucleophiles. Besides our own encounter of the interception of a iminocarbonium ion with 
HFIP to generate iminoether 16 (see Scheme 19; Section 1.3), we could only find one 
report where a iminocarbonium ion was incidentally trapped with trifluoroacetate and 
trichloroacetate ions to give iminoesters (Scheme 33b).
77a
 Iminocarbonium or nitrilium ions 
have also been implicated in the Beckmann rearrangement.
116
 These intermediates have 
been trapped with nucleophiles other than water in both intramolecular and intermolecular 
fashions to generate useful variants of the Beckmann reaction (Scheme 34).
5b,116-117
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Scheme 33. Trapping of Iminocarbonium Ion Intermediate in the Schmidt Reaction 
 
  
 Scheme 34. Representative Examples of Intercepted Beckmann Reactions 
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We found an opportunity to discover and develop the intercepted Schmidt reaction 
from the niche in scientific literature. One could envisage the utility of this variant and the 
products resulting from the trapping of iminocarbonium ions by a variety of nucleophiles, 
further expanding the scope of the Schmidt reaction. We put our thoughts into action and 
ran reactions with three different nucleophiles to test our premise (Scheme 35). The 
reaction was performed with a premixed solution of 4-phenylcyclohexanone 12b, TMSN3, 
and a nucleophile in HFIP and then treated with a substoichiometric amount of TfOH. The 
reaction with allyl silane nucleophile in theory should have led to monoallyl azepine 38, 
diallyl azepane 39, or both (Scheme 35a). However, desired allyl substituted products were 
not observed and a small amount of tetrazole product 13b was obtained along with mixtures 
of unidentified byproducts. Similarly, we had hoped to get the triazole product 40 from the 
cycloaddition of diazomethane to the iminocarbonium ion (Scheme 35b). Nevertheless, 
instead of the desired triazole 40, again tetrazole 13b arising from the cycloaddition of 
another molecule of TMSN3 to the iminocarbonium ion was obtained in a small amount. 
We observed a violent exothermic reaction during the addition of diazomethane to the 
reaction mixture, which suggests that HFIP reacted with diazomethane to form a methyl 
ether of HFIP.
118
 It is very probable that none of the diazomethane was left in the reaction 
mixture to form the anticipated cycloaddition product 40.  
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Scheme 35. Interception of the Iminocarbonium Ion Generated from 4-Phenyl-
cyclohexanone 12b and TMSN3 
 
 
On the contrary, we were delighted to observe the expected furan-substituted azepine 
product 41, when the reaction was carried out with a furan nucleophile (Scheme 35c). 
Although, 41 was obtained in low yield, its formation validated the proof of concept that 
the interception of the iminocarbonium ion in the Schmidt reaction is feasible. Future 
efforts will be directed toward identifying suitable conditions with a hope to achieve a 
broader substrate scope and high yields for the intercepted products. 
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1.8   Experimental Section 
General Information. Reactions were performed under an inert atmosphere (argon 
or nitrogen) either in flame-dried or oven-dried glassware, or glass sample vials with TFE-
lined cap. The stainless steel needles used for handling anhydrous solvents and reagents 
were oven dried and flushed with nitrogen prior to use. Plastic syringes were flushed with 
nitrogen before use. All chemicals were used as received from commercial source without 
further purification, except L-menthone and -tetralone, which were purified on RediSep 
normal-phase silica flash columns using a CombiFlash Rf system (Teledyne Isco). A new 
container of HFIP was used. New containers were also used for most catalysts such as 
BF3∙OEt2, TiCl4, and TfOH. Methylene chloride (CH2Cl2) and THF were dried by passage 
through neutral alumina columns using a commercial solvent purification system prior to 
use. TLC was performed using commercial glass-backed silica plates (250 microns) with an 
organic binder. Preparative TLC was carried out using silica gel GF TLC plates (UV 254 
nm, 1000 microns). Visualization was accomplished with UV light and Seebach’s stain or 
aqueous KMnO4 by heating. Purification was achieved by flash chromatography either on a 
standard grade silica gel (40–63 m particle size, 230  400 mesh) with compressed 
nitrogen as a source of positive pressure or on a CombiFlash Rf (automated flash 
chromatography/medium pressure liquid chromatography, MPLC) system with RediSep 
normal-phase silica flash columns (4, 12, 24, 48, or 80 g). IR spectra were acquired as thin 
films or solids. All NMR spectra (
1
H, 
13
C, APT, COSY, HSQC, HMBC, and NOESY) were 
acquired on either a 400 MHz or a 500 MHz with a dual carbon/proton cryoprobe 
instrument. NMR samples were mostly recorded in deuterated chloroform (CDCl3) with 
few exceptions, where deuterated methanol (CD3OD), deuterated HFIP ((CF3)2CDOD), and 
deuterated DCM (CD2Cl2) were used. Chemical shifts are reported in parts per million 
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(ppm) and are referenced to the center line of the solvent (For CDCl3,  7.26 ppm for 
1
H 
NMR and 77.23 ppm for 13C NMR, and for CD2Cl2,  5.32 ppm for 
1
H NMR and  54.00 
ppm for 
13
C NMR). Coupling constants are given in Hertz (Hz). CDCl3 with 
tetramethylsilane as an internal standard (TMS,  0.00 ppm for 1H NMR) was used to 
record NMR for Job plots and NMR titration experiments. HRMS data were collected with 
a LCT Premier time-of-flight mass spectrometer and an electrospray ion source. Melting 
points were determined in open capillary tubes using an automated melting point apparatus 
and are uncorrected. Reaction mixtures were concentrated under nitrogen gas using a 
sample concentrator. Microsyringes (flushed with nitrogen prior to use) or calibrated 
micropipettes were used to measure and deliver volumes between 1.00–100 L. Single-
crystal X-ray analyses were performed using Cu K radiation ( = 1.54178 Å) with either 
Bruker APEX2 or Platinum 135 CCD detector. X-rays were provided by a Bruker 
MicroStar microfocus rotating anode equipped with Helios multilayer optics.  
In general, complete spectroscopic data (
1
H NMR, 
13
C NMR, IR, and HRMS) are 
provided for compounds, which are reported in the literature with partial or no 
characterization data. 
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Experimental Procedures for Section 1.2 
List of Known Compounds. The following substrates, 2-(3′-azidopropyl)-
cyclopentanone (1a),
12-13
 2-(3′-azidopropyl)-2-methylcyclohexane-1,3-dione (1b),
18a
 2-(3′-
azidopropyl)cyclohexanone (1c),
12-13
 ethyl 1-(3′-azidopropyl)-2-oxocyclohexane-
carboxylate (1d),
12-13
 3-(3′-azidopropyl)-3,4-dihydronaphthalen-2(1H)-one (1g),
12-13,119
 2-
(2′-(azidomethyl)allyl)cyclohexanone (1h),
17m,64
 2-(3′-azidopropyl)cycloheptanone (1i),
13
 
2-(3′-azidopropyl)cyclooctanone (1j),
13
 6-azidohexan-2-one (1m),
13
 1-(2′-(azidomethyl)-
phenyl)propan-2-one (1n),
64
 2-(3′-azidopropyl)-2-phenylcyclohexan-1-one (1o),
37
 4-azido-
2-benzylbutanal (1q),
111
 and 2-(4′-azidobutyl)cyclohexanone (1r)
13
 are known and were 
either synthesized according to the literature procedures or with slight modification thereof. 
Details for syntheses of compounds 1b, 1m, and 1n are described below. 
Spectroscopic data for the following lactams, hexahydroindolizin-5(1H)-one (2a),
12-13
 
9a-methyltetrahydro-1H-pyrrolo[1,2-a]azepine-5,9(6H,9aH)-dione (2b),
18a
 hexahydro-1H-
pyrrolo[1,2-a]azepin-5(6H)-one (2c),
12-13
 ethyl 5-oxooctahydro-1H-pyrrolo[1,2-a]azepine-
9a-carboxylate (2d),
12-13
 2,3,11,11a-tetrahydro-1H-benzo[d]pyrrolo[1,2-a]azepin-5(6H)-
one (2g),
12-13,119
 2-methylenehexahydro-1H-pyrrolo[1,2-a]azepin-5(6H)-one (2h),
17m,64
 
octahydropyrrolo[1,2-a]azocin-5(1H)-one (2i),
13
 octahydro-1H-pyrrolo[1,2-a]azonin-
5(6H)-one (2j),
13
 3-phenyl-1-(pyrrolidin-1-yl)propan-1-one (2l),
120
 1-phenethylpiperidin-2-
one (3l),
121
 1-(pyrrolidin-1-yl)ethanone (2m),
13
 N-methyl-2-piperidone (3m),
122
 2-methyl-
1,2-dihydroisoquinolin-3(4H)-one (2n),
123
 1-(isoindolin-2-yl)ethanone (3n),
124
 9a-
phenyloctahydro-5H-pyrrolo[1,2-a]azepin-5-one (2o),
37
 2-benzylhexahydro-1H-
pyrrolo[1,2-a][1,4]diazepin-5(2H)-one (2p),
64
 3-benzylpyrrolidin-2-one (2q),
111
 and 
octahydropyrido[1,2-a]azepin-6(2H)-one (2r)
13
 prepared according to the catalytic 
methodology described in Section 1.2 matches with those reported in the literature. 
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2-(3′-Azidopropyl)-2-methylcyclohexane-1,3-dione (1b).
18a
 Following the literature 
procedure,
125
 2-(3′-chloropropyl)-2-methylcyclohexane-1,3-dione (chloro diketone) 1ba 
was prepared from 2-methylcyclohexane-1,3-dione in the following manner: 
To a pale yellow solution of 2-methylcyclohexane-1,3-dione (6.30 g, 49.9 mmol, 1.0 
equiv) in anhydrous DMF (70 mL) in a flame-dried flask at rt under argon atmosphere was 
added Cs2CO3 (17.9 g, 54.9 mmol, 1.1 equiv) and the resulting pale orange suspension was 
stirred at rt for 15 min. 1-Chloro-3-iodopropane (16.1 mL, 150 mmol, 3.0 equiv) was added 
at once and a cream-colored suspension was stirred at rt for 14 h. The reaction mixture was 
diluted with water and extracted with EtOAc (5 × 40 mL). The combined organic extracts 
were washed with water (4 × 50 mL), brine (2 × 50 mL), dried over sodium sulfate 
(Na2SO4), and concentrated under reduced pressure. Purification using a 80 g flash column 
on a CombiFlash Rf system (0–40% EtOAc/hexanes over 90 min) afforded chloro diketone 
1ba
125
 as a pale yellow oil in 39% yield (3.92 g, 19.3 mmol) and 3-(3′-chloropropoxy)-2-
methylcyclohex-2-enone 1bb
125
 as a yellow oil in 48% yield (4.86 g, 24.0 mmol). 
To a solution of chloro diketone 1ba (2.30 g, 11.3 mmol, 1.0 equiv) in anhydrous 
DMF (15 mL) at rt under nitrogen atmosphere was added sodium iodide (NaI; 2.21 g, 14.8 
mmol, 1.3 equiv) followed by sodium azide (NaN3; 1.62 g, 25.0 mmol, 2.2 equiv) and the 
resulting yellow suspension was stirred at 80 C for 1.5 h. The reaction mixture was cooled 
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to rt, diluted with water and extracted with ether (Et2O) (4 × 25 mL). The combined organic 
extracts were washed with water (3 × 80 mL), brine (1 × 50 mL), dried over Na2SO4, and 
concentrated under reduced pressure. Purification using a 40 g flash column on a 
CombiFlash Rf system (0–20% EtOAc/hexanes over 65 min) afforded azido ketone 1b as a 
yellow oil in 87% yield (2.07 g, 9.89 mmol). 
 
 
 (2S,4S)-rel-2-(3′-Azidopropyl)-4-phenylcyclohexanone (cis-1e) and (2R,4S)-rel-2-
(3′-Azidopropyl)-4-phenylcyclohexanone (trans-1f). A solution of 4-phenyl-
cyclohexanone (15.0 g, 86.1 mmol, 1.0 equiv), N,N-dimethylhydrazine (19.6 mL, 258 
mmol, 3.0 equiv) and PTSA (0.818 g, 4.30 mmol, 0.050 equiv) in benzene (100 mL) was 
vigorously refluxed for 28 h under nitrogen atmosphere with removal of water by a Dean–
Stark apparatus. The reaction mixture was concentrated under reduced pressure and the 
crude hydrazone obtained as an orange oil was used for the next alkylation reaction without 
further purification. 
To a cooled 1.0 M LDA solution (94.7 mL, 94.7 mmol, 1.1 equiv) in THF at 0 °C 
under nitrogen atmosphere was added a solution of hydrazone (18.6 g, 86.1 mmol, 1.0 
equiv) in THF (40 mL) slowly over 25 min, and the reaction mixture was allowed to stir at 
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0 °C for 5 h. The reaction mixture was then cooled to –78 °C and a solution of 1-chloro-3-
iodopropane (10.9 mL, 103 mmol, 1.2 equiv) in THF (30 mL) was added slowly over 25 
min. The reaction was warmed to rt and stirred for 15 h. The reaction mixture was diluted 
with ether (50 mL) and then treated with an ice-cold solution of dilute H2SO4 (50 mL) and 
the resulting reddish-orange solution was stirred at rt for 1 h to hydrolyze the hydrazone. 
The reaction mixture was diluted with water and extracted with ether (3 × 60 mL). The 
combined organic extracts were washed with water (2 × 60 mL), saturated aqueous sodium 
bicarbonate (NaHCO3) solution (1 × 50 mL), brine (1 × 50 mL), dried over Na2SO4, and 
concentrated under reduced pressure. The reddish-orange oil was dried under vacuum to 
afford a crude mixture of cis and trans chloro ketone (1ea and 1fa), which was used for the 
subsequent nucleophilic displacement reaction without further purification.  
To a solution of a crude mixture of cis and trans chloro ketone, 1ea and 1fa (21.0 g, 
83.8 mmol, 1.0 equiv) in anhydrous DMF (60 mL) at rt under nitrogen atmosphere was 
added sodium iodide (15.1 g, 101 mmol, 1.2 equiv) followed by sodium azide (10.9 g, 168 
mmol, 2.0 equiv) and the resulting yellow suspension was stirred at 45 C for 18 h. The 
reaction mixture was cooled to rt, diluted with water and extracted with ether (4 × 75 mL). 
The combined organic extracts were washed with water (4 × 250 mL), dried over Na2SO4, 
and concentrated under reduced pressure. Purification by chromatography on a silica gel 
(4–6% EtOAc/hexanes) afforded a mixture of 1e and 1f and a partial separation of 1e. 
Subsequent purifications of the mixture using a 40 g flash column on a CombiFlash Rf 
system (0–10% EtOAc/hexanes over 50 min) afforded the partial separation of 1e and 1f as 
pale pinkish-orange oils and a mixture of 1e and 1f as a pale orange oil (16.7 g, 75% 
combined yield; 1e:1f = 47:53 by 
1
H NMR or UPLC). Azido ketone (cis-1e): Rf = 0.56 
(10% EtOAc/hexanes, run for four times); IR (neat) 2091, 1709, 1256 cm
–1
; 
1
H NMR (400 
MHz, CDCl3)  1.24–1.33 (m, 1H), 1.52–1.70 (m, 3H), 1.83–1.96 (m, 2H), 2.21–2.29 (m, 
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2H), 2.47–2.58 (m, 3H), 3.12 (tt, J = 12.3, 3.2 Hz, 1H), 3.21–3.31 (m, 2H), 7.21–7.24 (m, 
3H), 7.30–7.34 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  26.4, 26.5, 34.9, 41.3, 41.7, 43.3, 
49.4, 51.5, 126.62, 126.66, 128.6, 144.5, 211.5; HRMS (ESI) m/z calcd for C15H20NO [M + 
H – N2]
+ 
230.1545, found 230.1550.  
Azido ketone (trans-1f): Rf = 0.50 (10% EtOAc/hexanes, run for four times); IR 
(neat) 2094, 1708, 1256 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.52–1.66 (m, 3H), 1.87–2.10 
(m, 3H), 2.13–2.23 (m, 2H), 2.39 (dtd, J = 14.7, 4.5, 1.1 Hz, 1H), 2.44–2.50 (m, 1H), 2.54–
2.62 (m, 1H), 3.18 (m, 1H), 3.30 (t, J = 6.4 Hz, 2H), 7.21–7.28 (m, 3H), 7.31–7.35 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  26.7, 28.4, 33.2, 37.3, 38.3, 38.4, 48.7, 51.1, 126.5, 126.7, 
128.6, 144.2, 213.4; HRMS (ESI) m/z calcd for C15H20NO [M + H –N2]
+ 
230.1545, found 
230.1546.  
 
 
(1S,3S,4R)-rel-3-(3′-Azidopropyl)bicyclo[2.2.1]heptan-2-one (1k).
17i
 To a cooled 
1.0 M LDA solution (32.7 mL, 32.7 mmol, 1.2 equiv) in THF at –78 °C in a flame-dried 
flask under argon atmosphere was added a solution of norcamphor (3.00 g, 27.2 mmol, 1.0 
equiv) in THF (10 mL) slowly over 10 min and the reaction mixture was allowed to stir at –
78 °C for 1 h. To the resulting white suspension was added HMPA (20 mL) followed by 1-
chloro-3-iodopropane (5.85 mL, 54.5 mmol, 2.0 equiv) over 10 min. The yellow suspension 
was stirred at –78 °C for 1 h, warmed to rt, and stirred for 1 h. The reaction mixture was 
quenched with saturated aqueous solution of ammonium chloride (NH4Cl) (50 mL) and 
diluted with water (50 mL) followed by extraction with ether (3 × 40 mL). The combined 
organic extracts were washed with water (1 × 70 mL), brine (1 × 70 mL), dried over 
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Na2SO4, and concentrated under reduced pressure. Purification using a 40 g flash column 
on a CombiFlash Rf system (0–10% EtOAc/hexanes over 40 min) afforded 1ka as an 
impure material. Subsequent purification of impure 1ka using a 40 g flash column on a 
CombiFlash Rf system (0–10% EtOAc/hexanes over 100 min) afforded the partial 
separation of 1ka as a pale yellow oil. Vacuum distillation (ca. 1.3 mbar) at ca. 93 °C of the 
remaining impure 1ka afforded sufficiently pure 1ka as a pale yellow oil (3.22 g, 17.2 
mmol, 63% combined yield). (1S,3S,4R)-rel-3-(3′-Chloropropyl)bicyclo[2.2.1]heptan-2-one 
(chloro ketone) 1ka: Rf = 0.57 (10% EtOAc/hexanes, run twice); IR (neat) 1738, 1081 cm
–
1
; 
1
H NMR (400 MHz, CDCl3)  1.27–1.44 (complex, 4H), 1.48–1.60 (m, 2H), 1.65–1.82 
(complex, 5H), 2.30 (m, 1H), 2.41–2.42 (m, 1H), 3.42 (m, 2H); 
13
C NMR (100 MHz, 
CDCl3)  23.8, 26.5, 27.8, 31.0, 34.7, 39.4, 44.6, 49.3, 52.8, 219.2; HRMS (ESI) m/z calcd 
for C10H16ClO [M H]
+ 
187.0890, found 187.0892. 
To a solution of chloro ketone 1ka (1.84 g, 9.86 mmol, 1.0 equiv) in anhydrous DMF 
(12 mL) at rt under nitrogen atmosphere was added sodium iodide (1.77 g, 11.8 mmol, 1.2 
equiv) followed by sodium azide (1.28 g, 19.7 mmol, 2.0 equiv) and the resulting 
suspension was stirred at 80 C for 2 h. The reaction mixture was cooled to rt, diluted with 
water (75 mL) and extracted with ether (3 × 35 mL). The combined organic extracts were 
washed with water (4 × 60 mL), dried over Na2SO4, and concentrated under reduced 
pressure. Purification using a 40 g flash column on a CombiFlash Rf system (0–10% 
EtOAc/hexanes over 80 min) afforded 1k as a colorless oil in 97% yield (1.84 g, 9.52 
mmol). Azido ketone 1k: Rf = 0.51 (10% EtOAc/hexanes, run twice); IR (neat) 2090, 1738, 
1263 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.21–1.45 (complex, 4H), 1.46–1.55 (m, 1H), 
1.58–1.68 (complex, 3H), 1.69–1.79 (complex, 3H), 2.33 (m, 1H), 2.45 (m, 1H), 3.20 (m, 
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2H); 
13
C NMR (100 MHz, CDCl3)  23.9, 26.3, 27.5, 27.9, 34.7, 39.4, 49.4, 51.1, 53.2, 
219.3; HRMS (ESI) m/z calcd for C10H16NO [M H – N2]
+ 
166.1232, found 166.1247. 
 
 
7-Azido-1-phenylheptan-3-one (1l). To a stirring suspension of magnesium turnings 
(0.434 g, 17.9 mmol, 1.2 equiv) in ether (12 mL) in a flame-dried flask under argon 
atmosphere was added five drops of 1-bromo-4-chlorobutane and the mixture was gently 
refluxed for 30 min. A solution of 1-bromo-4-chlorobutane (2.06 mL, 17.9 mmol, 1.2 
equiv) in ether (8 mL) was then added slowly over 20 min via a syringe. After refluxing 
gently for another 30 min, the reaction mixture was cooled to 0 °C and a solution of 
hydrocinnamaldehyde 21i (2.00 g, 14.9 mmol, 1.0 equiv) in ether (10 mL) was added 
slowly over 10 min. The reaction mixture was stirred at 0 °C for 15 min, warmed to rt over 
15 min, and stirred at rt for 1 h. The reaction mixture was quenched with a saturated 
aqueous solution of NH4Cl (50 mL) and extracted with ether (2 × 30 mL). The combined 
organic extracts were washed with brine (2 × 75 mL), dried over Na2SO4, and concentrated 
under reduced pressure to afford the crude alcohol as a pale yellow oil, which was used for 
the next oxidation step without further purification. 
To a stirring solution of crude alcohol in CH2Cl2 (40 mL) under nitrogen atmosphere 
was added PCC (6.42 g, 29.8 mmol, 2.0 equiv) and Celite (7.00 g), and the reaction was 
stirred at rt for 1.5 h. The reaction mixture was concentrated under reduced pressure and the 
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brownish-black residue obtained was suspended in ether (20 mL). The suspension was 
sonicated for few minutes and filtered through Celite. The residue was rinsed with several 
portions of ether (6 × 15 mL) and the combined filtrates were concentrated under reduced 
pressure. Purification using a 40 g flash column on a CombiFlash Rf system (0–10% 
EtOAc/hexanes over 55 min) afforded 1la as an impure material. Subsequent purification 
of impure 1la using a 40 g flash column on a CombiFlash Rf system (0–5% EtOAc/hexanes 
over 50 min) afforded 1la
126
 as a colorless oil in 33% yield over two steps (1.12 g, 4.98 
mmol). 7-Chloro-1-phenylheptan-3-one (chloro ketone) 1la: Rf = 0.57 (10% 
EtOAc/hexanes, run twice); IR (neat) 1711, 1453, 1095 cm
–1
; 
1
H NMR (400 MHz, CDCl3) 
 1.66–1.78 (m, 4H), 2.41 (t, J = 6.8 Hz, 2H), 2.73 (t, J = 7.5 Hz, 2H), 2.90 (t, J = 7.5 Hz, 
2H), 3.50 (m, 2H), 7.17–7.21 (m, 3H), 7.26–7.30 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  
21.0, 29.8, 31.9, 42.0, 44.3, 44.7, 126.2, 128.4, 128.5, 141.1, 209.4; HRMS (ESI) m/z calcd 
for C13H18ClO [M + H]
+ 
225.1046, found 225.1083. 
To a solution of chloro ketone 1la (1.08 g, 4.81 mmol, 1.0 equiv) in anhydrous DMF 
(10 mL) at rt under nitrogen atmosphere was added sodium iodide (0.864 g, 5.77 mmol, 1.2 
equiv) followed by sodium azide (0.625 g, 9.61 mmol, 2.0 equiv) and the resulting 
suspension was stirred at 80 C for 1 h. The reaction mixture was cooled to rt, diluted with 
water and extracted with ether (3 × 30 mL). The combined organic extracts were washed 
with water (3 × 60 mL), brine (1 × 60 mL), dried over Na2SO4, and concentrated under 
reduced pressure. Purification using a 24 g flash column on a CombiFlash Rf system (0–5% 
EtOAc/hexanes over 40 min) afforded 1l as a colorless oil in 90% yield (0.995 g, 4.30 
mmol). Azido ketone 1l: Rf = 0.50 (10% EtOAc/hexanes, run twice); IR (neat) 2090, 1711, 
1453, 1106 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.50–1.58 (m, 2H), 1.59–1.67 (m, 2H), 
2.41 (t, J = 7.0 Hz, 2H), 2.72 (t, J = 7.5 Hz, 2H), 2.90 (t, J = 7.5 Hz, 2H), 3.24 (t, J = 6.6 
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Hz, 2H), 7.17–7.21 (m, 3H), 7.26–7.30 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  20.8, 28.3, 
29.8, 42.2, 44.3, 51.2, 126.2, 128.4, 128.5, 141.0, 209.4; HRMS (ESI) m/z calcd for 
C13H18NO [M H – N2]
+ 
204.1388, found 204.1386. 
 
 
6-Azidohexan-2-one (1m).
13
 To a solution of 6-chlorohexan-2-one 1ma (1.50 g, 11.1 
mmol, 1.0 equiv) in anhydrous DMF (10 mL) at rt under nitrogen atmosphere was added 
sodium iodide (2.00 g, 13.4 mmol, 1.2 equiv) followed by sodium azide (1.45 g, 22.3 
mmol, 2.0 equiv) and the resulting suspension was stirred at 80 C for 2 h. The reaction 
mixture was cooled to rt, diluted with water and extracted with ether (3 × 30 mL). The 
combined organic extracts were washed with water (4 × 50 mL), brine (1 × 50 mL), dried 
over Na2SO4, and concentrated under reduced pressure. Purification using a 24 g flash 
column on a CombiFlash Rf system (0–15% EtOAc/hexanes over 25 min) afforded pure 
azido ketone 1m as a pale yellow oil in 59% yield (0.920 g, 6.52 mmol). The product was 
found to be slightly volatile. 
 
 
1-(2′-(Azidomethyl)phenyl)propan-2-one (1n).
64
 To a solution of 1-(2′-
(bromomethyl)phenyl)propan-2-one 1na
64
 (0.540 g, 2.38 mmol, 1.0 equiv) in anhydrous 
DMF (5 mL) at rt under nitrogen atmosphere was added sodium iodide (0.427 g, 2.85 
mmol, 1.2 equiv) followed by sodium azide (0.309 g, 4.76 mmol, 2.0 equiv) and the 
resulting suspension was stirred at 80 C for 40 min. The reaction mixture was cooled to rt, 
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diluted with water (40 mL), and extracted with ether (3 × 20 mL). The combined organic 
extracts were washed with water (2 × 40 mL), brine (1 × 40 mL), dried over Na2SO4, and 
concentrated under reduced pressure. Purification using a 12 g flash column on a 
CombiFlash Rf system (0–10% EtOAc/hexanes over 35 min) afforded azido ketone 1n as a 
pale orange oil in 92% yield (0.415 g, 2.19 mmol). 
 
 
3-(3′-Azidopropyl)-1-benzylpiperidin-4-one (1p).
64
 To a solution of 1-benzyl-3-(3′-
chloropropyl)piperidin-4-one 1pa
64
 (0.195 g, 0.734 mmol, 1.0 equiv) in anhydrous DMF (5 
mL) at rt under nitrogen atmosphere was added sodium iodide (0.132 g, 0.880 mmol, 1.2 
equiv) followed by sodium azide (0.0954 g, 1.47 mmol, 2.0 equiv) and the resulting 
suspension was stirred at 80 C for 1 h. The reaction mixture was cooled to rt, diluted with 
water (50 mL) and extracted with CH2Cl2 (3 × 25 mL). The combined organic extracts 
were washed with water (2 × 50 mL), brine (1 × 50 mL), dried over Na2SO4, and 
concentrated under reduced pressure. Purification using a 4 g flash column on a 
CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 30 min) afforded 1p as a pale yellow oil 
in 83% yield (0.166 g, 0.609 mmol). Azido ketone 1p: Rf = 0.42 (2% MeOH/CH2Cl2, run 
twice); IR (neat) 2092, 1712, 1453, 1258 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.29 (m, 
1H), 1.55 (m, 2H), 1.82 (m, 1H), 2.22 (m, 1H), 2.36 (m, 1H), 2.43–2.59 (m, 3H), 2.97–3.05 
(m, 2H), 3.24 (m, 2H), 3.56 (1/2 AB, J = 13.1 Hz, 1H), 3.64 (1/2 AB, J = 13.1 Hz, 1H), 
7.25–7.29 (m, 1H), 7.30–7.36 (m, 4H); 
13
C NMR (100 MHz, CDCl3)  24.8, 26.7, 41.1, 
49.4, 51.5, 53.7, 58.9, 61.9, 127.4, 128.5, 128.9, 138.2, 210.4; HRMS (ESI) m/z calcd for 
C15H21N2O [M H – N2]
+ 
245.1654, found 245.1645. 
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Preliminary Screening of Reaction Conditions for the Intramolecular Schmidt 
Reaction 
Table S1. Preliminary Screening with 5 and 10 mol % Sc(OTf)3 by Sze-Wan Li 
 
entry n conditions 
product conversion 
(%)
a,b
 
1 2 5 mol % CuSO4∙H2O, H2O, 180 C, 4 h 37 
2 2 10 mol % Sc(OTf)3, CH3CN, 80 C, 16 h 47 
3 2 5 mol % Sc(OTf)3, t-BuOH, 140 C, 4 h 26 
4 2 5 mol % Sc(OTf)3, H2O, 160 C, 4 h 80 
5 2 5 mol % Sc(OTf)3, H2O, 180 C, 4 h >95 (78) 
6 2 5 mol % Sc(OTf)3, H2O/CH3CN (1:1), 180 C, 4 h >95 (88) 
7 2 10 mol % Sc(OTf)3, CH2Cl2, DBU (20 mol %), rt, O/N 9 
8 2 5 mol % Sc(OTf)3, CH2Cl2, rt, O/N 10 
9 2 5 mol % Sc(OTf)3, C2H4Cl2, reflux, O/N 16 
10 2 5 mol % TiCl4, CH2Cl2, rt, 16 h 8 
11 1 10 mol % Sc(OTf)3, H2O, 180 C, 4 h 42 
a
Product conversion was determined by 
1
H NMR. 
b
Yield in parentheses represents isolated 
yield. O/N = Overnight.  
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Table S2. Preliminary Catalyst Screening in H2O at 180 C by Erin Hirt 
 
entry n conditions 
product conversion 
(%)
a
 
1 2 5 mol % Sc(OTf)3, H2O, 180 C, 4 h 50 
2 2 10 mol % Sc(OTf)3, H2O, 180 C, 4 h >95 (73) 
3 2 25 mol % LiClO4, toluene, 180 C, 4 h <20 
4 2 25 mol % LiClO4, H2O, 180 C, 4 h <20 
5 2 25 mol % AuCl, H2O, 180 C, 4 h >95 
6 2 25 mol % Yb(OTf)3, H2O, 180 C, 4 h 46 
7 2 25 mol % Eu(OTf)3, H2O, 180 C, 4 h <10 
8 2 25 mol % Ho(OTf)3, H2O, 180 C, 4 h 26 
9 2 25 mol % Gd(OTf)3, H2O, 180 C, 4 h <15 
10 2 25 mol % Dy(OTf)3, H2O, 180 C, 4 h 37 
11 1 10 mol % Sc(OTf)3, H2O, 180 C, 4 h NR 
12 1 25 mol % Sc(OTf)3, H2O, 180 C, 4 h NR 
13 2 25 mol % Yb(OTf)3, 10 mol % n-Bu4NOH, H2O, 180 C, 4 h 38 
14 2 25 mol % Eu(OTf)3, 10 mol % n-Bu4NOH, H2O, 180 C, 4 h <10 
15 2 25 mol % Ho(OTf)3, 10 mol % n-Bu4NOH, H2O, 180 C, 4 h 31 
16 2 25 mol % Sc(OTf)3, 10 mol % n-Bu4NOH, H2O, 180 C, 4 h >95 
17 2 38 mol % HCl, 10 mol % n-Bu4NOH, H2O, 180 C, 4 h <10 
18 2 10 mol % n-Bu4NOH, H2O, W, 180 C, 4 h <5 
19 1 25 mol % Sc(OTf)3, 10 mol % n-Bu4NOH, H2O, W, 180 C, 4 h >95 (54) 
a
Product conversion was determined by 
1
H NMR. 
b
Yield in parentheses represents isolated yield. 
NR = No reaction. 
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Table S3. Preliminary Catalyst Screening in CH3CN at 200 C by Charlie Fehl 
 
entry conditions 
product conversion 
(%)
a
 
1 25 mol % Sc(OTf)3, CH3CN, rt, 18 h 25 
2 25 mol % TiCl4, CH3CN, rt, 18 h 25 
3 30 mol % CF3SO3H, CH3CN, rt, 18 h 40 
4 25 mol % Sc(OTf)3, CH3CN,W, 200 C, 30 min >95 
5 10 mol % Sc(OTf)3, CH3CN,W, 200 C, 2 h 70 
6 5 mol % Sc(OTf)3, CH3CN,W, 200 C, 2 h 30 
7 25 mol % TiCl4, CH3CN,W, 200 C, 30 min 60 
8 25 mol % BF3∙OEt2, CH3CN,W, 200 C, 30 min 70 
9 25 mol % Yb(OTf)3, CH3CN,W, 200 C, 30 min 80 
10 25 mol % CF3CO2H, CH3CN,W, 200 C, 30 min 25 
a
Product conversion was determined either by 
1
H NMR or by UPLC. 
 
List of Additives Screened with or without Sc(OTf)3 
(1) Salts: NaOAc, NaOPh, Na2CO3, NaOTs, NaBr, NaCl, KCl, KF, and AgOTf. 
(2) Amines: (Me)2NNH2, (Me)2NH, Et3N, DABCO, DMAP, DMF, DMA, and 
TMANO. 
(3) Ligands: (R)-BINOL, 1,3-di-o-tolyl-2-thiourea, and PYBOX such as 2,6-bis[(4R)-
(+)-isopropyl-2-oxazolin-2-yl]pyridine. 
(4) Phosphines: PPh3, PBu3, tri(o-tolyl)phosphine, and tri(2-furyl)phosphine.  
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In-Depth Screening of Reaction Conditions for the Intramolecular Schmidt Reaction 
Based on the Screening Flowchart (Scheme 10 and Figure 4) 
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Solvent Screening 
General Procedure for Solvent Screening. To a mixture of trans azido ketone 1f 
(25.7 mg, 0.100 mmol, 1.0 equiv) and Sc(OTf)3 (9.84 mg, 0.0200 mmol, 0.20 equiv) in a 
microwave vial at rt was added a solvent (0.5 mL). The vial was capped and the reaction 
mixture was stirred at 150 C for 16 h under conventional heating using a pie-block. After 
16 h, the reaction mixture was allowed to cool to rt over 2 h. The cap was removed and the 
reaction mixture was analyzed by ultra performance liquid chromatography (UPLC) using 
1-benzyl-2-pyrrolidinone as an internal standard (IS). 1-Benzyl-2-pyrrolidinone was chosen 
as the IS because it is a lactam and has a chromophore for UPLC analysis. 
Analysis of Reaction Mixture by UPLC. After cooling, the reaction mixture was 
diluted with CH2Cl2 to a final volume of 1.0 mL (differences in initial volumes were 
observed for some reactions due to solvent loss). To the vial was added 1-benzyl-2-
pyrrolidinone (16.0 L, 0.100 mmol) using a microsyringe and the resulting mixture was 
mixed well to ensure homogeneity. An aliquot (10 L) of the reaction mixture was diluted 
with 1.0 mL of CH3OH in a sample vial and analyzed by UPLC. 
Samples for UPLC analysis for the solvent screening were run on two instruments: 
(1) Waters Acquity System (Waters LCT premier with ESI and PDA detector). Waters 
Acquity BEH C18 column (2.1 x 50 mm, 1.7 m) was employed with a basic method using 
a linear gradient elution of 95:5 (water:ACN, pH 9.8) to 0:100 (water:ACN) at a flow rate 
of 0.6 mL/min over 2.7 minutes. (2) Waters Acquity System (Waters Acquity SQ detector 
with ESI and Acquity TUV detector). Waters Acquity BEH Shield C18 column (2.1 x 50 
mm, 1.7 m) was employed with a basic method using a linear gradient elution of 90:10 
(water:ACN, pH 9.8) to 40:60 (water:ACN) at a flow rate of 0.6 mL/min over 5.7 minutes 
followed by a flush with 100% ACN for 0.1 min. 
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Calibration was carried out each time with the IS before analyzing a batch of reaction 
mixture to determine a normalization factor (NF) for substrate 1f and products 2f and 2e in 
order to correct for the differences in extinction coefficients between the IS and substrate 1f 
and products 2f and 2e. 
For the calculation of NFsubstrate, 1-benzyl-2-pyrrolidinone (4.00 L, 0.0250 mmol) 
and substrate 1f (6.43 mg, 0.0250 mmol) were dissolved in CH2Cl2 (125 L) to give a 
concentration of 0.2 M. A drop of this 0.2 M solution was diluted with 1.0 mL of CH3OH 
in a sample vial and analyzed by UPLC. A retention time (tR) in min for various peaks was 
obtained from a chromatogram (tR for IS and 1f = 1.24 and 2.15 mins, respectively for the 
first UPLC instrument and tR for IS, 1f, and 1e = 1.92, 5.15, and 5.38 mins, respectively for 
the second UPLC instrument). 
For the calculation of NFproducts, 1-benzyl-2-pyrrolidinone (4.00 L, 0.0250 mmol) 
and mixture of products 2f and 2e (5.73 mg, 0.0250 mmol) were dissolved in CH2Cl2 (125 
L) to give a concentration of 0.2 M. A drop of this 0.2 M solution was diluted with 1.0 mL 
of CH3OH in a sample vial and analyzed by UPLC. A retention time (tR) in min for various 
peaks was obtained from a chromatogram (tR for IS, 2f, and 2e = 1.24, 1.56, and 1.60 mins, 
respectively for the first UPLC instrument and tR for IS, 2f, and 2e = 1.92, 3.11, and 3.23 
mins, respectively for the second UPLC instrument). AUC = Area under the curve. 
                             ⁄  
                           ⁄  
 
Products (2f and 2e) conversion (%) was calculated as:  
                                                        ⁄   
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Unreacted substrate 1f and its epimer 1e recoveries (in %) were calculated as:  
                                                         ⁄   
Ratio of products (2f:2e) was determined by UPLC for product conversion and by 
1
H NMR 
when products were isolated. 
Purification of Products (2f and 2e) by Preparative TLC. Reaction mixture was 
applied on a preparative TLC plate and developed twice with 2% MeOH/CH2Cl2. The band 
corresponding to the products was scraped and eluted with 5% MeOH/CH2Cl2 through a 
phase separator tabless. Evaporation of elution under reduced pressure gave a mixture of 
products (2f and 2e) as a colorless oil, which was further dried under vacuum. 
 
Table S4. Solvent Screening with 20 mol % Sc(OTf)3
a
 
entry solvent 
unreacted substrate 
product 
conversion 
(2f:2e) 
other 
byproducts 
observed 1f 1e 
1 Neat ND 7% 73% (~1:2.5) ≥1 
2 Acetone ND ND 57% (~1:4) ≥3 
3 Ethyl acetate ND 11% 76% (~1:6) ≥2 
4 Dioxane trace 19% 64% (~1:3) ≥2 
5 Dimethoxyethane ND 10% 67% (~1:6) ND 
6 Tetrahydrofuran ND 26% 53% (~1:6) ≥3 
7 Dichloroethane trace 23% 67% (~1:1) ≥3 
8 Toluene ND 25% 65% (~1:1) ≥1 
9 Cyclohexane trace 27% 62% (~1:1.5) ≥3 
10 Fluorobenzene trace 25% 66% (~1:1)
b
 ≥2 
11 Nitrobenzene ND 5% 69% (~1:1) ≥1 
12 N-Methylpyrrolidinone 15% 65% 0% ≥3 
13 Diethyl Carbonate ND trace 49% (~1:3) ≥4 
14 Water 3% 13% 55% (~1:5) ≥3 
15 Acetic acid ND ND 94% (~1:1) ≥1 
16 Formic acid ND ND 67% (~2.5:1)
c
 ND 
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entry solvent unreacted substrate 
product 
conversion 
(2f:2e) 
other 
byproducts 
observed   1f 1e 
17 Nitromethane ND 5% 84% (~1:1.5) ≥1 
18 Acetonitrile trace 11% 72% (~1:1) ≥2 
19 Benzonitrile ND 8% ~91% (~1:2)
d
 ND 
20 Butyronitrile ND 14% 75% (~1:2.5) ≥1 
21 Pentafluorobenzonitrile ND ND 89% (~1:3.5) ≥1 
22 BMIMBF4 ND ND 98% (~1:1) ≥1 
23 Trifluoroethanol ND ND 87% (~2:1) ≥2 
24 Isopropanol ND ND 22% (~1:4) ≥3 
a
All reactions were run with 20 mol % Sc(OTf)3 at 150 C for 16 h.
 b
Solvent peak 
overlaps with product 2e peak. 
c
Isolated yield was 55% after preparative TLC 
purification. 
d
Solvent peak overlaps with IS peak. ND = Not detected.  
 
Table S5. Solvent Screening with 10 mol % Sc(OTf)3
a
 
entry solvent catalyst 
unreacted substrate 
product 
conversion 
(2f:2e) 
other 
byproducts 
observed 1f 1e 
1 Nitromethane 
CH3CO2H  
(1 equiv) 
50% 32% trace ≥5 
2 Formic acid – trace trace 46% (~2:1) ≥5 
3 Nitromethane Sc(OTf)3 trace 12% 69% (~1:1.4) ≥3 
4 BMIMBF4 – 13% 34% trace ≥2 
5 BMIMBF4 Sc(OTf)3 ND trace 66% (~1:2) ≥3 
6 Trifluoroethanol Sc(OTf)3 ND trace 89% (~1:1)
b
 ≥2 
7 Acetic acid – 11% 39% 21% (~1:10) ≥3 
8 Benzonitrile Sc(OTf)3 ND ~32% ~61% (~1:2)
c
 ≥2 
a
All reactions were run with 10 mol % Sc(OTf)3 at 150 C for 16 h.
 b
Isolated yield was 74% after 
preparative TLC purification. 
c
Solvent peak overlaps with IS peak. ND = Not detected. 
BMIMBF4 = 1-Butyl-3-methylimidazolium tetrafluoroborate. Acetic acid (AcOH) = CH3CO2H. 
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Figure S1. Representative UPLC chromatogram for entry 3, Table S5 (retention time (tR) 
for IS, 2f, 2e, and 1e = 1.92, 3.11, 3.23, and 5.38 mins, respectively). 
 
 
Catalyst Screening 
General Procedure for Catalyst Screening. To a mixture of trans azido ketone 1f 
(25.7 mg, 0.100 mmol, 1.0 equiv) and catalyst (0.0100 mmol, 0.10 equiv or 0.00500 mmol, 
0.050 equiv) in a microwave vial at rt was added TFE (0.5 mL). The vial was capped and 
the reaction mixture was stirred at 80 C, 50 C, or 25 C for 16 h under conventional 
heating using a pie-block. The reaction mixture was allowed to cool to rt over 15 min. The 
cap was removed and the reaction mixture was analyzed by UPLC using 1-benzyl-2-
pyrrolidinone as the IS. Catalysts were weighed or measured either in the argon glove box 
or under nitrogen blanket created with the help of wide mouth funnels connected to in-
house nitrogen gas through Tygon
®
 tubing. 
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Analysis of Reaction Mixture by UPLC. To the vial was added 1-benzyl-2-
pyrrolidinone (16.0 L, 0.100 mmol) using a microsyringe and the resulting mixture was 
mixed well to ensure homogeneity. An aliquot (10 L) of the reaction mixture was diluted 
with 1.0 mL of CH3OH in a sample vial and analyzed by UPLC. 
Samples for UPLC analysis for the catalyst screening were run on Waters Acquity 
System (Waters Acquity SQ detector with ESI and Acquity TUV detector). Waters Acquity 
BEH Shield C18 column (2.1 x 50 mm, 1.7 m) was employed with a basic method using a 
linear gradient elution of 90:10 (water:ACN, pH 9.8) to 40:60 (water:ACN) at a flow rate 
of 0.6 mL/min over 5.7 minutes followed by a flush with 100% ACN for 0.1 min. 
Calibration was carried out each time with the IS before analyzing a batch of reaction 
mixture to determine the normalization factor (NF) for substrate 1f and products 2f and 2e 
in a similar way as described before in the section for solvent screening. 
For calculation of NFsubstrate and NFproducts, 1-benzyl-2-pyrrolidinone (4.00 L, 0.0250 
mmol), substrate 1f (6.43 mg, 0.0250 mmol), and mixture of products 2f and 2e (5.73 mg, 
0.0250 mmol) were dissolved in CH2Cl2 (125 L) to give a concentration of 0.2 M. A drop 
of this 0.2 M solution was diluted with 1.0 mL of CH3OH in a sample vial and analyzed by 
UPLC. A retention time (tR) in min for various peaks was obtained from a chromatogram 
(tR for IS, 1f, 2f, 1e, and 2e were 1.92, 5.15, 3.11, 5.38 and 3.23 mins, respectively). 
                             ⁄  
                           ⁄  
Products (2f and 2e) conversion (%) was calculated as:  
                                                        ⁄   
Unreacted substrate 1f and its epimer 1e recoveries (in %) were calculated as:  
                                                         ⁄   
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Purification of Products (2f and 2e) by Preparative TLC. Reaction mixture was 
applied on a preparative TLC plate and developed twice with 2% MeOH/CH2Cl2. The band 
corresponding to the products was scraped and eluted with 5% MeOH/CH2Cl2 through a 
phase separator tabless. Evaporation of elution under reduced pressure gave a mixture of 
products (2f and 2e) as a colorless oil, which was further dried under vacuum. 
 
Table S6. Transition Metal Lewis Acid Catalyst Screening with TFE
a
 
entry 
catalyst 
(10 mol %) 
unreacted substrate 
product 
conversion 
(2f:2e) 
other 
byproducts 
observed
b
 1f 1e 
1 Sc(OTf)3 10% 15% 65% (~2:1) ≥1 
2 Sc(NTf2)3 10% 15% 63% (~2.5:1) ≥1 
3 ScCl3∙xH2O 26% 17% 46% (~2:1) ≥2 
4 TiCl4
c
 ND ND 94% (~1.6:1) ≥2 
5 TiCl(O
i
Pr)3
d
 16% 10% 61% (~2:1) ≥3 
6 CrCl2 36% 8% 39% (~3:1) ≥3 
7 Mn(OTf)2 66% trace 20% (~7:1) ≥2 
8 Fe(OTf)3 ND ND 84% (~7:1) ≥1 
9 Fe(OTf)2 15% trace 61% (~9:1) ≥4 
10 FeCl3 42% 3% 10% ≥6 
11 Fe(ClO4)3∙xH2O 18% trace 66% (~7.5:1) ≥3 
12 Ferrocenium PF6 71% 3% 15% (~6.5:1) ≥3 
13 Co(ClO4)2∙6H2O 14% trace 69% (~6:1) ≥2 
14 Ni(OTf)3 53% 3% 38% (~6:1) ≥2 
15 Cu(OTf)2 trace trace 43% (~9:1) ≥6 
16 Zn(OTf)2 21% 11% 58% (~3:1) ≥1 
17 Y(OTf)3 17% 31% 44% (~2:1) ≥2 
18 ZrCl4 ND ND 98% (~1:2.5) ≥2 
19 NbCl5 ND ND 92% (~1.3:1) ≥3 
20 RuCl3 89% 5% ND ≥3 
21 RhCl3∙xH2O 55% 3% 10% ≥3 
22 PdCl2 ND ND 2% ≥6 
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entry 
catalyst 
(10 mol %) 
unreacted substrate 
product 
conversion 
(2f:2e) 
other 
byproducts 
observed
b
 1f 1e 
23 AgOTf 73% 3% 18% (~7:1) ≥1 
24 CdCl2 96% 4% ND ≥1 
25 Hf(OTf)4 hydrate ND ND 86% (~5.5:1) ≥3 
26 HfCl4 4% 3% 81% (~1.4:1) ≥2 
27 WCl6 ND ND 84% (~2:1) ≥3 
28 AuCl3 ND ND 81% (~2:1) ≥4 
29 HgCl2 92% 4% ND ≥1 
a
All reactions were run at 80 C for 16 h in TFE.
 b
In most cases one of the 
byproducts observed was bridged lactam 3f with a tR of 3.43 min. 
c
A 1.0 M 
solution in CH2Cl2 was used. 
d
A 1.0 M solution in hexanes was used. ND = Not 
detected. 
 
Table S7. Post-Transition Metal, Metalloid, and Lanthanoid Lewis Acid Catalyst 
Screening with TFE
a
 
entry 
catalyst 
(10 mol %) 
unreacted substrate 
product 
conversion 
(2f:2e) 
other 
byproducts 
observed
b
 1f 1e 
1 Al(OTf)3 3% trace 81% (~6:1) ≥1 
2 EtAlCl2
c
 19% 7% 62% (~2:1) ≥4 
3 In(OTf)3 ND ND 85% (~6:1) ≥1 
4 InCl3 55% 3% 34% (~7:1) ≥2 
5 Sn(OTf)2 21% trace 53% (~3:1) ≥1 
6 SnCl4
d
 trace trace 77% (~3:1) ≥4 
7 Bi(OTf)3 ND ND 85% (~4:1) ≥1 
8 BiCl3 3% trace 80% (~2:1) ≥3 
9 TlOTf 85% 17% ND ≥1 
10 BF3∙OEt2
e
 38% trace 50% (~7:1) ≥3 
11 CBS catalyst
f
 52% 47% ND ≥3 
12 SiCl4
d
 ND ND 93% (~1.2:1) ≥2 
13 Yb(OTf)3 17% 23% 49% (~2.4:1) ≥3 
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a
All reactions were run at 80 C for 16 h in TFE.
 b
In most cases one of the 
byproducts observed was bridged lactam 3f with a tR of 3.43 min. 
c
1.0 M 
solution in hexanes was used. 
d
A 1.0 M solution in CH2Cl2 was used. 
e
A 
stock solution of catalyst in TFE was prepared and used. 
f
CBS catalyst 
(Corey–Bakshi–Shibata catalyst) = (R)-()-o-Tolyl-CBS-oxazaborolidine 
solution (0.5 M in toluene). ND = Not detected. 
 
Table S8. Alkali and Alkaline Earth Metal Lewis Acid and Brønsted Acid Catalyst 
Screening with TFE
a
 
entry 
catalyst 
(10 mol %) 
unreacted substrate 
product 
conversion 
(2f:2e) 
other 
byproducts 
observed
b
 1f 1e 
1 LiOTf 88% 6% ND ≥1 
2 Mg(OTf)2 90% 5% ~2% ≥1 
3 Ba(OTf)2 93% 5% ND ≥1 
4 CF3CO2H
c
 21% 11% 60% (~1.7:1) ≥3 
5 HCl
d
 17% 6% 66% (~1:1) ≥3 
6 BNDHP 11% 15% 71% (~1:1) ≥2 
7 Armstrong’s acid 4% trace 82% (~3:1) ≥2 
8 p-TsOH 41% 4% 48% (~5:1) ≥2 
9 CF3SO3H
c
 31% trace 57% (~7:1) ≥3 
a
All reactions were run at 80 C for 16 h in TFE.
 b
In most cases one of the 
byproducts observed was bridged lactam 3f with a tR of 3.43 min. 
c
A stock 
solution of catalyst in TFE was prepared and used. 
d
A 2.0 M solution in Et2O 
was used. ND = Not detected.  
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Table S9. Catalyst Screening with 5 mol % Sc(OTf)3 and 20 mol % HCl
a
 
entry catalyst 
catalyst 
(mol %) 
additive 
unreacted substrate 
product 
conversion 
(2f:2e)
b
 1f 1e 
1 Sc(OTf)3 5 – 28% 20% 40% (~2.5:1) 
2 Sc(OTf)3 5 
CH3CO2H 
(1 equiv) 
28% 5% 53% (~5:1) 
3 HCl
c
 20 – ND ND ~100% (~1:3.5) 
a
All reactions were run at 80 C for 16 h in TFE.
 b
Byproducts (≥2) were observed in all 
cases and one of the byproducts was bridged lactam 3f. 
c
A 2.0 M solution in ether was 
used. ND = Not detected.  
 
Table S10. Catalyst Screening at 50 C with TFE
a
 
entry 
catalyst 
(10 mol %) 
unreacted substrate 
product 
yield
b,c
 
(2f:2e) 1f 1e 
1 SiCl4
d
 ND ND 90% (~1:1) 
2 TiCl4
d
 ND ND 93% (~1.7:1) 
3 Hf(OTf)4 hydrate obs trace 73% (~7:1) 
4 Bi(OTf)3 trace trace 77% (~6.2:1) 
5 Fe(OTf)3 trace ND 68% (~6.7:1) 
6 ZrCl4 obs obs 73% (~1.7:1) 
7 WCl6 ND ND 80% (~2.3:1) 
8 AuCl3 obs obs 64% (~4.5:1) 
9 NbCl5 ND ND 89% (~1.1:1) 
a
All reactions were run at 50 C for 16 h in TFE.
 b
Represents isolated 
yield after preparative TLC purification. 
c
The ratio of products (2f:2e) 
was determined by 
1
H NMR. 
d
A 1.0 M solution in CH2Cl2 was used. 
ND = Not detected. obs = Substrate peak was observed by UPLC. 
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Table S11. Catalyst Screening at 25 C with TFE
a
 
entry catalyst 
catalysts 
(mol %) 
unreacted substrate 
product 
conversion 
(2f:2e)
b
 1f 1e 
1 SiCl4
c
 10 9% 3% 79% (1.4:1) 
2 SiCl4
c
 5 29% 5% 55% (1.7:1) 
3 TiCl4
c
 10 5% 2% 80% (3:1) 
4 TiCl4
c
 5 18% 3% 61% (4.2:1) 
5 WCl6 10 ND ND 57%
d
 (5.2:1) 
6 NbCl5 10 4% 2% 74% (3:1) 
a
All reactions were run at 25 C for 8 h in TFE.
 b
The ratio of products 
(2f:2e) was determined by UPLC except for entry 5. 
c
A 1.0 M solution 
in CH2Cl2 was used. 
d
Represents isolated yield after preparative TLC 
purification and the ratio of products (2f:2e) was determined by 
1
H 
NMR. ND = Not determined.  
 
Table S12. Catalyst Screening at 20 C
a
 
entry 
catalyst 
(10 mol %) 
solvent 
unreacted substrate 
product 
conversion 
(2f:2e)
b
 1f 1e 
A Bi(OTf)3 Trifluoroethanol 19% trace 61% (~3.5:1) 
B Fe(OTf)3 Trifluoroethanol 19% trace 62% (~7:1) 
C In(OTf)3 Trifluoroethanol 27% trace 56% (~7:1) 
D Al(OTf)3 Trifluoroethanol 37% trace 43% (~5.5:1) 
E ZrCl4 Trifluoroethanol 4% 28% 61% (~1:12) 
F Armstrong’s acid Trifluoroethanol 30% trace 50% (~6:1) 
G Fe(OTf)3 Nitromethane 25% trace 33% (~6:1) 
H ZrCl4 Nitromethane trace 69% 14% 
a
All reactions were run at 20 C for 16 h (extending the reaction period to 24 h had 
minimal effect in increasing the product conversion). 
b
Byproducts (≥2) were observed 
in all cases and one of the byproducts was bridged lactam 3f.  
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Table S13. Catalyst Screening at 25 C with HFIP
a
 
entry 
catalyst 
(10 mol %) 
product 
yield
b,c
 
(2f:2e) 
bridged 
lactam
b
 (3f) 
A TiCl4
d
 85% (9:1) ~4% 
B SiCl4
d
 84% (4.7:1) ~4% 
a
All reactions were run at 25 C for 4 h in HFIP.
 
b
Represents isolated yield after preparative TLC 
purification. 
c
The ratio of products (2f:2e) was 
determined by 
1
H NMR. 
d
A 1.0 M solution in CH2Cl2 was 
used.  
 
 
 
Figure S2. Representative UPLC chromatogram showing AUC for the possible outcomes 
of an incomplete intramolecular Schmidt reaction for one of the entries during catalyst 
screening.  
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General Procedure for Reaction Conditions Optimization (Table 1). To a solution 
of trans azido ketone 1f (0.0257 g, 0.100 mmol, 1.0 equiv) in solvent (0.50 mL) at rt was 
added catalyst (5–20 mol %) and/or an additive under nitrogen or argon atmosphere in a 
one dram vial. The vial was capped and the reaction mixture was stirred at 25 or 37 C for 
12–38 h. The reaction progress was monitored by UPLC. The reaction mixture was 
concentrated under nitrogen gas. The residue obtained was diluted with CH2Cl2 and applied 
on a preparative TLC plate. Preparative TLC plate was either developed once or twice with 
100 % CH2Cl2 or 2% MeOH/CH2Cl2. Bands corresponding to substrates (1f and 1e), 
products (2f and 2e), and bridged lactam (3f) were scraped and eluted with 100% CH2Cl2 or 
5% MeOH/CH2Cl2 through a phase separator tabless. Evaporation of elution under reduced 
pressure provided recovered substrates (trans azido ketone 1f and cis azido ketone 1e), 
products (trans fused lactam 2f and cis fused lactam 2e), and bridged lactam 3f, 
respectively. Ratios of 1f:1e and 2f:2e were determined by 
1
H NMR or UPLC. 
 
General Procedure A for the Catalytic Intramolecular Schmidt Reaction using 
TiCl4 (Tables 3 and 4). To a solution of azido ketone in HFIP in a nitrogen-flushed four 
dram vial was added a 1.0 M solution of TiCl4 in CH2Cl2 (2.5–35 mol %). The vial was 
capped and the reaction mixture was stirred at 25 C for 18–62 h (gas evolution was 
observed upon addition of TiCl4). The reaction mixture was concentrated under nitrogen 
gas. The residue obtained was diluted with CH2Cl2 and loaded on a silica gel in a 5 g 
sample cartridge. Purification using a 4 g normal phase silica flash column on a 
CombiFlash Rf system with a gradient elution of 0–5% MeOH/CH2Cl2 afforded the 
corresponding lactam products after concentration of appropriate fractions.  
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Hexahydro-1H-pyrrolo[1,2-a]azepin-5(6H)-one (2c). To a solution of 2-(3′-
azidopropyl)cyclohexanone 1c (0.0725 g, 0.400 mmol, 1.0 equiv) in HFIP (2.0 mL) in a 
nitrogen-flushed four dram vial was added a 1.0 M solution of TiCl4 in CH2Cl2 (10.0 L, 
0.0100 mmol, 0.025 equiv). The vial was capped and the reaction mixture was stirred at 25 
C for 20 h. The reaction mixture was concentrated under nitrogen gas. The residue 
obtained was diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. 
Purification using a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 
over 45 min) afforded lactam 2c as a pale yellow oil in 94% yield (0.0575 g, 0.375 mmol). 
 
 
(8S,9aS)-rel-8-Phenylhexahydro-1H-pyrrolo[1,2-a]azepin-5(6H)-one (cis-2e). To 
a solution of (2S,4S)-rel-2-(3′-azidopropyl)-4-phenylcyclohexanone 1e (0.103 g, 0.400 
mmol, 1.0 equiv) in HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added a 1.0 M 
solution of TiCl4 in CH2Cl2 (10.0 L, 0.0100 mmol, 0.025 equiv). The vial was capped and 
the reaction mixture was stirred at 25 C for 20 h. The reaction mixture was concentrated 
under nitrogen gas. The residue obtained was diluted with CH2Cl2 and loaded on a silica gel 
in a 5 g sample cartridge. Purification using a 4 g flash column on a CombiFlash Rf system 
(0–5% MeOH/CH2Cl2 over 45 min) afforded 2e as a pale yellow oil in 98% yield (0.0901 
g, 0.393 mmol). Lactam (cis-2e): Rf = 0.31 (2% MeOH/CH2Cl2); IR (neat) 1626, 1450, 
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1425 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.59–1.79 (m, 4H), 1.81–1.88 (m, 1H), 1.90–
1.97 (m, 2H), 2.18–2.26 (m, 1H), 2.50–2.64 (m, 2H), 2.75 (tt, J = 12.2, 3.3 Hz, 1H), 3.37–
3.44 (m, 1H), 3.69 (m, 1H), 3.79–3.85 (m, 1H), 7.11–7.18 (m, 3H), 7.24–7.27 (m, 2H); 
13
C 
NMR (100 MHz, CDCl3)  23.4, 30.6, 34.9, 37.4, 43.5, 46.9, 48.1, 57.9, 126.5, 126.6, 
128.6, 146.4, 173.4; HRMS (ESI) m/z calcd for C15H20NO [M H]
+ 
230.1545, found 
230.1555; Anal. Calcd for C15H19NO: C, 78.56; H, 8.35; N, 6.11. Found: C, 78.08; H, 8.28; 
N 5.98; Cl, 0.43 (the presence of chlorine in the sample could be from the residual CH2Cl2 
used for transferring the sample or from a trace amount of HCl complexed with the lactam). 
 
The cis configuration for lactam 2e was determined by NOESY experiment. 
 
 
(8S,9aR)-rel-8-Phenylhexahydro-1H-pyrrolo[1,2-a]azepin-5(6H)-one (trans-2f) 
and (4R,6R)-rel-4-Phenyl-1-azabicyclo[4.3.1]decan-10-one (3f). To a solution of (2R,4S)-
rel-2-(3′-azidopropyl)-4-phenylcyclohexanone 1f (0.103 g, 0.400 mmol, 1.0 equiv) in HFIP 
(2.0 mL) in a nitrogen-flushed four dram vial was added a 1.0 M solution of TiCl4 in 
CH2Cl2 (20.0 L, 0.0200 mmol, 0.050 equiv). The vial was capped and the reaction 
mixture was stirred at 25 C for 38 h. The reaction mixture was concentrated under 
nitrogen gas. The residue obtained was diluted with CH2Cl2 and applied on a preparative 
TLC plate. Preparative TLC plate was developed twice with 2% MeOH/CH2Cl2. Bands 
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corresponding to fused lactam 2f and bridged lactam 3f were scraped and eluted with 5% 
MeOH/CH2Cl2 through a phase separator tabless. Evaporation of elution under reduced 
pressure afforded 2f as a pale yellow oil in 87% yield (0.0796 g, 0.347 mmol) and 3f as a 
colorless oil in ca. 2% yield (0.00220 g, 0.00959 mmol). Fused lactam (trans-2f): Rf = 0.18 
(2% MeOH/CH2Cl2); IR (neat) 1628, 1426 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.61–1.70 
(m, 1H), 1.72–1.81 (m, 1H), 1.84–1.96 (m, 2H), 2.01 (m, 1H), 2.09–2.20 (m, 3H), 2.46–
2.53 (m, 1H), 2.71 (m, 1H), 3.02 (m, 1H), 3.48–3.60 (m, 2H), 3.98 (m, 1H), 7.19–7.23 (m, 
3H), 7.29–7.33 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  23.0, 27.6, 34.2, 34.6, 39.5, 39.6, 
46.8, 54.7, 126.4, 127.3, 128.8, 144.6, 172.3; HRMS (ESI) m/z calcd for C15H20NO [M 
H]
+ 
230.1545, found 230.1545.  
Bridged lactam 3f: Rf = 0.25 (2% MeOH/CH2Cl2); IR (neat) 1675, 1492 cm
–1
; 
1
H 
NMR (500 MHz, CDCl3)  1.56–1.65 (m, 1H), 1.67–1.76 (m, 1H), 1.77–1.93 (complex, 
4H), 2.24 (m, 1H), 2.42 (dtd, J = 14.5, 11.2, 7.4 Hz, 1H), 2.75 (ddd, J = 13.8, 11.2, 6.4 Hz, 
1H), 3.00 (td, J = 11.8, 2.0 Hz, 1H), 3.08 (dtd, J = 10.2, 5.1, 2.0 Hz, 1H), 3.39 (td, J = 11.4, 
3.1 Hz, 1H), 3.60–3.64 (m, 1H), 3.89 (dd, J = 13.8, 7.3 Hz, 1H), 7.11–7.13 (m, 2H), 7.17–
7.20 (m, 1H), 7.26–7.30 (m, 2H); 
13
C NMR (125 MHz, CDCl3)  22.4, 28.3, 32.5, 39.9, 
45.2, 46.0, 49.1, 54.3, 126.4, 126.7, 128.8, 148.0, 184.9; HRMS (ESI) m/z calcd for 
C15H20NO [M H]
+ 
230.1545, found 230.1566. Bridged lactam 3f seemed to be unstable. 
 
 
9a-Methyltetrahydro-1H-pyrrolo[1,2-a]azepine-5,9(6H,9aH)-dione (2b). To a 
solution of 2-(3′-azidopropyl)-2-methylcyclohexane-1,3-dione 1b (0.0837 g, 0.400 mmol, 
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1.0 equiv) in HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added a 1.0 M 
solution of TiCl4 in CH2Cl2 (20.0 L, 0.0200 mmol, 0.050 equiv). The vial was capped and 
the reaction mixture was stirred at 25 C for 24 h. The reaction mixture was concentrated 
under nitrogen gas. The residue obtained was diluted with CH2Cl2 and loaded on a silica gel 
in a 5 g sample cartridge. Purification using a 4 g flash column on a CombiFlash Rf system 
(0–5% MeOH/CH2Cl2 over 50 min) afforded lactam 2b as a cream-yellow solid in 94% 
yield (0.0681 g, 0.376 mmol). 
 
 
Ethyl 5-oxooctahydro-1H-pyrrolo[1,2-a]azepine-9a-carboxylate (2d). To a 
solution of ethyl 1-(3′-azidopropyl)-2-oxocyclohexanecarboxylate 1d (0.101 g, 0.400 
mmol, 1.0 equiv) in HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added a 1.0 M 
solution of TiCl4 in CH2Cl2 (20.0 L, 0.0200 mmol, 0.050 equiv). The vial was capped and 
the reaction mixture was stirred at 25 C for 40 h. The reaction mixture was concentrated 
under nitrogen gas. The residue obtained was diluted with CH2Cl2 and loaded on a silica gel 
in a 5 g sample cartridge. Purification using a 4 g flash column on a CombiFlash Rf system 
(0–5% MeOH/CH2Cl2 over 30 min) afforded lactam 2d as a white solid in 94% yield 
(0.0850 g, 0.377 mmol). 
The reaction of 1d (0.101 g, 0.400 mmol, 1.0 equiv) with 1.0 M solution of TiCl4 in 
CH2Cl2 (40 L, 0.0400 mmol, 0.10 equiv) for 18 h in a similar way as described above 
afforded 2d in 95% yield (0.0856 g, 0.380 mmol). 
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2,3,11,11a-Tetrahydro-1H-benzo[d]pyrrolo[1,2-a]azepin-5(6H)-one (2g). To a 
solution of 3-(3′-azidopropyl)-3,4-dihydronaphthalen-2(1H)-one 1g (0.0917 g, 0.400 mmol, 
1.0 equiv) in HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added a 1.0 M 
solution of TiCl4 in CH2Cl2 (20.0 L, 0.0200 mmol, 0.050 equiv). The vial was capped and 
the reaction mixture was stirred at 25 C for 24 h. The reaction mixture was concentrated 
under nitrogen gas. The residue obtained was diluted with CH2Cl2 and loaded on a silica gel 
in a 5 g sample cartridge. Purification using a 4 g flash column on a CombiFlash Rf system 
(0–5% MeOH/CH2Cl2 over 45 min) afforded lactam 2g as a pale orange solid in 89% yield 
(0.0720 g, 0.358 mmol). 
 
 
2-Methylenehexahydro-1H-pyrrolo[1,2-a]azepin-5(6H)-one (2h). To a solution of 
2-(2′-(azidomethyl)allyl)cyclohexanone 1h (0.0773 g, 0.400 mmol, 1.0 equiv) in HFIP (2.0 
mL) in a nitrogen-flushed four dram vial was added a 1.0 M solution of TiCl4 in CH2Cl2 
(20.0 L, 0.0200 mmol, 0.050 equiv). The vial was capped and the reaction mixture was 
stirred at 25 C for 24 h. The reaction mixture was concentrated under nitrogen gas. The 
residue obtained was diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample 
cartridge. Purification using a 4 g flash column on a CombiFlash Rf system (0–5% 
MeOH/CH2Cl2 over 35 min) afforded lactam 2h as a pale orange oil in 84% yield (0.0554 
g, 0.335 mmol). 
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Hexahydroindolizin-5(1H)-one (2a). To a solution of 2-(3′-azidopropyl)-
cyclopentanone 1a (0.0669 g, 0.400 mmol, 1.0 equiv) in HFIP (2.0 mL) in a nitrogen-
flushed four dram vial was added a 1.0 M solution of TiCl4 in CH2Cl2 (80.0 L, 0.0800 
mmol, 0.20 equiv). The vial was capped and the reaction mixture was stirred at 25 C for 
24 h. The reaction mixture was concentrated under nitrogen gas. The residue obtained was 
diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. Purification using 
a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 30 min) 
afforded lactam 2a as a pale yellow oil in 87% yield (0.0485 g, 0.348 mmol). 
The reaction of 1a (0.0669 g, 0.400 mmol, 1.0 equiv) with 1.0 M solution of TiCl4 in 
CH2Cl2 (60.0 L, 0.0600 mmol, 0.15 equiv) for 44 h in a similar way as described above 
afforded 2a in 79% yield (0.0440 g, 0.316 mmol).  
The reaction of 1a (0.0669 g, 0.400 mmol, 1.0 equiv) with a 1.0 M solution of TiCl4 
in CH2Cl2 (40.0 L, 0.0400 mmol, 0.10 equiv) for 44 h in a similar way as described above 
afforded 2a in 60% yield (0.0333 g, 0.239 mmol; 78% brsm). Azido ketone 1a was 
recovered in 23% yield (0.0157 g, 0.0939 mmol).  
 
 
Octahydropyrrolo[1,2-a]azocin-5(1H)-one (2i) and 1-Azabicyclo[5.3.1]undecan-
11-one (3i). To a solution of 2-(3′-azidopropyl)cycloheptanone 1i (0.0781 g, 0.400 mmol, 
1.0 equiv) in HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added a 1.0 M 
129 
 
solution of TiCl4 in CH2Cl2 (80.0 L, 0.0800 mmol, 0.20 equiv). The vial was capped and 
the reaction mixture was stirred at 25 C for 48 h. The reaction mixture was concentrated 
under nitrogen gas. The residue obtained was diluted with CH2Cl2 and loaded on a silica gel 
in a 5 g sample cartridge. Purification using a 4 g flash column on a CombiFlash Rf system 
(0–5% MeOH/CH2Cl2 over 45 min) afforded fused lactam 2i as a colorless oil in 86% yield 
(0.0573 g, 0.343 mmol) and 3i as a colorless oil in ca. 2% yield (0.00170 g, 0.0102 mmol). 
Bridged lactam 3i: Rf = 0.22 (2% MeOH/CH2Cl2); IR (neat) 1643, 1445, 1170 cm
–1
; 
1
H 
NMR (500 MHz, CDCl3)  1.44–1.54 (m, 3H), 1.60–1.76 (m, 3H), 1.77–1.88 (m, 3H), 1.96 
(m, 1H), 2.06 (m, 1H), 2.17–2.24 (m, 1H), 2.72 (dd, J = 13.6, 4.7 Hz, 1H), 2.74–2.79 (m, 
1H), 3.20 (ddd, J = 11.4, 6.5, 2.7 Hz, 1H), 3.64 (td, J = 11.7, 3.0 Hz, 1H), 4.58 (td, J = 13.3, 
4.1 Hz, 1H); 
13
C NMR (125 MHz, CDCl3)  22.6, 23.7, 25.5, 26.6, 32.4, 42.0, 42.1, 48.1, 
49.8, 181.3; HRMS (ESI) m/z calcd for C10H18NO [M + H]
+ 
168.1388, found 168.1392. 
The reaction of 1i (0.0781 g, 0.400 mmol, 1.0 equiv) with a 1.0 M solution of TiCl4 
in CH2Cl2 (20.0 L, 0.0200 mmol, 0.050 equiv) for 62 h in a similar way as described 
above afforded 2i in 34% yield (0.0228 g, 0.136 mmol; 85% brsm). Azido ketone 1i was 
recovered in 60% yield (0.0469 g, 0.240 mmol).  
 
 
Octahydro-1H-pyrrolo[1,2-a]azonin-5(6H)-one (2j). To a solution of 2-(3′-
azidopropyl)cyclooctanone 1j (0.0837 g, 0.400 mmol, 1.0 equiv) in HFIP (2.0 mL) in a 
nitrogen-flushed four dram vial was added a 1.0 M solution of TiCl4 in CH2Cl2 (100 L, 
0.100 mmol, 0.25 equiv). The vial was capped and the reaction mixture was stirred at 25 C 
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for 62 h. The reaction mixture was concentrated under nitrogen gas. The residue obtained 
was diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. Purification 
using a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 35 min) 
afforded lactam 2j as a colorless oil in 90% yield (0.0651 g, 0.359 mmol). 
 
 
(6S,9R,9aS)-rel-Hexahydro-1H-6,9-methanopyrrolo[1,2-a]azepin-5(6H)-one (2k). 
To a solution of (1S,3S,4R)-rel-3-(3′-azidopropyl)bicyclo[2.2.1]heptan-2-one 1k (0.0773 g, 
0.400 mmol, 1.0 equiv) in HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added a 
1.0 M solution of TiCl4 in CH2Cl2 (100 L, 0.100 mmol, 0.25 equiv). The vial was capped 
and the reaction mixture was stirred at 25 C for 62 h. The reaction mixture was 
concentrated under nitrogen gas. The residue obtained was diluted with CH2Cl2 and loaded 
on a silica gel in a 5 g sample cartridge. Purification using a 4 g flash column on a 
CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 35 min) afforded 2k as a colorless oil in 
87% yield (0.0574 g, 0.347 mmol; 90% brsm). Azido ketone 1k was recovered in 3% yield 
(0.00250 g, 0.0129 mmol). Lactam 2k: Rf = 0.19 (2% MeOH/CH2Cl2); IR (neat) 1641, 
1432, 1129 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  1.30–1.39 (m, 1H), 1.45 (dt, J = 11.8, 4.3 
Hz, 1H), 1.56–1.61 (m, 1H), 1.65 (d, J = 11.8 Hz, 1H), 1.68–1.90 (complex, 6H), 2.40 (m, 
1H), 2.70 (m, 1H), 3.00 (m, 1H), 3.08 (dd, J = 11.7, 4.7 Hz, 1H), 3.80 (ddd, J = 11.9, 8.9, 
7.6 Hz, 1H); 
13
C NMR (125 MHz, CDCl3)  21.9, 28.4, 29.5, 30.4, 32.1, 36.3, 43.0, 43.6, 
65.6, 175.2; HRMS (ESI) m/z calcd for C10H16NO [M H]
+ 
166.1232, found 166.1226. 
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The reaction of 1k (0.0773 g, 0.400 mmol, 1.0 equiv) with a 1.0 M solution of TiCl4 
in CH2Cl2 (40.0 L, 0.0400 mmol, 0.10 equiv) for 62 h in a similar way as described above 
afforded 2k in 43% yield (0.0285 g, 0.172 mmol; 78% brsm). Azido ketone 1k was 
recovered in 45% yield (0.0346 g, 0.179 mmol).  
 
 
3-Phenyl-1-(pyrrolidin-1-yl)propan-1-one (2l) and 1-Phenethylpiperidin-2-one 
(3l). To a solution of 7-azido-1-phenylheptan-3-one 1l (0.0925 g, 0.400 mmol, 1.0 equiv) in 
HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added a 1.0 M solution of TiCl4 in 
CH2Cl2 (100 L, 0.100 mmol, 0.25 equiv). The vial was capped and the reaction mixture 
was stirred at 25 C for 32 h. The reaction mixture was concentrated under nitrogen gas. 
The residue obtained was diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample 
cartridge. Purification using a 4 g flash column on a CombiFlash Rf system (0–5% 
MeOH/CH2Cl2 over 45 min) afforded a mixture of amide 2l and lactam 3l as a colorless oil 
in 94% yield (0.0763 g, 0.375 mmol; 2l:3l = 93:7 by 
1
H NMR).  
The reaction of 1l (0.0925 g, 0.400 mmol, 1.0 equiv) with a 1.0 M solution of TiCl4 
in CH2Cl2 (80.0 L, 0.0800 mmol, 0.20 equiv) for 24 h in a similar way as described above 
afforded a mixture of 2l and 3l as a pale yellow oil in 79% yield (0.0640 g, 0.315 mmol, 
96% brsm; 2l:3l = 93:7 by 
1
H NMR). Azido ketone 1l was recovered in 18% yield (0.0165 
g, 0.0713 mmol).  
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1-(Pyrrolidin-1-yl)ethanone (2m) and N-Methyl-2-piperidone (3m). To a solution 
of 6-azidohexan-2-one 1m (0.0564 g, 0.400 mmol, 1.0 equiv) in HFIP (2.0 mL) in a 
nitrogen-flushed four dram vial was added a 1.0 M solution of TiCl4 in CH2Cl2 (80.0 L, 
0.0800 mmol, 0.20 equiv). The vial was capped and the reaction mixture was stirred at 25 
C for 24 h. The reaction mixture was concentrated under nitrogen gas. The residue 
obtained was diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. 
Purification using a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 
over 45 min) afforded a mixture of amide 2m and lactam 3m as a colorless oil in 86% yield 
(0.0390 g, 0.345 mmol; 2m:3m = 97:3 by 
1
H NMR).  
The reaction of 1m (0.0564 g, 0.400 mmol, 1.0 equiv) with a 1.0 M solution of TiCl4 
in CH2Cl2 (60.0 L, 0.0600 mmol, 0.15 equiv) for 24 h in a similar way as described above 
afforded a mixture of 2m and 3m as a colorless oil in 77% yield (0.0350 g, 0.309 mmol, 
81% brsm; 2m:3m = 97:3 by 
1
H NMR). Azido ketone 1m was recovered in 4% yield 
(0.00250 g, 0.0177 mmol).  
The reaction of 1m (0.0564 g, 0.400 mmol, 1.0 equiv) with a 1.0 M solution of TiCl4 
in CH2Cl2 (40.0 L, 0.0400 mmol, 0.10 equiv) for 36 h in a similar way as described above 
afforded a mixture of 2m and 3m as a colorless oil in 73% yield (0.0331 g, 0.292 mmol; 
2m:3m = 97:3 by 
1
H NMR). 
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2-Methyl-1,2-dihydroisoquinolin-3(4H)-one (2n) and 1-(Isoindolin-2-yl)ethanone 
(3n). To a solution of 1-(2′-(azidomethyl)phenyl)propan-2-one 1n (0.0757 g, 0.400 mmol, 
1.0 equiv) in HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added a 1.0 M 
solution of TiCl4 in CH2Cl2 (60.0 L, 0.0600 mmol, 0.15 equiv). The vial was capped and 
the reaction mixture was stirred at 25 C for 24 h. The reaction mixture was concentrated 
under nitrogen gas. The residue obtained was diluted with CH2Cl2 and loaded on a silica gel 
in a 5 g sample cartridge. Purification using a 4 g flash column on a CombiFlash Rf system 
(0–5% MeOH/CH2Cl2 over 45 min) afforded a mixture of lactam 2n and amide 3n as a 
yellow oil in 64% yield (0.0411 g, 0.255 mmol; 2n:3n = 79:21 (ca. 4:1) by 
1
H NMR).  
The reaction of 1n (0.0757 g, 0.400 mmol, 1.0 equiv) with a 1.0 M solution of TiCl4 
in CH2Cl2 (40.0 L, 0.0400 mmol, 0.10 equiv) for 24 h in a similar way as described above 
afforded a mixture of 2n and 3n as a yellow oil in 58% yield (0.0376 g, 0.233 mmol, 64% 
brsm; 2n:3n = 77:23 by 
1
H NMR). Azido ketone 1n was recovered in 9% yield (0.00700 g, 
0.0370 mmol).  
 
 
9a-Phenyloctahydro-5H-pyrrolo[1,2-a]azepin-5-one (2o) and 6-Phenyl-1-
azabicyclo[4.3.1]decan-10-one (3o). To a solution of 2-(3′-azidopropyl)-2-phenyl-
cyclohexan-1-one 1o (0.103 g, 0.400 mmol, 1.0 equiv) in HFIP (2.0 mL) in a nitrogen-
flushed four dram vial was added a 1.0 M solution of TiCl4 in CH2Cl2 (100 L, 0.100 
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mmol, 0.25 equiv). The vial was capped and the reaction mixture was stirred at 25 C for 
48 h. The reaction mixture was concentrated under nitrogen gas. The residue obtained was 
diluted with CH2Cl2 (1.0 mL), quenched with Et3N (0.10 mL), and reconcentrated. A 
solution of the resulting residue in CH2Cl2 was loaded on a silica gel in a 5 g sample 
cartridge. Purification using a 4 g flash column on a CombiFlash Rf system (0–5% 
MeOH/CH2Cl2 over 50 min) afforded 3o (eluted between 0.8–1.2% MeOH/CH2Cl2) as a 
pale yellow waxy solid in 5% yield (0.0050 g, 0.022 mmol) and fused lactam 2o (eluted 
between 1.3–1.7% MeOH/CH2Cl2) as a pale orange solid in 87% yield (0.0802 g, 0.350 
mmol). Bridged lactam 3o: Rf = 0.39 (2% MeOH/CH2Cl2); IR (neat) 1664, 1177 cm
–1
; 
1
H 
NMR (500 MHz, CDCl3)  1.78–1.87 (complex, 3H), 1.88–1.96 (complex, 2H), 1.97–2.04 
(complex, 3H), 2.09–2.13 (m, 1H), 2.25 (m, 1H), 2.65–2.70 (m, 1H), 3.42 (m, 1H), 3.60 
(m, 1H), 3.92 (m, 1H), 7.19–7.22 (m, 1H), 7.29–7.34 (m, 4H); 
13
C NMR (125 MHz, 
CDCl3)  22.5, 22.7, 24.9, 38.0, 41.1, 49.1, 53.0, 56.7, 126.4, 126.5, 128.6, 147.1, 183.9; 
HRMS (ESI) m/z calcd for C15H20NO [M H]
+
 230.1545, found 230.1538. 
 
 
2-Benzylhexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-5(2H)-one (2p). To a solution 
of 3-(3′-azidopropyl)-1-benzylpiperidin-4-one 1p (0.109 g, 0.400 mmol, 1.0 equiv) in HFIP 
(2.0 mL) in a nitrogen-flushed four dram vial was added a 1.0 M solution of TiCl4 in 
CH2Cl2 (140 L, 0.140 mmol, 0.35 equiv). The vial was capped and the reaction mixture 
was stirred at 25 C for 20 h. The reaction mixture was concentrated under nitrogen gas. 
The residue obtained was diluted with CH2Cl2, neutralized with saturated aqueous NaHCO3 
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solution (0.6 mL), dried over Na2SO4, and concentrated under reduced pressure. The orange 
residue obtained was re-dissolved in CH2Cl2 and loaded on a silica gel in a 5 g sample 
cartridge. Purification using a 4 g flash column on a CombiFlash Rf system (0–5% 
MeOH/CH2Cl2 over 35 min) afforded lactam 2p as a colorless oil in 90% yield (0.0876 g, 
0.359 mmol).  
During the initial addition of TiCl4 solution up to 25 mol %, a formation of yellow 
solid was observed (presumably, the HCl salt of amine). Work-up with aqueous NaHCO3 
was necessary to neutralize the amine salt into free amine base for purification and TLC 
monitoring. 
 
 
3-Benzylpyrrolidin-2-one (2q). To a solution of 4-azido-2-benzylbutanal 1q (0.0813 
g, 0.400 mmol, 1.0 equiv) in HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added 
a 1.0 M solution of TiCl4 in CH2Cl2 (20.0 L, 0.0200 mmol, 0.05 equiv). The vial was 
capped and the reaction mixture was stirred at 25 C for 24 h. The reaction mixture was 
concentrated under nitrogen gas. The residue obtained was diluted with CH2Cl2 and loaded 
on a silica gel in a 5 g sample cartridge. Purification using a 4 g flash column on a 
CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 35 min) afforded lactam 2q as a pale 
blue crystalline solid in 86% yield (0.0604 g, 0.345 mmol). 
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Octahydropyrido[1,2-a]azepin-6(2H)-one (2r). To a solution of 2-(4′-
azidobutyl)cyclohexanone 1r (0.0781 g, 0.400 mmol, 1.0 equiv) in HFIP (2.0 mL) in a 
nitrogen-flushed four dram vial was added a 1.0 M solution of TiCl4 in CH2Cl2 (80.0 L, 
0.0800 mmol, 0.20 equiv). The vial was capped and the reaction mixture was stirred at 25 
C for 60 h. The reaction mixture was concentrated under nitrogen gas. The residue 
obtained was diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. 
Purification using a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 
over 45 min) afforded lactam 2r as a pale yellow oil in 11% yield (0.00720 g, 0.0431 
mmol; 20% brsm). Azido ketone 1r was recovered in 47% yield (0.0370 g, 0.190 mmol).  
 
General Procedure for Reaction Conditions Optimization (Table 5). To a solution 
of 2-(3′-azidopropyl)cyclopentanone 1a (0.0167 g, 0.100 mmol, 1.0 equiv) in HFIP (0.50 
mL) at rt was added catalyst (5–40 mol %) and/or additive (5–80 mol %) under nitrogen 
atmosphere in a one dram vial. The vial was capped and the reaction mixture was stirred at 
25 C for 24 h. The reaction mixture was concentrated under nitrogen gas. The residue 
obtained was diluted with 5% MeOH/CH2Cl2 and eluted through a phase separator tabless 
containing a short bed of silica gel. Evaporation of elution under reduced pressure provided 
a mixture of 1a and hexahydroindolizin-5(1H)-one 2a, whose ratios were determined by 
1
H 
NMR. 
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General Procedure B for the Catalytic Intramolecular Schmidt Reaction using 
AcCl (Table 6). To a solution of azido ketone in HFIP in a nitrogen-flushed four dram vial 
was added AcCl (10–100 mol %). The vial was capped and the reaction mixture was stirred 
at 25 C for 20–62 h (gas evolution was observed upon addition of AcCl). The reaction 
mixture was concentrated under nitrogen gas. The residue obtained was diluted with 
CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. Purification using a 4 g normal 
phase silica flash column on a CombiFlash Rf system with a gradient elution of 0–5% 
MeOH/CH2Cl2 afforded the corresponding lactam products after concentration of 
appropriate fractions.  
 
 
Hexahydro-1H-pyrrolo[1,2-a]azepin-5(6H)-one (2c). To a solution of 2-(3′-
azidopropyl)cyclohexanone 1c (0.0725 g, 0.400 mmol, 1.0 equiv) in HFIP (2.0 mL) in a 
nitrogen-flushed four dram vial was added AcCl (2.84 L, 0.0400 mmol, 0.10 equiv). The 
vial was capped and the reaction mixture was stirred at 25 C for 20 h. The reaction 
mixture was concentrated under nitrogen gas. The residue obtained was diluted with 
CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. Purification using a 4 g flash 
column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 45 min) afforded lactam 2c 
as a pale yellow oil in 95% yield (0.0582 g, 0.380 mmol). 
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(8S,9aS)-rel-8-Phenylhexahydro-1H-pyrrolo[1,2-a]azepin-5(6H)-one (cis-2e). To 
a solution of (2S,4S)-rel-2-(3′-azidopropyl)-4-phenylcyclohexanone 1e (0.103 g, 0.400 
mmol, 1.0 equiv) in HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added AcCl 
(2.84 L, 0.0400 mmol, 0.10 equiv). The vial was capped and the reaction mixture was 
stirred at 25 C for 20 h. The reaction mixture was concentrated under nitrogen gas. The 
residue obtained was diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample 
cartridge. Purification using a 4 g flash column on a CombiFlash Rf system (0–5% 
MeOH/CH2Cl2 over 45 min) afforded cis fused lactam 2e as a colorless oil in 98% yield 
(0.0897 g, 0.391 mmol).  
 
 
(8S,9aR)-rel-8-Phenylhexahydro-1H-pyrrolo[1,2-a]azepin-5(6H)-one (trans-2f) 
and (4R,6R)-rel-4-Phenyl-1-azabicyclo[4.3.1]decan-10-one (3f). To a solution of (2R,4S)-
rel-2-(3′-azidopropyl)-4-phenylcyclohexanone 1f (0.0257 g, 0.100 mmol, 1.0 equiv) in 
HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added AcCl (1.42 L, 0.0200 
mmol, 0.20 equiv). The vial was capped and the reaction mixture was stirred at 25 C for 
38 h. The reaction mixture was concentrated under nitrogen gas. The residue obtained was 
diluted with CH2Cl2 and applied on a preparative TLC plate. Preparative TLC plate was 
developed twice with 2% MeOH/CH2Cl2. Bands corresponding to trans fused lactam 2f and 
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bridged lactam 3f were scraped and eluted with 5% MeOH/CH2Cl2 through a phase 
separator tabless. Evaporation of elution under reduced pressure afforded 2f as a colorless 
oil in 90% yield (0.0206 g, 0.0898 mmol) and 3f as a colorless oil in ca. 3% yield 
(0.000600 g, 0.00261 mmol).  
 
 
9a-Methyltetrahydro-1H-pyrrolo[1,2-a]azepine-5,9(6H,9aH)-dione (2b). To a 
solution of 2-(3′-azidopropyl)-2-methylcyclohexane-1,3-dione 1b (0.0837 g, 0.400 mmol, 
1.0 equiv) in HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added AcCl (5.70 L, 
0.0800 mmol, 0.20 equiv). The vial was capped and the reaction mixture was stirred at 25 
C for 24 h. The reaction mixture was concentrated under nitrogen gas. The residue 
obtained was diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. 
Purification using a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 
over 50 min) afforded lactam 2b as a cream-yellow solid in 95% yield (0.0692 g, 0.382 
mmol). 
 
 
2-Methylenehexahydro-1H-pyrrolo[1,2-a]azepin-5(6H)-one (2h). To a solution of 
2-(2′-(azidomethyl)allyl)cyclohexanone 1h (0.0773 g, 0.400 mmol, 1.0 equiv) in HFIP (2.0 
mL) in a nitrogen-flushed four dram vial was added AcCl (5.70 L, 0.0800 mmol, 0.20 
equiv). The vial was capped and the reaction mixture was stirred at 25 C for 24 h. The 
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reaction mixture was concentrated under nitrogen gas. The residue obtained was diluted 
with CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. Purification using a 4 g 
flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 45 min) afforded 
lactam 2h as a pale orange oil in 77% yield (0.0508 g, 0.307 mmol). 
 
 
2-Methyl-1,2-dihydroisoquinolin-3(4H)-one (2n) and 1-(Isoindolin-2-yl)ethanone 
(3n). To a solution of 1-(2′-(azidomethyl)phenyl)propan-2-one 1n (0.0757 g, 0.400 mmol, 
1.0 equiv) in HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added AcCl (17.1 L, 
0.240 mmol, 0.60 equiv). The vial was capped and the reaction mixture was stirred at 25 C 
for 24 h. The reaction mixture was concentrated under nitrogen gas. The residue obtained 
was diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. Purification 
using a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 45 min) 
afforded a mixture of lactam 2n and amide 3n as a yellow oil in 68% yield (0.0437 g, 0.271 
mmol; 2n:3n = 65:35 by 
1
H NMR).  
 
 
Hexahydroindolizin-5(1H)-one (2a). To a solution of 2-(3′-azidopropyl)-
cyclopentanone 1a (0.0669 g, 0.400 mmol, 1.0 equiv) in HFIP (2.0 mL) in a nitrogen-
flushed four dram vial was added AcCl (22.8 L, 0.320 mmol, 0.80 equiv). The vial was 
capped and the reaction mixture was stirred at 25 C for 24 h. The reaction mixture was 
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concentrated under nitrogen gas. The residue obtained was diluted with CH2Cl2 and loaded 
on a silica gel in a 5 g sample cartridge. Purification using a 4 g flash column on a 
CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 45 min) afforded lactam 2a as a pale 
yellow oil in 90% yield (0.0503 g, 0.361 mmol). 
 
 
Octahydropyrrolo[1,2-a]azocin-5(1H)-one (2i) and 1-Azabicyclo[5.3.1]undecan-
11-one (3i). To a solution of 2-(3′-azidopropyl)cycloheptanone 1i (0.0781 g, 0.400 mmol, 
1.0 equiv) in HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added AcCl (22.8 L, 
0.320 mmol, 0.80 equiv). The vial was capped and the reaction mixture was stirred at 25 C 
for 48 h. The reaction mixture was concentrated under nitrogen gas. The residue obtained 
was diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. Purification 
using a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 45 min) 
afforded fused lactam 2i as a pale yellow oil in 87% yield (0.0583 g, 0.349 mmol) and 
bridged lactam 3i as a pale yellow oil in ca. 3% yield (0.00220 g, 0.0132 mmol).  
 
 
(6S,9R,9aS)-rel-Hexahydro-1H-6,9-methanopyrrolo[1,2-a]azepin-5(6H)-one (2k). 
To a solution of (1S,3S,4R)-rel-3-(3′-azidopropyl)bicyclo[2.2.1]heptan-2-one 1k (0.0773 g, 
0.400 mmol, 1.0 equiv) in HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added 
AcCl (28.4 L, 0.400 mmol, 1.0 equiv). The vial was capped and the reaction mixture was 
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stirred at 25 C for 62 h. The reaction mixture was concentrated under nitrogen gas. The 
residue obtained was diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample 
cartridge. Purification using a 4 g flash column on a CombiFlash Rf system (0–5% 
MeOH/CH2Cl2 over 45 min) afforded lactam 2k as a colorless oil in 92% yield (0.0610 g, 
0.369 mmol).  
 
 
3-Phenyl-1-(pyrrolidin-1-yl)propan-1-one (2l) and 1-Phenethylpiperidin-2-one 
(3l). To a solution of 7-azido-1-phenylheptan-3-one 1l (0.0925 g, 0.400 mmol, 1.0 equiv) in 
HFIP (2.0 mL) in a nitrogen-flushed four dram vial was added AcCl (28.4 L, 0.400 mmol, 
1.0 equiv). The vial was capped and the reaction mixture was stirred at 25 C for 32 h. The 
reaction mixture was concentrated under nitrogen gas. The residue obtained was diluted 
with CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. Purification using a 4 g 
flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 45 min) afforded a 
mixture of amide 2l and lactam 3l as a pale yellow oil in 96% yield (0.0784 g, 0.386 mmol; 
2l:3l = 93:7 by 
1
H NMR).  
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Experimental Procedure for the Synthesis of 17-Azaestrone Analogues 7 and 8 
(Schemes 11 and 12) 
 
(8R,9S,13S,14S,16R)-16-(3′-Chloropropyl)-3-methoxy-13-methyl-7,8,9,11,12,13, 
15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one (5). To a cooled 1.0 M 
LDA solution (2.11 mL, 2.11 mmol, 1.2 equiv) in THF at –78 °C in a flame-dried flask 
under argon atmosphere was added a suspension of estrone 3-methyl ether 4 (0.500 g, 1.76 
mmol, 1.0 equiv) in THF (10 mL) slowly over 10 min, and the reaction mixture was 
allowed to warmed to rt over 30 min. The resulting colorless solution was cooled to –78 °C 
and HMPA (1.5 mL) was added followed by 1-chloro-3-iodopropane (0.226 mL, 2.11 
mmol, 1.2 equiv) over 5 min. The pale yellow solution was stirred at –78 °C for 1 h, 
warmed to rt and stirred for 1.5 h. The reaction mixture was quenched with saturated 
aqueous solution of NH4Cl (25 mL) and extracted with ether (3 × 30 mL). The combined 
organic extracts were washed with water (2 × 50 mL), brine (1 × 50 mL), dried over 
Na2SO4, and concentrated under reduced pressure. Purification using a 24 g flash column 
on a CombiFlash Rf system (0–10% EtOAc/hexanes over 55 min) afforded a mixture of 5, 
4, and some unidentified byproducts. Subsequent purification of this mixture using a 24 g 
flash column on a CombiFlash Rf system (0–10% EtOAc/hexanes over 70 min) afforded a 
small amount of a mixture of 5, 4, and some unidentified byproducts along with the partial 
separation of 5 (C16- diastereomer) containing a little bit of byproduct (could be a C16- 
diastereomer of 5)
44
 as a colorless semisolid (0.420 g, 1.16 mmol, 66% corrected yield by 
1
H NMR). Chloro ketone 5: Rf = 0.47 (10% EtOAc/hexanes, run twice); IR (neat) 2930, 
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2863, 1733, 1609, 1499, 1038 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.95 (s, 3H), 1.37–1.63 
(complex, 6H), 1.77 (ddd, J = 12.6, 6.3, 1.6 Hz, 1H), 1.85–2.02 (complex, 6H), 2.24 (td, J 
= 10.4, 4.3 Hz, 1H), 2.36–2.41 (m, 1H), 2.49 (m, 1H), 2.91 (m, 2H), 3.56 (m, 2H), 3.78 (s, 
3H), 6.65 (d, J = 2.7 Hz, 1H), 6.72 (dd, J = 8.6, 2.8 Hz, 1H), 7.20 (d, J = 8.5 Hz, 1H); 
13
C 
NMR (100 MHz, CDCl3)  14.7, 25.9, 26.6, 27.7, 28.7, 29.7, 31.3, 31.8, 38.4, 44.1, 44.2, 
44.9, 48.4, 48.8, 55.3, 111.6, 114.0, 126.4, 132.1, 137.8, 157.7, 221.5; HRMS (ESI) m/z 
calcd for C22H30ClO2 [M H]
+ 
361.1934, found 361.1972. 
 
 
(8R,9S,13S,14S,16R)-16-(3′-Azidopropyl)-3-methoxy-13-methyl-7,8,9,11,12,13, 
15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one (6). To a solution of 
(8R,9S,13S,14S,16R)-16-(3′-chloropropyl)-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one 5 (0.352 g, 0.975 mmol, 1.0 equiv) 
in anhydrous DMF (5.0 mL) at rt under nitrogen atmosphere was added sodium iodide 
(0.175 g, 1.17 mmol, 1.2 equiv) followed by sodium azide (0.127 g, 1.95 mmol, 2.0 equiv), 
and the resulting pale yellow suspension was stirred at 80 C for 1 h. The reaction mixture 
was cooled to rt, diluted with water (40 mL), and extracted with ether (3 × 30 mL). The 
combined organic extracts were washed with water (3 × 40 mL), brine (1 × 40 mL), dried 
over Na2SO4, and concentrated under reduced pressure. Purification using a 24 g flash 
column on a CombiFlash Rf system (0–10% EtOAc/hexanes over 75 min) afforded a 
mixture of 6 and an unidentified byproduct (could be a C16- diastereomer of 6) along with 
the partial separation of 6 as a colorless waxy solid (0.267 g, 0.727 mmol, 74% corrected 
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yield by 
1
H NMR). Azido ketone 6: Rf = 0.42 (10% EtOAc/hexanes, run twice); IR (neat) 
2930, 2861, 2093, 1735, 1609, 1499, 1040 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.95 (s, 
3H), 1.32–1.63 (complex, 6H), 1.66–2.02 (complex, 7H), 2.24 (td, J = 10.4, 4.1 Hz, 1H), 
2.36–2.41 (m, 1H), 2.48 (m, 1H), 2.91 (m, 2H), 3.31 (m, 2H), 3.78 (s, 3H), 6.65 (d, J = 2.6 
Hz, 1H), 6.72 (dd, J = 8.5, 2.7 Hz, 1H), 7.20 (d, J = 8.5 Hz, 1H); 
13
C NMR (100 MHz, 
CDCl3)  14.7, 25.9, 26.6, 27.64, 27.67, 28.4, 29.7, 31.8, 38.4, 44.0, 44.4, 48.3, 48.7, 51.4, 
55.2, 111.6, 113.9, 126.4, 132.0, 137.8, 157.7, 221.4; HRMS (ESI) m/z calcd for 
C22H30NO2 [M H N2]
+ 
340.2277, found 340.2301. 
 
 
(4bS,6aS,11aR,12aS,12bR)-2-Methoxy-6a-methyl-4b,5,6,6a,9,10,11,11a,12,12a, 
13,14-dodecahydronaphtho[2,1-f]pyrrolo[1,2-b]isoquinolin-7(12bH)-one (7). To a 
solution of (8R,9S,13S,14S,16R)-16-(3′-azidopropyl)-3-methoxy-13-methyl-7,8,9,11,12,13, 
15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one 6 (0.0735 g, 0.200 mmol, 1.0 
equiv) in HFIP (1.0 mL) in a nitrogen-flushed two dram vial was added a 1.0 M solution of 
TiCl4 in CH2Cl2 (50.0 L, 0.0500 mmol, 0.25 equiv). The vial was capped and the reaction 
mixture was stirred at 25 C for 48 h (gas evolution was observed upon addition of TiCl4). 
The reaction mixture was concentrated under nitrogen gas. The residue obtained was 
diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. Purification using 
a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 50 min) 
afforded 7 (eluted between 1.5–2.1% MeOH/CH2Cl2) as an off-white solid in 73% yield 
(0.0495 g, 0.146 mmol; 88% brsm). Starting azido ketone 6 was also recovered during this 
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purification in 17% yield (0.0125 g, 0.0340 mmol). Methoxy lactam 7: Rf = 0.17 (2% 
MeOH in CH2Cl2); mp 134–137 C; IR (neat) 2939, 2863, 1640, 1501, 1442, 1041 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.07 (s, 3H), 1.23–1.37 (complex, 2H), 1.37–1.57 (m, 3H), 
1.67–1.80 (complex, 3H), 1.88–1.95 (m, 1H), 1.97–2.04 (m, 2H), 2.10–2.26 (m, 3H), 2.36 
(dq, J = 13.3, 3.6 Hz, 1H), 2.84 (m, 2H), 3.39 (ddd, J = 12.0, 9.7, 2.3 Hz, 1H), 3.55–3.64 
(m, 2H), 3.76 (s, 3H), 6.61 (d, J = 2.7 Hz, 1H), 6.71 (dd, J = 8.6, 2.7 Hz, 1H), 7.23 (d, J = 
8.5 Hz, 1H); 
13
C NMR (100 MHz, CDCl3)  15.1, 22.1, 26.0, 26.6, 28.4, 30.2, 33.8, 35.6, 
40.3, 40.7, 42.0, 42.7, 44.6, 53.8, 55.3, 111.7, 113.6, 126.6, 132.3, 137.6, 157.6, 176.1; 
HRMS (ESI) m/z calcd for C22H30NO2 [M H]
+ 
340.2277, found 340.2299. 
 
 
To a solution of (8R,9S,13S,14S,16R)-16-(3′-azidopropyl)-3-methoxy-13-methyl-
7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one 6 (0.0368 g, 
0.100 mmol, 1.0 equiv) in CH2Cl2 (0.30 mL) in a nitrogen-flushed one dram vial was added 
a 1.0 M solution of TiCl4 in CH2Cl2 (0.200 mL, 0.200 mmol, 2.0 equiv). The vial was 
capped and the reaction mixture was stirred at 25 C for 1.5 h. The reaction mixture was 
quenched with five drops of Et3N and concentrated under nitrogen gas. The residue 
obtained was diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. 
Purification using a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 
over 50 min) afforded methoxy lactam 7 (eluted between 1.5–1.9% MeOH/CH2Cl2) as a 
creamish solid in 96% yield (0.0325 g, 0.0957 mmol). 
 
147 
 
 
(4bS,6aS,11aR,12aS,12bR)-2-Hydroxy-6a-methyl-4b,5,6,6a,9,10,11,11a,12,12a, 
13,14-dodecahydronaphtho[2,1-f]pyrrolo[1,2-b]isoquinolin-7(12bH)-one (8). To a 
solution of (4bS,6aS,11aR,12aS,12bR)-2-methoxy-6a-methyl-4b,5,6,6a,9,10,11,11a,12,12a, 
13,14-dodecahydronaphtho[2,1-f]pyrrolo[1,2-b]isoquinolin-7(12bH)-one 7 (0.0339 g, 0.100 
mmol, 1.0 equiv) in anhydrous CH2Cl2 (2.5 mL) at –78 °C under nitrogen atmosphere was 
added a 1.0 M solution of boron tribromide (BBr3) in CH2Cl2 (0.800 mL, 0.800 mmol, 8.0 
equiv) over 5 min. The reaction mixture was stirred at –78 °C for 1 h, warmed to rt over 4 
h, and continued stirring at rt for 1 h (pinkish-orange suspension). The reaction mixture was 
quenched with two drops of water and the residue was dissolved in CH2Cl2–MeOH mixture 
and loaded on a silica gel in a 5 g sample cartridge. Purification using a 4 g flash column on 
a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 50 min) afforded 8 as a colorless solid 
in 94% yield (0.0306 g, 0.0940 mmol). Hydroxy lactam 8: Rf = 0.15 (2% MeOH/CH2Cl2, 
run twice); mp >250 °C, dec.; IR (neat) 3294, 2931, 2865, 1621, 1605, 1505, 1447, 1326, 
1224, 921 cm
–1
; 
1
H NMR (400 MHz, CD2Cl2 + (CF3)2CDOD)  1.15 (s, 3H), 1.33–1.46 
(complex, 2H), 1.50–1.58 (m, 2H), 1.59–1.75 (m, 2H), 1.81–1.93 (complex, 2H), 2.00–2.15 
(complex, 4H), 2.24–2.32 (m, 2H), 2.42–2.46 (m, 1H), 2.88–2.90 (m, 2H), 3.53 (m, 2H), 
3.72 (m, 1H), 6.66 (d, J = 2.6 Hz, 1H), 6.72 (dd, J = 8.4, 2.7 Hz, 1H), 7.29 (d, J = 8.5 Hz, 
1H); 
13
C NMR (125 MHz, CD2Cl2 + (CF3)2CDOD)  15.1, 22.8, 26.7, 27.4, 28.8, 30.8, 
34.8, 35.9, 41.8, 42.1, 43.1, 43.9, 46.7, 56.5, 114.0, 116.3, 128.4, 135.4, 140.5, 153.2, 
181.4; HRMS (ESI) m/z calcd for C21H28NO2 [M H]
+ 
326.2120, found 326.2132. Since 8 
was insoluble in most commonly used organic solvents, (CF3)2CDOD) was used to dissolve 
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8 for its characterization. Hydrogen bonding between lactam 8 and (CF3)2CDOD) may have 
changed the actual chemical shifts of 8. For (C
1
F3)2C
2
D
1
OD
2
): 
1
H NMR (400 MHz)  4.13 
(br s, D
2
), 4.46 (m, D
1
); 
13
C NMR (125 MHz)  69.9–71.3 (C2), 119.5–126.3 (C1). Residual 
CH2Cl2 was observed at  5.33 as a singlet. 
 
 
Experimental Procedure for the Reaction of AcCl with HFIP to Probe the In Situ 
Generation of HCl Through the Formation of HFIP Acetate. In a nitrogen-flushed vial 
at rt was added HFIP (0.500 mL, 4.80 mmol, 2.0 equiv) followed by AcCl (0.170 mL, 2.40 
mmol, 1.0 equiv), and the solution was mixed gently (white fumes of HCl were observed). 
Aliquots (35 L) were withdrawn at different time intervals and diluted with 0.45 mL of 
CDCl3 in NMR tubes. 
1
H NMR integrations were used to determine the conversion ratio 
(see Figure 5 for 
1
H NMR spectra). The graph was plotted using Microsoft Excel 2010. 
 
time  
(min) 
% conversion to 
HFIP acetate 
% remaining of 
AcCl 
0 0 100 
1 19 81 
6 47 53 
10 55 45 
20 67 33 
30 74 26 
60 84 16 
120 91 9 
160 93 7 
240 96 4 
480 99 1 
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Figure S3. Reaction rate for the conversion of AcCl to HFIP acetate. 
 
 
Procedure for the Competition and Product Inhibition Experiments (Scheme 15 and 
Figure 7) 
Nonlinear regression (curve fit) analysis was performed using GraphPad Prism 5 software. 
 
(a) Competition Experiment Between Azido Ketones 1e and 1a. To a solution of 
(2R,4S)-rel-2-(3′-azidopropyl)-4-phenylcyclohexanone 1e (0.0257 g, 0.100 mmol, 1.0 
equiv) and 2-(3′-azidopropyl)cyclopentanone 1a (0.0167 g, 0.100 mmol, 1.0 equiv) in HFIP 
(0.50 mL) at rt was added AcCl (1.42 L, 0.0200 mmol, 0.20 equiv) under nitrogen 
atmosphere in a 1 dram vial. The vial was capped and the reaction mixture was stirred at 25 
C for 24 h. Aliquots (50 L) were withdrawn using a micropipette at different time points 
(0 min, 20 min, 3 h, 6 h, 12 h, and 24 h) into sample vials and concentrated under nitrogen 
gas. The residues were diluted with 0.50 mL of CDCl3 and transferred into NMR tubes and 
1
H NMR integrations were used to determine the conversion ratio.  
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(b) Product Inhibition Experiment of 1e with Added Lactam 2e at the Outset of 
the Reaction. To a solution of cis azido ketone 1e (0.0257 g, 0.100 mmol, 1.0 equiv) and 
(8S,9aS)-rel-8-phenylhexahydro-1H-pyrrolo[1,2-a]azepin-5(6H)-one 2e (0.0229 g, 0.100 
mmol, 1.0 equiv) in HFIP (0.50 mL) at rt was added AcCl (1.42 L, 0.0200 mmol, 0.20 
equiv) under nitrogen atmosphere in a one dram vial. The vial was capped and the reaction 
mixture was stirred at 25 C for 24 h. Aliquots (50 L) were withdrawn using a 
micropipette at different time points into sample vials and concentrated under nitrogen gas. 
The residues were diluted with 0.50 mL of CDCl3 and transferred into NMR tubes and 
1
H 
NMR integrations were used to determine the conversion ratio. Since complete conversion 
was observed within 12 h, reaction graph was plotted only up to 12 h. 
 
 
(c) Product Inhibition Experiment of 1e with Added Lactam 2a at the Outset of 
the Reaction. To a solution of cis azido ketone 1e (0.0257 g, 0.100 mmol, 1.0 equiv) and 
hexahydroindolizin-5(1H)-one 2a (0.0139 g, 0.100 mmol, 1.0 equiv) in HFIP (0.50 mL) at 
rt was added AcCl (1.42 L, 0.0200 mmol, 0.20 equiv) under nitrogen atmosphere in a one 
dram vial. The vial was capped and the reaction mixture was stirred at 25 C for 24 h. 
Aliquots (50 L) were withdrawn using a micropipette at different time points into sample 
vials and concentrated under nitrogen gas. The residues were diluted with 0.50 mL of 
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CDCl3 and transferred into NMR tubes and 
1
H NMR integrations were used to determine 
the conversion ratio. 
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Figure 7. Nonlinear regression analysis for relative reaction rates for 1e and 1a 
(competition experiment), 1e with 1 equiv of 2e added at the outset of the reaction (product 
inhibition experiment with added 2e), and 1e with 1 equiv of 2a added at the outset of the 
reaction (product inhibition experiment with added 2a). The curve fitting for the 
competiton experiment (shown in blue line) gives the impression that the complete 
conversion of 1e to 2e occurred in 1 h, since no data were collected at time points between 
20 min and 3 h. However, complete conversion may have occurred in ca. 3 h (cf. Figure 8).  
 
 
 
Experimental Procedure for the Determination of the Reaction Rate for 1e in 
HFIP-d2 (Figure 8). A solution of cis azido ketone 1e (0.0257 mg, 0.100 mmol, 1.0 equiv) 
in HFIP-d2 (0.50 mL) in a nitrogen-flushed vial at rt was added AcCl (1.4 L, 0.020 mmol, 
0.20 equiv) and the pale yellow solution was transferred to the NMR tube after 2 min. 
1
H 
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NMR data were collected at different time points (The cap of the NMR tube was opened 
after every NMR experiment to release the nitrogen gas). 
1
H NMR integrations were used 
to determine the conversion ratio. The graph was plotted using Microsoft Excel 2010 
software. 
 
time  
(h) 
% conversion  
to 2e 
% remaining  
of 1e 
0 0 100 
0.17 58 42 
0.5 76 24 
1 88 12 
2 95 5 
4 >98 <2 
6 >99 <1 
 
 
 
Figure 8. Reaction rate for 1e in HFIP-d2 (blue line represents the % conversion to 2e and 
red line represents the % remaining of 1e). 
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HCl salt of Hexahydroindolizin-5(1H)-one (2aHCl; Scheme 16). To a solution of 
2-(3′-azidopropyl)cyclopentanone 1a (0.0669 g, 0.400 mmol, 1.0 equiv) in HFIP (2.0 mL) 
in a nitrogen-flushed four dram vial was added AcCl (25.6 L, 0.360 mmol, 0.90 equiv). 
The vial was capped and the reaction mixture was stirred at 25 C for 24 h. The reaction 
mixture was concentrated under nitrogen gas and the pale yellow oily residue obtained was 
dried under vacuum. Initial recrystallization attempts from CH2Cl2–Et2O mixture failed to 
give diffractable crystals. Therefore, the sample was concentrated and the resulting solid 
residue was suspended in EtOAc. The suspension was warmed gently and CH2Cl2 was 
added drop wise to obtain a clear solution. The vial was sealed with a septum and pierced 
with a hollow needle for slow evaporation of solvents at rt. After 24 h, colorless plate-like 
crystals obtained were used for single-crystal X-ray analysis (see Table S14). For 2aHCl: 
Crude 
1
H NMR (400 MHz, CDCl3)  1.28 (m, 1H), 1.46 (qd, J = 12.2, 7.2 Hz, 1H), 1.70 
(m, 1H), 1.80 (m, 1H), 1.91–2.02 (m, 2H), 2.12–2.20 (m, 2H), 2.47 (m, 1H), 2.68 (dd, J = 
19.0, 6.4 Hz, 1H), 3.46–3.56 (complex, 3H), 10.67 (br s, 1H). 
 
 
HCl salt of (6S,9R,9aS)-rel-Hexahydro-1H-6,9-methanopyrrolo[1,2-a]azepin-
5(6H)-one (2kHCl; Scheme 16). To a solution of (1S,3S,4R)-rel-3-(3′-
azidopropyl)bicyclo[2.2.1]heptan-2-one 1k (0.0773 g, 0.400 mmol, 1.0 equiv) in HFIP (2.0 
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mL) in a nitrogen-flushed four dram vial was added AcCl (35.6 L, 0.500 mmol, 1.25 
equiv). The vial was capped and the reaction mixture was stirred at 25 C for 32 h. The 
reaction mixture was concentrated under nitrogen gas and the pale yellow oily residue 
obtained was dried under vacuum. The resulting solid residue was suspended in EtOAc, 
followed by a drop wise addition of CH2Cl2 to obtain a clear solution upon warming. The 
solution was left open to the atmosphere at rt for slow evaporation of solvents. After 24 h, 
colorless plate-like crystals obtained were used for single-crystal X-ray analysis (see Table 
S14). For 2kHCl: Crude 
1
H NMR (400 MHz, CDCl3)  1.40 (m, 1H), 1.54 (m, 1H), 1.58–
1.64 (m, 2H), 1.79–2.00 (complex, 6H), 2.48 (apparent t, J = 4.5 Hz, 1H), 3.05 (apparent 
dd, J = 7.0, 4.2 Hz, 1H), 3.15 (m, 1H), 3.23 (apparent dd, J = 12.2, 4.9 Hz, 1H), 3.73 (m, 
1H), 10.11 (br s, 1H); crude 
13
C NMR (100 MHz, CDCl3)  21.2, 28.6, 29.0, 29.6, 31.6, 
35.6, 40.5, 44.2, 66.9, 177.8. 
 
Table S14. Selected Crystallographic and Refinement Parameters for Lactam Salts 
Lactam 2aHCl 2kHCl 
Empirical formula C8H13ClNO C10H15ClNO 
Formula wt. 174.64 200.68 
Temperature 100(2) K 100(2) K 
Crystal system Triclinic Orthorhombic 
Crystal size (mm
3
) 0.10  0.03  0.01 0.22  0.15  0.12 
Space group P1 Pna2(1) 
a [Å] 7.1423(6) 9.7402(4) 
b [Å] 7.1462(7) 14.2950(5) 
c [Å] 10.0804(8) 7.3235(3) 
 [deg] 95.684(6) 90 
[deg] 97.147(6) 90 
 [deg] 117.026(5) 90 
Z 2 4 
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Lactam 2aHCl 2kHCl 
Volume [Å
3
] 447.66(7) 1019.70(7) 
Dcalc [Mg/m
3
] 1.296 1.307 
F (000) 186 428 
Absorption coefficient  [mm–1] 3.326 2.991 
Theta range for data collection 4.49 to 58.56 4.54 to 69.62 
Range h –7<=h<=7 –11<=h<=11 
Range k –6<=k<=7 –13<=k<=16 
Range l –11<=l<=11 –7<=l<=8 
Reflections collected 1711 8615 
Independent reflections 1101 1633 
Rint 0.0216 0.0248 
Data / Restraints / Parameters 1101 / 12 / 101 1633 / 30 / 118 
Final R indices [I>2(I)] 0.1491 0.0978 
wR2 0.3958 0.2053 
Goodness-of-fit on F
2
 1.017 1.014 
R-factor (%) 14.91 9.78 
Largest diff. peak and hole (eÅ
–3
) 1.110 and –0.585 1.411 and –0.548 
 
 
 
Experimental Procedure for Job Plots to Determine the Stoichiometry of Binding 
using 
1
H NMR (Figure 9). Commercially purchased HFIP was distilled from sodium 
carbonate and dried over molecular sieves before use. CDCl3 was passed through basic 
alumina.  
 
0.10 M stock solutions of HFIP (31.6 L, 0.300 mmol, 1.0 equiv) and lactam 2a (41.8 
mg, 0.300 mmol, 1.0 equiv) were prepared in 3.0 mL of CDCl3 each. The total 
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concentration of HFIP and 2a was kept constant. Eleven NMR samples were prepared with 
a constant volume of 0.50 mL, where the mole fractions of HFIP and 2a varied from 0.0 to 
1.0 (see Table S15). The Job plot was obtained by plotting the mole fraction multiplied by 
the change in chemical shifts (Δ) of the hydroxyl proton of HFIP against the mole fraction 
of HFIP. 
 
Table S15. Mole Fractions and Measured Chemical Shift Change (Δ) for HFIP and 
2a Complex 
HFIP 
(mmol) 
volume of 
HFIP in 
NMR tube 
(mL) 
2a 
(mmol) 
volume  
of 2a in 
NMR tube 
(mL) 
mole 
fraction  
of HFIP 
(cHFIP) 
mole 
fraction 
of 2a 
 of 
hydroxyl 
proton 
of 
hydroxyl 
proton 
(cHFIP) 
0.050 0.500 0.000 0.000 1.000 0.000 3.07 0.00 0.000 
0.045 0.450 0.005 0.050 0.900 0.100 3.82 0.75 0.675 
0.040 0.400 0.010 0.100 0.800 0.200 4.56 1.49 1.192 
0.035 0.350 0.015 0.150 0.700 0.300 5.34 2.27 1.589 
0.030 0.300 0.020 0.200 0.600 0.400 6.12 3.05 1.830 
0.025 0.250 0.025 0.250 0.500 0.500 6.84 3.77 1.885 
0.020 0.200 0.030 0.300 0.400 0.600 7.35 4.28 1.712 
0.015 0.150 0.035 0.350 0.300 0.700 7.65 4.58 1.374 
0.010 0.100 0.040 0.400 0.200 0.800 7.86 4.79 0.958 
0.005 0.050 0.045 0.450 0.100 0.900 7.99 4.92 0.492 
0.000 0.000 0.050 0.500 0.000 1.000 0.00 0.00 0.000 
  
 
In a similar way as described above for 2a, 0.10 M stock solutions of HFIP (31.6 L, 
0.300 mmol, 1.0 equiv) and azido ketone 1a (50.2 mg, 0.300 mmol, 1.0 equiv) were 
prepared in 3.0 mL of CDCl3 each and the Job plot was generated (see Table S16).  
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Table S16. Mole Fractions and Measured Chemical Shift Change (Δ) for HFIP and 
1a Complex 
HFIP 
(mmol) 
volume of 
HFIP in 
NMR tube 
(mL) 
1a 
(mmol) 
volume  
of 1a in 
NMR tube 
(mL) 
mole 
fraction  
of HFIP 
(cHFIP) 
mole 
fraction 
of 1a 
 of 
hydroxyl 
proton 
of 
hydroxyl 
proton 
(cHFIP) 
0.050 0.500 0.000 0.000 1.000 0.000 3.19 0.00 0.000 
0.045 0.450 0.005 0.050 0.900 0.100 3.31 0.12 0.108 
0.040 0.400 0.010 0.100 0.800 0.200 3.47 0.28 0.224 
0.035 0.350 0.015 0.150 0.700 0.300 3.63 0.44 0.308 
0.030 0.300 0.020 0.200 0.600 0.400 3.79 0.60 0.360 
0.025 0.250 0.025 0.250 0.500 0.500 3.93 0.74 0.370 
0.020 0.200 0.030 0.300 0.400 0.600 4.08 0.89 0.356 
0.015 0.150 0.035 0.350 0.300 0.700 4.19 1.00 0.300 
0.010 0.100 0.040 0.400 0.200 0.800 4.31 1.12 0.224 
0.005 0.050 0.045 0.450 0.100 0.900 4.43 1.24 0.124 
0.000 0.000 0.050 0.500 0.000 1.000 0.00 0.00 0.000 
 
 
 
General Procedure C for NMR Titration Experiments for the Determination of 
Ka for Hydrogen-Bonded Complexes of HFIP with Azido Ketones and Lactams 
(Figures 11–14 and Table 8). 21.1 L (0.200 mmol) of HFIP (host) was diluted with 10 
mL CDCl3 (contains TMS as an internal standard) to give a stock solution A (concentration 
of HFIP is 20 mM or 0.020 M). A measured amount of an azido ketone or a lactam (guest) 
was dissolved in a specified amount of stock solution A to give a stock solution B. 
Depending on the experiments, 10 or 11 NMR tubes were used. The first NMR tube 
contained only stock solution A and the last NMR tube contained only stock solution B. 
Increasing amounts of stock solution B was added from second to penultimate NMR tubes. 
To maintain the HFIP concentration constant throughout the experiment, the final volume 
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in the NMR tube to 0.60 mL was made with stock solution A (0.60 mL of stock solution 
contained 0.012 mmol of HFIP, which is present in each NMR tube). The solution was 
properly mixed in the NMR tube and 
1
H NMR was recorded. The change in the chemical 
shift () for the hydroxyl proton of HFIP was measured for each sample. The absolute value 
of , which is a measured change in chemical shift (upon addition of guest species) 
referenced to that of the uncomplexed host, i.e.,  value obtained for the first NMR sample 
containing only stock solution A. The absolute value of the measured chemical shift change 
(Δ) was plotted against the concentration of the guest compound using one site specific 
binding model in GraphPad Prism. The value of dissociation constant (Kd) was obtained 
from which the values of association constant (Ka) and hydrogen-bond basicity constant 
(pKHB or pKa which is equal to log10Ka) were calculated. 
 
 
NMR Titration of HFIP at 20 mM Concentration with Azido Ketone 1a (11 
Titration Points). Following the general procedure C, 21.1 L (0.200 mmol) of HFIP was 
diluted with 10 mL CDCl3 to give a stock solution A (concentration of HFIP is 20 mM or 
0.020 M). 82.4 mg (0.493 mmol) of 1a was dissolved in 1.64 mL (no volume was 
accounted for 82.4 mg of 1a) of stock solution A to give a corresponding stock solution B 
(concentration of 1a is 300 mM or 0.300 M). The titration was carried out by preparing a 
series of 11 different concentrations (see Table S17 below), where increasing amounts of 
1a as stock solution B was added up to 15 equiv in to individual NMR tubes. The final 
volume was maintained at 0.60 mL with stock solution A (0.60 mL of stock solution 
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contained 0.012 mmol of HFIP). 
1
H NMR were recorded and a titration curve was obtained 
from GraphPad Prism.  
 
Table S17. Concentrations, Dilution Volumes, and Measured Chemical Shift Change 
(Δ) for HFIP and 1a Complex (11 Dilutions) 
NMR tube 
dilution 
factor  
(equiv 
of 1a)* 
1a 
(mmol) 
amount 
of 1a 
(mg) 
volume 
of stock 
B (L) 
dilution 
volume 
of stock 
A (L) 
concn 
of 1a 
(mM) 
 of 
hydroxyl 
proton 

1 (stock A) 0.00 0.00 0.00 0.00 600 0.000 2.959 0.000 
2 0.20 0.0024 0.400 8.00 592 4.004 3.053 0.0940 
3 0.40 0.0048 0.800 16.0 584 8.008 3.146 0.187 
4 0.60 0.0072 1.21 24.0 576 12.01 3.241 0.282 
5 0.80 0.0096 1.61 32.0 568 16.02 3.304 0.345 
6 1.0 0.012 2.01 40.0 560 20.02 3.391 0.432 
7 2.0 0.024 4.02 80.0 520 40.04 3.732 0.773 
8 4.0 0.048 8.03 160 440 80.09 4.200 1.241 
9 7.0 0.084 14.1 280 320 140.2 4.682 1.723 
10 10 0.12 20.1 400 200 200.2 5.027 2.068 
11 (stock B) 15 0.18 30.1 600 0.00 300.3 5.372 2.413 
*
Dilution factor is the number of equiv of 1a to 1 equiv of HFIP (0.012 mmol of HFIP is present 
in 0.60 mL). 
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One site – Specific binding 
 
 Best-fit values 
 
Bmax 3.616 
Kd 151 mM (0.151 M) 
Ka 0.00662 mM
–1
 (6.62 M
–1
) 
pKa 0.821 
 Standard error 
 
Bmax 0.03491 
Kd 3.030 mM 
 95% Confidence intervals 
 
Bmax 3.537 to 3.695 
Kd 144.0 to 157.7 mM 
 Goodness of fit 
 
Degrees of freedom 9 
R² 0.9998 
Absolute sum of squares 0.001120 
 Number of points 
 
Analyzed 11 
 
 
NMR Titration of HFIP at 20 mM Concentration with Azido Ketone 1a (10 
Titration Points). Following the general procedure C, 21.1 L (0.200 mmol) of HFIP was 
diluted with 10 mL CDCl3 to give a stock solution A (concentration of HFIP is 20 mM or 
0.020 M). 97.4 mg (0.583 mmol) of 1a was dissolved in 1.375 mL of stock solution A to 
give 1.455 mL (ca. 80 L was accounted for 97.4 mg of 1a since density was unknown) of 
a corresponding stock solution B (concentration of 1a is 400 mM or 0.400 M). The titration 
was carried out by preparing a series of 10 different concentrations (see Table S18 below), 
where increasing amounts of 1a as stock solution B was added up to 20 equiv in to 
individual NMR tubes. The final volume was maintained at 0.60 mL with stock solution A. 
1
H NMR were recorded and a titration curve was obtained from GraphPad Prism.  
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Table S18. Concentrations, Dilution Volumes, and Measured Chemical Shift Change 
(Δ) for HFIP and 1a Complex (10 Dilutions) 
NMR tube 
dilution 
factor 
(equiv 
of 1a) 
1a 
(mmol) 
amount 
of 1a 
(mg) 
volume 
of stock 
B (L) 
dilution 
volume 
of stock 
A (L) 
concn 
of 1a 
(mM) 
 of 
hydroxyl 
proton 
 
1 (stock A) 0.00 0.00 0.00 0.00 600 0.000 2.888 0.000 
2 0.25 0.0030 0.500 7.50 592.5 5.005 3.047 0.159 
3 0.50 0.0060 1.00 15.0 585 10.01 3.165 0.277 
4 0.75 0.0090 1.51 22.5 577.5 15.02 3.289 0.401 
5 1.0 0.012 2.01 30.0 570 20.02 3.384 0.496 
6 2.0 0.024 4.02 60.0 540 40.04 3.727 0.839 
7 4.0 0.048 8.03 120 480 80.09 4.254 1.366 
8 8.0 0.096 16.1 240 360 160.2 4.856 1.968 
9 12 0.14 24.1 360 240 240.3 5.215 2.327 
10 (stock B) 20 0.24 40.2 600 0.00 400.4 5.622 2.734 
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One site – Specific binding 
 
 Best-fit values 
 
Bmax 3.596 
Kd 130 mM (0.130 M) 
Ka 0.00769 mM
–1
 (7.69 M
–1
) 
pKa 0.886 
 Standard error 
 
Bmax 0.04059 
Kd 3.536 
 95% Confidence intervals 
 
Bmax 3.503 to 3.690 
Kd 121.6 to 137.9 
 Goodness of fit 
 
Degrees of freedom 8 
R² 0.9997 
Absolute sum of squares 0.002903 
 Number of points 
 
Analyzed 10 
 
 
 
NMR Titration of HFIP at 20 mM Concentration with Lactam 2a (10 Titration 
Points). Following the general procedure C, 21.1 L (0.200 mmol) of HFIP was diluted 
with 10 mL CDCl3 to give a stock solution A (concentration of HFIP is 20 mM or 0.020 
M). 81.1 mg (0.583 mmol) of 2a was dissolved in 1.375 mL of stock solution A to give 
1.455 mL (ca. 80 L was accounted for 81.1 mg of 2a since density was unknown) of a 
corresponding stock solution B (concentration of 2a is 400 mM or 0.400 M). The titration 
was carried out by preparing a series of 10 different concentrations (see Table S19 below), 
where increasing amounts of 2a as stock solution B was added up to 20 equiv in to 
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individual NMR tubes. The final volume was maintained at 0.60 mL with stock solution A. 
1
H NMR were recorded and a titration curve was obtained from GraphPad Prism.  
 
Table S19. Concentrations, Dilution Volumes, and Measured Chemical Shift Change 
(Δ) for HFIP and 2a Complex (10 Dilutions)  
NMR tube 
dilution 
factor 
(equiv 
of 2a) 
2a 
(mmol) 
amount 
of 2a 
(mg) 
volume 
of stock 
B (L) 
dilution 
volume 
of stock 
A (L) 
concn 
of 2a 
(mM) 
 of 
hydroxyl 
proton 
 
1 (stock A) 0.00 0.00 0.00 0.00 600 0.000 2.899 0.000 
2 0.25 0.0030 0.420 7.50 592.5 5.005 3.900 1.001 
3 0.50 0.0060 0.840 15.0 585 10.01 4.937 2.038 
4 0.75 0.0090 1.25 22.5 577.5 15.02 5.684 2.785 
5 1.0 0.012 1.67 30.0 570 20.02 6.231 3.332 
6 2.0 0.024 3.34 60.0 540 40.04 7.296 4.397 
7 4.0 0.048 6.69 120 480 80.09 7.908 5.009 
8 8.0 0.096 13.4 240 360 160.2 8.205 5.306 
9 12 0.14 20.1 360 240 240.3 8.301 5.402 
10 (stock B) 20 0.24 33.4 600 0.00 400.4 8.378 5.479 
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One site – Specific binding 
 
 Best-fit values 
 
Bmax 5.874 
Kd 16.8 mM (0.0168 M) 
Ka 0.0595 mM
–1
 (59.5 M
–1
) 
pKa 1.77 
 Standard error 
 
Bmax 0.1287 
Kd 1.458 
 95% Confidence intervals 
 
Bmax 5.577 to 6.171 
Kd 13.41 to 20.13 
 Goodness of fit 
 
Degrees of freedom 8 
R² 0.9918 
Absolute sum of squares 0.2876 
 Number of points 
 
Analyzed 10 
 
 
NMR Titration of HFIP at 20 mM Concentration with Lactam 2a (11 Titration 
Points). Following the general procedure C, 21.1 L (0.200 mmol) of HFIP was diluted 
with 10 mL CDCl3 to give a stock solution A (concentration of HFIP is 20 mM or 0.020 
M). 41.0 mg (0.294 mmol) of 2a was dissolved in 1.430 mL of stock solution A to give 
1.470 mL (ca. 40 L was accounted for 41.0 mg of 2a) of a corresponding stock solution B 
(concentration of 2a is 200 mM or 0.200 M). The titration was carried out by preparing a 
series of 11 different concentrations (see Table S20 below), where increasing amounts of 
2a as stock solution B was added up to 10 equiv in to individual NMR tubes. The final 
volume was maintained at 0.60 mL with stock solution A. 
1
H NMR were recorded and a 
titration curve was obtained from GraphPad Prism.  
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Table S20. Concentrations, Dilution Volumes, and Measured Chemical Shift Change 
(Δ) for HFIP and 2a Complex (11 Dilutions) 
NMR tube 
dilution 
factor 
(equiv of 
2a) 
2a 
(mmol) 
amount of 
2a (mg) 
volume of 
stock B 
(L) 
dilution 
volume of 
stock A 
(L) 
concn of 
2a (mM) 
 of 
hydroxyl 
proton 
 
1 (stock A) 0.00 0.00 0.00 0.00 600 0.000 2.850 0.000 
2 0.20 0.0024 0.330 12.0 588 4.004 3.733 0.8830 
3 0.40 0.0048 0.670 24.0 576 8.008 4.534 1.684 
4 0.60 0.0072 1.00 36.0 564 12.01 5.027 2.177 
5 0.80 0.0096 1.34 48.0 552 16.02 5.713 2.863 
6 1.0 0.012 1.67 60.0 540 20.02 6.128 3.278 
7 1.5 0.018 2.51 90.0 510 30.03 6.865 4.015 
8 2.0 0.024 3.34 120 480 40.04 7.331 4.481 
9 3.0 0.036 5.02 180 420 60.06 7.726 4.876 
10 5.0 0.060 8.36 300 300 100.1 8.041 5.191 
11 (stock B) 10 0.12 16.7 600 0.00 200.2 8.271 5.421 
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One site – Specific binding 
 
 Best-fit values 
 
Bmax 6.210 
Kd 18.8 mM (0.0188 M) 
Ka 0.0532 mM
–1
 (53.2 M
–1
) 
pKa 1.73 
 Standard error 
 
Bmax 0.1865 
Kd 1.709 
 95% Confidence intervals 
 
Bmax 5.788 to 6.632 
Kd 14.93 to 22.66 
 Goodness of fit 
 
Degrees of freedom 9 
R² 0.9900 
Absolute sum of squares 0.3293 
 Number of points 
 
Analyzed 11 
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Figure S4. Representative stacked 
1
H NMR spectra displaying a change in the chemical 
shift for the hydroxyl proton of HFIP upon titration of HFIP with increasing amounts of 
lactam 2a. 
 
 
 
NMR Titration of HFIP at 20 mM Concentration with Lactam 2e (11 Titration 
Points). Following the general procedure C, 21.1 L (0.200 mmol) of HFIP was diluted 
with 10 mL CDCl3 to give a stock solution A (concentration of HFIP is 20 mM or 0.020 
M). 67.5 mg (0.294 mmol) of 2e was dissolved in 1.403 mL of stock solution A to give 
1.470 mL (ca. 67 L was accounted for 67.5 mg of 2e) of a corresponding stock solution B 
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(concentration of 2e is 200 mM or 0.200 M). The titration was carried out by preparing a 
series of 11 different concentrations (see Table S21 below), where increasing amounts of 2e 
as stock solution B was added up to 10 equiv in to individual NMR tubes. The final volume 
was maintained at 0.60 mL with stock solution A. 
1
H NMR were recorded and a titration 
curve was obtained from GraphPad Prism. 
 
Table S21. Concentrations, Dilution Volumes, and Measured Chemical Shift Change 
(Δ) for HFIP and 2e Complex 
NMR tube 
dilution 
factor 
(equiv 
of 2e) 
2e 
(mmol) 
amount 
of 2e 
(mg) 
volume 
of stock 
B (L) 
dilution 
volume 
of stock 
A (L) 
concn 
of 2e 
(mM) 
 of 
hydroxyl 
proton 
 
1 (stock A) 0.00 0.00 0.00 0.00 600 0.000 2.868 0.000 
2 0.20 0.0024 0.550 12.0 588 4.004 3.674 0.8060 
3 0.40 0.0048 1.10 24.0 576 8.008 4.341 1.473 
4 0.60 0.0072 1.65 36.0 564 12.01 4.900 2.032 
5 0.80 0.0096 2.20 48.0 552 16.02 5.373 2.505 
6 1.0 0.012 2.75 60.0 540 20.02 5.761 2.893 
7 1.5 0.018 4.13 90.0 510 30.03 6.436 3.568 
8 2.0 0.024 5.51 120 480 40.04 6.941 4.073 
9 3.0 0.036 8.26 180 420 60.06 7.367 4.499 
10 5.0 0.060 13.8 300 300 100.1 7.744 4.876 
11 (stock B) 10 0.12 27.6 600 0.00 200.2 8.047 5.179 
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One site – Specific binding 
 
 Best-fit values 
 
Bmax 5.929 
Kd 21.3 mM (0.0213 M) 
Ka 0.0469 mM
–1
 (46.9 M
–1
) 
pKa 1.67 
 Standard error 
 
Bmax 0.1336 
Kd 1.396 
 95% Confidence intervals 
 
Bmax 5.627 to 6.231 
Kd 18.14 to 24.46 
 Goodness of fit 
 
Degrees of freedom 9 
R² 0.9948 
Absolute sum of squares 0.1507 
 Number of points 
 
Analyzed 11 
 
 
 
NMR Titration of HFIP at 20 mM Concentration with Lactam 2f (11 Titration 
Points). Following the general procedure C, 21.1 L (0.200 mmol) of HFIP was diluted 
with 10 mL CDCl3 to give a stock solution A (concentration of HFIP is 20 mM or 0.020 
M). 67.5 mg (0.294 mmol) of 2f was dissolved in 1.403 mL of stock solution A to give 
1.470 mL (ca. 67 L was accounted for 67.5 mg of 2f) of a corresponding stock solution B 
(concentration of 2f is 200 mM or 0.200 M). The titration was carried out by preparing a 
series of 11 different concentrations (see Table S22 below), where increasing amounts of 2f 
170 
 
as stock solution B was added up to 10 equiv in to individual NMR tubes. The final volume 
was maintained at 0.60 mL with stock solution A. 
1
H NMR were recorded and a titration 
curve was obtained from GraphPad Prism.  
 
Table S22. Concentrations, Dilution Volumes, and Measured Chemical Shift Change 
(Δ) for HFIP and 2f Complex 
NMR tube 
dilution 
factor 
(equiv 
of 2f) 
2f 
(mmol) 
amount 
of 2f 
(mg) 
volume 
of stock 
B (L) 
dilution 
volume 
of stock 
A (L) 
concn 
of 2f 
(mM) 
 of 
hydroxyl 
proton 
 
1 (stock A) 0.00 0.00 0.00 0.00 600 0.000 2.855 0.000 
2 0.20 0.0024 0.550 12.0 588 4.004 3.668 0.8130 
3 0.40 0.0048 1.10 24.0 576 8.008 4.400 1.545 
4 0.60 0.0072 1.65 36.0 564 12.01 5.000 2.145 
5 0.80 0.0096 2.20 48.0 552 16.02 5.532 2.677 
6 1.0 0.012 2.75 60.0 540 20.02 5.904 3.049 
7 1.5 0.018 4.13 90.0 510 30.03 6.643 3.788 
8 2.0 0.024 5.51 120 480 40.04 7.005 4.150 
9 3.0 0.036 8.26 180 420 60.06 7.433 4.578 
10 5.0 0.060 13.8 300 300 100.1 7.811 4.956 
11 (stock B) 10 0.12 27.6 600 0.00 200.2 8.081 5.226 
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One site – Specific binding 
 
 Best-fit values 
 
Bmax 5.946 
Kd 19.6 mM (0.0196 M) 
Ka 0.0510 mM
–1
 (51.0 M
–1
) 
pKa 1.71 
 Standard error 
 
Bmax 0.1451 
Kd 1.428 
 95% Confidence intervals 
 
Bmax 5.618 to 6.274 
Kd 16.36 to 22.82 
 Goodness of fit 
 
Degrees of freedom 9 
R² 0.9936 
Absolute sum of squares 0.1921 
 Number of points 
 
Analyzed 11 
 
 
 
NMR Titration of HFIP at 20 mM Concentration with Lactam 2k (11 Titration 
Points). Following the general procedure C, 21.1 L (0.200 mmol) of HFIP was diluted 
with 10 mL CDCl3 to give a stock solution A (concentration of HFIP is 20 mM or 0.020 
M). 48.6 mg (0.294 mmol) of 2k was dissolved in 1.422 mL of stock solution A to give 
1.470 mL (ca. 48 L was accounted for 48.6 mg of 2k) of a corresponding stock solution B 
(concentration of 2k is 200 mM or 0.200 M). The titration was carried out by preparing a 
series of 11 different concentrations (see Table S23 below), where increasing amounts of 
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2k as stock solution B was added up to 10 equiv in to individual NMR tubes. The final 
volume was maintained at 0.60 mL with stock solution A. 
1
H NMR were recorded and a 
titration curve was obtained from GraphPad Prism.  
 
Table S23. Concentrations, Dilution Volumes, and Measured Chemical Shift Change 
(Δ) for HFIP and 2k Complex 
NMR tube 
dilution 
factor 
(equiv 
of 2k) 
2k 
(mmol) 
amount 
of 2k 
(mg) 
volume 
of stock 
B (L) 
dilution 
volume 
of stock 
A (L) 
concn 
of 2k 
(mM) 
 of 
hydroxyl 
proton 
 
1 (stock A) 0.00 0.00 0.00 0.00 600 0.000 2.877 0.000 
2 0.20 0.0024 0.400 12.0 588 4.004 3.673 0.7960 
3 0.40 0.0048 0.790 24.0 576 8.008 4.364 1.487 
4 0.60 0.0072 1.19 36.0 564 12.01 4.968 2.091 
5 0.80 0.0096 1.59 48.0 552 16.02 5.448 2.571 
6 1.0 0.012 1.98 60.0 540 20.02 5.851 2.974 
7 1.5 0.018 2.98 90.0 510 30.03 6.531 3.654 
8 2.0 0.024 3.97 120 480 40.04 6.951 4.074 
9 3.0 0.036 5.95 180 420 60.06 7.413 4.536 
10 5.0 0.060 9.92 300 300 100.1 7.766 4.889 
11 (stock B) 10 0.12 19.9 600 0.00 200.2 8.055 5.178 
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One site – Specific binding 
 
 Best-fit values 
 
Bmax 5.911 
Kd 20.5 mM (0.0205 M) 
Ka 0.0488 mM
–1
 (48.8 M
–1
) 
pKa 1.69 
 Standard error 
 
Bmax 0.1386 
Kd 1.413 
 95% Confidence intervals 
 
Bmax 5.598 to 6.225 
Kd 17.26 to 23.65 
 Goodness of fit 
 
Degrees of freedom 9 
R² 0.9943 
Absolute sum of squares 0.1686 
 Number of points 
 
Analyzed 11 
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Experimental Procedures for Section 1.3 
General Procedure for the Optimization of Reaction Conditions for Tetrazole 
Synthesis (Table 9) 
Procedure for Reactions Carried out under Heating at 55 °C. Either to a neat 
suspension of cyclohexanone 12a (39.3 mg, 0.400 mmol, 1.0 equiv) and TMSN3 (138 mg, 
1.20 mmol, 3.0 equiv) or to a solution of 12a (0.400 mmol) and TMSN3 (1.20 mmol) in 
HFIP (1.0 mL) in a nitrogen-flushed microwave reaction vial (2–5 mL capacity) was added 
catalyst (5–10 mol %). The vial was sealed and the reaction mixture was allowed to stir at 
55 °C for 16 h (effervescence due to nitrogen gas evolution was observed upon addition of 
a catalyst). Reaction mixture was cooled to room temperature, concentrated under nitrogen 
using a sample concentrator. The residue obtained was diluted with CH2Cl2 and loaded on 
silica gel in a 5 g sample cartridge. Purification was carried out using a 4 g normal phase 
silica flash column on a CombiFlash Rf MPLC system with a gradient elution from 0–5% 
MeOH/CH2Cl2 over 50 min. Concentration of appropriate fractions afforded tetrazole 13a. 
Procedure for Reactions Carried out at Room Temperature. Either to a neat 
suspension of 4-phenylcyclohexanone 12b (34.9mg, 0.200 mmol, 1.0 equiv) and TMSN3 
(57.6mg, 0.500 mmol, 2.5 equiv) or to a solution of 12b (0.200 mmol) and TMSN3 (1.5–3.0 
equiv) in HFIP (0.5 mL) in a nitrogen-flushed two dram vial was added catalyst (10–25 mol 
%) unless otherwise noted (see Table 9 footnotes). The vial was capped and the reaction 
mixture was allowed to stir at room temperature for 1–22 h (slight exotherm and 
effervescence due to nitrogen gas evolution was immediately observed upon addition of a 
catalyst for a successful reaction). Reaction mixture was concentrated under nitrogen. The 
residue obtained was diluted with CH2Cl2 and loaded on silica gel in a 5 g sample cartridge. 
Purification was carried out using a 4 g normal phase silica flash column on a CombiFlash 
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Rf MPLC system with a gradient elution from 0–5% MeOH/CH2Cl2 over 30–50 min. 
Concentration of appropriate fractions afforded products 13b, 14b, and 15b. 
 
General Procedure D for the Synthesis of Tetrazoles from Ketones (Table 10). 
To a solution of ketone (0.400 mmol, 1.0 equiv) and TMSN3 (1.00 mmol, 2.5 equiv) in 
HFIP (1.0 mL) in a nitrogen-flushed two dram vial was added TfOH (0.100–0.400 mmol, 
0.25–1.0 equiv). The vial was capped and the reaction mixture was allowed to stir at room 
temperature for 2–22 h (exotherm and brisk effervescence due to nitrogen gas evolution 
was immediately observed upon addition of TfOH). The reaction mixture was concentrated 
under nitrogen. The residue obtained was diluted with CH2Cl2 (unless otherwise noted) and 
loaded on a silica gel in a 5 g sample cartridge. Purification was carried out using a 4 or 12 
g normal phase silica flash column on a CombiFlash Rf MPLC system with a gradient 
elution from 0–5% MeOH/CH2Cl2 over 50 min (unless otherwise noted). Concentration of 
appropriate fractions afforded products. In most cases, recrystallization of products from 
solvents afforded after solvent evaporation, plate-like crystals or crystalline solids, which 
were utilized for determining melting point, and in two cases for acquiring single-crystal X-
ray diffraction data. Unreacted starting materials (ketones) were not recovered in few cases 
where reaction did not go to completion. 
 
 
6,7,8,9-Tetrahydro-5H-tetrazolo[1,5-a]azepine (13a)
127
 and 4,5,6,7,8,9-
Hexahydrotetrazolo[1,5-a][1,3]diazocine (15a). Following the general procedure D, a 
solution of cyclohexanone 12a (39.3 mg, 0.400 mmol, 1.0 equiv) and TMSN3 (115 mg, 
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1.00 mmol, 2.5 equiv) in HFIP (1.0 mL) was treated with TfOH (8.90 L, 0.100 mmol, 
0.25 equiv). The reaction mixture was stirred at room temperature for 2 h. Purification 
using a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 50 min) 
afforded tetrazole 13a (eluted between 1.2–2.7% MeOH/CH2Cl2) as a colorless partially 
crystalline semisolid (50.3 mg, 0.364 mmol, 91% yield) and aminotetrazole 15a (eluted 
between 3.4–3.5% MeOH/CH2Cl2) as a colorless waxy solid (2.5 mg, 0.016 mmol, 4% 
yield). Recrystallization of 13a from EtOAc–hexanes mixture under cold conditions 
afforded after solvent evaporation, colorless plate-like crystals. Tetrazole 13a: Rf = 0.53 
(2% MeOH/CH2Cl2, run twice); mp 57–59.5 C (lit.
77b
 mp 57–58 C and lit.
77g
 mp 59 C).  
Aminotetrazole 15a: Rf = 0.14 (2% MeOH/CH2Cl2, run twice); IR (neat) 3263, 1601, 
1100 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  1.60–1.65 (m, 2H), 1.87 (m, 2H), 2.04 (p, J = 6.4 
Hz, 2H), 3.57 (q, J = 6.1 Hz, 2H), 4.58 (t, J = 6.5 Hz, 2H), 6.00 (br s, 1H); 
13
C NMR (125 
MHz, CDCl3)  21.2, 28.7, 30.2, 42.2, 46.5, 157.0; HRMS (ESI) m/z calcd for C6H12N5 [M 
+ H]
+ 
154.1093, found 154.1086. 
 
 
7-Phenyl-6,7,8,9-tetrahydro-5H-tetrazolo[1,5-a]azepine (13b), 5-Phenylazepan-2-
one (14b),
128
 and 7-Phenyl-4,5,6,7,8,9-hexahydrotetrazolo[1,5-a][1,3]diazocine (15b). 
Following the general procedure D, a solution of 4-phenylcyclohexanone 12b (69.7 mg, 
0.400 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 mmol, 2.5 equiv) in HFIP (1.0 mL) was 
treated with TfOH (8.90 L, 0.100 mmol, 0.25 equiv). The reaction mixture was stirred at 
room temperature for 2 h. Purification using a 4 g flash column on a CombiFlash Rf system 
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(0–5% MeOH/CH2Cl2 over 50 min) afforded tetrazole 13b (eluted between 1.3–2.6% 
MeOH/CH2Cl2) as a colorless solid (71.7 mg, 0.335 mmol, 84% yield) and an impure 
mixture of lactam 14b and aminotetrazole 15b (eluted between 3.3–3.5% MeOH/CH2Cl2) 
as a colorless solid. The impure mixture of 14b and 15b was purified by preparative TLC 
developing two times with 2% MeOH/CH2Cl2 and one time with 60% EtOAc/hexanes. 
Bands corresponding to 15b (top band) and 14b (bottom band) were scraped from the plate 
and eluted separately with 2% MeOH/CH2Cl2 through a phase separator tabless. 
Concentration afforded 14b as a colorless solid (2.4 mg, 0.013 mmol, 3% yield) and 15b as 
a colorless solid (8.6 mg, 0.038 mmol, 9% yield). Recrystallization of 15b from CH2Cl2–
EtOH mixture through slow solvent evaporation afforded colorless fine crystals, which 
were used for X-ray diffraction analysis (see Table S24). Tetrazole 13b: Rf = 0.53 (2% 
MeOH/CH2Cl2, run twice); mp 128–130 C; IR (neat) 1602, 1531, 1244 cm
–1
; 
1
H NMR 
(500 MHz, CDCl3)  1.71 (m, 1H), 1.89 (m, 1H), 2.19–2.28 (m, 2H), 2.84 (ddd, J = 15.5, 
12.9, 2.3 Hz, 1H), 2.96 (tt, J = 11.8, 2.4 Hz, 1H), 3.61 (ddd, J = 15.7, 5.8, 1.9 Hz, 1H), 4.20 
(m, 1H), 5.01 (ddd, J = 14.6, 5.1, 2.3 Hz, 1H), 7.15 (m, 2H), 7.23 (m, 1H), 7.32 (m, 2H); 
13
C NMR (125 MHz, CDCl3)  23.6, 32.2, 34.5, 48.2, 48.4, 126.6, 127.1, 129.1, 145.8, 
156.2; HRMS (ESI) m/z calcd for C12H15N4 [M + H]
+ 
215.1297, found 215.1275.  
Lactam 14b: Rf = 0.18 (80% EtOAc/hexanes); mp 193–195 C (lit.
128
 mp 199–200 
°C); IR (neat) 3194, 1661 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.68–1.85 (m, 2H), 1.98–
2.04 (m, 2H), 2.53–2.67 (m, 2H), 2.76 (tt, J = 12.1, 3.4 Hz, 1H), 3.26–3.42 (m, 2H), 6.72 
(br s, 1H), 7.16–7.23 (m, 3H), 7.29–7.32 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  30.7, 
36.1, 37.6, 42.3, 49.0, 126.7, 126.8, 128.8, 146.5, 178.7; HRMS (ESI) m/z calcd for 
C12H16NO [M + H]
+ 
190.1232, found 190.1238.  
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Aminotetrazole 15b: Rf = 0.32 (80% EtOAc/hexanes); mp 190–192 C; IR (neat) 
3245, 1624, 1605, 1491 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  2.02 (ddt, J = 15.5, 12.1, 3.7 
Hz, 1H), 2.11 (ddt, J = 16.3, 12.6, 3.8 Hz, 1H), 2.17–2.23 (m, 1H), 2.32–2.40 (m, 1H), 2.86 
(tt, J = 12.2, 3.3 Hz, 1H), 3.51 (dtd, J = 15.6, 6.3, 3.5 Hz, 1H), 3.87 (m, 1H), 4.62 (ddd, J = 
15.3, 6.0, 3.5 Hz, 1H), 4.75 (m, 1H), 6.65 (t, J = 6.3 Hz, 1H), 7.12 (d, J = 7.3 Hz, 2H), 7.18 
(m, 1H), 7.26 (m, 2H); 
13
C NMR (125 MHz, CDCl3)  36.7, 38.3, 40.1, 41.6, 46.0, 127.0, 
127.1, 129.0, 145.4, 156.8; HRMS (ESI) m/z calcd for C12H16N5 [M + H]
+ 
230.1400, found 
230.1391. 
 
Table S24. Selected Crystallographic and Refinement Parameters for 15b 
Compound Aminotetrazole 15b 
Empirical formula C12H15N5 
Formula wt. 229.29 
Temperature 100(2) K 
Crystal system Monoclinic 
Crystal size (mm
3
) 0.28  0.17  0.01 
Space group P21/c 
a [Å] 5.9910(6) 
b [Å] 28.946(3) 
c [Å] 7.1474(7) 
 [deg] 90 
[deg] 111.950(6) 
 [deg] 90 
Z 4 
Volume [Å
3
] 1149.62(19) 
Dcalc [Mg/m
3
] 1.325 
F (000) 488 
Absorption coefficient  [mm–1] 0.680 
Theta range for data collection 3.05 to 69.84 
Range h –6<=h<=7 
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Compound Aminotetrazole 15b 
Range k –34<=k<=34 
Range l –8<=l<=8 
Reflections collected 8327 
Independent reflections 2031 
Rint 0.0353 
Data / Restraints / Parameters 2031 / 62 / 309 
Final R indices [I>2(I)] 0.0651 
wR2 0.1880 
Goodness-of-fit on F
2
 1.063 
R-factor (%) 6.51 
Largest diff. peak and hole (eÅ
–3
) 0.253 and –0.219 
 
 
 
7-(tert-Butyl)-6,7,8,9-tetrahydro-5H-tetrazolo[1,5-a]azepine (13c) and 7-(tert-
Butyl)-4,5,6,7,8,9-hexahydrotetrazolo[1,5-a][1,3]diazocine (15c). Following the general 
procedure D, a solution of 4-tert-butylcyclohexanone 12c (61.7 mg, 0.400 mmol, 1.0 equiv) 
and TMSN3 (115 mg, 1.00 mmol, 2.5 equiv) in HFIP (1.0 mL) was treated with TfOH (8.9 
L, 0.100 mmol, 0.25 equiv). The reaction mixture was stirred at room temperature for 2 h. 
Purification using a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 
over 50 min) afforded tetrazole 13c (eluted between 1.0–2.4% MeOH/CH2Cl2) as a 
colorless crystalline solid (64.5 mg, 0.332 mmol, 83% yield) and aminotetrazole 15c 
(eluted between 2.8–3.0% MeOH/CH2Cl2) as a colorless solid (7.6 mg, 0.036 mmol, 9% 
yield). Recrystallization of 13c from EtOAc–CH2Cl2 mixture afforded colorless, long plate-
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like crystals. A small amount (ca. 2%) of impure lactam 14c
129
 was also obtained during 
this purification but was not completely characterized. Tetrazole 13c: Rf = 0.39 (2% 
MeOH/CH2Cl2); mp 131–132 C (lit.
130
 mp 132.5–133 C); IR (neat) 1537, 1476 cm
–1
; 
1
H 
NMR (400 MHz, CDCl3)  0.86 (s, 9H), 1.10 (m, 1H), 1.23–1.38 (m, 2H), 2.14–2.24 (m, 
2H), 2.58 (ddd, J = 15.4, 12.6, 2.4 Hz, 1H), 3.46 (ddd, J = 15.8, 6.3, 1.9 Hz, 1H), 3.92–3.99 
(m, 1H), 4.88 (ddd, J = 14.4, 5.6, 2.1 Hz, 1H); 
13
C NMR (100 MHz, CDCl3)  23.5, 25.8, 
27.7, 28.4, 33.9, 48.5, 52.2, 156.4; HRMS (ESI) m/z calcd for C10H19N4 [M + H]
+ 
195.1610, found 195.1607. 
Aminotetrazole 15c: Rf = 0.12 (2% MeOH/CH2Cl2); mp 164–165 C; IR (neat) 3264 
(br), 3071, 1621, 1604, 1365 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.86 (s, 9H), 1.22 (m, 
1H), 1.44 (m, 1H), 1.60 (m, 1H), 2.09 (m, 1H), 2.29 (m, 1H), 3.33 (m, 1H), 3.71 (m, 1H), 
4.50–4.61 (m, 2H), 5.73 (m, 1H); 
13
C NMR (125 MHz, CDCl3)  27.7, 30.0, 30.8, 33.6, 
43.4, 44.1, 45.8, 157.2; HRMS (ESI) m/z calcd for C10H20N5 [M + H]
+ 
210.1719, found 
210.1704. 
 
 
6,8-Dimethyl-6,7,8,9-tetrahydro-5H-tetrazolo[1,5-a]azepine (13d) and 6,8-
Dimethyl-4,5,6,7,8,9-hexahydrotetrazolo[1,5-a][1,3]diazocine (15d). Following the 
general procedure D, a solution of 3,5-dimethylcyclohexanone 12d, mixture of isomers, ca. 
95% major isomer (50.5 mg, 0.400 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 mmol, 2.5 
equiv) in HFIP (1.0 mL) was treated with TfOH (8.9 L, 0.100 mmol, 0.25 equiv). The 
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reaction mixture was stirred at room temperature for 1.5 h. Purification using a 4 g flash 
column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 50 min) afforded a mixture 
of tetrazole isomers, ca. 97% of major isomer 13d (eluted between 1.0–2.2% 
MeOH/CH2Cl2) as a colorless solid and an impure aminotetrazole 15d (eluted between 3.0–
3.1% MeOH/CH2Cl2). Further purification of tetrazole isomers using a 4 g flash column on 
a CombiFlash Rf system (0–3% MeOH/CH2Cl2 over 45 min) afforded a partial separation 
of major tetrazole isomer 13d as a colorless crystalline solid and remaining as a mixture of 
tetrazole isomers (ca. 97% of 13d) as a colorless solid (13d: 55.0 mg, 0.331 mmol, 83% 
corrected yield). Recrystallization of 13d from EtOAc afforded large, colorless, rectangular 
plate-like crystals. Impure aminotetrazole 15d was purified by preparative TLC developing 
two times with 3% MeOH/CH2Cl2. The band corresponding to 15d was scraped from the 
plate and eluted with 5% MeOH/CH2Cl2 through a phase separator tabless. Concentration 
afforded a slightly impure sample of 15d as a colorless waxy solid film (2.2 mg, 0.012 
mmol, ca. 3% yield). Recrystallization of 15d from EtOAc–CH2Cl2 mixture afforded partial 
recrystallization into colorless, tiny plate-like crystals and an off-white solid film (quantity 
of 15d was not sufficient for determining the melting point). Tetrazole 13d: Rf = 0.38 (2% 
MeOH/CH2Cl2); mp 152–155 C (lit.
130
 mp 156 C); IR (neat) 1525, 1455, 1255 cm
–1
; 
1
H 
NMR (400 MHz, CDCl3)  1.10 (dd, J = 8.3, 6.8 Hz, 6H), 1.30 (m, 1H), 1.65–1.76 (m, 1H), 
1.77–1.89 (m, 1H), 1.96 (dp, J = 14.2, 2.2 Hz, 1H), 2.48 (dd, J = 15.3, 11.7 Hz, 1H), 3.34 
(dt, J = 15.3, 2.0 Hz, 1H), 3.78 (dd, J = 14.2, 11.0 Hz, 1H), 4.72 (dt, J = 14.2, 2.2 Hz, 1H); 
13
C NMR (100 MHz, CDCl3)  20.8, 24.1, 31.5, 31.7, 33.3, 47.9, 54.7, 155.3; HRMS (ESI) 
m/z calcd for C8H15N4 [M + H]
+ 
167.1297, found 167.1306.  
Aminotetrazole 15d: Rf = 0.10 (2% MeOH/CH2Cl2); IR (neat) 3259, 1599, 1385 cm
–
1
; 
1
H NMR (500 MHz, CDCl3)  1.03 (t, J = 6.6 Hz, 6H), 1.04–1.11 (m, 1H), 1.54 (dt, J = 
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15.2, 3.6 Hz, 1H), 2.00 (m, 1H), 2.20 (m, 1H), 3.10 (d, J = 15.6 Hz, 1H), 3.91 (dd, J = 15.6, 
3.6 Hz, 1H), 4.36 (dd, J = 15.2, 1.6 Hz, 1H), 4.70 (dd, J = 15.2, 4.8 Hz, 1H), 5.79 (br s, 
1H); 
13
C NMR (125 MHz, CDCl3)  21.5, 22.1, 34.3, 34.8, 37.7, 47.5, 51.9 (peak for a 
quaternary carbon of tetrazole ring was not observed); HRMS (ESI) m/z calcd for C8H16N5 
[M + H]
+ 
182.1406, found 182.1399. 
 
 
5,6,8,9-Tetrahydrotetrazolo[1,5-d][1,4]oxazepine (13e), 1,4-Oxazepan-5-one 
(14e),
66d
 and (5,6,8,9-Tetrahydro-4H-tetrazolo[1,5-d][1,4,6]oxadiazocine (15e). 
Following the general procedure D, a solution of tetrahydro-4H-pyran-4-one 12e (40.1 mg, 
0.400 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 mmol, 2.5 equiv) in HFIP (1.0 mL) was 
treated with TfOH (15.9 L, 0.180 mmol, 0.45 equiv). The reaction mixture was stirred at 
room temperature for 2.5 h. Purification using a 4 g flash column on a CombiFlash Rf 
system (0–5% MeOH/CH2Cl2 over 50 min) afforded tetrazole 13e (eluted between 1.1–
3.1% MeOH/CH2Cl2) as a colorless solid (30.0 mg, 0.214 mmol, 53% yield) and a slightly 
impure mixture of lactam 14e and aminotetrazole 15e (eluted between 3.9–4.3% 
MeOH/CH2Cl2) as a colorless solid (for 14e: ca. 3.4 mg, 0.30 mmol, 7% corrected yield 
and for 15e: ca. 1.8 mg, 0.012 mmol, 3% corrected yield; ratio of 14e:15e = ca. 66:34 by 
1
H 
NMR).  
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Similarly, the solution of 12e (40.1 mg, 0.400 mmol, 1.0 equiv) and TMSN3 (115 mg, 
1.00 mmol, 2.5 equiv) in HFIP (1.0 mL) was treated with TfOH (17.7 L, 0.200 mmol, 
0.50 equiv) at room temperature for 1 h. Concentration, followed by quenching with 
triethylamine (Et3N) (ca. 0.10 mL), and purification using a 4 g flash column on a 
CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 50 min) afforded tetrazole 13e (eluted 
between 2.4–2.7% MeOH/CH2Cl2) as a colorless solid (26.5 mg, 0.189 mmol, 47% yield) 
and a mixture of lactam 14e and aminotetrazole 15e (eluted between 3.6–3.7% 
MeOH/CH2Cl2, pure fractions only) as a colorless solid (for 14e: ca. 0.50 mg, 0.0043 
mmol, 1% corrected yield and for 15e: ca. 1.3 mg, 0.0084 mmol, 2% corrected yield; ratio 
of 14e:15e = ca. 29:71 by 
1
H NMR). Tetrazole 13e: Rf = 0.36 (2% MeOH/CH2Cl2); mp 
157–159 C; IR (neat) 1530, 1468, 1143 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  3.30 (m, 2H), 
3.90 (m, 2H), 3.96 (m, 2H), 4.61 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  27.5, 51.4, 68.3, 
69.4, 155.5; HRMS (ESI) m/z calcd for C5H9N4O [M + H]
+ 
141.0776, found 141.0787.  
Mixture of lactam 14e and aminotetrazole 15e (14e:15e = ca. 29:71): Rf = 0.31 (4% 
MeOH/CH2Cl2); IR (neat) 3261, 3130, 3074, 1665 (lactam), 1633 (aminotetrazole), 1547 
cm
–1
. For lactam 14e in a mixture: 
1
H NMR (500 MHz, CDCl3) 
 
2.72 (m, 2H), 3.35 (m, 
2H), 3.77 (m, 2H), 3.81 (m, 2H), 6.14 (br s, 1H); 
13
C NMR (125 MHz, CDCl3)  41.1, 45.0, 
65.7, 71.8, 177.5; HRMS (ESI) m/z calcd for C5H10NO2 [M + H]
+ 
116.0712, found 
116.0711. For aminotetrazole 15e in a mixture: 
1
H NMR (500 MHz, CDCl3)  3.54 
(apparent q, J = 5.2 Hz, 2H), 3.90 (apparent t, J = 5.0 Hz, 2H), 3.98 (t, J = 5.5 Hz, 2H), 
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4.61 (t, J = 5.5 Hz, 2H), 5.61 (br s, 1H); 
13
C NMR (125 MHz, CDCl3)  46.3, 47.5, 68.3, 
71.2, 157.6; HRMS (ESI) m/z calcd for C5H10N5O [M + H]
+ 
156.0885, found 156.0896.  
 
 
(5S,8R)-5-Isopropyl-8-methyl-6,7,8,9-tetrahydro-5H-tetrazolo[1,5-a]azepine 
(13f).
130-131
 Following the general procedure D, a solution of purified L-menthone 12f (61.7 
mg, 0.400 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 mmol, 2.5 equiv) in HFIP (1.0 mL) 
was treated with TfOH (17.7 L, 0.200 mmol, 0.50 equiv). The reaction mixture was 
stirred at room temperature for 6 h. Purification using a 4 g flash column on a CombiFlash 
Rf system (0–5% MeOH/CH2Cl2 over 50 min) afforded a single tetrazole regioisomer 13f 
(eluted between 1.1–2.0% MeOH/CH2Cl2) as a colorless oil (67.6 mg, 0.348 mmol, 87% 
yield). Tetrazole 13f: Rf = 0.50 (2% MeOH/CH2Cl2); IR (neat) 2962, 1520, 1459, 1429 cm
–
1
; 
1
H NMR (400 MHz, CDCl3)  0.78 (d, J = 6.7 Hz, 3H), 0.81 (d, J = 7.0 Hz, 3H), 1.03 (d, 
J = 6.6 Hz, 3H), 1.58 (m, 1H), 1.79–1.87 (m, 1H), 1.91–1.99 (m, 1H), 2.05–2.13 (complex, 
2H), 2.40 (m, 1H), 3.03 (d, J = 4.1 Hz, 2H), 4.33 (ddd, J = 9.0, 6.1, 3.0 Hz, 1H); 
13
C NMR 
(100 MHz, CDCl3)  18.7, 18.9, 19.9, 23.9, 28.6, 28.9, 30.2, 31.6, 65.8, 154.1; HRMS 
(ESI) m/z calcd for C10H19N4 [M + H]
+ 
195.1610, found 195.1620. 
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Phenyl(5,6,8,9-tetrahydro-7H-tetrazolo[1,5-d][1,4]diazepin-7-yl)methanone (13g) 
(mixture of rotamers) and 1-Benzoyl-1,4-diazepan-5-one (14g)
132
 (mixture of 
rotamers). Following the general procedure D, a solution of 1-benzoyl-4-piperidone 12g 
(81.3 mg, 0.400 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 mmol, 2.5 equiv) in HFIP 
(1.0 mL) was treated with TfOH (23.0 L, 0.260 mmol, 0.65 equiv). The reaction mixture 
was stirred at room temperature for 2.5 h. Purification using a 12 g flash column on a 
CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 45 min) afforded impure tetrazole 13g 
as a mixture of rotamers (eluted between 3.5–3.7% MeOH/CH2Cl2) and impure lactam 14g 
as a mixture of rotamers (eluted between 4.5–4.9% MeOH/CH2Cl2). The impure tetrazole 
13g was purified by preparative TLC developing four times with 2% MeOH/CH2Cl2. The 
band corresponding to 13g was scraped from the plate and eluted with 5% MeOH/CH2Cl2 
through a phase separator tabless. Concentration afforded 13g (mixture of rotamers) as a 
colorless crystalline solid (49.0 mg, 0.201 mmol, 50% yield; ratio of rotamers = 70:30). 
Recrystallization of 13g with CH2Cl2–MeOH mixture afforded almost colorless, large 
plate-like crystals. Similarly, the impure lactam 14g was purified twice by preparative TLC 
developing three times each with 3% MeOH/CH2Cl2. The band corresponding to 14g was 
scraped from the plate and eluted with 5% MeOH/CH2Cl2 through a phase separator 
tabless. Concentration afforded 14g (mixture of rotamers) as a colorless amorphous solid 
(12.5 mg, 0.0573 mmol, 14% yield; ratio of rotamers = 65:35). Recrystallization of 14g 
with CH2Cl2 afforded colorless small plate-like crystals.  
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Tetrazole 13g: Rf = 0.37 (3% MeOH/CH2Cl2, run twice); mp 197–199 C; IR (neat) 
1631, 1423, 1265 cm
–1
; 
1
H NMR (500 MHz, CDCl3, mixture of rotamers)  3.17 and 3.41 
(br s, 2H, rotamers), 3.72 and 3.94 (br s, 2H, rotamers), 3.85 and 4.08 (br s, 2H, rotamers), 
4.49 and 4.75 (br s, 2H, rotamers), 7.41–7.43(m, 2H), 7.46–7.51 (complex, 3H); 
1
H NMR 
(major rotamer, diagnostic peaks only)  3.17 (br s, 1.4 H), 3.72 (br s, 1.4 H), 4.08 (br s, 1.4 
H), 4.75 (br s, 1.4 H); 
1
H NMR (minor rotamer, diagnostic peaks only)  3.41 (br s, 0.6 H), 
3.85 (br s, 0.6 H), 3.94 (br s, 0.6 H), 4.49 (br s, 0.6 H); 
13
C NMR (125 MHz, CDCl3, 
mixture of rotamers)  25.4, 27.0, 43.4, 45.3, 47.6, 49.3, 49.9, 50.8, 126.8, 129.2, 130.6, 
135.1, 154.6, 155.5, 171.9; 
13
C NMR (major rotamer, diagnostic peaks only)  27.0, 45.3, 
47.6, 49.9, 154.6; 
13
C NMR (minor rotamer, diagnostic peaks only)  25.4, 43.4, 49.3, 50.8, 
155.5; HRMS (ESI) m/z calcd for C12H14N5O [M + H]
+ 
244.1198, found 244.1219.  
Lactam 14g: Rf = 0.15 (3% MeOH/CH2Cl2, run twice); mp 170–173 C, melted 
slowly above 155 °C; IR (neat) 3280, 1659, 1626, 1433, 1263 cm
–1
; 
1
H NMR (500 MHz, 
CDCl3, mixture of rotamers)  2.59 and 2.75 (br s, 2H, rotamers), 3.25 and 3.42 (br s, 2H, 
rotamers), 3.58 (br s, 2H, rotamers), 3.91 (br s, 2H, rotamers), 6.44 (br s, 1H), 7.37–7.39 
(complex, 2H), 7.41–7.45 (complex, 3H); 
1
H NMR (major rotamer, diagnostic peaks only) 
 2.59 (br s, 1.3 H), 3.42 (br s, 1.3 H); 1H NMR (minor rotamer, diagnostic peaks only)  
2.75 (br s, 0.7 H), 3.25 (br s, 0.7 H); 
13
C NMR (125 MHz, CDCl3, mixture of rotamers)  
38.5, 39.4, 40.4, 43.2, 44.1, 45.4, 46.9, 52.1, 127.0, 129.0, 130.2, 135.7, 171.4, 176.4, 
177.3; 
13
C NMR (major rotamer, diagnostic peaks only)  39.4, 43.2, 45.4, 46.9, 176.4; 13C 
NMR (minor rotamer, diagnostic peaks only)  38.5, 40.4, 44.1, 52.1, 177.3; HRMS (ESI) 
m/z calcd for C12H15N2O2 [M + H]
+ 
219.1134, found 219.1134. 
 
 
187 
 
 
5,6,7,8-Tetrahydrotetrazolo[1,5-a]pyridine (13h)
77g
 and 5,6,7,8-Tetrahydro-4H-
tetrazolo[1,5-a][1,3]diazepine (15h). Following the general procedure D, a solution of 
cyclopentanone 12h (33.7 mg, 0.400 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 mmol, 
2.5 equiv) in HFIP (1.0 mL) was treated with TfOH (17.7 L, 0.200 mmol, 0.50 equiv). 
The reaction mixture was stirred at room temperature for 6 h. Concentration, followed by 
quenching with Et3N (ca. 0.10 mL), and purification using a 4 g flash column on a 
CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 50 min) afforded tetrazole 13h (eluted 
between 1.9–2.8% MeOH/CH2Cl2) as a colorless solid (25.3 mg, 0.204 mmol, 51% yield) 
and aminotetrazole 15h (eluted between 3.2–3.4% MeOH/CH2Cl2) as a colorless waxy 
solid film (3.8 mg, 0.027 mmol, 7% yield). Recrystallization of 15h from CH2Cl2 afforded 
small, almost colorless crystals. Tetrazole 13h: Rf = 0.32 (2% MeOH/CH2Cl2); mp 114–116 
C (lit.
77g
 mp 116 C and lit.
77b
 mp 115–116 C); IR (neat) 1532, 1448 cm
–1
; 
1
H NMR (400 
MHz, CDCl3)  1.98–2.05 (m, 2H), 2.07–2.14 (m, 2H), 3.02 (t, J = 6.4 Hz, 2H), 4.35 (t, J = 
6.1 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  20.2, 20.9, 22.4, 45.7, 152.1; HRMS (ESI) m/z 
calcd for C5H9N4 [M + H]
+ 
125.0827, found 125.0825. 
Aminotetrazole 15h: Rf = 0.26 (4% MeOH/CH2Cl2); mp 100–104 C, melted slowly 
above 92 C; IR (neat) 3250, 3063, 1591, 1397 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  1.92–
1.98 (complex, 4H), 3.23 (m, 2H), 4.32 (m, 2H), 5.58 (br s, 1H); 
13
C NMR (125 MHz, 
CDCl3)  26.5, 29.7, 45.7, 49.0, 159.6; HRMS (ESI) m/z calcd for C5H10N5 [M + H]
+ 
140.0936, found 140.0940. 
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5,6,7,8,9,10-Hexahydrotetrazolo[1,5-a]azocine (13i)
77g
 and 5,6,7,8,9,10-
Hexahydro-4H-tetrazolo[1,5-a][1,3]diazonine (15i). Following the general procedure D, 
a solution of cycloheptanone 12i (44.9 mg, 0.400 mmol, 1.0 equiv) and TMSN3 (115 mg, 
1.00 mmol, 2.5 equiv) in HFIP (1.0 mL) was treated with TfOH (21.2 L, 0.240 mmol, 
0.60 equiv). The reaction mixture was stirred at room temperature for 2 h. Purification 
using a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 50 min) 
afforded tetrazole 13i (eluted between 1.3–2.9% MeOH/CH2Cl2) as a colorless waxy solid 
(56.5 mg, 0.371 mmol, 93% yield) and an impure aminotetrazole 15i (eluted between 3.2–
3.5% MeOH/CH2Cl2), which was purified by preparative TLC developing one time with 
3% MeOH/CH2Cl2 and one time with 60% EtOAc/hexanes. The band corresponding to 15i 
was scraped from the plate and eluted with 5% MeOH/CH2Cl2 through a phase separator 
tabless. Concentration afforded 15i as a colorless solid film (1.1 mg, 0.0066 mmol, ca. 2% 
yield). Tetrazole 13i: Rf = 0.34 (2% MeOH/CH2Cl2); mp 66.5–68.5 C (lit.
133
 mp 68 C and 
lit.
77b
 mp 66–67 C); IR (neat) 1525, 1471 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.28–1.36 
(m, 2H), 1.38–1.46 (m, 2H), 1.84 (m, 2H), 1.91 (m, 2H), 3.01 (m, 2H), 4.44 (m, 2H); 
13
C 
NMR (100 MHz, CDCl3)  22.2, 23.7, 25.0, 29.7, 30.5, 45.8, 155.8; HRMS (ESI) m/z calcd 
for C7H13N4 [M + H]
+ 
153.1140, found 153.1140.  
Aminotetrazole 15i: Rf = 0.14 (2% MeOH/CH2Cl2); IR (neat) 3253, 3074, 1616, 1390 
cm
–1
; 
1
H NMR (500 MHz, CDCl3)  1.50 (m, 2H), 1.67 (m, 4H), 1.92 (m, 2H), 3.55 (m, 
2H), 4.52 (m, 2H), 5.35 (m, 1H); 
13
C NMR (125 MHz, CDCl3)  23.4, 24.2, 30.8, 32.3, 
42.4, 47.5, 156.6; HRMS (ESI) m/z calcd for C7H14N5 [M + H]
+ 
168.1249, found 168.1249. 
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6,7,8,9,10,11-Hexahydro-5H-tetrazolo[1,5-a]azonine (13j).
77g
 Following the 
general procedure D, a solution of cyclooctanone 12j (50.5 mg, 0.400 mmol, 1.0 equiv) and 
TMSN3 (115 mg, 1.00 mmol, 2.5 equiv) in HFIP (1.0 mL) was treated with TfOH (21.2 L, 
0.240 mmol, 0.60 equiv). The reaction mixture was stirred at room temperature for 2 h. 
Purification using a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 
over 50 min) afforded tetrazole 13j (eluted between 1.2–2.7% MeOH/CH2Cl2) as a 
colorless viscous oil (57.5 mg, 0.346 mmol, 86% yield). Tetrazole 13j: Rf = 0.38 (2% 
MeOH/CH2Cl2); IR (neat) 1520, 1474 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.25–1.32 (m, 
2H), 1.33–1.40 (m, 2H), 1.43–1.49 (m, 2H), 1.85–1.91 (m, 2H), 1.97 (m, 2H), 3.04 (m, 
2H), 4.47 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  22.4, 23.5, 25.6, 25.8, 26.4, 28.5, 47.6, 
156.3; HRMS (ESI) m/z calcd for C8H15N4 [M + H]
+ 
167.1297, found 167.1297. 
 
 
1,5-Dibutyl-1H-tetrazole (13k)
134
 and N-Butylpentanamide (14k).
135
 Following 
the general procedure D, a solution of 5-nonanone 12k (56.9 mg, 0.400 mmol, 1.0 equiv) 
and TMSN3 (115 mg, 1.00 mmol, 2.5 equiv) in HFIP (1.0 mL) was treated with TfOH (28.3 
L, 0.320 mmol, 0.80 equiv). The reaction mixture was stirred at room temperature for 3 h. 
Purification using a 12 g flash column on a CombiFlash Rf system (0–2% MeOH/CH2Cl2 
over 45 min) afforded tetrazole 13k (eluted between 0.4–0.7% MeOH/CH2Cl2) as a pale 
yellow oil and a mixture of 13k and amide 14k (eluted between 0.7–1.0% MeOH/CH2Cl2; 
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ca. 41:59 ratio of 13k:14k by 
1
H NMR) as a pale yellow oil (for 13k: 29.4 mg, 0.161 mmol, 
40% corrected yield and for 14k: 11.8 mg, 0.0750 mmol, 19% corrected yield). The 
unreacted 5-nonanone was not isolated during this purification. For amide 14k in a mixture 
of 13k and 14k (13k:14k = ca. 41:59 by 
1
H NMR): Rf = 0.36 (2% MeOH/CH2Cl2); IR 
(neat) 3303, 1648 cm
–1
; 
1
H NMR (500 MHz, CDCl3, amide 14k)  0.89 (td, J = 7.3, 3.9 Hz, 
6H), 1.28–1.38 (complex, 4H, partially obscured by peaks of 13k), 1.39–1.49 (complex, 
2H, partially obscured by peaks of 13k), 1.59 (m, 2H), 2.14 (t, J = 7.7 Hz, 2H), 3.22 (m, 
2H), 5.57 (br s, 1H); 
13
C NMR (125 MHz, CDCl3, amide 14k)  13.9, 14.0, 20.2, 22.6, 
28.1, 31.9, 36.8, 39.4, 173.3; HRMS (ESI) m/z calcd for C9H20NO [M + H]
+ 
158.1545, 
found 158.1561. 
 
 
1,5-Dicyclohexyl-1H-tetrazole (13l).
136
 Following the general procedure D, a 
solution of dicyclohexylketone 12l (77.7 mg, 0.400 mmol, 1.0 equiv) and TMSN3 (115 mg, 
1.00 mmol, 2.5 equiv) in HFIP (1.0 mL) was treated with TfOH (31.9 L, 0.360 mmol, 
0.90 equiv). The reaction mixture was stirred at room temperature for 6 h. Concentration, 
followed by quenching with Et3N (ca. 0.050 mL), and purification using a 12 g flash 
column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 55 min) afforded tetrazole 
13l (eluted between 1.0–1.2% MeOH/CH2Cl2) as a colorless crystalline solid, followed by a 
mixture of 13l and an unidentified byproduct (eluted between 1.2–1.9% MeOH/CH2Cl2; ca. 
88:12 ratio of 13l:byproduct by 
1
H NMR), and an impure mixture of 13l and byproduct 
(eluted between 1.9–2.6% MeOH/CH2Cl2). Further purification of the impure mixture of 
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13l and byproduct using a 4 g flash column on a CombiFlash Rf system (0–5% 
MeOH/CH2Cl2 over 25 min) afforded 13l with a trace amount of byproduct (eluted between 
2.4–3.2% MeOH/CH2Cl2) as a colorless solid (for 13l: 69.8 mg, 0.298 mmol, 74% 
corrected overall yield) and an impure mixture of byproduct with a little bit of 13l (eluted 
between 3.2–3.4% MeOH/CH2Cl2). Subsequent purification of the impure mixture in order 
to obtain an analytically pure sample of byproduct for characterization was unsuccessful. 
HRMS of a mixture of 13l and byproduct showed molecular ion peaks [M + H]
+
 for both 
13l and amide (for amide: HRMS (ESI) m/z calcd for C13H24NO [M + H]
+ 
210.1858, found 
210.1828). The byproduct could not be confirmed as amide due to lack of complete 
spectroscopic data. The unreacted dicyclohexylketone was not isolated during this 
purification. Tetrazole 13l: Rf = 0.56 (2% MeOH/CH2Cl2); mp 173–177 C (lit.
136
 mp 
179.5–180 C); IR (neat) 2928, 1501, 1450, 1096 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  
1
H 
NMR (400 MHz, CDCl3)  1.27–1.48 (complex, 6H), 1.70–1.80 (complex, 4H), 1.85–2.08 
(complex, 10H), 2.75 (tt, J = 11.6, 3.5 Hz, 1H), 4.11 (m, 1H); 
13
C NMR (100 MHz, CDCl3) 
 13C NMR (100 MHz, CDCl3)  25.0, 25.57, 25.63, 26.1, 31.6, 33.4, 33.7, 57.5, 157.7; 
HRMS (ESI) m/z calcd for C13H23N4 [M + H]
+ 
235.1923, found 235.1904. 
 
 
1,5-Diethyl-1H-tetrazole (13m).
77b,137
 Following the general procedure D, a solution 
of 3-pentanone 12m (34.5 mg, 0.400 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 mmol, 
2.5 equiv) in HFIP (1.0 mL) was treated with TfOH (31.9 L, 0.360 mmol, 0.90 equiv). 
The reaction mixture was stirred at room temperature for 6 h. Concentration, followed by 
quenching with Et3N (ca. 0.050 mL), and purification using a 12 g flash column on a 
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CombiFlash Rf system (0–10% MeOH/CH2Cl2 over 55 min) afforded tetrazole 13m (eluted 
between 1.1–1.9% MeOH/CH2Cl2) as a pale yellow oily solid (33.6 mg, 0.266 mmol, 66% 
yield). Tetrazole 13m: Rf = 0.50 (2% MeOH/CH2Cl2); IR (neat) 2985, 1521, 1456, 1426, 
1094 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.39 (t, J = 7.6 Hz, 3H), 1.51 (t, J = 7.3 Hz, 3H), 
2.84 (q, J = 7.6 Hz, 2H), 4.28 (q, J = 7.3 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  11.6, 
15.1, 16.9, 42.2, 155.5; HRMS (ESI) m/z calcd for C5H11N4 [M + H]
+ 
127.0984, found 
127.0961. A small amount of impure amide was also obtained during this purification.  
 
 
6-Phenyl-5,6-dihydrobenzo[f]tetrazolo[1,5-d][1,4]oxazepine (13n),
91a
 2-Phenyl-
3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one (14na),
91a
 2-Phenyl-2,3-dihydrobenzo-
[b][1,4]oxazepin-4(5H)-one (14nb),
91a
 5-((1,1,1,3,3,3-Hexafluoropropan-2-yl)oxy)-2-
phenyl-2,3-dihydrobenzo[f][1,4]oxazepine (16), (E)-2-Azido-5-phenyl-4,5-dihydro-1H-
benzo[b][1,4,6]oxadiazocine (17), and 2-(Benzo[d]oxazol-2-ylamino)-1-phenylethan-1-
ol (18; Scheme 19). Following the general procedure D, a solution of flavanone 12n (89.7 
mg, 0.400 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 mmol, 2.5 equiv) in HFIP (1.0 mL) 
was treated with TfOH (35.4 L, 0.400 mmol, 1.0 equiv). The reaction mixture was stirred 
at room temperature for 5 h. The reaction mixture was concentrated under nitrogen gas; the 
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residue obtained was diluted with hexanes–CH2Cl2 mixture, and loaded on silica gel in a 5 
g sample cartridge. Purification using a 12 g flash column on a CombiFlash Rf system (0–
90% EtOAc/hexanes over 55 min) afforded iminoether 16 (eluted at 100% hexanes) as a 
colorless oil (28.1 mg, 0.0722 mmol, 18% yield), tetrazole 13n (eluted between 3.0–5.0% 
EtOAc/hexanes) as a colorless amorphous solid (52.0 mg, 0.197 mmol, 49% yield), an 
impure mixture of guanyl azide 17 and lactam 14nb (eluted between 15–35% 
EtOAc/hexanes), and an impure mixture of aminobenzoxazole 18 and lactam 14na (eluted 
between 40–60% EtOAc/hexanes). The unreacted flavanone was not isolated during this 
purification. Recrystallization of 13n from EtOAc afforded colorless, thick plate-like 
crystals. The impure mixture of guanyl azide 17 and lactam 14nb was purified by 
preparative TLC developing two times with 30% EtOAc/hexanes. Bands corresponding to 
17 and 14nb were scraped from the plate and separately eluted with 1% MeOH/CH2Cl2 
through a phase separator tabless. Concentration afforded 17 as a pale orange amorphous 
solid (8.5 mg, 0.030 mmol, 8% yield) and 14nb as a colorless waxy solid film (1.1 mg, 
0.0046 mmol, ca. 1% yield). Recrystallization of 17 from CH2Cl2–hexanes mixture 
afforded colorless, thread-like, fine crystals. Similarly, the impure mixture of 
aminobenzoxazole 18 and lactam 14na was purified by preparative TLC developing two 
times with 40% EtOAc/hexanes. Bands corresponding to 18 and 14na were scraped from 
the plate and separately eluted with 2% MeOH/CH2Cl2 through a phase separator tabless. 
Concentration afforded a slightly impure sample of 18 as a colorless waxy solid film (2.8 
mg, 0.011 mmol, ca. 3% yield) and 14na as colorless viscous oil (7.0 mg, 0.029 mmol, 7% 
yield). Recrystallization of 18 from EtOAc–hexanes mixture afforded partial 
recrystallization into almost colorless, thin plate-like crystals and a pale brownish residue. 
Crystals of 18 were utilized for acquiring a single-crystal X-ray diffraction data (see Table 
S25) and for determining the melting point. Recrystallization of 14na from CH2Cl2 
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afforded partially crystalline, off-white waxy solid. Tetrazole 13n: Rf = 0.33 (20% 
EtOAc/hexanes); mp 124.5–126.5 C (lit.
77a
 mp 136–137 C and lit.
91a
 mp 137–138 C); IR 
(neat) 1609, 1484, 1045 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  4.83 (dd, J = 14.6, 9.8 Hz, 
1H), 5.12 (dd, J = 14.6, 1.5 Hz, 1H), 5.26 (dd, J = 9.8, 1.3 Hz, 1H), 7.18 (dd, J = 8.3, 1.0 
Hz, 1H), 7.26 (m, 1H), 7.44–7.56 (m, 6H), 8.57 (dd, J = 8.0, 1.7 Hz, 1H); 
13
C NMR (100 
MHz, CDCl3)  56.4, 79.1, 113.1, 121.7, 124.2, 126.2, 129.3, 129.4, 130.5, 133.4, 136.5, 
152.1, 157.0; HRMS (ESI) m/z calcd for C15H13N4O [M + H]
+ 
265.1089, found 265.1071.  
Lactam 14na: Rf = 0.34 (50% EtOAc/hexanes); mp 122.5–125.5 C (lit.
91a
 mp 125–
126 C); IR (neat) 3222, 1654, 1603, 1459 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  3.54 (dt, J 
= 15.4, 5.8 Hz, 1H), 3.67 (ddd, J = 15.4, 6.2, 3.5 Hz, 1H), 5.46 (dd, J = 6.1, 3.5 Hz, 1H), 
6.87 (br s, 1H), 7.09 (dd, J = 8.1, 0.9 Hz, 1H), 7.22 (td, J = 7.5, 1.0 Hz, 1H), 7.34–7.42 (m, 
5H), 7.48 (m, 1H), 7.87 (dd, J = 7.8, 1.7 Hz, 1H); 
13
C NMR (125 MHz, CDCl3)  46.6, 
86.0, 122.7, 124.0, 126.1, 126.5, 128.8, 128.9, 131.2, 133.6, 139.2, 154.8, 171.0; HRMS 
(ESI) m/z calcd for C15H14NO2 [M + H]
+ 
240.1025, found 240.1012. 
Lactam 14nb: Rf = 0.21 (30% EtOAc/hexanes); IR (neat) 3214, 1673, 1597, 1497 
cm
–1
; 
1
H NMR (500 MHz, CDCl3)  2.99 (ddd, J = 14.8, 4.1, 0.8 Hz, 1H), 3.09 (dd, J = 
14.8, 8.8 Hz, 1H), 5.66 (dd, J = 8.8, 4.1 Hz, 1H), 6.95–6.98 (m, 1H), 7.05–7.13 (complex, 
3H), 7.34–7.44 (complex, 6H); 
13
C NMR (125 MHz, CDCl3)  42.1, 83.3, 122.1, 123.8, 
124.6, 126.2, 126.3, 128.8, 128.9, 130.2, 140.2, 148.4, 171.1; HRMS (ESI) m/z calcd for 
C15H14NO2 [M + H]
+ 
240.1025, found 240.1039. 
Iminoether 16: Rf = 0.78 (20% EtOAc/hexanes); IR (neat) 1685, 1605, 1190 cm
–1
; 
1
H 
NMR (400 MHz, CDCl3)  3.96 (dd, J = 15.5, 7.8 Hz, 1H), 4.05 (dd, J = 15.5, 2.2 Hz, 1H), 
5.35 (dd, J = 7.8, 2.2 Hz, 1H), 6.51 (hept, J = 6.5 Hz, 1H), 7.16–7.21 (m, 2H), 7.38–7.43 
(m, 1H), 7.45 (m, 4H), 7.50 (m, 1H), 7.91 (dd, J = 7.9, 1.6 Hz, 1H); 
13
C NMR (100 MHz, 
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CDCl3)  54.9, 66.9 (p, J = 135.1 Hz, 1C), 85.7, 118.2, 120.1, 121.9, 122.7, 122.9, 126.3, 
128.5, 128.9, 129.8, 133.7, 139.5, 155.4, 158.2; HRMS (ESI) m/z calcd for C18H14F6NO2 
[M + H]
+ 
390.0929, found 390.0900. 
Guanyl azide 17: Rf = 0.43 (30% EtOAc/hexanes); mp 99.5–101 C; IR (neat) 3209, 
2101, 1643, 1583, 1459 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  3.62 (dd, J = 14.0, 8.8 Hz, 
1H), 3.81 (dd, J = 14.0, 5.1 Hz, 1H), 4.92 (dd, J = 8.8, 5.1 Hz, 1H), 5.46 (br s, 1H), 7.07 
(td, J = 7.8, 1.1 Hz, 1H), 7.19 (td, J = 7.7, 1.0 Hz, 1H), 7.27 (m, 1H), 7.36–7.44 (complex, 
6H); 
13
C NMR (125 MHz, CDCl3)  48.4, 65.2, 109.2, 116.8, 121.5, 124.3, 127.3, 129.2, 
129.3, 136.7, 142.7, 148.7, 161.5; HRMS (ESI) m/z calcd for C15H14N5O [M + H]
+ 
280.1198, found 280.1183. 
Aminobenzoxazole 18: Rf = 0.39 (50% EtOAc/hexanes); mp 118–121 C; IR (neat) 
3255, 1647, 1585, 1461 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  3.64 (dd, J = 14.1, 8.0 Hz, 
1H), 3.84 (dd, J = 14.0, 3.4 Hz, 1H), 5.05 (dd, J = 7.9, 3.4 Hz, 1H), 5.45 (br s, 1H), 7.05 
(td, J = 7.8, 1.1 Hz, 1H), 7.18 (td, J = 7.7, 1.0 Hz, 1H), 7.24–7.26 (m, 2H), 7.31 (m, 1H), 
7.36–7.39 (complex, 3H), 7.42–7.44 (m, 2H); 
13
C NMR (125 MHz, CDCl3)  50.8, 73.7, 
109.1, 116.7, 121.4, 124.3, 126.1, 128.3, 128.9, 141.6, 142.5, 148.8, 162.6; HRMS (ESI) 
m/z calcd for C15H15N2O2 [M + H]
+ 
255.1134, found 255.1136. 
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Table S25. Selected Crystallographic and Refinement Parameters for 18 
Compound Aminobenzoxazole 18 
Empirical formula C15H14N2O2 
Formula wt. 254.28 
Temperature 100(2) K 
Crystal system Monoclinic 
Crystal size (mm
3
) 0.11  0.08  0.05 
Space group P21/c 
a [Å] 12.8994(7) 
b [Å] 10.6296(5) 
c [Å] 9.5520(5) 
 [deg] 90 
[deg] 99.3230(10) 
 [deg] 90 
Z 4 
Volume [Å
3
] 1292.43(11) 
Dcalc [Mg/m
3
] 1.307 
F (000) 536 
Absorption coefficient  [mm–1] 0.715 
Theta range for data collection 5.42 to 68.04 
Range h –15<=h<=15 
Range k –8<=k<=12 
Range l –10<=l<=11 
Reflections collected 7865 
Independent reflections 2262 
Rint 0.0178 
Data / Restraints / Parameters 2262 / 12 / 248 
Final R indices [I>2(I)] 0.0501 
wR2 0.1214 
Goodness-of-fit on F
2
 1.113 
R-factor (%) 5.01 
Largest diff. peak and hole (eÅ
–3
) 0.265 and –0.162 
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(E)-5-Phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)-4,5-dihydro-1H-benzo[b][1,4,6]-
oxadiazocine (19; Scheme 21). Following a slight modification of the reported 
procedure,
138
 in a one dram vial, to a clear colorless solution of guanyl azide 17 (4.0 mg, 
0.014 mmol, 1.0 equiv) and phenyl acetylene (1.8 mg, 0.017 mmol, 1.2 equiv) in tert-
butanol and deionized water mixture (0.6 mL, 1:1) was added copper(II) sulfate 
pentahydrate (3.6 mg, 0.014 mmol, 1.0 equiv) and (+)-sodium L-ascorbate (5.7 mg, 0.029 
mmol, 2.0 equiv). The vial was capped and the resulting pale yellowish-blue turbid 
suspension was stirred at room temperature for 18 h. The reaction mixture was partially 
concentrated under N2, diluted with CH2Cl2 (1.0 mL), and quenched with NH4OH solution 
(five drops). After stirring at room temperature for 5 min, the biphasic mixture was passed 
through a hydrophobic phase separator tabless, which allowed the CH2Cl2 layer to pass 
through the tabless. The blue aqueous layer was further washed with CH2Cl2 (2  1 mL) 
and the CH2Cl2 layer was allowed to pass through the tabless. The combined CH2Cl2 layers 
were concentrated and the residue was purified by preparative TLC developing one time 
with 2% MeOH/CH2Cl2. The band corresponding to guanidino triazole 19 was scraped 
from the plate and eluted with 5% MeOH/CH2Cl2 through a phase separator tabless. 
Concentration afforded 19 as a colorless amorphous solid (5.2 mg, 0.014 mmol, 95% 
yield). Guanidino triazole 19: Rf = 0.18 (2% MeOH/CH2Cl2); mp 216.5–218.5 C; IR (neat) 
3087, 1668, 1641, 1586, 1459 cm
–1
; 
1
H NMR (500 MHz, CDCl3 + CD3OD)  4.31 (dd, J = 
14.6, 4.3 Hz, 1H), 4.51 (dd, J = 14.6, 9.9 Hz, 1H), 6.03 (dd, J = 9.8, 4.4 Hz, 1H), 7.04 (t, J 
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= 7.8 Hz, 1H), 7.17 (t, J = 7.4 Hz, 1H), 7.23 (d, J = 7.8 Hz, 1H), 7.30 (m, 1H), 7.34–7.40 
(complex, 8H), 7.74–7.76 (m, 3H); 
13
C NMR (125 MHz, CDCl3 + CD3OD)  47.1, 64.3, 
109.3, 116.5, 121.1, 121.6, 124.3, 125.9, 127.0, 128.6, 129.0, 129.3, 129.4, 130.2, 136.8, 
142.2, 148.2, 148.6, 161.6; HRMS (ESI) m/z calcd for C23H20N5O [M + H]
+ 
382.1668, 
found 382.1647. 
 
 
6,11-Dihydro-5H-benzo[d]tetrazolo[1,5-a]azepine (13oa),
77d
 10,11-Dihydro-5H-
benzo[e]tetrazolo[1,5-a]azepine (13ob),
77d
 1,3,4,5-Tetrahydro-2H-benzo[d]azepin-2-
one (14oa),
139
 1,2,4,5-Tetrahydro-3H-benzo[c]azepin-3-one (14ob),
140
 4,5,10,11-Tetra-
hydrobenzo[e]tetrazolo[1,5-a][1,3]diazocine (15oa), and 4,5,6,11-Tetrahydrobenzo[f]-
tetrazolo[1,5-a][1,3]diazocine (15ob; Scheme 22). Following the general procedure D, a 
solution of purified -tetralone 12o (58.5 mg, 0.400 mmol, 1.0 equiv) and TMSN3 (115 mg, 
1.00 mmol, 2.5 equiv) in HFIP (1.0 mL) was treated with TfOH (10.6 L, 0.120 mmol, 
0.30 equiv). The reaction mixture was stirred at room temperature for 22 h. Purification 
with a 4 g normal phase silica flash column on a CombiFlash Rf system with a gradient 
elution from 0–35% EtOAc/hexanes over 60 min afforded tetrazole regioisomer 13oa 
(eluted between 25–28% EtOAc/hexanes) as a pale creamish-orange solid, followed by a 
mixture of tetrazole regioisomers 13oa and 13ob (eluted between 28–30% EtOAc/hexanes) 
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as an off-white solid, and tetrazole regioisomer 13ob (eluted between 30–32% 
EtOAc/hexanes) as a creamish solid (combined yield of 13oa and 13ob: 37.3 mg, 0.200 
mmol, 50% yield; ratio of 13oa:13ob = 58:42). Recrystallization of 13oa from CH2Cl2–
hexanes mixture afforded colorless square-shaped, plate-like crystals. Recrystallization of 
13ob from EtOAc afforded colorless plate-like crystals. Continuation with the 
chromatography by changing to a more polar solvent system (0–5% MeOH/CH2Cl2 over 30 
min) afforded an impure mixture of lactams 14oa and 14ob, and aminotetrazoles 15oa and 
15ob (eluted between 3.0–3.3% MeOH/CH2Cl2) as an orange semisolid. This mixture of 
four compounds was further purified by preparative TLC developing three times with 70% 
EtOAc/hexanes. Bands corresponding to aminotetrazoles (high Rf two overlapping bands) 
and lactams (low Rf two overlapping bands) were scraped from the plate and eluted 
separately with 5% MeOH/CH2Cl2 through a phase separator tabless. Concentration of 
elutions containing low Rf bands afforded lactam 14oa as a colorless amorphous solid and a 
slightly impure mixture of lactams 14oa and 14ob as a colorless waxy solid (combined 
yield of 14oa and 14ob: 5.0 mg, 0.031 mmol, 8% yield; ratio of 14oa:14ob = 69:31). 
Recrystallization of 14oa from CH2Cl2 afforded colorless fine crystals. Concentration of 
elutions containing high Rf bands afforded a slightly impure aminotetrazole 15oa as a 
colorless waxy solid and a mixture of aminotetrazoles 15oa and 15ob as a colorless solid 
(combined yield of 15oa and 15ob: 8.0 mg, 0.040 mmol, 10% yield; ratio of 15oa:15ob = 
60:40). Recrystallization of 15oa from CH2Cl2–MeOH mixture afforded partial 
recrystallization into colorless, fine plate-like crystals and an off-white solid film. Tetrazole 
13oa: Rf = 0.42 (50% EtOAc/hexanes); mp 148–151 C (lit.
77d
 mp 156–157 C); IR (neat) 
1525, 1471 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  3.37 (m, 2H), 4.40 (s, 2H), 4.61 (m, 2H), 
7.25–7.32 (m, 4H); 
13
C NMR (100 MHz, CDCl3)  29.7, 30.5, 49.3, 128.4, 128.9, 129.4, 
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129.5, 134.5, 137.0, 151.6; HRMS (ESI) m/z calcd for C10H11N4 [M + H]
+ 
187.0984, found 
187.0978. 
Tetrazole 13ob: Rf = 0.32 (50% EtOAc/hexanes); mp 135.5–137 C (lit.
77d
 mp 145–
146 C); IR (neat) 1524, 1417 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  3.22–3.25 (m, 2H), 
3.35–3.38 (m, 2H), 5.63 (s, 2H), 7.27–7.31 (m, 1H), 7.34–7.41 (m, 3H); 
13
C NMR (100 
MHz, CDCl3)  25.4, 29.0, 51.5, 127.9, 129.3, 129.6, 130.3, 132.7, 139.9, 153.1; HRMS 
(ESI) m/z calcd for C10H11N4 [M + H]
+ 
187.0984, found 187.0981.  
Lactam 14oa: Rf = 0.39 (70% EtOAc/hexanes, run three times); mp 154–157 C, 
melted slowly above 125 °C (lit.
139
 mp 159–160 C); IR (neat) 3176, 1660, 1641 cm
–1
; 
1
H 
NMR (400 MHz, CDCl3)  3.13 (m, 2H), 3.58 (m, 2H), 3.85 (s, 2H), 6.05 (br s, 1H), 7.11–
7.22 (m, 4H); 
13
C NMR (125 MHz, CDCl3)  33.5, 41.7, 42.7, 127.1, 127.5, 130.0, 130.6, 
132.0, 137.0, 173.7; HRMS (ESI) m/z calcd for C10H12NO [M + H]
+ 
162.0919, found 
162.0920. 
For lactam 14ob in a mixture of 14oa and 14ob (ratio of 14oa:14ob = ca. 14:86 by 
1
H 
NMR): Rf = 0.34 (70% EtOAc/hexanes, run three times); IR (neat, for a mixture) 3247, 
1661 cm
–1
; 
1
H NMR (500 MHz, CDCl3, lactam 14ob)  2.82 (m, 2H), 3.11 (m, 2H, 
partially obscured by peaks of 14oa), 4.37 (d, J = 5.4 Hz, 2H), 6.38 (br s, 1H), 7.11–7.12 
(m, 1H, partially obscured by peaks of 14oa), 7.16–7.21 (m, 2H, partially obscured by 
peaks of 14oa), 7.25–7.28 (m, 1H); 
13
C NMR (125 MHz, CDCl3, lactam 14ob)  28.7, 
34.6, 46.2, 126.7, 128.4, 128.5, 129.8, 136.1, 139.2, 175.4; HRMS (ESI) m/z calcd for 
C10H12NO [M + H]
+ 
162.0919, found 162.0929. 
Aminotetrazole 15oa: Rf = 0.67 (70% EtOAc/hexanes, run three times); mp 174–180 
°C, melted slowly above 140 °C; IR (neat) 3231, 1585 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  
3.52 (t, J = 6.6 Hz, 2H), 4.51 (s, 2H), 4.78 (t, J = 6.6 Hz, 2H), 5.91 (br s, 1H), 7.14–7.17 
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(m, 1H), 7.21–7.26 (complex, 3H; partially obscured by solvent peak); 
13
C NMR (125 
MHz, CDCl3)  34.4, 46.4, 48.6, 128.4, 129.3, 131.0, 131.6, 135.3, 135.9 (peak for a 
quaternary carbon of tetrazole ring was not observed); HRMS (ESI) m/z calcd for C10H12N5 
[M + H]
+ 
202.1093, found 202.1096. 
For aminotetrazole 15ob in a mixture of 15oa and 15ob (ratio of 15oa:15ob = ca. 
37:63 by 
1
H NMR): Rf = 0.62 (70% EtOAc/hexanes, run three times); IR (neat, for a 
mixture) 3246, 1597 cm
–1
; 
1
H NMR (400 MHz, CDCl3, aminotetrazole 15ob)  3.26 (m, 
2H), 3.51 (m, 2H, partially obscured by peaks of 15oa), 5.44 (s, 2H), 5.59 (br s, 1H), 7.18–
7.23 (m, 1H, partially obscured by peaks of 15oa), 7.25–7.34 (m, 2H), 7.45 (dd, J = 7.3, 1.5 
Hz, 1H); 
13
C NMR (125 MHz, CDCl3, aminotetrazole 15ob)  36.8, 46.6, 50.1, 128.1, 
130.1, 130.8, 131.4, 132.3, 139.7, 157.7 (crossover peaks for the quaternary carbon of the 
tetrazole ring for 15oa and 15ob were observed in HMBC); HRMS (ESI) m/z calcd for 
C10H12N5 [M + H]
+ 
202.1093, found 202.1088. 
 
 
5,10-Dihydrotetrazolo[1,5-b]isoquinoline (13p) and 5,10-Dihydro-4H-
benzo[e]tetrazolo[1,5-a][1,3]diazepine (15p; Scheme 22). Following the general 
procedure D, a solution of 2-indanone 12p (52.9 mg, 0.400 mmol, 1.0 equiv) and TMSN3 
(115 mg, 1.00 mmol, 2.5 equiv) in HFIP (1.0 mL) was treated with TfOH (17.7 L, 0.200 
mmol, 0.50 equiv). The reaction mixture was stirred at room temperature for 22 h. 
Purification using a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 
over 50 min) afforded impure tetrazole 13p (eluted between 1.4–2.6% MeOH/CH2Cl2) and 
impure aminotetrazole 15p (eluted between 3.2–3.5% MeOH/CH2Cl2). Subsequent 
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purification of impure tetrazole 13p using a 4 g flash column on a CombiFlash Rf system 
(0–40% EtOAc/hexanes over 35 min) afforded 13p (eluted between 30–36% 
EtOAc/hexanes) as a colorless solid (8.4 mg, 0.049 mmol, 12% yield). The impure 
aminotetrazole 15p was further purified by preparative TLC developing two times with 2% 
MeOH/CH2Cl2 and one time with 60% EtOAc/hexanes. The band corresponding to 15p 
was scraped from the plate and eluted with 2% MeOH/CH2Cl2 through a phase separator 
tabless. Concentration afforded 15p as a colorless crystalline solid (6.7 mg, 0.036 mmol, 
9% yield). Tetrazole 13p: Rf = 0.43 (2% MeOH/CH2Cl2); mp 164–167 C; IR (neat) 1544, 
1500, 1088 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  4.41 (t, J = 2.6 Hz, 2H), 5.63 (t, J = 2.5 
Hz, 2H), 7.35–7.43 (m, 4H); 
13
C NMR (125 MHz, CDCl3)  25.6, 48.0, 127.0, 127.6, 
128.2, 128.6, 128.9, 129.5, 150.9; HRMS (ESI) m/z calcd for C9H9N4 [M + H]
+ 
173.0827, 
found 173.0857. 
Aminotetrazole 15p: Rf = 0.14 (2% MeOH/CH2Cl2); mp 177–180 C; IR (neat) 3245, 
1611 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  4.55 (d, J = 4.7 Hz, 2H), 5.60 (s, 2H), 7.24 (m, 
1H), 7.33–7.42 (m, 4H); 
13
C NMR (125 MHz, CDCl3)  45.4, 50.2, 129.0, 129.2 (2C), 
130.2, 133.0, 136.8, 155.7; HRMS (ESI) m/z calcd for C9H10N5 [M + H]
+ 
188.0936, found 
188.0932. 
 
 
(5r,7R,9S,11s)-6,7,8,9,10,11-Hexahydro-5H-5,9:7,11-dimethanotetrazolo[1,5-a]-
azonine (13q),
93
 (1R,3R,5S)-rel-Bicyclo[3.3.1]non-6-ene-3-carbonitrile (20),
93
 
(1R,3r,6s,8S)-4-Azatricyclo[4.3.1.1
3,8
]undecan-5-one (14q),
141
 and (5s,7R,9S,11r)-4,5,6, 
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7,8,9,10,11-Octahydro-5,9:7,11-dimethanotetrazolo[1,5-a][1,3]diazecine (15q; Scheme 
23). Following the general procedure D, a solution of 2-adamantanone 12q (60.1 mg, 0.400 
mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 mmol, 2.5 equiv) in HFIP (1.0 mL) was 
treated with TfOH (8.9 L, 0.100 mmol, 0.25 equiv). The reaction mixture was stirred at 
room temperature for 2 h. Purification using a 4 g flash column on a CombiFlash Rf system 
(0–5% MeOH/CH2Cl2 over 50 min) afforded an impure carbonitrile 20 (eluted between 
100% CH2Cl2), tetrazole 13q containing grease (eluted between 1.0–2.4% MeOH/CH2Cl2), 
and a slightly impure mixture of lactam 14q and aminotetrazole 15q (eluted at 2.9–3.7% 
MeOH/CH2Cl2). The unreacted 2-adamantanone was not isolated during this purification. 
Further purification of carbonitrile 20 using a 4 g flash column on a CombiFlash Rf system 
(0–5% EtOAc/hexanes over 25 min) afforded 20 (eluted between 2.8–3.4% 
EtOAc/hexanes) as a colorless amorphous solid (23.0 mg, 0.156 mmol, 39% yield). 
Trituration of tetrazole 13q with hexanes twice, pipetting out the hexanes layers, and drying 
the solid under vacuum afforded 13q as a colorless crystalline solid (11.4 mg, 0.0599 
mmol, 15% yield). Recrystallization of 13q from EtOAc afforded colorless, plate-like 
crystals. The impure mixture of lactam 14q and aminotetrazole 15q was purified by 
preparative TLC developing two times with 3% MeOH/CH2Cl2. A single band 
corresponding to both 14q and 15q was scraped from the plate and eluted with 6% 
MeOH/CH2Cl2 through a phase separator tabless. Concentration afforded a very slightly 
impure mixture of 14q and 15q as a colorless solid (for 14q: ca. 1.7 mg, 0.010 mmol, 2% 
corrected yield and for 15q: ca. 7.0 mg, 0.034 mmol, 8% corrected yield; ratio of 14q:15q 
= ca. 20:80 by 
1
H NMR). Tetrazole 13q: Rf = 0.35 (2% MeOH/CH2Cl2); mp 225–229 C, 
melted slowly above 195 C with decomposition (lit.
93
 mp 253–255 C); IR (neat) 2907, 
1459 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.79–1.83 (m, 2H), 1.87–1.93 (complex, 4H), 
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2.05–2.16 (complex, 4H), 2.26 (br s, 2H), 3.66 (t, J = 5.7 Hz, 1H), 5.06 (m, 1H); 
13
C NMR 
(125 MHz, CDCl3)  26.7 (2C), 27.1, 32.0 (2C), 33.8 (2C), 34.6, 53.0, 160.6; HRMS (ESI) 
m/z calcd for C10H15N4 [M + H]
+ 
191.1297, found 191.1298. 
Carbonitrile 20: Rf = 0.39 (10% EtOAc/hexanes); mp 165–180 C, melted slowly 
with decomposition (lit.
93
 mp 160–165 C and lit.
142
 mp 176.5–181.5 C); IR (neat) 3023, 
2229, 1439 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.51 (m, 1H), 1.71–1.80 (m, 2H), 1.88–
1.95 (m, 2H), 2.02 (m, 1H), 2.17–2.26 (m, 2H), 2.39–2.49 (m, 2H), 2.95 (m, 1H), 5.83–
5.94 (m, 2H); 
13
C NMR (125 MHz, CDCl3)  21.1, 25.7, 27.5, 30.4, 30.5, 31.9, 34.5, 124.3, 
129.4, 131.8; HRMS (ESI) m/z calcd for C10H14N [M + H]
+ 
148.1126, found 148.1134. 
Mixture of lactam 14q and aminotetrazole 15q (ca. 20:80): Rf = 0.33 (3% 
MeOH/CH2Cl2); IR (neat) 3267, 3202, 3069, 1634 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  
1.54–1.61 (m, 3H), 1.67–1.86 (complex, 10H), 1.89–1.98 (complex, 5H), 2.10 (m, 2H), 
2.30 (m, 4H), 2.70 (m, 1H), 3.32 (m, 1H), 3.92 (q, J = 8.4 Hz, 1H), 5.31 (t, J = 8.0 Hz, 1H), 
6.65 (br s, 1H), 7.44 (d, J = 7.4 Hz, 1H); 
1
H NMR (14q, diagnostic peaks only)  2.10 (m, 
2H), 2.70 (m, 1H), 3.32 (m, 1H), 6.65 (br s, 1H); 
1
H NMR (15q, diagnostic peaks only)  
3.92 (q, J = 8.4 Hz, 1H), 5.31 (t, J = 8.0 Hz, 1H), 7.44 (d, J = 7.4 Hz, 1H); 
13
C NMR (125 
MHz, CDCl3, peaks of 14q in a mixture)  27.2 (2C), 30.9 (2C), 34.9, 36.7 (2C), 41.7, 46.0, 
182.5; 
13
C NMR (125 MHz, CDCl3, peaks of 15q in a mixture)  22.6 (2C), 32.4, 35.8 
(2C), 37.8 (2C), 43.6, 49.5, 153.1; HRMS (ESI) m/z calcd for 14q, C10H16NO [M + H]
+ 
166.1232, found 166.1230; HRMS (ESI) m/z calcd for 15q, C10H16N5 [M + H]
+ 
206.1406, 
found 206.1405. 
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(5aS,5bR,7aS,9S,11aS,11bS,13aS)-11a,13a-Dimethyl-4,5,5a,5b,6,7,7a,8,9,10,11, 
11a,11b,12,13,13a-hexadecahydronaphtho[2,1-f]tetrazolo[1,5-a]quinolin-9-ol (13r; 
Scheme 23). Following the general procedure D, a solution of trans-androsterone 12r (58.1 
mg, 0.200 mmol, 1.0 equiv) and TMSN3 (57.6 mg, 0.500 mmol, 2.5 equiv) in HFIP (0.50 
mL) was treated with TfOH (17.7 L, 0.200 mmol, 1.0 equiv). The reaction mixture was 
stirred at room temperature for 3 h. Concentration, followed by quenching with Et3N (ca. 
0.050 mL), and purification using a 4 g flash column on a CombiFlash Rf system (0–10% 
MeOH/CH2Cl2 over 60 min) afforded an impure tetrazole 13r (eluted between 2.8–3.5% 
MeOH/CH2Cl2). Further purification of the impure tetrazole 13r using a 12 g flash column 
on a CombiFlash Rf system (0–60% EtOAc/hexanes over 65 min) afforded a slightly 
impure 13r (eluted between ca. 52–57% EtOAc/hexanes) as a colorless solid (32.0 mg, 
0.0968 mmol, 48% corrected yield; ca. 94% pure by 
1
H NMR). Tetrazole 13r: Rf = 0.18 
(60% EtOAc/hexanes, run twice); IR (neat) 3391, 1522, 1452, 1041 cm
–1
; 
1
H NMR (500 
MHz, CDCl3)  0.82 (s, 3H), 0.84–0.88 (m, 1H), 0.93–1.03 (m, 2H), 1.12 (tt, J = 12.5, 3.1 
Hz, 1H), 1.25–1.34 (complex, 2H), 1.35 (s, 3H), 1.36–1.46 (complex, 3H), 1.48–1.53 
(complex, 2H), 1.54–1.62 (m, 2H), 1.66–1.76 (m, 2H), 1.80–1.90 (complex, 3H), 1.95 (m 
1H), 2.18 (apparent dd, J = 13.1, 7.7 Hz, 1H), 2.79 (dt, J = 12.8, 3.4 Hz, 1H), 2.87 (m, 1H), 
3.21 (m, 1H), 3.59 (m, 1H); 
13
C NMR (125 MHz, CDCl3)  12.4, 18.4, 20.5, 21.2, 21.6, 
28.4, 31.2, 31.4, 35.2, 35.8, 36.9, 37.1, 37.9, 44.3, 49.0, 53.4, 61.5, 71.0, 151.0; HRMS 
(ESI) m/z calcd for C19H31N4O [M + H]
+ 
331.2498, found 331.2484. 
 
206 
 
Experimental Procedures for Section 1.4 
General Procedure for the Optimization of Reaction Conditions for the 
Synthesis of 4-Nitrobenzonitrile 22a (Table 11). To a solution of 4-nitrobenzaldehyde 
21a (0.25 or 0.50 mmol, 1.0 equiv) and NaN3 or TMSN3 (1.5–2.0 equiv) in HFIP or 
HFIP/ACN mixture (0.50, 1.0, or 2.0 mL) was added a catalyst (effervescence due to 
nitrogen gas evolution was immediately observed). The vial was capped and the reaction 
mixture was allowed to stir at rt (23 or 25 °C) for a specified period (45 min to 24 h). The 
reaction mixture was concentrated under nitrogen. The residue obtained was diluted with an 
appropriate solvent (CH2Cl2 or EtOAc) and was either filtered through a Pasteur pipette 
containing a cotton plug to get a crude 
1
H NMR ratio (for entries 1 and 2) or purified using 
a 4 or 12 g flash column on a CombiFlash Rf system with a gradient elution of 0–10% 
EtOAc/hexanes (for entries 3–7). Concentration of the appropriate fractions afforded 4-
nitrobenzonitrile 22a containing a small amount (ca. 3–6%) of 21a (except for entry 5, 
where 22a was obtained pure).  
 
General Procedure E for the Synthesis of Aromatic Nitriles (Table 12). To a 
solution of aromatic aldehyde (0.500 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 mmol, 
2.0 equiv) in a premixed HFIP/ACN mixture (2.0 mL, 1:1) in a nitrogen-flushed two dram 
vial was added TfOH (17.7 L, 0.200 mmol, 0.40 equiv) (exotherm and brisk effervescence 
due to nitrogen gas evolution was immediately observed). The vial was capped and the 
reaction mixture was allowed to stir at rt for 20–45 min. The reaction mixture was 
concentrated under nitrogen. The residue obtained was suspended in CH2Cl2–hexanes 
mixture and loaded on a silica gel in a 5 g sample cartridge. Purification using a 4 g flash 
column on a CombiFlash Rf system with a gradient elution of either 0–10 or 0–30% 
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EtOAc/hexanes over 40 min afforded a corresponding aromatic nitrile upon concentration 
of appropriate fractions. 
 
 
4-Nitrobenzonitrile (22a).
66j
 Following the general procedure E, a solution of 4-
nitrobenzaldehyde 21a (75.6 mg, 0.500 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 mmol, 
2.0 equiv) in HFIP/ACN mixture (2.0 mL, 1:1) was treated with TfOH (17.7 L, 0.200 
mmol, 0.40 equiv). The reaction mixture was stirred at rt for 45 min. Purification using a 4 
g flash column on a CombiFlash Rf system (0–10% EtOAc/hexanes over 40 min) afforded 
4-nitrobenzonitrile 22a along with a small amount of unreacted 21a (eluted between 2.3–
4.0% EtOAc/hexanes) as a colorless crystalline solid (61.6 mg, 0.416 mmol, 83% corrected 
yield; contains ca. 4% of 21a as determined by 
1
H NMR).  
 
 
Methyl 4-cyanobenzoate (22b).
66j
 Following the general procedure E, a solution of 
methyl 4-formylbenzoate 21b (82.1 mg, 0.500 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 
mmol, 2.0 equiv) in HFIP/ACN mixture (2.0 mL, 1:1) was treated with TfOH (17.7 L, 
0.200 mmol, 0.40 equiv). The reaction mixture was stirred at rt for 30 min. Purification 
using a 4 g flash column on a CombiFlash Rf system (0–10% EtOAc/hexanes over 40 min) 
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afforded methyl 4-cyanobenzoate 22b (eluted between 2.5–4.2% EtOAc/hexanes) as a 
colorless crystalline solid (63.0 mg, 0.391 mmol, 78% yield).  
 
 
4-Hydroxybenzonitrile (22c).
66j
 Following the general procedure E, a solution of 4-
hydroxybenzaldehyde 21c (61.1 mg, 0.500 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 
mmol, 2.0 equiv) in HFIP/ACN mixture (2.0 mL, 1:1) was treated with TfOH (17.7 L, 
0.200 mmol, 0.40 equiv). The reaction mixture was stirred at rt for 30 min. Purification 
using a 4 g flash column on a CombiFlash Rf system (0–30% EtOAc/hexanes over 40 min) 
afforded 4-hydroxybenzonitrile 22c (eluted between 15–20% EtOAc/hexanes) as a 
colorless crystalline solid (56.5 mg, 0.474 mmol, 95% yield).  
 
 
4-Methoxybenzonitrile (22d).
66j
 Following the general procedure E, a solution of p-
anisaldehyde 21d (68.1 mg, 0.500 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 mmol, 2.0 
equiv) in HFIP/ACN mixture (2.0 mL, 1:1) was treated with TfOH (17.7 L, 0.200 mmol, 
0.40 equiv). The reaction mixture was stirred at rt for 30 min. Purification using a 4 g flash 
column on a CombiFlash Rf system (0–10% EtOAc/hexanes over 40 min) afforded 4-
methoxybenzonitrile 22d (eluted between 2.3–3.2% EtOAc/hexanes) as a colorless 
crystalline solid (54.4 mg, 0.409 mmol, 82% yield).  
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3,4-Dimethoxybenzonitrile (22e).
66j
 Following the general procedure E, a solution 
of 3,4-dimethoxybenzaldehyde 21e (83.1 mg, 0.500 mmol, 1.0 equiv) and TMSN3 (115 mg, 
1.00 mmol, 2.0 equiv) in HFIP/ACN mixture (2.0 mL, 1:1) was treated with TfOH (17.7 
L, 0.200 mmol, 0.40 equiv). The reaction mixture was stirred at rt for 20 min. Purification 
using a 4 g flash column on a CombiFlash Rf system (0–30% EtOAc/hexanes over 40 min) 
afforded 3,4-dimethoxybenzonitrile 22e (eluted between 11–16% EtOAc/hexanes) as a 
colorless crystalline solid (70.0 mg, 0.429 mmol, 86% yield).  
 
 
4-(Benzyloxy)benzonitrile (22f).
66j
 Following the general procedure E, a solution of 
4-(benzyloxy)benzaldehyde 21f (106 mg, 0.500 mmol, 1.0 equiv) and TMSN3 (115 mg, 
1.00 mmol, 2.0 equiv) in HFIP and ACN mixture (2.0 mL, 1:1) was treated with TfOH 
(17.7 L, 0.200 mmol, 0.40 equiv). The reaction mixture was stirred at rt for 20 min. 
Purification using a 4 g flash column on a CombiFlash Rf system (0–10% EtOAc/hexanes 
over 40 min) afforded 4-(benzyloxy)benzonitrile 22f (eluted between 2.3–3.2% 
EtOAc/hexanes) as a colorless crystalline solid (74.1 mg, 0.354 mmol, 71% yield). 
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2-Bromobenzonitrile (22g).
66j
 Following the general procedure E, a solution of 2-
bromobenzaldehyde 21g (92.5 mg, 0.500 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 
mmol, 2.0 equiv) in HFIP/ACN mixture (2.0 mL, 1:1) was treated with TfOH (17.7 L, 
0.200 mmol, 0.40 equiv). The reaction mixture was stirred at rt for 30 min. Purification 
using a 4 g flash column on a CombiFlash Rf system (0–10% EtOAc/hexanes over 40 min) 
afforded 2-bromobenzonitrile 22g (eluted between 2.0–2.5% EtOAc/hexanes) as a colorless 
crystalline solid (61.7 mg, 0.339 mmol, 68% yield). 
 
 
Cinnamonitrile (22h).
66j
 Following the general procedure E, a solution of trans-
cinnamaldehyde 21h (66.1 mg, 0.500 mmol, 1.0 equiv) and TMSN3 (115 mg, 1.00 mmol, 
2.0 equiv) in HFIP/ACN mixture (2.0 mL, 1:1) was treated with TfOH (17.7 L, 0.200 
mmol, 0.40 equiv). The reaction mixture was stirred at rt for 45 min. Purification using a 4 
g flash column on a CombiFlash Rf system (0–10% EtOAc/hexanes over 40 min) afforded 
cinnamonitrile 22h (eluted between 2.3–2.8% EtOAc/hexanes) as a colorless oil (58.0 mg, 
0.449 mmol, 90% yield). 
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3-Phenylpropionitrile (22i).
143
 Following a slight modification of the general 
procedure E, a solution of hydrocinnamaldehyde 21i, ca. 77% pure (26.8 mg, 0.200 mmol, 
1.0 equiv) and TMSN3 (69.1 mg, 0.600 mmol, 3.0 equiv) in HFIP/ACN mixture (1.0 mL, 
1:1) was treated with TfOH (4.4 L, 0.0500 mmol, 0.25 equiv). The reaction mixture was 
stirred at rt for 1 h. Purification using a 4 g flash column on a CombiFlash Rf system (0–
5% EtOAc/hexanes over 40 min) afforded 3-phenylpropionitrile 22i (eluted between 2.8–
3.4% EtOAc/hexanes) as a colorless oil (8.0 mg, 0.061 mmol, 30% yield). 
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Experimental Procedures for Section 1.5 
General Procedure F for the Preliminary Optimization of Reaction Conditions 
for the Synthesis of N-Hydroxyalkyl Lactams 25 (Table 13). To a solution of ketone 12 
(0.400 or 1.00 mmol, 1.0 equiv) and 2-azidoethan-1-ol 24a (0.520–1.50 mmol, 1.3–1.5 
equiv) in HFIP (1.6 or 2.5 mL) in a nitrogen-flushed two or four dram vial was added a 
catalyst (0.0400–0.400 mmol, 0.10–1.0 equiv) (effervescence due to nitrogen gas evolution 
and/or slight exotherm was observed). The vial was capped and the reaction mixture was 
stirred at rt or 25 °C for 0.5–24 h. The reaction mixture was concentrated under nitrogen 
gas. The residue obtained was treated with a saturated aqueous NaHCO3 solution (1.0–2.0 
mL) at rt or 25 °C for 6–20 h. Purification using a 4 g flash column on a CombiFlash Rf 
system with a gradient elution of 0–5 or 0–10% MeOH/CH2Cl2 over 50 min afforded 25 
after concentration of appropriate fractions. 
 
 
1-(2-Hydroxyethyl)azepan-2-one (25a).
105a
 Following the general procedure F, a 
solution of cyclohexanone 12a (98.1 mg, 1.00 mmol, 1.0 equiv) and 2-azidoethanol 24a 
(131 mg, 1.50 mmol, 1.5 equiv; a solution of 24a in Et2O was used) in HFIP (2.5 mL) was 
treated with BF3∙OEt2 (30.9 L, 0.250 mmol, 0.25 equiv). The vial was capped and the 
reaction mixture was stirred at rt for 0.5 h. The reaction mixture was concentrated under 
nitrogen gas. To the resulting residue was added a saturated aqueous NaHCO3 solution (2.0 
mL) and CH2Cl2 (1.0 mL), and the reaction mixture was stirred at rt for 12 h. The CH2Cl2 
layer was removed and the aqueous layer was extracted with CH2Cl2 (1  2 mL) and the 
combined organic layers were loaded on a silica gel/Na2SO4 mixture in a sample cartridge. 
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Purification using a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 
over 50 min) afforded 25a (eluted between 2.4–3.2% MeOH/CH2Cl2) as a pale yellow oil 
(32.0 mg, 0.204 mmol, 20%).   
 
 
Following the general procedure F, a solution of cyclohexanone 12a (98.1 mg, 1.00 
mmol, 1.0 equiv) and 2-azidoethanol 24a (131 mg, 1.50 mmol, 1.5 equiv; a solution of 24a 
in Et2O was used) in HFIP (2.5 mL) was treated with a 1.0 M solution of TiCl4 in CH2Cl2 
(0.250 mL, 0.250 mmol, 0.25 equiv). The vial was capped and the reaction mixture was 
stirred at rt for 0.5 h. The reaction mixture was concentrated under nitrogen gas. To the 
resulting residue was added a saturated aqueous NaHCO3 solution (2.0 mL) and CH2Cl2 
(1.0 mL), and the reaction mixture was stirred at rt for 12 h. The CH2Cl2 layer was removed 
and the aqueous emulsion was extracted with CH2Cl2 (1  2 mL) and the combined organic 
layers were loaded on a silica gel/Na2SO4 mixture in a sample cartridge. Purification using 
a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 50 min) 
afforded 25a (eluted between 1.9–3.4% MeOH/CH2Cl2) as a yellow oil (119 mg, 0.757 
mmol, 76%).   
 
 
Following the general procedure F, a solution of cyclohexanone 12a (39.3 mg, 0.400 
mmol, 1.0 equiv) and 2-azidoethanol 24a (45.3 mg, 0.520 mmol, 1.3 equiv; a solution of 
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24a in Et2O was used) in HFIP (1.6 mL) was treated with a 1.0 M solution of TiCl4 in 
CH2Cl2 (40.0 L, 0.0400 mmol, 0.10 equiv). The vial was capped and the reaction mixture 
was stirred at 25 °C for 24 h. The reaction mixture was concentrated under nitrogen gas and 
dried under vacuum. To a suspension of the resulting residue in CH2Cl2 (1.0 mL) was added 
a saturated aqueous NaHCO3 solution (1.0 mL) and the reaction mixture was stirred at 25 
°C for 20 h. The reaction mixture was again concentrated under nitrogen gas and the 
residue obtained was diluted with CH2Cl2 and dried over Na2SO4. The solution in CH2Cl2 
was loaded on a silica gel in a sample cartridge. Purification using a 4 g flash column on a 
CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 50 min) afforded 25a (eluted between 
2.7–3.5% MeOH/CH2Cl2) as a pale yellow oil (25.0 mg, 0.159 mmol, 40%).   
 
 
1-(2-Hydroxyethyl)-5-phenylazepan-2-one (25b).
108
 Following the general 
procedure F, a solution of 4-phenylcyclohexanone 12b (69.7 mg, 0.400 mmol, 1.0 equiv) 
and 2-azidoethanol 24a (52.3 mg, 0.600 mmol, 1.5 equiv; contains some unidentified 
impurities) in HFIP (1.6 mL) was treated with TfOH (35.4 L, 0.400 mmol, 1.0 equiv). The 
vial was capped and the reaction mixture was stirred at rt for 1 h. The reaction mixture was 
concentrated under nitrogen gas and dried under vacuum. The colorless residue was treated 
with a saturated aqueous NaHCO3 solution (1.0 mL) at rt for 6 h. The reaction mixture was 
again concentrated under nitrogen gas and the residue obtained was suspended in 
CH2Cl2/MeOH mixture and loaded on a silica gel in a sample cartridge. Purification using a 
4 g flash column on a CombiFlash Rf system (0–10% MeOH/CH2Cl2 over 50 min) afforded 
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25b (eluted between 6.4–7.2% MeOH/CH2Cl2) as an off-white oily solid (92.7 mg, 0.397 
mmol, 99% corrected yield; contains a trace amount of the similar impurities present in 
24a). 
 
General Experimental Procedure for the Initial Screening of Reaction 
Conditions for the Synthesis of Dihydrooxazines 26 (Table 14). To a solution of 4-
nitrobenzaldehyde 21a (30.2 mg, 0.200 mmol, 1.0 equiv) or benzaldehyde 21j (21.2 mg, 
0.200 mmol, 1.0 equiv) and 3-azidopropan-1-ol 24b (30.3 mg, 0.300 mmol, 1.5 equiv; 
contains some unidentified impurities) in HFIP (0.5 mL) in a nitrogen-flushed vial was 
added a catalyst (0.0200 or 0.0500 mmol, 0.10 or 0.25 equiv). The vial was capped and the 
reaction mixture was stirred at rt for 6 or 24 h. The reaction mixture was concentrated 
under nitrogen gas and dried under vacuum. A solution of the resulting residue in CH2Cl2 
was loaded on a silica gel in a sample cartridge. Purification using a 4 g flash column on a 
CombiFlash Rf system with a gradient elution of 0–5% MeOH/CH2Cl2 over 45 or 50 min 
afforded impure 26 after concentration of appropriate fractions (for entries 1, 3, and 4: 
slightly impure samples of 26 were obtained; for entry 2: the isolated sample of 26 contains 
ca. 50% of unidentified impurities, which was originally present in 24b).  
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Experimental Procedures for Section 1.7 
Experimental Procedure for the Synthesis of N-(3-Phenylpropyl)benzamide (30j)
144
 
via a Decarboxylative Amidation Reaction (Table 16, entry 1) 
 
To a solution of phenylglyoxylic acid 36 (50.0 mg, 0.333 mmol, 1.0 equiv) and (3-
azidopropyl)benzene 29 (64.3 mg, 0.400 mmol, 1.2 equiv) in CD2Cl2 (1.0 mL) at rt under 
nitrogen atmosphere was added BF3∙OEt2 (0.144 mL, 1.17 mmol, 3.5 equiv) slowly over 2 
min and the resulting yellow solution was stirred at rt for 52 h. The reaction mixture was 
quenched with a saturated aqueous NaHCO3 solution and extracted with EtOAc twice. The 
combined organic layers were washed with brine once, dried over Na2SO4, and 
concentrated. A solution of the resulting residue in CH2Cl2 was loaded on a silica gel in a 
sample cartridge. Purification using a 4 g flash column on a CombiFlash Rf system (0–25% 
EtOAc/hexanes) afforded 30j (eluted out at 20% EtOAc/hexanes) as a pale yellow oil (13.0 
mg, 0.0544 mmol, 16%).   
 
Experimental Procedure for the Synthesis of 7-(Furan-2-yl)-4-phenyl-3,4,5,6-
tetrahydro-2H-azepine (41)
145
 via an Intercepted Schmidt Reaction with Furan 
(Scheme 35c) 
 
To a solution of 4-phenylcyclohexanone 12b (34.9 mg, 0.200 mmol, 1.0 equiv), 
TMSN3 (24.2 mg, 0.210 mmol, 1.05 equiv), and furan (40.8 mg, 0.600 mmol, 3.0 equiv) in 
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HFIP (0.5 mL) at rt in a nitrogen-flushed one dram vial was added TfOH (3.6 L, 0.0400 
mmol, 0.20 equiv). The vial was capped and the reaction mixture was stirred at rt for 22 h. 
The reaction mixture was concentrated under nitrogen gas. The residue obtained was 
diluted with CH2Cl2 and loaded on a silica gel in a 5 g sample cartridge. Purification using 
a 4 g flash column on a CombiFlash Rf system (0–5% MeOH/CH2Cl2 over 50 min) 
afforded 41 (eluted between 4.0–4.8% MeOH/CH2Cl2) as a pale yellow oil in 24% yield 
(11.5 mg, 0.0481 mmol). Rf = 0.31 (5% MeOH/CH2Cl2); IR (neat) 1627, 1485 cm
–1
; 
1
H 
NMR (500 MHz, CDCl3)  1.49 (apparent q, J = 12.8 Hz, 1H), 1.64 (m, 1H), 1.92–2.01 (m, 
2H), 2.64 (m, 1H), 2.87 (tt, J = 12.2, 3.5 Hz, 1H), 3.01 (ddd, J = 14.4, 6.9, 1.0 Hz, 1H), 
3.60 (t, J = 11.8 Hz, 1H), 4.23 (ddd, J = 12.6, 6.3, 1.2 Hz, 1H), 6.44 (dd, J = 3.4, 1.8 Hz, 
1H), 6.79 (d, J = 3.3 Hz, 1H), 7.12–7.18 (m, 3H), 7.23–7.28 (m, 2H), 7.50 (m, 1H); 
13
C 
NMR (125 MHz, CDCl3)  29.3, 31.3, 33.9, 49.7, 51.5, 111.7, 112.0, 126.5, 126.9, 128.7, 
144.9, 147.2, 153.6, 164.8; HRMS (ESI) m/z calcd for C16H18NO [M H]
+ 
240.1388, found 
240.1385. 
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Chapter 2 
Copper-Catalyzed Oxaziridine-Mediated C–H Bond Oxidation 
 
2.1   Introduction 
Oxaziridine 
Oxaziridines were first reported by Emmons
146
 and by virtue of their inherently weak 
N–O bond in a strained three-membered heterocyclic ring, they possess unusually high 
reactivity.
147
 These characteristics also impart low basicity to the oxaziridine nitrogen 
compared to amines. Due to ring strain and inductive effect of adjacent oxygen atom, 
nitrogen tends to be more pyramidal and has a high inversion barrier.
148
 The configurational 
stability at the nitrogen atom can lead to chirality in oxaziridine, and may allow for the 
preferential formation of a single enantiomer or diastereomer depending on the N-
substituent.
148-149
 For N-alkyl oxaziridines, the energy barrier for nitrogen inversion was 
determined to be 25–32 kcal/mol. The inversion barrier was found to be smaller for N-
substituents capable of -conjugation or hyperconjugation.148 Thermal isomerizations of 
oxaziridines have been shown to involve only nitrogen inversion mechanism without bond 
cleavage (Figure 17).
149c,150
  
 
 
Figure 17. Thermal epimerization of an oxaziridine. 
 
The oxygen and the nitrogen atom in the neutral oxaziridine behave as electrophiles 
and this unusual property has been exploited for a variety of heteroatom-transfer reactions 
and rearrangements
151
 (Figure 18).
147b,c,152
 Oxaziridines such as N-sulfonyloxaziridines 
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(Davis' oxaziridines)
153
 have been widely utilized for oxidation reactions such as 
epoxidation of alkenes, oxidation of sulfides to sulfoxides, and -hydroxylation of carbonyl 
compounds, in addition to various amination
152a,154
 and cycloaddition
155
 reactions.
147b,153
 An 
asymmetric -hydroxylation reaction153,156 using a chiral (camphorsulfonyl)oxaziridine was 
one of the key step in the total synthesis of Taxol both by Holton
157
 and Wender.
158
  
 
 
Figure 18. Reactions of oxaziridines. 
 
The most common approaches for oxaziridine synthesis are: (a) the oxidation of 
imines with peracids such as m-CPBA or Oxone, and (b) the electrophilic amination of 
carbonyl compounds with N-chloroalkylamines or N-alkylhydroxylamine-O-sulfonic acids 
(Scheme 36).
147a,b,152a
 Enantiopure oxaziridines could be prepared via either the oxidation 
of chiral imines or oxidation of imines with chiral peracids. Other less common methods 
for the synthesis of oxaziridines involve photoisomerization of nitrones
159
 and conjugate 
addition of hydroxamic acids to methyl propiolate.
160
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Scheme 36. Main Synthetic Routes to Oxaziridines 
 
 
The mechanism for the formation of oxaziridine through imine oxidation by peracids 
has been well-studied.
151b,161
 The two-step nucleophilic, Baeyer–Villiger type mechanism is 
generally accepted for the oxidation of imines rather than the concerted “butterfly 
mechanism”
162
 commonly believed for the epoxidation of alkenes (Scheme 37). In the 
Baeyer–Villiger type process, the peracid first adds to the imine to form a tetrahedral 
intermediate, which is followed by the nucleophilic attack of the nitrogen onto the electron-
deficient oxygen atom to afford the oxaziridine. The oxidation of imines is stereoselective 
but lacks stereospecificity as the initial imine geometry is not reflected in the oxaziridine 
products. The electron-poor imines can also be preferentially oxidized at much lower 
temperatures in the presence of alkenes suggesting the electrophilic attack of the imines. 
Such circumstantial evidence in addition to computational study
161e
 and detailed kinetic 
study of the oxidation reaction
161a,b
 have supported the two-step Baeyer–Villiger 
mechanism and the initial addition of peracids to the imine was found to be rate-
determining under most conditions.  
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Scheme 37. Plausible Mechanisms for the Oxidation of Imines by Peracids 
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2.2   Copper-Catalyzed Oxaziridine-Mediated Intramolecular C–H Bond Oxidation 
The past decade has seen numerous advances in the development of new and versatile 
reagents and catalysts to mimic nature’s ability to selectively oxidize C–H bonds, which 
has long intrigued synthetic chemists.
163,164
 C–H oxidation reactions, in particular allylic C–
H oxidations, have received substantial attention due to their considerable potential for 
synthetic applications.
165 
The copper-catalyzed allylic oxidation using organic peroxide is 
well-known and often referred to as the Kharasch–Sosnovsky reaction.
166
  
The oxidizing ability of oxaziridines resulting from the presence of strong electron-
withdrawing substituents such as perfluoroalkyl groups have been utilized for the 
oxygenation of unactivated tertiary C–H bonds (Scheme 38).
152b,167
 The use of 
perfluorinated oxaziridines has been limited as the syntheses of such compounds are often 
difficult and expensive.
152b,167b
 Moreover, the oxidized products are often obtained in 
modest yields and the reactions have limited substrate scope especially insofar as the 
presence of alkene always leads to epoxide formation rather than C–H oxidation.
167a,b
  
 
Scheme 38. Oxaziridine-Mediated Oxidation of Unactivated C–H Bonds 
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Recently, copper and other transition metal-catalyzed aminohydroxylation reactions 
of olefins using N-sulfonyloxaziridines have been developed by Yoon and co-workers 
(Scheme 39a).
168
 They also reported the copper-catalyzed oxaziridine-mediated 
regioselective intramolecular C–H bond amination reaction (Scheme 39b).
169
 This first 
reported example of formal nitrogen insertion from N-sulfonyl oxaziridines constitutes a 
radical-mediated reaction of oxaziridines, in which a benzylic C–H hydrogen atom was 
ultimately transferred to a Cu(II)-coordinated oxaziridine. 
 
Scheme 39. Oxaziridine-Mediated Aminohydroxylation and C–H Bond Amination 
Reactions 
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Scheme 40. Copper(I)-Catalyzed Reaction of Oxaziridines 
 
 
In 1992, Aubé and co-workers reported the copper-catalyzed reactions of chiral 3-aryl 
oxaziridines to afford enantiomerically-pure pyrrolines and aziridines (Scheme 40).
170
 The 
stereochemistry of the starting oxaziridines was found to have a remarkable influence on 
the course of the reaction. Thus, either pyrrolines or aziridines were obtained through two 
different highly selective reaction pathways. In each case, the oxaziridine ring-opening 
occurred via single-electron transfer (SET) to afford a nitrogen-center radical/oxygen anion 
pair. This mode of reaction was related to that previously proposed by Emmons, Minisci, 
Black, and other pioneers of oxaziridine chemistry for reactions promoted by low-valent 
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metals like Fe(II) or Cu(I).
146,171
 This reactive intermediate then underwent addition to the 
attached olefin; the product observed depended on the relative stereochemistry between the 
 center of the N-phenylethyl group and the oxaziridine C-3 atom.  
While exploring the scope of the reactions shown in Scheme 40, Belgin Gülgeze 
extended the linker between the oxaziridine and alkene from two to three carbons (cf. 
Schemes 40 and 41).
172
 Under identical conditions as before, she found that the reaction of 
oxaziridine with a three carbon linker 42aa afforded an allylic alcohol 43a in 71% yield 
(Scheme 41)
172
 instead of a tetrahydropyridine or aziridine, either of which might have 
been expected in analogy with Scheme 40. These results were interesting, in part because 
they represented the chemoselective oxidation of an sp
3
 C–H bond, but also because they 
diverged from previously reported oxaziridine reactivity. For example, C–H oxidation by 
oxaziridines typically requires strong electron-withdrawing substituents.
152b,167
 Moreover, 
alkene epoxidation has been observed with oxaziridines
152b,167b,171e,173
 but no epoxide was 
formed in these reactions.  
 
Scheme 41. Copper(I)-Catalyzed Oxaziridine-Mediated Intramolecular C–H Bond 
Oxidation 
 
 
For the reasons mentioned above and because of general contemporary interest in 
mild means of carrying out C–H oxidation chemistry, we chose to further investigate this 
reaction through a collection of studies of catalyst optimization, substrate scope, and 
preliminary mechanistic studies.
174
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Results and Discussions 
Initial Observations and Mechanistic Framework. We believe that the reaction of 
oxaziridine 42aa proceeds through a radical mechanism as outlined in Scheme 42a. In the 
first step, SET from the metal catalyst to the oxaziridine gives a radical/anion pair S as 
previously proposed.
170a,171e,175
 1,5-Hydrogen atom transfer to the nitrogen-centered radical 
via abstraction from the allylic C–H bond
164j,176
 then generates the carbon-centered allylic 
radical T. Presumably, the longer tether length, which permits a six-membered transition 
structure culminating in an allylic hydrogen atom makes this hydrogen transfer step more 
facile compared to addition to the olefin as observed previously.
170a
 Conversion of T to 
intermediate U can be viewed in several ways. First, an oxygen-centered radical would be 
generated via homolysis, coupled with regeneration of the Cu(I) catalyst; the 2-
aminotetrahydrofuran intermediate U might then form by radical recombination. 
Alternatively, the radical species might attack the bound copper atom to afford an allyl 
Cu(III) oxide, which would undergo reductive elimination (related Cu(III) species have 
been proposed in ring-opening reactions of diaziridinones
177
). Finally, SET between the 
allylic radical and the oxygen radical could afford an allylic cation/oxygen-centered anion 
pair that would suffer cyclization to afford the hemiaminal U. In any case, hydrolysis of U 
then leads to the observed allylic alcohol product 43a.  
The major side product of the reaction is unoxidized ketone 44a from which the 
oxaziridine was initially derived (Scheme 42b). This could in principle arise from Lewis 
acid-catalyzed hydrolysis of the oxaziridine (path a)
146,178
 or by a mechanism involving the 
intermolecular quenching of the allylic radical V or the primary intermediate similar to S by 
solvent (path b).
171a,179
 We note that ketones and other byproducts have also been observed 
in other SET reactions of oxaziridines with ferrous ions.
146,171a 
When one example of an 
oxaziridine 42ab (for structure, see Table 17, entry 2) was subjected to the above 
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conditions in THF-d8, no incorporation of deuterium was observed in the ketone isolated 
from that experiment, which is consistent with path a being operative for this side reaction. 
 
Scheme 42. Proposed Mechanism 
 
 
Exploration of Reaction Conditions. To examine this oxaziridine-mediated 
intramolecular C–H bond oxidation, we began with the screening of nitrogen substituents 
on the oxaziridine and optimization of the reaction conditions. To do so, oxaziridines were 
prepared as described in previous reports.
151c,161f,170a,c
 In general, imines were formed by 
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combining ketone 44 and the respective amine 45 in refluxing toluene using a Dean–Stark 
apparatus. The imine solution was then cooled to –78 C and treated with purified m-CPBA 
(olefin epoxidation is known not to compete with oxaziridination under these 
circumstances
161f,170a,180
 and that was the case here as well; Scheme 43). The oxidation of a 
mixture (E and Z isomers) of chiral, enantiomerically pure imines by peracid can give rise 
to four non-racemic oxaziridine diastereomers (see isomers I–IV in Figure 19).
149b,c,181
 
Where possible, a pure oxaziridine isomer was isolated from the stereoisomeric mixture of 
oxaziridines. The stereochemical assignments for oxaziridine diastereomers were made 
based on established spectroscopic trends (see Table S26 in the Experimental 
Section).
151b,161f,170a,181-182
  
 
Scheme 43. General Preparation of Oxaziridines 
 
 
Although there is no particular nomenclature for assigning oxaziridine stereoisomers, 
we and others have used cis or syn versus trans or anti to describe the relationship between 
the nitrogen substituent and the highest priority substituent at C-3 of the oxaziridine ring 
(Figure 19).
151c,161c,181,183
 For example, in I and II, the nitrogen substituent (-methylbenzyl 
group) and aryl group (Ar) are on the same side with respect to the oxaziridine ring and 
thus are designated as cis isomers. On the other hand, for III and IV, those two substituents 
are on opposite side of the oxaziridine ring and are therefore classified as trans isomers. 
229 
 
Additionally, in cases where the nitrogen atom bears a chiral substituent, the use of like and 
unlike may be used to describe the relative stereochemical relationships between the chiral 
substituent on the nitrogen atom and the stereogenic nitrogen center of the oxaziridine 
ring.
181,184
 Hence, in the case of I and IV, where the nitrogen center has an R configuration 
and its substituent (-methylbenzyl group) has an S configuration, they are assigned as 
unlike, whereas in the case of II and III, where the nitrogen center has an S configuration, 
they are assigned as like.
181
 Previous work has shown that the ratio of oxaziridine 
diastereomers are obtained in a following order (I > IV > II > III) when synthesized 
through the peracid oxidation of imine.
172,181
 Also, E- and Z-nomenclature have been 
commonly used for assigning the stereochemistry of oxaziridines.
149b,185
 In this context, we 
prefer using cis and trans notation for assigning oxaziridine diastereomers bearing an 
achiral nitrogen substituent as shown for V (Figure 19).  
 
 
Figure 19. Stereochemical nomenclature for oxaziridine stereoisomers. 
 
Experiments using the single diastereomer of oxaziridine 42aa with [Cu(PPh3)Cl]4 
(shown in Schemes 41 and 42a) gave racemic allylic alcohol 43a in 71% yield 
(enantiomeric composition of 43a was determined by Mosher ester analysis).
172
 The same 
reaction of oxaziridine 42aa with [Cu(PPh3)Cl]4 was repeated to afford 43a in 69% yield 
(ca. 5% ee by chiral GC analysis) demonstrating good reproducibility of the transformation 
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(Table 17, entry 1). Consequently, we focused our initial efforts on exploring the racemic 
reaction of oxaziridines derived from simple primary amines and aryl-4-alkenyl ketones 
(Table 17). Although a variety of oxaziridines derived from branched amines were effective 
in executing the transformation to allylic alcohols, no such product was obtained from an 
oxaziridine bearing an N-benzyl group (Table 17, entry 4). It is possible that the relatively 
more accessible nitrogen atom in this system is better able to directly coordinate with the 
copper catalyst, resulting in hydrolysis being more competitive with SET, but the reasons 
for the failure of this substrate to undergo the catalytic process of interest were not further 
explored. Among the various nitrogen substituents tried, oxaziridines derived from 
cyclohexylamine 45b gave the best results and were chosen for the optimization of reaction 
conditions and exploration of substrate scope. Such oxaziridines gave results comparable to 
those from -methylbenzylamine (cf. entries 1 and 2, 5 and 6, and 7 and 8). Moreover, 
cyclohexylamine is inexpensive, achiral (thus lowering the number of oxaziridine 
stereoisomers), and conveniently has a relatively high boiling point compared to other 
simple aliphatic amines.  
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Table 17. Screening of Amine Substituent
a
  
 
entry 
oxaziridine 
42 
Ar R
1
 R
2
 
oxaziridine 
(cis:trans ratio)  
product 
43 
yield (%)
b,c
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
42aa 
42ab 
42ac 
42ad 
42ba 
42bb 
42ca 
42cb 
42cc 
Ph 
Ph 
Ph 
Ph 
3,4-di-OMePh 
3,4-di-OMePh 
Ph 
Ph 
Ph 
(S)-PhCH(Me) 
c-C6H11 
Ph2CH 
PhCH2 
(S)-PhCH(Me) 
c-C6H11 
(S)-PhCH(Me) 
c-C6H11 
Ph2CH 
H 
H 
H 
H 
H 
H 
Me 
Me 
Me 
ca. 92:8
d
 
>98:2
e
 
77:23
f
 
>95:5 
>98:2
e
 
>98:2
e
 
90:10 
63:37 
70:30 
43a 
43a 
43a 
43a 
43b 
43b 
43c 
43c 
43c 
69 
74 
22 (26)
g,h,i
 
0
j
 
48 
37
k
 
74
i
 
64
k
 
65
l,m
 
a
Reaction was performed using 1 equiv of oxaziridine and 5 mol % [Cu(PPh3)Cl]4 in THF (10–20 
mL) under refluxing conditions for 3 h under an argon atmosphere, unless otherwise noted. 
b
Isolated yields. 
c
In all cases, unoxidized ketones 44 were also obtained (see the Experimental 
Section for details). 
d
Oxaziridine diastereomers were contaminated with ca. 12% of 44a. 
e
Only 
single diastereomer was observed by 
1
H and 
13
C NMR. 
f
Oxaziridine diastereomers were 
contaminated with ca. 12% of dibenzhydrylamine impurity. 
g
Yield in parentheses is based on the 
recovery of the oxaziridine substrate. 
h
The reaction mixture was refluxed for 1.5 h. 
i
4.5 mol % 
[Cu(PPh3)Cl]4 was used. 
j
Unoxidized ketone 44a was the only observed product (recovered in 96% 
yield). 
k
The reaction mixture was refluxed for 1 h. 
l
3.7 mol % [Cu(PPh3)Cl]4 was used. 
m
The 
reaction mixture was refluxed for 8 h. c-C6H11 = Cyclohexyl.  
 
The initial results for the transformation of the oxaziridines to allylic alcohols with 
[Cu(PPh3)Cl]4 (Scheme 41) were encouraging, so we examined the reactions of an equal 
mixture of cis- and trans-oxaziridine diastereomers of 42ab with other copper and iron 
salts, known to promote SET reactions (Table 18).
146,170a,c,171a,179a
 In general, all of the 
reactions examined afforded varying quantities of oxidized product 43a with unoxidized 
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ketone 44a except for the control reaction (entry 1), in which no product was observed in 
the absence of copper source. In some cases, minor side products were also observed but 
not characterized.
170c,171a
 A range of results were obtained when we examined the effects of 
solvent and different copper salts (entries 2–15). Use of either Cu(II) (entry 13) or Cu(I) 
(entry 14) sources resulted in similar yield for the reaction. In contrast, iron salts were 
wholly ineffective (entries 10–12).  
 
Table 18. Optimization of Reaction Conditions for the Transformation of 
Oxaziridines to Allylic Alcohols
a 
 
entry 
catalyst 
(5 mol %) 
ligand 
(5 mol %) 
solvent 
yield (%)
b
 
43a 44a 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
none 
[Cu(PPh3)Cl]4 
[Cu(PPh3)Cl]4 
[Cu(PPh3)Cl]4 
[Cu(PPh3)Cl]4 
[Cu(PPh3)Cl]4 
Cu(OTf)2 
Cu(acac)2
d
 
CuBr·SMe2 
Fe(acac)2
c,e
 
Fe(acac)3
c
 
FeBr2
c,f
 
CuCl2 
CuCl 
CuCl and LiCl 
CuCl 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
2,2-Bipyridyl 
THF 
THF 
Toluene 
i-PrOH 
Benzene 
CH2Cl2 
THF 
THF 
THF 
THF 
THF 
THF 
THF 
THF 
THF 
THF 
– 
46 
14 
30 
6 
41 
53 
16 
16 
– 
– 
4 
50 
50 
31 
51 
trace
c
 
23 
47 
25 
72 
36 
26 
9 
67 
– 
– 
14 
22 
17 
31 
14 
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17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
CuCl 
CuCl 
CuCl 
CuCl
h
 
CuCl
i
 
CuCl 
CuCl 
CuCl
c
 
CuCl 
CuCl 
CuCl 
(S)-BINAP 
rac-BINAP 
rac-BINAP 
rac-BINAP
h
 
rac-BINAP
i
 
rac-BINAP 
dppp
k
 
Xantphos 
dcppe
l
 
(S)-Xylyl-P-Phos 
bdppmb
m
 
THF 
THF 
CH3CN 
THF 
THF 
MeOH 
THF 
THF 
THF 
THF 
THF 
61
g
 
63 
63 
58 
54 
–
j
 
43 
– 
53 
50 
56 
9 
9 
8 
8 
3 
76 
9 
11 
6 
5 
17 
a
Reaction was performed using 1 equiv of oxaziridine, 5 mol % catalyst, and 5 mol % ligand in 
solvent under refluxing conditions for 1 h under an argon atmosphere, unless otherwise noted. 
b
Isolated yields. 
c
Oxaziridine was completely recovered except for entries 12 and 24. 
d
The 
reaction mixture was refluxed for 1.5 h. 
e
The reaction mixture was refluxed for 4 h. 
f
The 
reaction mixture was refluxed for 2.5 h. 
g
Allylic alcohol 43a was obtained in ca. 5% ee by 
chiral GC analysis. 
h
10 mol % of CuCl and rac-BINAP were used. 
i
1 mol % of CuCl and rac-
BINAP were used. 
j
No product was observed in this case. 
k
dppp = 1,3-
Bis(diphenylphosphino)propane. 
l
dcppe = Bis(dicyclohexylphosphinophenyl)ether. 
m
bdppmb = 
1,2-Bis(diphenylphosphinomethyl)benzene.  
 
We also investigated various additives in attempts to improve the conversion to 
desired product (Table 18, entries 16–27). Interestingly, allylic alcohol 43a was obtained in 
significantly higher yield when the reaction was catalyzed by a CuCl/BINAP complex 
(entries 17–19). Moreover, the ratio of 43a to 44a was considerably increased using these 
conditions (cf. entry 2 with entry 18). No improvement in yield was observed with other 
phosphine ligands (entries 23–27). No enantioselectivity was observed with (S)-BINAP 
(entry 17) and the yield obtained was comparable to that obtained using rac-BINAP. On the 
basis of these results, we chose to adopt CuCl and rac-BINAP as our standard reaction 
conditions, along with the originally identified [Cu(PPh3)Cl]4, both in 5 mol % (note that 
for the tetrameric [Cu(PPh3)Cl]4, this corresponds to 20 mol % of Cu(I)). Reaction yields 
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were only slightly affected when the reaction was carried out with 10 vs 1 mol % of 
CuCl/rac-BINAP (cf. entries 20 and 21). Solvent had a substantial effect on reaction yields, 
either with or without additives, with THF and ACN being best among those examined 
(entries 18 and 19). In contrast, nonpolar hydrophobic solvents were essentially useless in 
this context (entries 3 and 5). 
We observed initially that the reaction of non-racemic 42aa with achiral 
[Cu(PPh3)Cl]4 gave racemic allylic alcohol 43a (see Schemes 41 and 42a and Table 17, 
entry 1). Similarly, the reaction of racemic mixture of diastereomers 42ab (cis:trans = 1:1) 
with chiral CuCl/(S)-BINAP complex did not afford any enantioselectivity (see Table 18, 
entry 17). Finally, the combination of chiral substrate 42aa and chiral CuCl/(S)-BINAP 
complex to bring about the asymmetric transformation was attempted. Unfortunately, again 
allylic alcohol 43a was obtained as a racemic mixture (ca. 5% ee by chiral GC analysis) 
and with a significantly lower yield of 30% (Scheme 44).  
 
Scheme 44. Reaction of Non-Racemic Oxaziridine Diastereomer with Chiral 
Catalyst/Ligand Complex 
 
 
The absence of enantioselectivity of the reaction may be explained in the context of 
the proposed mechanism (Scheme 42a). Even if the hydrogen abstraction step were 
stereoselective, the conformational flexibility of the allylic side chain could combine with a 
lack of facial selectivity in the ensuing radical- or SET-mediated recombination step. The 
failure of a chiral additive to overcome these obstacles could be due to (1) too much 
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distance between the ligand and the forming C–O bond, (2) the complete disassociation of 
the ligand prior to this stage of the reaction, or (3) simply not enough chiral differentiation 
afforded by the ligands tried.  
We were able to separate the two oxaziridine diastereomers of the 3,4-
dimethoxyphenyl substrate 42bb. Subjecting each separately to identical reaction 
conditions afforded 43b in comparable yields (Scheme 45). Pragmatically, this means that 
one need not worry about obtaining diastereomerically pure samples for carrying out the 
oxidation process (in stark contrast to the chemistry shown in Scheme 40). It is also 
consistent with a mechanism in which N–O bond cleavage is the first step (affording, here, 
enantiomeric intermediates; also see Scheme 42a). 
 
Scheme 45. Examination of Oxaziridine Diastereomers  
 
 
The involvement of radicals in the copper-catalyzed allylic oxidations by peroxy 
esters, also accounting for the regeneration of the active copper(I) species, has been 
supported by kinetic and electron spin resonance (ESR) studies.
166b,186
 Recently, Yoon and 
co-workers have proposed and provided good evidence for a radical mechanism for the 
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oxaziridine-mediated oxyamination reaction and oxidative functionalization of alkenes with 
Davis-type oxaziridines.
168c,e
 Although strong evidence for the generation of the radical 
species was obtained, they were unable to trap the radical intermediate leading to the 
aminohydroxylation product using standard trapping reagents such as TEMPO.
168c
 In order 
to support the mechanistic hypothesis proposed for the present C–H oxidation, we too 
decided to attempt a radical-trapping experiment with TEMPO.
171b,187
 
 
Scheme 46. Radical-Trapping Experiment with TEMPO 
 
 
To this end, the reaction was carried out under the standard conditions with a 
stoichiometric amount of TEMPO added (Scheme 46). The product profile of this 
experiment included three products that incorporated TEMPO in addition to allylic alcohol 
43a, which was obtained in 23% yield. Thus, the internally substituted product 46a was 
obtained in 19% yield and terminal radical-trapped products were obtained as a mixture of 
trans and cis isomers (46b:46c = 62:38) in a combined 18% yield. The formation of these 
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TEMPO adducts provides strong evidence for the intermediacy of the allylic radical en 
route to the allylic alcohol. 
 
Reaction Scope and Limitations. The scope of this transformation was then 
investigated (Table 19). Oxaziridine substrates were tested with two catalyst systems, 
[Cu(PPh3)Cl]4 and a mixture of CuCl and rac-BINAP. For the simple phenyl-substituted 
compound, both catalysts gave similar yields (entry 1). Substrates containing electron-rich 
(Table 19, entry 2 and Scheme 45) and electron-poor (entry 3) aromatic ring, as well as a 
furanyl group at C-3 (entry 4), all led to oxidation product. As observed for cis- and trans -
42bb (Scheme 45), oxaziridine diastereomers 42gb containing a naphthyl substituent also 
afforded the product 43g in comparable yield (entries 5 and 6). The reaction proceeded in 
good yields with substituted alkenes as well (entries 7 and 8). Consistent with the proposed 
mechanism (see Scheme 42a), oxidation of the methylene group closest to the oxaziridine 
was exclusively observed. The use of CuCl/BINAP complex resulted in better yields in 
most but not all cases (e.g., the sterically demanding case in entries 5 and 6). Oxaziridines 
bearing ortho substitution on the C-3 phenyl group or with substitution alpha to the 
oxaziridine ring could not be synthesized using our standard protocol, presumably because 
of an increase in the steric environment around the carbonyl group (Figure 20). 
Replacement of phenyl with cyclohexene group also did not lead to the oxaziridine 
formation. The synthesis of N-sulfonyloxaziridine with tethered alkene at C-3 was 
unsuccessful as the formation of imine with benzenesulfonamide could not be achieved 
under various conditions (Figure 20). 
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Table 19. Substrate Scope for Intramolecular C–H Oxidation
a
 
 
entry
 
oxaziridine
 cis:trans 
ratio
 product
 catalyst: yield 
(%)
b,c 
1
 
 
>98:2
d 
 
I
e
: 74
 
>98:2
d 
II: 74
 
 
42ab
 
 43a
 
 
2
 
 
–
 
 
I: ND
 
48:52 II: 57 
 
42db
 
 43d
 
 
3
 
 
88:12
 
 
I: 50
 
58:42
 
II: 66
 
 
42eb
 
 43e
 
 
4
 
 
>95:5
 
 
I: 51
 
– II: ND 
 
42fb
 
 43f
 
 
5
 
 
90:10
 
 
I
e
: 57
f 
90:10 II: 46 (57)
g
 
 
cis-42gb
 
 43g
 
 
6
 
 
16:84
 
 
I
e
: 41
h 
16:84 II: 53 (73)
g
 
 
trans-42gb
 
 43g
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entry
 
oxaziridine
 cis:trans 
ratio
 product
 catalyst: yield 
(%)
b,c 
7
 
 
63:37
 
 
I: 64
 
>95:5 II: 75 
 
42cb
 
 43c
 
 
8
 
 
60:40
 
 
I: 72
 
60:40 II: 69 
 
42hb
 
 43h
 
 
a
Reaction was performed using 1 equiv of oxaziridine, 5 mol % catalyst, and 5 mol % ligand in 
THF under refluxing conditions for 1 h under an argon atmosphere, unless otherwise noted. 
b
Isolated yields. 
c
In all cases, unoxidized ketones 44 were obtained as a side product. 
d
Only single 
diastereomer was observed by 
1
H and 
13
C NMR. 
e
The reaction mixture was refluxed for 3 h. 
f
4.5 
mol % [Cu(PPh3)Cl]4 was used. 
g
Yield in parentheses represents the yield based on the recovery of 
the starting oxaziridine. 
h
4.2 mol % [Cu(PPh3)Cl]4 was used. ND = Not determined. 
 
 
Figure 20. Unsuccessfully targeted oxaziridines. 
 
In addition to the olefin-containing substrates, it proved possible to oxidize benzylic 
and propargylic C–H bonds in modest to good yields (Scheme 47). The potential versatility 
of this transformation was further shown through the oxidation of the unactivated tertiary 
C–H bond to afford the tertiary alcohol 52a, albeit in low yield (Scheme 47). In this case, a 
cyclized product 52b was also obtained, which could result from radical cyclization 
between the tertiary radical and the phenyl group
170b,c
 or from electrophilic aromatic 
substitution with a tertiary carbocation formed from the ionization of tertiary alcohol.
188
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Scheme 47. Survey of Non-Alkenyl Oxaziridines 
 
 
Two additional cases help delineate the limits of this oxidation reaction. When we 
examined the behavior of a single diastereomer cis-53 of the oxaziridine substrate bearing a 
four-carbon tether in the presence of [Cu(PPh3)Cl]4 (Scheme 48), we observed three 
different products in low yields in addition to the usual reversion to ketone. Allylic alcohol 
54a arising from 1,6-hydrogen transfer was obtained in very low yield, whereas 
homoallylic alcohol 54b from 1,5-hydrogen transfer was formed in trace amount. Amide 
54c was also obtained in low yield resulting from -scission.146,170c These results are 
consistent with the need for both a stable radical intermediate for oxidation as well as a 
favorable geometry for hydrogen atom abstraction. Similar transformation of the mixture of 
oxaziridine diastereomers (cis- and trans-53) with CuCl/BINAP complex was less effective 
than the [Cu(PPh3)Cl]4 (see the Experimental Section for details).
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Scheme 48. Reaction of Oxaziridine with a Four-Carbon Tether 
 
 
In our previous work, we found that the cyclization reactions shown in Scheme 40 
were derailed when the oxaziridine′s C-3 aryl group was replaced with an alkyl substituent 
capable of forming a stable carbon-centered radical. In those instances, the main reaction 
pathway was -scission of the C–C bond adjacent to the proposed N-centered radical.170b,c 
In the present case, we found divergent behavior for primary vs secondary alkyl groups at 
the analogous position. Accordingly, the substrate bearing an n-butyl subsituent at C-3 
afforded the allylic alcohol 56 in good yield but the cleaved amide product 58 was observed 
upon reaction of the oxaziridine with a cyclohexyl substituent (Scheme 49). 
 
Scheme 49. Dependence of Product on 3-Alkyl Substituent
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Another oxaziridine substrate with an ethyl subsituent at C-3 was also examined. 
Thus, reactions of trans- and cis-diastereomers of oxaziridine 59 were performed separately 
with [Cu(PPh3)Cl]4 and CuCl/rac-BINAP, respectively (Scheme 50). In both cases, allylic 
alcohol 60 obtained was contaminated with unidentified byproducts and impurities. 
Although various purification attempts were unsuccessful, 
1
H NMR spectra for the impure 
sample of 60 in both cases showed characteristic peaks of allylic alcohol. However, the 
product was volatile and obtained in a small amount rendering its further purification 
unfeasible. 
 
Scheme 50. Evaluation of Oxaziridine Substrate with 3-Ethyl Substituent 
 
 
Given the success with the transformation of oxaziridines to allylic alcohols, we 
considered the formation of amino alcohol from an analogous transformation by changing 
the position of the reactive site on the oxaziridine substrate. During this attempt, we 
synthesized oxaziridine diastereomers 61, which incorporated a potentially labile C–H bond 
as a part of the amine substituent rather than the oxaziridine C-3 alkyl side chain. The 
formation of 62 was expected based on the mechanism shown in Scheme 51, where initial 
1,5-hydrogen atom transfer to a nitrogen-centered radical W could in principle lead to a 
carbon-centered benzylic radical X. The radical recombination of an ensuing oxygen-
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centered radical and the benzylic radical would then form the heminaminal intermediate Y, 
which upon hydrolysis would yield the desired product 62 and acetophenone (PhCOMe). 
Unfortunately, the reaction of oxaziridine diastereomer cis-61 with CuCl/rac-BINAP under 
analogous reaction conditions did not lead to amino alcohol 62 (Scheme 51). Instead, a 
complex mixture was observed from which acetophenone was recovered in ca. 59% yield. 
The slower ring-closure kinetic rate for the formation of seven-membered cyclic 
heminaminal Y compared to the faster Lewis acid-catalyzed hydrolysis of oxaziridine 61 to 
acetophenone could be one potential reason for the failure of this reaction.  
 
Scheme 51. Failed Attempt towards the Synthesis of Amino Alcohol 62 
 
 
When ,-unsaturated ketone 44q was subjected to oxaziridination conditions, an 
unexpected product trans-63 was obtained instead of the desired cis- and trans-oxazirdine 
diastereomers containing the cinnamyl group at C-3 position (shown in the box; Scheme 
52). The formation of trans-63 could be explained through the mechanism shown in 
Scheme 53. Instead of a desired 1,2-addition to provide imine, a conjugate addition (1,4-
addition) of cyclohexylamine 45b to enone 44q could form an aminoenol intermediate AA, 
which can tautomerize to an aminoketone AB. Under thermal conditions in the presence of 
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the acid catalyst, the aminoketone AB could undergo retro-Mannich reaction
189
 to give 
aldimine isomers AC and heptenone AD. Presumably, the E- and Z-isomerization of AC 
could result in a thermodynamically more stable anti isomer (E)-AC at lower 
temperature,
190
 which upon oxidation with m-CPBA would yield oxaziridine trans-63. The 
structure of trans-63 was determined by NMR and HRMS and was further confirmed by 
comparing the chemical shifts of its characteristic peaks in 
1
H and 
13
C NMR with the 
reported values.
185,191
   
 
Scheme 52. Unexpected Formation of Oxaziridine trans-63 
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Scheme 53. Plausible Mechanism for the Formation of trans-63 
 
 
The transformation of allylic and benzylic alcohols to their corresponding ether 
derivatives through solvolytic etherification is known.
192
 When allylic alcohol 56 was 
treated with methanol (MeOH, CH3OH) in the presence of HCl, allylic ether 64 was 
obtained in good yield (Scheme 54). The reaction proceeds via the formation of a stabilized 
carbonium intermediate. Although allylic transposition is possible, however, given the 
stability of highly conjugated allylic carbocation, only a direct substitution of the acid-
activated alcohol by MeOH takes place giving rise to the more stable product.
193
 Reaction 
with p-TsOH using superstoichiometric amount of MeOH (ca. 20 equiv) in CDCl3 gave a 
complex mixture (Scheme 54). For the HCl-catalyzed reaction of 56, changing the 
nucleophile from alcohol to allyl silane did not lead to the desired allyl-substituted product 
65. 
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Scheme 54. Conversion of Allylic Alcohol to Allylic Ether 
 
 
Conclusions 
In summary, we have developed an efficient regio- and chemoselective copper-
catalyzed transformation of oxaziridines to allylic alcohols via an intramolecular C–H bond 
oxidation. The reaction works well with a variety of substrates, but activated C–H bonds 
are preferred. Support for a radical mechanism has been demonstrated through radical-
trapping experiment with TEMPO. Future work will focus on further development of the 
scope of this oxidation reaction, including additional substrate types (hopefully to include 
intermolecular variations) and the exploration of asymmetric transformations. 
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2.3   Experimental Section 
General Information. All reactions were performed under an inert atmosphere 
(argon or nitrogen) in flame-dried glassware. The stainless steel needles used for handling 
anhydrous solvents and reagents were oven dried and flushed with dry argon prior to use. 
Plastic syringes were flushed with dry argon before use. All chemicals were used as 
received from commercial source without further purification. Methylene chloride and THF 
were dried by passage through neutral alumina columns using a commercial solvent 
purification system prior to use. TLC was performed using commercial glass-backed silica 
plates (250 microns) with an organic binder. Preparative TLC was carried out using silica 
gel GF TLC plates (UV 254 nm, 1000 microns). Visualization was accomplished with UV 
light and Seebach’s stain or aqueous KMnO4 by heating. Flash chromatography was carried 
out using standard grade silica gel (40–63 m particle size, 230  400 mesh) with 
compressed nitrogen as a source of positive pressure. Preparative reverse-phase HPLC 
purification was performed using UV detection (photodiode array detector). The method 
utilized a Prep C18 OBD column (30  150 mm, 5 m) and gradient system eluting from 
70:30 (B:A) to 99:1 (B:A) (solvent system A: water:ACN (99:1) containing 0.10% TFA 
and solvent system B: ACN:water (99:1) containing 0.1% TFA) at a constant flow rate of 
50 mL/min and a run time of 13 min. The fractions were collected using an automated 
fraction collector. IR spectra were acquired as thin films or solids. All NMR samples were 
recorded in CDCl3. Chemical shifts are reported in parts per million (ppm) and are 
referenced to the center line of the solvent ( 7.26 ppm for 1H NMR and  77.23 ppm for 
13
C NMR). Coupling constants are given in Hertz (Hz). HRMS data were taken using a 
time of flight (TOF) mass analyzer and an electrospray ion source. Melting points were 
determined in open capillary tubes using a capillary melting point apparatus and are 
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uncorrected. Chiral gas chromatography was carried out on a GC System with triple-axis 
HED-EM detector (5975C VL MSD) and helium as the carrier gas; a B-DM chiral capillary 
column (30.0 m  250 m  0.12 m nominal) was employed. The temperature was 
programmed from 45 C to 190 C with a run time of 24.50 min.  
 
Experimental Procedures 
General Procedure G for the Synthesis of Oxaziridine Substrates. To a solution 
of starting ketone 44 (1.0 equiv) in toluene was added amine 45 (1.5 equiv), PTSA (0.050 
equiv), and activated 4 or 5 Å molecular sieves and the reaction mixture was allowed to 
reflux using a Dean–Stark apparatus for 60 h (24 h for compound 42aa, 42aa, and 42aa 
and 72 h for compound 42ba and 42ba) under nitrogen atmosphere (most of the toluene 
was distilled off into Dean–Stark trap before cooling). The crude solution of imine was then 
cooled to –78 C, diluted with CH2Cl2, and treated slowly with a solution of purified m-
CPBA
194
 (>95%, 1.2 equiv) in CH2Cl2 under nitrogen atmosphere. The reaction was stirred 
for 30 min at –78 C, quenched with saturated aqueous solution of sodium thiosulfate 
(Na2S2O3), and allowed to warm to rt. The resulting mixture was filtered under suction and 
washed with CH2Cl2. The filtrate was diluted with water and the layers were separated. The 
aqueous layer was extracted with CH2Cl2 once, and the combined organic extracts were 
washed with saturated aqueous NaHCO3 twice and brine once, dried over Na2SO4, and 
concentrated under reduced pressure. Purification by chromatography on a silica gel or 
preparative TLC afforded the product. The assignment of oxaziridine diastereomers with 
their structures is given at the end of the Experimental Section (see Table S26). 
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General Procedure H for Grignard Reaction Followed by PCC Oxidation. 
Grignard reaction. A flame-dried two-necked round bottom flask equipped with a 
dropping funnel was charged with magnesium turnings (1.2 equiv) and 1–2 small crystals 
of iodine in THF under an argon atmosphere. A solution of 5-bromo-1-pentene (1.2 equiv) 
in THF was added drop wise to the stirring suspension of magnesium to maintain a gentle 
refluxing of THF (I2 color disappears). After the addition, the reaction mixture was gently 
refluxed for 1 h, after which it was cooled to 0 C. A solution of aldehyde (1.0 equiv) in 
THF was added slowly to the cooled suspension at 0 C over 10 min. The reaction mixture 
was then stirred at rt for 1–2 h. The reaction mixture was quenched with a saturated 
aqueous solution of NH4Cl and extracted with ether twice. The combined organic extracts 
were washed with water and brine once, dried over Na2SO4, and concentrated under 
reduced pressure to afford the crude alcohol, which was used for the next oxidation step 
without purification.  
PCC Oxidation. To a stirring solution of a crude alcohol in CH2Cl2 was added 
pyridinium chlorochromate (PCC) (1.5–2.0 equiv) and the reaction mixture was stirred at rt 
under nitrogen atmosphere for 1.5–2 h (12 h for compound 44f). The reaction mixture was 
filtered through Celite, rinsing with several portions of CH2Cl2 or ether, and the filtrate was 
concentrated under reduced pressure. Purification by chromatography on a silica gel 
afforded the ketone product. 
 
General Procedure I for Intramolecular CH Oxidation Using [Cu(PPh3)Cl]4.
195
 
A flame-dried two-necked round bottom flask equipped with a reflux condenser was 
charged with [Cu(PPh3)Cl]4 and THF under an argon atmosphere. The solution was 
degassed with argon at rt for ca. 5 min and was then allowed to reflux for 30 min. A 
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solution of oxaziridine in THF was added slowly by a syringe to the refluxing solution of 
the catalyst, and refluxing was continued for an additional 1–3 h. The solvent was removed 
under reduced pressure, and the crude mixture was purified by chromatography on a silica 
gel to afford the product. All successful oxidation products were accompanied by 
unoxidized ketones 44 (eluted out at 100% CH2Cl2 during chromatographic purification), 
from which oxaziridine was initially derived. 
 
General Procedure J for Intramolecular CH Oxidation Using CuCl and rac-
BINAP. A flame-dried two-necked round bottom flask equipped with a reflux condenser 
was charged with CuCl, rac-BINAP, and THF under an argon atmosphere. The solution 
was degassed with argon at rt for ca. 5 min and was then allowed to reflux for 30 min. A 
solution of oxaziridine in THF was added slowly by a syringe to the refluxing solution of 
the catalyst, and refluxing was continued for an additional 1 h. The solvent was removed 
under reduced pressure, and the crude mixture was purified by chromatography on a silica 
gel to afford the product. All successful oxidation products were accompanied by 
unoxidized ketones 44 (eluted out at 100% CH2Cl2 during chromatographic purification), 
from which oxaziridine was initially derived. 
 
General Procedure for the Screening of Amine Substituent Using [Cu(PPh3)Cl]4 
(Table 17). A flame-dried two-necked round bottom flask equipped with a reflux 
condenser was charged with [Cu(PPh3)Cl]4 (3.7–5.0 mol %) and THF (7–13 mL) under an 
argon atmosphere. The solution was degassed with argon at rt for ca. 5 min and was then 
allowed to reflux for 30 min. A solution of oxaziridine (1.0 equiv) in THF (3–8 mL) was 
added slowly by a syringe to the refluxing solution of the catalyst, and refluxing was 
continued for an additional 1–8 h. The solvent was removed under reduced pressure, and 
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the crude mixture was purified by chromatography on a silica gel to afford the product. All 
successful oxidation products were accompanied by unoxidized ketones 44 (eluted out at 
100% CH2Cl2 during chromatographic purification), from which oxaziridine was initially 
derived. 
 
 
1-Phenylhex-5-en-1-one (44a).
196
 A solution of acetophenone (20.0 g, 166 mmol, 
1.0 equiv), N,N-dimethylhydrazine (25.0 g, 416 mmol, 2.5 equiv), and PTSA (1.58 g, 8.32 
mmol, 0.050 equiv) in benzene (110 mL) was refluxed for 23 h under nitrogen atmosphere 
with removal of water by a Dean–Stark apparatus. The reaction mixture was concentrated 
and the residue was purified by vacuum distillation to afford the corresponding hydrazone 
as a yellow oil in 96% yield (26.0 g, 160 mmol).  
To a cooled 1.0 M LDA solution (47.5 mL, 47.5 mmol, 1.1 equiv) in THF at 0 C 
under nitrogen atmosphere was added the solution of hydrazone (7.00 g, 43.2 mmol, 1.0 
equiv) in THF (30 mL) slowly over 15 min and the reaction mixture was allowed to stir at 0 
C for 5 h. The reaction mixture was then cooled to –78 C and a solution of 4-bromo-1-
butene (7.00 g, 51.8 mmol, 1.2 equiv) in THF (15 mL) was added slowly over 10 min. The 
reaction was warmed to rt and stirred for 16 h. The reaction mixture was concentrated and 
the residue was diluted with ether (30 mL) and then treated with an ice-cold solution of 
dilute H2SO4 (30 mL) for 30 min to hydrolyze the hydrazone. The resulting solution was 
diluted with water and extracted with ether (2  35 mL) and the combined organic extracts 
were washed with water (2  25 mL) and brine (20 mL), dried over Na2SO4, and 
252 
 
concentrated. Purification by chromatography on a silica gel (1% ether/hexanes) afforded 
the ketone 44a as a colorless oil in 79% yield (6.00 g, 34.5 mmol). 
 
 
(2R,3S,1′S)-3-(Pent-4′′-en-1′′-yl)-3-phenyl-2-(1′-phenylethyl)-1,2-oxaziridine 
(unlike, cis-42aa), (2S,3R,1′S)-3-(Pent-4′′-en-1′′-yl)-3-phenyl-2-(1′-phenylethyl)-1,2-
oxaziridine (like, cis-42aa), and (2R,3R,1′S)-3-(Pent-4′′-en-1′′-yl)-3-phenyl-2-(1′-
phenylethyl)-1,2-oxaziridine (unlike, trans-42aa). Following the general procedure G, 
starting ketone 44a (1.00 g, 5.74 mmol, 1.0 equiv), (S)--methylbenzylamine 45a (0.950 
mL, 7.46 mmol, 1.3 equiv), PTSA (54.4 mg, 0.287 mmol, 0.050 equiv), and activated 4 Å 
molecular sieves (10.0 g) in toluene (50 mL) was refluxed for 24 h. The crude solution of 
imine was cooled to rt, diluted with CH2Cl2 (25 mL), and was transferred to a flask 
containing a suspension of purified m-CPBA (1.18 g, 6.88 mmol, 1.2 equiv) in CH2Cl2 (15 
mL) at –78 C under nitrogen atmosphere. The reaction was stirred for 30 min at –78 C, 
quenched with saturated Na2S2O3, and allowed to warm to rt. The resulting mixture was 
filtered and washed with CH2Cl2. The filtrate was diluted with water and the layers were 
separated. The aqueous layer was extracted with CH2Cl2 (15 mL), and the combined 
organic extracts were washed with saturated aqueous NaHCO3 (2  15 mL) and brine (15 
mL), dried over Na2SO4, and concentrated. Purification by chromatography on a silica gel 
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(0.5% ether/hexanes) afforded a mixture of three oxaziridine diastereomers (42aa, 42aa, 
and 42aa) and starting ketone 44a as a colorless oil (1.28 g, 4.36 mmol, 76% corrected 
yield; 42aa:42aa:42aa = ca. 91:5:4 by 
1
H NMR). Subsequent purification by 
chromatography on a silica gel (0.5% EtOAc/hexanes) again afforded a mixture of 
oxaziridine diastereomers and starting ketone 44a (42aa:42aa+42aa:44a = ca. 74:14:12 
by 
1
H NMR), followed by another mixture of oxaziridine diastereomers and 44a 
(42aa:42aa:42aa:44a = ca. 71:9:6:14 by 
1
H NMR). A pure sample of 42aa for 
characterization was obtained from a fraction collected during this purification. First 
diastereomer 42aa (major): Rf = 0.72 (5% EtOAc/hexanes, run twice);
 
IR (neat) 2976, 2928, 
1640, 1448 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.19–1.31 (m, 2H), 1.40–1.51 (m, 1H), 
1.48 (d, J = 6.4 Hz, 3H), 1.74 (m, 1H), 1.91–2.05 (m, 2H), 2.21 (m, 1H), 2.99 (q, J = 6.4 
Hz, 1H), 4.86–4.94 (m, 2H), 5.68 (m, 1H), 6.86–6.91 (m, 2H), 7.12 (br s, 2H), 7.19–7.23 
(m, 3H), 7.26–7.30 (m, 2H), 7.33–7.37 (m, 1H); 
13
C NMR (100 MHz, CDCl3)  23.1, 23.2, 
33.7, 37.9, 62.8, 88.4, 115.0, 127.6, 127.6, 127.9, 128.2, 128.4, 128.8, 135.0, 138.4, 140.8; 
HRMS (ESI) m/z calcd for C20H24NO [M + H]
+ 
294.1858, found 294.1840.  
From a mixture of 42aa, 42aa, and 42aa containing 44a: Second diastereomer 
42aa: Rf = 0.60 (5% EtOAc/hexanes, run twice); 
1
H NMR (400 MHz, CDCl3; diagnostic 
peaks only)  1.14 (d, J = 6.6 Hz, 3H). Third diastereomer 42aa: Rf = 0.60 (5% 
EtOAc/hexanes, run twice); 
1
H NMR (400 MHz, CDCl3; diagnostic peaks only)  1.62 (d, J 
= 6.3 Hz, 3H). 
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4-Hydroxy-1-phenylhex-5-en-1-one (43a; Table 17, entry 1). Following the 
general procedure I, [Cu(PPh3)Cl]4 (49.1 mg, 0.0341 mmol, 0.050 equiv) in THF (13 mL) 
was reacted with a solution of the mixture of oxaziridine diastereomers 42aa, 42aa, and 
42aa (ca. 200 mg, 0.682 mmol, 1.0 equiv; 42aa+42aa:42aa (cis:trans) = ca. 92:8, 
contains ca. 12% of starting ketone 44a) in THF (2 mL). The reaction mixture was refluxed 
for 3 h. Purification by chromatography on a silica gel (100% CH2Cl2 to 0.5% 
MeOH/CH2Cl2) afforded 90.0 mg (0.473 mmol, 69% yield; ca. 5% ee by chiral GC, 
retention times for the two enantiomers were 13.88 and 13.99 min, respectively) of the 
allylic alcohol 43a as a yellow oil. Allylic alcohol 43a: Rf = 0.32 (25% EtOAc/hexanes); IR 
(neat) 3420, 1678 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.90–1.98 (m, 1H), 2.01–2.09 (m, 
1H), 2.12 (d, J = 3.4 Hz, 1H), 3.13 (t, J = 7.0 Hz, 2H), 4.24 (br s, 1H), 5.13 (dt, J = 10.4, 
1.3 Hz, 1H), 5.27 (dt, J = 17.2, 1.4 Hz, 1H), 5.86–5.94 (m, 1H), 7.43–7.47 (m, 2H), 7.53–
7.57 (m, 1H), 7.96–7.98 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  31.0, 34.5, 72.4, 115.1, 
128.2, 128.7, 133.3, 137.0, 140.8, 200.7; HRMS (ESI) m/z calcd for C12H15O2 [M + H]
+ 
191.1072, found 191.1091. Ketone 44a was not recovered. 
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Conversion of 42aa into 43a (Scheme 44). Following the general procedure J, CuCl 
(1.69 mg, 0.0170 mmol, 0.049 equiv) and (S)-BINAP (10.6 mg, 0.0170 mmol, 0.049 equiv) 
in THF (9 mL) was reacted with a solution of the mixture of oxaziridine diastereomers 
42aa, 42aa, and 42aa (ca. 102 mg, 0.348 mmol, 1.0 equiv; 42aa+42aa:42aa (cis:trans) 
= ca. 92:8, contains ca. 12% of starting ketone 44a) in THF (3 mL). The reaction mixture 
was refluxed for 1 h. Purification by chromatography on a silica gel (100% CH2Cl2 to 
CH2Cl2:acetone:MeOH, 98.7:1.0:0.3) afforded 20.0 mg (0.105 mmol, 30% yield; ca. 5% ee 
by chiral GC) of 43a as a pale yellow oil and 39.0 mg of the mixture of oxaziridine dias-
tereomers 42aa, 42aa, and 42aa and ketone 44a (42aa+42aa+42aa:44a = ca. 70:30). 
 
 
(2R,3S)-rel-2-Cyclohexyl-3-(pent-4′-en-1′-yl)-3-phenyl-1,2-oxaziridine (cis-42ab) 
and (2S,3S)-rel-2-Cyclohexyl-3-(pent-4′-en-1′-yl)-3-phenyl-1,2-oxaziridine (trans-
42ab). Following the general procedure G, ketone 44a (5.50 g, 31.6 mmol, 1.0 equiv), 
cyclohexylamine 45b (5.42 mL, 47.4 mmol, 1.5 equiv), PTSA (300 mg, 1.58 mmol, 0.050 
equiv), and activated 5 Å molecular sieves (35.0 g) in toluene (150 mL) was refluxed for 60 
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h, followed by oxidation with m-CPBA (6.54 g, 37.9 mmol, 1.2 equiv) in CH2Cl2 (150 
mL). Purification by chromatography on a silica gel (0.5–1.0% EtOAc/hexanes) afforded 
the mixture of major diastereomer cis-42ab and 44a, followed by the mixture of major and 
minor trans-42ab diastereomers as colorless oils (7.80 g, 28.7 mmol, 91% yield; cis-
42ab:trans-42ab = ca. 59:41 by 
1
H NMR). Subsequent purification of the mixture of cis-
42ab and 44a by chromatography on a silica gel (0.5% EtOAc/hexanes) afforded cis-42ab.  
A pure sample of major diastereomer cis-42ab and minor diastereomer trans-42ab 
for characterization was obtained from another experiment, where ketone 44a (1.00 g, 5.75 
mmol, 1.0 equiv), cyclohexylamine 45b (0.986 mL, 8.62 mmol, 1.5 equiv), PTSA (54.6 
mg, 0.287 mmol, 0.050 equiv), and activated 5 Å molecular sieves (7.00 g) in toluene (35 
mL) was refluxed for 60 h, followed by oxidation with m-CPBA (1.19 g, 6.90 mmol, 1.2 
equiv) in CH2Cl2 (25 mL). Purification by chromatography on a silica gel (0.5–1.0% 
EtOAc/hexanes) afforded major diastereomer cis-42ab, minor diastereomer trans-42ab, 
and their mixture as colorless oils (1.12 g, 4.13 mmol, 72% yield; cis-42ab:trans-42ab = 
ca. 55:45 by 
1
H NMR). Major diastereomer cis-42ab: Rf = 0.62 (5% EtOAc/hexanes, run 
twice); IR (neat) 2931, 1448 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.72–0.83 (m, 1H), 0.97–
1.18 (m, 2H), 1.19–1.35 (m, 3H), 1.40–1.51 (m, 3H), 1.52–1.60 (m, 1H), 1.67–1.76 (m, 
3H), 1.83–1.88 (m, 1H), 1.93–2.07 (m, 2H), 2.36 (m, 1H), 4.87–4.96 (m, 2H), 5.70 (m, 
1H), 7.35–7.42 (m, 5H); 
13
C NMR (100 MHz, CDCl3)  23.2, 24.1, 24.2, 25.8, 28.6, 31.8, 
33.7, 38.1, 61.0, 87.7, 115.0, 127.8, 128.2, 128.7, 135.3, 138.5; HRMS (ESI) m/z calcd for 
C18H26NO [M + H ]
+ 
272.2014, found 272.1992.  
Minor diastereomer trans-42ab: Rf = 0.52 (5% EtOAc/hexanes, run twice); IR (neat) 
2932, 1449cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.17–1.38 (m, 3H), 1.40–1.59 (m, 4H), 
1.65–1.73 (m, 2H), 1.81–1.84 (m, 2H), 1.97–2.14 (m, 4H), 2.29 (m, 1H), 2.58 (m, 1H), 
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4.93–5.01 (m, 2H), 5.72 (m, 1H), 7.27–7.38 (m, 5H); 
13
C NMR (100 MHz, CDCl3)  24.4, 
24.6, 24.7, 25.9, 29.1, 29.3, 32.1, 33.8, 61.3, 85.8, 115.4, 126.1, 128.2, 128.3, 128.5, 138.0, 
139.9; HRMS (ESI) m/z calcd for C18H26NO [M + H]
+ 
272.2014, found 272.1988. 
 
 
Conversion of cis-42ab into 43a (Table 17, entry 2 and Table 19, entry 1). 
Following the general procedure I, [Cu(PPh3)Cl]4 (40.0 mg, 0.0276 mmol, 0.050 equiv) in 
THF (10 mL) was reacted with a solution of oxaziridine cis-42ab (150 mg, 0.553 mmol, 
1.0 equiv) in THF (5 mL). The reaction mixture was refluxed for 3 h. Purification by 
chromatography on a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 99.2:0.5:0.3) 
afforded 78.0 mg (0.410 mmol, 74% yield) of the allylic alcohol 43a as a yellow oil and 
18.0 mg (0.103 mmol, 19% yield) of 44a. 
  
 
Following the general procedure J, CuCl (2.73 mg, 0.0276 mmol, 0.050 equiv) and 
rac-BINAP (17.1 mg, 0.0276 mmol, 0.050 equiv) in THF (12 mL) was reacted with a 
solution of oxaziridine cis-42ab (150 mg, 0.553 mmol, 1.0 equiv) in THF (3 mL). The 
reaction mixture was refluxed for 1 h. Purification by chromatography on a silica gel 
(100% CH2Cl2 to CH2Cl2:acetone:MeOH, 98.7:1.0:0.3) afforded 78.0 mg (0.410 mmol, 
74% yield) of 43a as a yellow oil and 6.00 mg (0.0344mmol, 6% yield) of 44a. 
258 
 
 
Conversion of cis-42ab into 43a in THF-d8 (Scheme 42b). Following the general 
procedure I, [Cu(PPh3)Cl]4 (40.0 mg, 0.0276 mmol, 0.050 equiv) in THF-d8 (10 mL) was 
reacted with a solution of oxaziridine cis-42ab (150 mg, 0.553 mmol, 1.0 equiv) in THF-d8 
(5 mL). The reaction mixture was refluxed for 1 h. Purification by chromatography on a 
silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 99.2:0.5:0.3) afforded 70.0 mg (0.368 
mmol, 67% yield) of the allylic alcohol 43a as a yellow oil and 25.0 mg (0.143 mmol, 26% 
yield) of 44a. No deuterium incorporation was observed in 44a by 
1
H NMR and HRMS. 
 
 
(2R,3S)-rel-2-Benzhydryl-3-(pent-4′-en-1′-yl)-3-phenyl-1,2-oxaziridine (cis-42ac) 
and (2S,3S)-rel-2-Benzhydryl-3-(pent-4′-en-1′-yl)-3-phenyl-1,2-oxaziridine (trans-
42ac). Following the general procedure G, ketone 44a (0.500 g, 2.87 mmol, 1.0 equiv), 
benzhydrylamine 45c (0.743 mL, 4.31 mmol, 1.5 equiv), PTSA (27.3 mg, 0.143 mmol, 
0.050 equiv), and 5 Å molecular sieves (3.50 g) in toluene (35 mL) was refluxed for 60 h, 
followed by oxidation with m-CPBA (0.594 g, 3.44 mmol, 1.2 equiv) in CH2Cl2 (20 mL). 
Purification by chromatography on a silica gel (0.5% EtOAc/hexanes) afforded a partial 
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separation of impure cis-42ac and the mixture of major cis-42ac and minor trans-42ac 
diastereomers contaminated with dibenzhydrylamine impurity 45ca
197
 as a pale yellow oil 
(ca. 0.898 g, 2.53 mmol, 88% corrected yield; cis-42ac:trans-42ac = ca. 76:24 by 
1
H 
NMR). Subsequent purification of small amounts of impure cis-42ac and impure mixture of 
cis- and trans-42ac separately by preparative TLC on a silica gel (2% EtOAc/hexanes, 
multiple runs) gave bands corresponding to cis-42ac and trans-42ac, which were scraped 
from the plate and eluted with 100% CH2Cl2 through a short bed of silica gel. Evaporation 
of solvents afforded analytical samples of cis-42ac and trans-42ac as colorless oils for 
characterization. Major diastereomer cis-42ac: Rf = 0.67 (5% EtOAc/hexanes, run twice); 
IR (neat) 2926, 1448 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.24–1.36 (m, 1H), 1.46–1.57 
(m, 1H), 1.88 (m, 1H), 1.94–2.09 (m, 2H), 2.32 (m, 1H), 4.06 (s, 1H), 4.88–4.96 (m, 2H), 
5.70 (m, 1H), 6.94–6.97 (m, 2H), 7.18–7.23 (m, 5H), 7.27–7.31 (m, 4H), 7.36–7.40 (m, 
4H); 
13
C NMR (100 MHz, CDCl3)  23.1, 33.7, 37.7, 70.5, 88.6, 115.0, 127.3, 127.6, 127.9, 
128.1, 128.3, 128.4, 128.5, 129.0, 134.7, 138.5, 139.5, 142.3; HRMS (ESI) m/z calcd for 
C25H26NO [M + H]
+
 356.2014, found 356.2044.  
Minor diastereomer trans-42ac: Rf = 0.50 (5% EtOAc/hexanes, run twice); IR (neat) 
2930, 1450 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.14–1.24 (m, 1H), 1.32–1.43 (m, 1H), 
1.95–2.07 (m, 2H), 2.09–2.25 (m, 2H), 4.91–4.97 (m, 3H), 5.66 (m, 1H), 7.21–7.26 (m, 
1H), 7.28–7.34 (m, 8H), 7.35–7.39 (m, 2H), 7.43–7.45 (m, 2H), 7.48–7.51 (m, 2H); 
13
C 
NMR (100 MHz, CDCl3)  24.8, 29.7, 33.7, 70.7, 86.7, 115.4, 126.3, 127.5, 127.82, 
127.88, 128.0, 128.4, 128.6, 129.0, 138.0, 139.4, 140.1, 142.1; HRMS (ESI) m/z calcd for 
C25H26NO [M + H]
+
 356.2014, found 356.2014.  
Dibenzhydrylamine 45ca: 
1
H NMR (400 MHz, CDCl3; diagnostic peaks only)  4.77 
(s, 2H); 
13
C NMR (100 MHz, CDCl3; diagnostic peaks only)  63.7. 
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Conversion of 42ac into 43a (Table 17, entry 3). Following the general procedure I, 
[Cu(PPh3)Cl]4 (30.4 mg, 0.0211 mmol, 0.045 equiv) in THF (12 mL) was reacted with a 
solution of oxaziridine diastereomers 42ac (165 mg, 0.464 mmol, 1.0 equiv; cis:trans = ca. 
77:23, contaminated with 12% of dibenzhydrylamine) in THF (3 mL). The reaction mixture 
was refluxed for 1.5 h. Purification by chromatography on a silica gel (100% CH2Cl2 to 
CH2Cl2:acetone:MeOH, 98.7:1.0:0.3) afforded the mixture of product and impurities which 
was further purified by chromatography on a silica gel (100% CH2Cl2 to 2.5% 
acetone/CH2Cl2) to afford 19.0 mg (0.10 mmol, 22% yield; 26% brsm) of 43a as a yellow 
oil. Ketone 44a was also obtained in 48% yield (39.0 mg, 0.224 mmol; 57% brsm) during 
the initial purification. 
 
 
(2R,3S)-rel-2-Benzyl-3-(pent-4′-en-1′-yl)-3-phenyl-1,2-oxaziridine (cis-42ad) and 
(2S,3S)-rel-2-Benzyl-3-(pent-4′-en-1′-yl)-3-phenyl-1,2-oxaziridine (trans-42ad). 
Following the general procedure G, ketone 44a (0.600 g, 3.44 mmol, 1.0 equiv), 
benzylamine 45d (0.564 mL, 5.17 mmol, 1.5 equiv), PTSA (32.8 mg, 0.172 mmol, 0.050 
equiv), and activated 4 Å molecular sieves (5.0 g) in toluene (40 mL) was refluxed for 60 h, 
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followed by oxidation with m-CPBA (0.713 g, 4.13 mmol, 1.2 equiv) in CH2Cl2 (20 mL). 
Purification by chromatography on a silica gel (0.5–0.7% EtOAc/hexanes) afforded the 
mixture of major diastereomer cis-42ad and 44a, followed by the mixture of major and 
minor trans-42ad diastereomers as a colorless oil (ca. 0.866 g, 3.10 mmol, 90% corrected 
yield; cis-42ad:trans-42ad = ca. 87:13 by 
1
H NMR). Subsequent purification of the 
mixture of cis-42ad and trans-42ad by chromatography on a silica gel (0.6% 
EtOAc/hexanes) afforded a partial separation of pure cis-42ad and a small quantity of 
trans-42ad containing ca. 15% of cis-42ad. Major diastereomer cis-42ad: Rf = 0.55 (5% 
EtOAc/hexanes, run twice); IR (neat) 2927, 1448 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  
1.27–1.38 (m, 1H), 1.46–1.57 (m, 1H), 1.82 (m, 1H), 1.95–2.09 (m, 2H), 2.36 (m, 1H), 
3.43 (1/2 AB, J = 14.1 Hz, 1H), 3.52 (1/2 AB, J = 14.1 Hz, 1H), 4.89–4.97 (m, 2H), 5.71 
(m, 1H), 7.20–7.22 (m, 2H), 7.25–7.28 (m, 2H), 7.29–7.32 (m, 1H), 7.42 (s, 5H); 
13
C NMR 
(100 MHz, CDCl3)  23.1, 33.7, 37.7, 59.3, 87.9, 115.0, 127.6, 127.8, 128.4, 128.5, 128.8, 
129.0, 135.2, 136.7, 138.4; HRMS (ESI) m/z calcd for C19H22NO [M + H]
+ 
280.1701, found 
280.1739.  
Minor diastereomer trans-42ad: Rf = 0.45 (5% EtOAc/hexanes, run twice); IR (neat) 
2926, 1452 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.43–1.58 (m, 2H), 2.06–2.16 (m, 2H), 
2.19–2.36 (m, 2H), 4.16 (s, 2H), 4.96–5.03 (m, 2H), 5.74 (m, 1H), 7.27–7.34 (m, 4H), 
7.35–7.39 (m, 3H), 7.40–7.44 (m, 3H); 
13
C NMR (100 MHz, CDCl3)  24.7, 29.2, 33.8, 
58.2, 85.6, 115.6, 126.5, 127.8, 128.5, 128.6, 128.7, 128.8, 136.6, 137.9, 139.1; HRMS 
(ESI) m/z calcd for C19H22NO [M + H]
+ 
280.1701, found 280.1722. 
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1-(3,4-Dimethoxyphenyl)hex-5-en-1-one (44b). A solution of 3,4-dimethoxy-
acetophenone (15.0 g, 83.2 mmol, 1.0 equiv), N,N-dimethylhydrazine (15.0 g, 249 mmol, 
3.0 equiv) and PTSA (0.791 g, 4.16 mmol, 0.050 equiv) in benzene (80 mL) was refluxed 
for 23 h under nitrogen atmosphere with removal of water by a Dean–Stark apparatus. The 
reaction mixture was concentrated under reduced pressure and the residue was purified by 
vacuum distillation to afford the corresponding hydrazone as a pale yellow solid in 81% 
yield (15.0 g, 67.5 mmol).  
To a cooled 1.0 M LDA solution (9.90 mL, 9.90 mmol, 1.1 equiv) in THF at 0 C 
under nitrogen atmosphere was added the solution of hydrazone (2.00 g, 9.00 mmol, 1.0 
equiv) in THF (15 mL) slowly over 15 min and was allowed to stir at 0 C for 5 h. The 
reaction mixture was then cooled to –78 C and a solution of 4-bromo-1-butene (1.45 g, 
10.8 mmol, 1.2 equiv) in THF (5 mL) was added slowly over 10 min. The reaction was 
warmed to rt and stirred for 18 h. The reaction mixture was concentrated under reduced 
pressure and the residue was diluted with ether (15 mL) and then treated with an ice-cold 
solution of dilute H2SO4 (15 mL) for 30 min to hydrolyze the hydrazone. The resulting 
solution was diluted with water and extracted with ether (2  15 mL) and the combined 
organic extracts were washed with water (2  15 mL) and brine (15 mL), dried over 
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Na2SO4, and concentrated under reduced pressure. Purification by chromatography on a 
silica gel (10% EtOAc/hexanes) afforded the ketone 44b as a white solid in 71% yield (1.50 
g, 6.41 mmol). Ketone 44b: Rf = 0.41 (15% EtOAc/hexanes, run twice); mp 52–54 C; IR 
(neat) 1672 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.82 (m, 2H), 2.11–2.16 (m, 2H), 2.92 (t, 
J = 7.3 Hz, 2H), 3.92 (s, 3H), 3.93 (s, 3H), 4.96–5.06 (m, 2H), 5.81 (m, 1H), 6.86 (d, J = 
8.3 Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.56 (dd, J = 8.3, 2.0 Hz, 1H); 
13
C NMR (100 MHz, 
CDCl3)  23.8, 33.4, 37.4, 56.1, 56.2, 110.1, 110.3, 115.4, 122.8, 130.4, 138.2, 149.1, 
153.3, 199.0; HRMS (ESI) m/z calcd for C14H18O3 [M]
+ 
234.1256, found 234.1236. 
 
 
(2R,3S,1′S)-rel-3-(3,4-Dimethoxyphenyl)-3-(pent-4′′-en-1′′-yl)-2-(1′-phenylethyl)-
1,2-oxaziridine (unlike, cis-42ba), (2S,3R,1′S)-rel-3-(3,4-Dimethoxyphenyl)-3-(pent-4′′-
en-1′′-yl)-2-(1′-phenylethyl)-1,2-oxaziridine (like, cis-42ba). Following the general 
procedure G, ketone 44b (1.00 g, 4.27 mmol, 1.0 equiv), (S)-α-methylbenzylamine 45a 
(0.815 mL, 6.41 mmol, 1.5 equiv), PTSA (40.6 mg, 0.213 mmol, 0.050 equiv), and 
activated 4 Å molecular sieves (7.0 g) in toluene (50 mL) was refluxed for 72 h, followed 
by oxidation with m-CPBA (0.883 g, 5.12 mmol, 1.2 equiv) in CH2Cl2 (25 mL). 
Purification by chromatography on a silica gel (4–6% EtOAc/hexanes) afforded the major 
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42ba and the minor 42ba diastereomers as a colorless oil (0.940 g, 2.66 mmol, 62% yield; 
42ba:42ba = ca. 83:17). A pure sample of 42ba for characterization was obtained during 
this purification. Major diastereomer 42ba: Rf = 0.50 (10% EtOAc/hexanes, run twice);
 
IR 
(neat) 1605, 1452, 1257 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.19–1.31 (m, 1H), 1.40–1.51 
(m, 1H), 1.47 (d, J = 6.5 Hz, 3H), 1.70 (m, 1H), 1.90–2.05 (m, 2H), 2.17 (m, 1H), 3.01 (q, J 
= 6.4 Hz, 1H), 3.62 (br s, 3H), 3.88 (s, 3H), 4.85–4.93(m, 2H), 5.68 (m, 1H), 6.39 (br s, 
1H), 6.78 (d, J = 6.5 Hz, 2H), 6.92–6.96 (m, 2H), 7.18–7.24 (m, 3H); 
13
C NMR (100 MHz, 
CDCl3)  23.1, 23.2, 33.6, 37.9, 55.7, 56.0, 62.7, 88.2, 110.2, 110.8, 114.9, 120.6, 127.4, 
127.51, 127.56, 128.3, 138.4, 141.2, 148.1, 149.2; HRMS (ESI) m/z calcd for C22H28NO3 
[M + H]
+ 
354.2069, found 354.2074.  
Minor diastereomer 42ba: Rf = 0.41 (10% EtOAc/hexanes, run twice);
 
IR (neat) 
1604, 1453, 1259 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.15 (d, J = 6.6 Hz, 3H), 1.24–1.35 
(m, 1H), 1.43–1.54 (m, 1H), 1.81 (m, 1H), 1.95–2.09 (m, 2H), 2.44 (m, 1H), 3.09 (q, J = 
6.6 Hz, 1H), 3.92 (s, 3H), 3.94 (s, 3H), 4.89–4.97(m, 2H), 5.71 (m, 1H), 6.93 (d, J = 8.2 
Hz, 1H), 6.99 (d, J = 1.9 Hz, 1H), 7.07 (dd, J = 8.2, 2.0 Hz, 1H), 7.22–7.27 (m, 1H), 7.30– 
7.36 (m, 4H); 
13
C NMR (100 MHz, CDCl3)  19.2, 23.3, 33.7, 37.8, 56.1, 56.3, 61.4, 88.5, 
110.9, 111.2, 115.0, 120.6, 127.1, 127.2, 127.4, 128.6, 138.5, 143.2, 148.7, 149.5; HRMS 
(ESI) m/z calcd for C22H28NO3 [M + H]
+ 
354.2069, found 354.2076. 
 
 
1-(3,4-Dimethoxyphenyl)-4-hydroxyhex-5-en-1-one (43b; Table 17, entry 5). 
Following the general procedure I, [Cu(PPh3)Cl]4 (51.1 mg, 0.0354 mmol, 0.050 equiv) in 
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THF (12 mL) was reacted with a solution of oxaziridine 42ba (250 mg, 0.708 mmol, 1.0 
equiv) in THF (8 mL). The reaction mixture was refluxed for 3 h. Purification by 
chromatography on a silica gel (0–3% acetone/CH2Cl2) afforded 85.0 mg (0.340 mmol, 
48% yield) of the allylic alcohol 43b as a pink oil. Allylic alcohol 43b: Rf = 0.23 (3% 
acetone/CH2Cl2); IR (neat) 3435, 1668 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.87–1.96 (m, 
1H), 1.99–2.07 (m, 1H), 2.23 (d, J = 4.3 Hz, 1H), 3.08 (t, J = 7.0 Hz, 2H), 3.92 (s, 3H), 
3.93 (s, 3H), 4.23 (m, 1H), 5.12 (dt, J = 10.4, 1.4 Hz, 1H), 5.26 (dt, J = 17.2, 1.4 Hz, 1H), 
5.89 (m, 1H), 6.87 (d, J = 8.4 Hz, 1H), 7.52 (d, J = 2.0 Hz, 1H), 7.60 (dd, J = 8.4, 2.0 Hz, 
1H); 
13
C NMR (100 MHz, CDCl3)  31.3, 34.0, 56.1, 56.2, 72.4, 110.1, 110.3, 115.0, 123.0, 
130.2, 140.9, 149.1, 153.4, 199.3; HRMS (ESI) m/z calcd for C14H19O4 [M + H]
+ 
251.1283, 
found 251.1286. Ketone 44b was also obtained in 27% yield (45.0 mg, 0.192 mmol). 
 
 
(2R,3S)-rel-2-Cyclohexyl-3-(3,4-dimethoxyphenyl)-3-(pent-4′-en-1′-yl)-1,2-
oxaziridine (cis-42bb) and (2S,3S)-rel-2-Cyclohexyl-3-(3,4-dimethoxyphenyl)-3-(pent-
4′-en-1′-yl)-1,2-oxaziridine (trans-42bb). Following the general procedure G, ketone 44b 
(0.900 g, 3.84 mmol, 1.0 equiv), cyclohexylamine 45b (0.659 mL, 5.76 mmol, 1.5 equiv), 
PTSA (36.5 mg, 0.192 mmol, 0.050 equiv), and activated 5 Å molecular sieves (6.50 g) in 
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toluene (40 mL) was refluxed for 60 h, followed by oxidation with m-CPBA (0.796 g, 4.61 
mmol, 1.2 equiv) in CH2Cl2 (25 mL). Purification by chromatography on a silica gel (4–6% 
EtOAc/hexanes) afforded the major diastereomer cis-42bb (0.610 g, 1.84 mmol, 48% 
yield) as a colorless oil, followed by the mixture of 44b and minor diastereomer trans-42bb 
(0.246 g, 0.743 mmol, 19% corrected yield; cis-42bb:trans-42bb = ca. 71:29 by 
1
H NMR). 
Subsequent purification of the mixture of 44b and trans-42bb by chromatography on a 
silica gel (14% EtOAc/hexanes) afforded a partial separation of trans-42bb as a colorless 
oil. Major diastereomer cis-42bb: Rf = 0.33 (10% EtOAc/hexanes, run twice); IR (neat) 
2930, 1450, 1257 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.75–0.86 (m, 1H), 0.95–1.15 (m, 
2H), 1.16–1.32 (m, 3H), 1.39–1.48 (m, 3H), 1.52–1.56 (m, 1H), 1.63–1.70 (m, 2H), 1.72–
1.79 (m, 1H), 1.81–1.84 (m, 1H), 1.90–2.04 (m, 2H), 2.31 (m, 1H), 3.86 (s, 3H), 3.87 (s, 
3H), 4.85–4.93 (m, 2H), 5.67 (m, 1H), 6.84 (d, J = 8.3 Hz, 1H), 6.86 (d, J = 1.9 Hz, 1H), 
6.93 (dd, J = 8.2, 1.9 Hz, 1H); 
13
C NMR (100 MHz, CDCl3)  23.2, 24.11, 24.15, 25.8, 
28.7, 31.7, 33.7, 38.1, 55.9, 56.1, 60.7, 87.5, 110.7, 110.9, 114.9, 120.3, 127.6, 138.4, 
148.5, 149.1; HRMS (ESI) m/z calcd for C20H30NO3 [M + H]
+ 
332.2226, found 332.2223.  
Minor diastereomer trans-42bb: Rf = 0.13 (10% EtOAc/hexanes, run twice); IR 
(neat) 2932, 1452, 1265 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.16–1.36 (m, 3H), 1.41–1.55 
(m, 4H), 1.65–1.70 (m, 2H), 1.80–1.84 (m, 2H), 1.95–2.02 (m, 2H), 2.04–2.16 (m, 2H), 
2.28 (m, 1H), 2.56 (m, 1H), 3.85 (s, 3H), 3.87 (s, 3H), 4.94–5.01 (m, 2H), 5.73 (m, 1H), 
6.82 (d, J = 8.2 Hz, 1H), 6.88 (d, J = 1.9 Hz, 1H), 6.93 (dd, J = 8.2, 2.0 Hz, 1H); 
13
C NMR 
(100 MHz, CDCl3)  24.4, 24.6, 24.8, 25.8, 28.9, 29.2, 32.1, 33.8, 56.0, 56.1, 61.4, 85.4, 
109.3, 111.1, 115.4, 118.7, 132.5, 138.0, 149.13, 149.15; HRMS (ESI) m/z calcd for 
C20H30NO3 [M + H]
+ 
332.2226, found 332.2224. 
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Conversion of cis-42bb into 43b (Table 17, entry 6). Following the general 
procedure I, [Cu(PPh3)Cl]4 (21.8 mg, 0.0151 mmol, 0.050 equiv) in THF (7 mL) was 
reacted with a solution of oxaziridine cis-42bb (100 mg, 0.302 mmol, 1.0 equiv) in THF (3 
mL). The reaction mixture was refluxed for 1 h. Purification by chromatography on a silica 
gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 98.6:1.0:0.4) afforded 28.0 mg (0.112 mmol, 
37% yield) of the allylic alcohol 43b as a pink oil. Rf = 0.12 (35% EtOAc/hexanes). Ketone 
44b was also obtained in 57% yield (40.0 mg, 0.171 mmol). 
 
 
Conversion of cis-42bb into 43b (Scheme 45). Following the general procedure J, 
CuCl (2.24 mg, 0.0226 mmol, 0.050 equiv) and rac-BINAP (14.0 mg, 0.0226 mmol, 0.050 
equiv) in THF (12 mL) was reacted with a solution of oxaziridine cis-42bb (150 mg, 0.453 
mmol, 1.0 equiv) in THF (3 mL). The reaction mixture was refluxed for 1 h. Purification by 
chromatography on a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 98.6:1.0:0.4) 
afforded 76.0 mg (0.304 mmol, 67% yield; 73% brsm) of 43b as a yellow oil and ca. 18.0 
mg (0.0769 mmol, 17% corrected yield) of 44b.  
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Conversion of trans-42bb into 43b (Scheme 45). Following the general procedure 
J, CuCl (1.72 mg, 0.0173 mmol, 0.050 equiv) and rac-BINAP (10.8 mg, 0.0173 mmol, 
0.050 equiv) in THF (9 mL) was reacted with a solution of oxaziridine trans-42bb (115 
mg, 0.347 mmol, 1.0 equiv) in THF (3 mL). The reaction mixture was refluxed for 1 h. 
Purification by chromatography on a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 
98.6:1.0:0.4) afforded 58.0 mg (0.232 mmol, 67% yield) of 43b as a yellow oil and 12.0 mg 
(0.0512 mmol, 15% yield) of 44b.  
 
 
6-Methyl-1-phenylhept-5-en-1-one (44c). To a cooled 1.0 M LDA solution (10.1 
mL, 10.1 mmol, 1.1 equiv) in THF at 0 C under nitrogen atmosphere was added the 
solution of hydrazone (1.50 g, 9.25 mmol, 1.0 equiv) in THF (15 mL) slowly over 15 min 
and was allowed to stir at 0 C for 5 h. The reaction mixture was then cooled to –78 C and 
a solution of 5-bromo-2-methyl-2-pentene (1.47 mL, 11.1 mmol, 1.2 equiv) in THF (5 mL) 
was added slowly over 10 min. The reaction was warmed to rt and stirred for 18 h. The 
reaction mixture was concentrated under reduced pressure and the residue was diluted with 
ether (15 mL) and then treated with an ice-cold solution of dilute H2SO4 (15 mL) for 30 
min to hydrolyze the hydrazone. The resulting solution was diluted with water and 
extracted with ether (2  15 mL) and the combined organic extracts were washed with 
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water (2  15 mL) and brine (15 mL), dried over Na2SO4, and concentrated under reduced 
pressure. Purification by chromatography on a silica gel (0.2–0.5% EtOAc/hexanes) 
afforded the ketone 44c as a colorless oil in 89% yield (1.66 g, 8.24 mmol). Ketone 44c: Rf 
= 0.43 (5% EtOAc/hexanes, run twice); IR (neat) 1685 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  
1.59 (s, 3H), 1.69 (d, J = 1.0 Hz, 3H), 1.78 (m, 2H), 2.08 (q, J = 7.2 Hz, 2H), 2.95 (t, J = 
7.3 Hz, 2H), 5.13 (m, 1H), 7.43–7.47 (m, 2H), 7.52–7.56 (m, 1H), 7.93–7.96 (m, 2H); 
13
C 
NMR (100 MHz, CDCl3)  17.9, 24.6, 25.9, 27.6, 38.1, 124.0, 128.2, 128.7, 132.6, 133.0, 
137.3, 200.7; HRMS (EI) m/z calcd for C14H18O [M]
+ 
202.1358, found 202.1344. 
 
 
(2R,3S,1′S)-3-(5-Methylhex-4′′-en-1′′-yl)-3-phenyl-2-(1′-phenylethyl)-1,2-
oxaziridine (unlike, cis-42ca), (2S,3R,1′S)-3-(5-Methylhex-4′′-en-1′′-yl)-3-phenyl-2-(1′-
phenylethyl)-1,2-oxaziridine (like, cis-42ca), and (2R,3R,1′S)-3-(5-Methylhex-4′′-en-
1′′-yl)-3-phenyl-2-(1′-phenylethyl)-1,2-oxaziridine (unlike, trans-42ca). Following the 
general procedure G, 6-methyl-1-phenylhept-5-en-1-one 44c (1.00 g, 4.95 mmol, 1.0 
equiv), (S)-α-methylbenzylamine 45a (0.945 mL, 7.42 mmol, 1.5 equiv), PTSA (47.0 mg, 
0.247 mmol, 0.050 equiv), and activated 4 Å molecular sieves (7.0 g) in toluene (50 mL) 
was refluxed for 60 h, followed by oxidation with m-CPBA (1.02 g, 5.94 mmol, 1.2 equiv) 
in CH2Cl2 (25 mL). Purification by chromatography on a silica gel (0.5–1% 
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EtOAc/hexanes) afforded the mixture of oxaziridine diastereomers (42ca, 42ca, and 
42ca) and starting ketone 44c as a colorless oil. Subsequent purification by 
chromatography on a silica gel (0.2% EtOAc/hexanes) afforded a partial separation of the 
mixture of the two diastereomers (42ca and 42ca), followed by the mixture of three 
diastereomers (42ca, 42ca, and 42ca) containing a trace amount of 44c (1.11 g, 70% 
corrected yield; 42ca:42ca:42ca = ca. 50:14:36 by 
1
H NMR). A pure sample of the major 
diastereomer 42ca for characterization was obtained during this purification. Major 
diastereomer 42ca: Rf = 0.71 (5% EtOAc/hexanes, run twice);
 
IR (neat) 1448, 764, 698 cm
–
1
; 
1
H NMR (400 MHz, CDCl3)  1.12–1.23 (m, 1H), 1.33–1.44 (m, 1H), 1.48 (d, J = 6.4 
Hz, 3H), 1.51 (s, 3H), 1.62 (d, J = 0.9 Hz, 3H), 1.72 (m, 1H), 1.83–1.98 (m, 2H), 2.21 (m, 
1H), 2.99 (q, J = 6.4 Hz, 1H), 4.97–5.01(m, 1H), 6.87–6.91 (m, 2H), 7.12–7.23 (m, 5H), 
7.26–7.30 (m, 2H), 7.32–7.37 (m, 1H); 
13
C NMR (100 MHz, CDCl3)  17.8, 23.1, 24.1, 
25.8, 28.0, 38.1, 62.8, 88.6, 124.2, 127.6, 127.8, 128.2, 128.3, 128.8, 131.9, 135.0, 140.8; 
HRMS (ESI) m/z calcd for C22H28NO [M + H]
+ 
322.2171, found 322.2126.  
From a mixture of 42ca, 42ca, and 42ca containing 44c: Second diastereomer 
42ca: Rf = 0.60 (5% EtOAc/hexanes, run twice); 
1
H NMR (400 MHz, C6D6; diagnostic 
peaks only)  3.19 (q, J = 6.0 Hz, 1H); 13C NMR (100 MHz, C6D6; diagnostic peaks only)  
61.7, 87.8. Third diastereomer 42ca: Rf = 0.55 (5% EtOAc/hexanes, run twice); 
1
H NMR 
(400 MHz, C6D6; diagnostic peaks only)  3.82 (q, J = 6.3 Hz, 1H); 
13
C NMR (100 MHz, 
C6D6; diagnostic peaks only)  62.9, 85.8.  
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4-Hydroxy-6-methyl-1-phenylhept-5-en-1-one (43c; Table 17, entry 7). Following 
the general procedure I, [Cu(PPh3)Cl]4 (44.5 mg, 0.0342 mmol, 0.044 equiv) in THF (12 
mL) was reacted with a solution of oxaziridine diastereomers 42ca and 42ca (220 mg, 
0.685 mmol, 1.0 equiv; 42ca:42ca = 90:10) in THF (8 mL). The reaction mixture was 
refluxed for 3 h. Purification by chromatography on a silica gel (1.5–2% acetone/CH2Cl2) 
afforded 110 mg (0.504 mmol, 74% yield) of the allylic alcohol 43c as a yellow oil. Allylic 
alcohol 43c: Rf = 0.26 (20% EtOAc/hexanes); IR (neat) 3410, 1679 cm
–1
; 
1
H NMR (400 
MHz, CDCl3)  1.67 (d, J = 0.8 Hz, 3H), 1.71 (d, J = 0.6 Hz, 3H), 1.74–1.76 (m, 1H), 
1.87–2.01 (m, 2H), 3.08 (t, J = 7.3 Hz, 2H), 4.45 (m, 1H), 5.21 (m, 1H), 7.43–7.46 (m, 2H), 
7.53–7.56 (m, 1H), 7.95–7.97 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  18.4, 25.9, 32.0, 
34.8, 68.2, 127.9, 128.2, 128.7, 133.1, 135.7, 137.2, 200.6; HRMS (ESI) m/z calcd for 
C14H18O2Na [M + Na]
+ 
241.1204, found 241.1189. Ketone 44c was also obtained in 7% 
yield (10.0 mg, 0.0495 mmol). 
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(2R,3S)-rel-2-Cyclohexyl-3-(5-methylhex-4′-en-1′-yl)-3-phenyl-1,2-oxaziridine 
(cis-42cb) and (2S,3S)-rel-2-Cyclohexyl-3-(5-methylhex-4′-en-1′-yl)-3-phenyl-1,2-
oxaziridine (trans-42cb). Following the general procedure G, 6-methyl-1-phenylhept-5-
en-1-one 44c (0.700 g, 3.46 mmol, 1.0 equiv), cyclohexylamine 45b (0.594 mL, 5.19 
mmol, 1.5 equiv), PTSA (32.9 mg, 0.173 mmol, 0.050 equiv), and activated 5 Å molecular 
sieves (5.0 g) in toluene (35 mL) was refluxed for 60 h, followed by oxidation with m-
CPBA (0.717 g, 4.15 mmol, 1.2 equiv) in CH2Cl2 (25 mL). Purification by chromatography 
on a silica gel (0.5–0.6% EtOAc/hexanes) afforded a partial separation of the major 
diastereomer cis-42cb as a colorless oil, followed by the mixture of major and minor trans-
42cb diastereomers (0.760 g, 2.54 mmol, 73% yield; cis-42cb:trans-42cb = ca. 56:44). 
Major diastereomer cis-42cb: Rf = 0.58 (5% EtOAc/hexanes, run twice); IR (neat) 2929, 
1447 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.72–0.83 (m, 1H), 0.97–1.16 (m, 2H), 1.17–
1.28 (m, 2H), 1.31–1.42 (m, 2H), 1.43–1.49 (m, 2H), 1.52 (s, 3H), 1.52–1.58 (m, 1H), 1.62 
(d, J = 0.8 Hz, 3H), 1.66–1.76 (m, 3H), 1.84–1.95 (m, 3H), 2.35 (m, 1H), 5.00 (m, 1H), 
7.34–7.42 (m, 5H); 
13
C NMR (100 MHz, CDCl3)  17.8, 24.1, 24.1, 24.2, 25.8, 28.0, 28.6, 
31.8, 38.3, 60.9, 87.8, 124.3, 127.8, 128.1, 128.7, 131.9, 135.3; HRMS (ESI) m/z calcd for 
C20H30NO [M + H]
+ 
300.2327, found 300.2318.  
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An analytical sample of the minor diastereomer trans-42cb containing ca. 12% of cis-
42cb was obtained for characterization during the purification. Minor diastereomer trans-
42cb: Rf = 0.51 (5% EtOAc/hexanes, run twice);
 
IR (neat) 2930, 1448 cm
–1
; 
1
H NMR (400 
MHz, CDCl3)  1.20–1.35 (m, 3H), 1.36–1.49 (m, 3H), 1.52–1.59 (m, 1H), 1.56 (s, 3H), 
1.66 (d, J = 0.8 Hz, 3H ), 1.70–1.74 (m, 2H), 1.82–1.85 (m, 2H), 1.94–2.05 (m, 4H), 2.26 
(m, 1H), 2.59 (m, 1H), 5.03 (m, 1H), 7.28–7.37 (m, 5H); 
13
C NMR (100 MHz, CDCl3)  
17.9, 24.4, 24.7, 25.7, 25.9, 25.9, 28.2, 29.3, 29.4, 32.1, 61.2, 85.9, 123.9, 126.2, 128.2, 
128.4, 132.4, 140.0; HRMS (ESI) m/z calcd for C20H30NO [M + H]
+ 
300.2327, found 
300.2296. 
 
 
Conversion of 42cb into 43c (Table 17, entry 8 and Table 19, entry 7). Following 
the general procedure I, [Cu(PPh3)Cl]4 (36.2 mg, 0.0250 mmol, 0.050 equiv) in THF (12 
mL) was reacted with a solution of oxaziridine diastereomers 42cb (150 mg, 0.501 mmol, 
1.0 equiv; cis:trans = ca. 63:37) in THF (3 mL). The reaction mixture was refluxed for 1 h. 
Purification by chromatography on a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 
98.7:1.0:0.3) afforded ca. 70.0 mg (0.321 mmol, 64% corrected yield by 
1
H NMR; 
contaminated with ca. 10% of unidentified impurities) of the allylic alcohol 43c as a pink 
oil and 19.0 mg (0.0940 mmol, 19% yield) of 44c.  
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Conversion of 42cb into 43c (Table 19, entry 7). Following the general procedure 
J, CuCl (2.48 mg, 0.0250 mmol, 0.050 equiv) and rac-BINAP (15.6 mg, 0.0250 mmol, 
0.050 equiv) in THF (12 mL) was reacted with a solution of oxaziridine cis-42cb (150 mg, 
0.501 mmol, 1.0 equiv) in THF (3 mL). The reaction mixture was refluxed for 1 h. 
Purification by chromatography on a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 
98.7:1.0:0.3) afforded 82.0 mg (0.376 mmol, 75% yield) of 43c as a yellow oil and 6.00 mg 
(0.0297 mmol, 6% yield) of 44c.  
 
 
(2R,3S)-rel-2-Benzhydryl-3-(5-methylhex-4′-en-1′-yl)-3-phenyl-1,2-oxaziridine 
(cis-42cc) and (2S,3S)-rel-2-Benzhydryl-3-(5-methylhex-4′-en-1′-yl)-3-phenyl-1,2-
oxaziridine (trans-42cc). Following the general procedure G, 6-methyl-1-phenylhept-5-en-
1-one 44c (0.500 g, 2.47 mmol, 1.0 equiv), benzhydrylamine 45c (0.639 mL, 3.71 mmol, 
1.5 equiv), PTSA (23.5 mg, 0.123 mmol, 0.050 equiv), and activated 4 Å molecular sieves 
(3.0 g) in toluene (25 mL) was refluxed for 60 h, followed by oxidation with m-CPBA 
(0.510 g, 2.96 mmol, 1.2 equiv) in CH2Cl2 (12 mL). Purification by chromatography on a 
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silica gel (0.5–0.7% EtOAc/hexanes) afforded a mixture of major cis-42cc and minor trans-
42cc diastereomers containing ca. 6.5% of dibenzhydrylamine impurity and 4% of starting 
ketone 44c as a colorless oil (ca. 0.826 g, 2.16 mmol, 87% corrected yield; cis-42cc:trans-
42cc = ca. 72:28 by 
1
H NMR). An analytical sample of the major diastereomer cis-42cc 
accompanied with 9% of dibenzhydrylamine was obtained for characterization during this 
purification. Major diastereomer cis-42cc: Rf = 0.60 (5% EtOAc/hexanes, run twice);
 
IR 
(neat) 1448, 733 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.20–1.31 (m, 1H), 1.41–1.52 (m, 
1H), 1.55 (s, 3H), 1.66 (s, 3H), 1.86–2.02 (m, 3H), 2.35 (m, 1H), 4.09 (s, 1H), 5.04 (t, J = 
6.9 Hz, 1H), 6.98–7.00 (m, 2H), 7.22–7.26 (m, 4H), 7.29–7.35 (m, 5H), 7.38 (d, J = 8.5 Hz, 
2H), 7.42 (d, J = 7.6 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  17.8, 24.1, 25.8, 28.1, 37.9, 
70.5, 88.7, 124.3, 127.3, 127.6, 127.7, 127.8, 127.9, 128.1, 128.3, 128.4, 128.5, 128.6, 
128.9, 131.9, 134.8, 139.6, 142.4; HRMS (ESI) m/z calcd for C27H30NO [M + H]
+ 
384.2327, found 384.2337.  
From a mixture of cis-42cc and trans-42cc containing 44c and dibenzhydrylamine 
impurity: Minor diastereomer trans-42cc: Rf = 0.45 (5% EtOAc/hexanes, run twice); 
1
H 
NMR (400 MHz, CDCl3; diagnostic peaks only)  4.91 (s, 1H).  
 
 
Conversion of 42cc into 43c (Table 17, entry 9). Following the general procedure I, 
[Cu(PPh3)Cl]4 (37.7 mg, 0.0260 mmol, 0.037 equiv) in THF (12 mL) was reacted with a 
solution of oxaziridine diastereomers 42cc (269 mg, 0.702 mmol, 1.0 equiv; cis:trans = ca. 
70:30, containing ca. 6.4% of dibenzhydrylamine and 4% of 44c) in THF (8 mL). The 
reaction mixture was refluxed for 3 h. Purification by chromatography on a silica gel (0–
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1.5% acetone/CH2Cl2) afforded 100 mg (0.458 mmol, 65% yield) of the allylic alcohol 43c 
as a brown oil and 18.0 mg (0.0891 mmol, 13% yield) of 44c.  
 
 
1-(p-Tolyl)hex-5-en-1-one (44d). Following the general procedure H, a solution of 
5-bromo-1-pentene (1.77 mL, 14.9 mmol, 1.2 equiv) in THF (10 mL) was added drop wise 
to a stirring suspension of magnesium turnings (0.364 g, 14.9 mmol, 1.2 equiv) and one 
small crystal of iodine in THF (10 mL). After refluxing gently for 20 min, the reaction 
mixture was cooled to 0 C and treated with a solution of p-tolualdehyde (1.50 g, 12.4 
mmol, 1.0 equiv) in THF (5 mL). The reaction mixture was then stirred at rt for 1 h. The 
aqueous work-up afforded the crude alcohol (2.50 g) as a colorless oil, which was used for 
the next oxidation step without further purification.  
To a stirring solution of crude alcohol (2.47 g) in CH2Cl2 (50 mL) was added Celite 
(5.0 g) followed by PCC (5.38 g, 24.9 mmol, 2 equiv), and the reaction mixture was stirred 
at rt for 1.5 h. The reaction mixture was filtered through Celite, rinsing with several 
portions of CH2Cl2, and the filtrate was concentrated under reduced pressure. Purification 
by chromatography on a silica gel (0.8% EtOAc/hexanes) afforded 2.12 g (11.2 mmol, 90% 
yield over 2 steps) of the corresponding ketone 44d as a colorless oil. Ketone 44d: Rf = 
0.52 (10% EtOAc/hexanes); IR (neat) 1681, 1180 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  
1.78–1.85 (m, 2H), 2.13 (q, J = 7.1 Hz, 2H), 2.37 (s, 3H), 2.91 (t, J = 7.3 Hz, 2H), 4.95–
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5.05 (m, 2H), 5.80 (m, 1H), 7.21 (d, J = 7.9 Hz, 2H), 7.83 (d, J = 8.2 Hz, 2H); 
13
C NMR 
(100 MHz, CDCl3)  21.6, 23.4, 33.2, 37.6, 115.2, 128.1, 129.2, 134.6, 138.1, 143.6, 199.8; 
HRMS (ESI) m/z calcd for C13H17O [M + H]
+ 
189.1279, found 189.1284. 
 
 
(2R,3S)-rel-2-Cyclohexyl-3-(pent-4′-en-1′-yl)-3-(p-tolyl)-1,2-oxaziridine (cis-
42db) and (2S,3S)-rel-2-Cyclohexyl-3-(Pent-4′-en-1′-yl)-3-(p-tolyl)-1,2-oxaziridine 
(trans-42db). Following the general procedure G, 1-(p-tolyl)hex-5-en-1-one 44d (0.500 g, 
2.65 mmol, 1.0 equiv), cyclohexylamine 45b (0.456 mL, 3.98 mmol, 1.5 equiv), PTSA 
(25.2 mg, 0.132 mmol, 0.050 equiv), and activated 5 Å molecular sieves (3.50 g) in toluene 
(35 mL) was refluxed for 60 h, followed by oxidation with m-CPBA (0.550 g, 3.19 mmol, 
1.2 equiv) in CH2Cl2 (20 mL). Purification by chromatography on a silica gel (0.5% 
EtOAc/hexanes) afforded a mixture of oxaziridine diastereomers cis-42db and trans-42db 
and starting ketone 44d as a colorless oil (0.480 g, 1.70 mmol, 64% corrected yield; cis-
42db:trans-42db = ca. 55:45 by 
1
H NMR). Subsequent purification of the mixture of cis-
42db, trans-42db, and 44d by chromatography on a silica gel (0.2% EtOAc/hexanes) 
afforded a partial separation of the mixture of cis-42db and trans-42db as a colorless oil. A 
small amount of the mixture of cis-42db, trans-42db, and 44d was further purified by 
preparative TLC developing seven times with 2% EtOAc/hexanes. Bands corresponding to 
pure products were scraped from the plate and eluted with 100% CH2Cl2 through a short 
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bed of silica gel. Evaporation of solvents afforded analytical samples of the major cis-42db 
and the minor trans-42db diastereomers as colorless oils for characterization. Major 
diastereomer cis-42db: Rf = 0.65 (5% EtOAc/hexanes, run thrice); IR (neat) 2930, 1450 
cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.74–0.86 (m, 1H), 0.97–1.18 (m, 2H), 1.19–1.34 (m, 
3H), 1.39–1.58 (m, 4H), 1.66–1.78 (m, 3H), 1.83–1.87 (m, 1H), 1.92–2.06 (m, 2H), 2.30–
2.39 (m, 4H), 4.86–4.94 (m, 2H), 5.69 (m, 1H), 7.16 (d, J = 7.8 Hz, 2H), 7.28 (d, J = 8.1 
Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  21.4, 23.3, 24.0, 24.1, 25.8, 28.5, 31.7, 33.7, 38.1, 
60.7, 87.6, 114.8, 127.7, 128.8, 132.1, 138.4; HRMS (ESI) m/z calcd for C19H28NO [M + 
H]
+ 
286.2171, found 286.2137.  
Minor diastereomer trans-42db: Rf = 0.51 (5% EtOAc/hexanes, run thrice); IR (neat) 
2930, 1450 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.21–1.38 (m, 3H), 1.42–1.60 (m, 4H), 
1.64–1.73 (m, 2H), 1.81–1.85 (m, 2H), 1.96–2.13 (m, 4H), 2.25–2.33 (m, 4H), 2.58 (m, 
1H), 4.94–5.02 (m, 2H), 5.74 (m, 1H), 7.15 (d, J = 7.9 Hz, 2H), 7.26 (d, J = 8.1 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  21.3, 24.3, 24.6, 24.7, 25.8, 29.0, 29.2, 32.1, 33.8, 61.2, 
85.6, 115.3, 126.0, 129.1, 136.9, 138.03, 138.07; HRMS (ESI) m/z calcd for C19H28NO [M 
+ H]
+ 
286.2171, found 286.2162. 
 
 
4-Hydroxy-1-(p-tolyl)hex-5-en-1-one (43d; Table 19, entry 2). Following the 
general procedure J, CuCl (2.60 mg, 0.0263 mmol, 0.050 equiv) and rac-BINAP (16.3 mg, 
0.0263 mmol, 0.050 equiv) in THF (12 mL) was reacted with a solution of oxaziridine 
diastereomers 42db (150 mg, 0.526 mmol, 1.0 equiv; cis:trans = ca. 48:52) in THF (3 mL). 
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The reaction mixture was refluxed for 1 h. Purification by chromatography on a silica gel 
(100% CH2Cl2 to CH2Cl2:acetone:MeOH, 98.8:1.0:0.2) afforded 61.0 mg (0.299 mmol, 
57% yield) of the allylic alcohol 43d as a yellow oil. Allylic alcohol 43d: Rf = 0.32 (25% 
EtOAc/hexanes); IR (neat) 3411, 1674 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.88–1.97 (m, 
1H), 1.99–2.07 (m, 1H), 2.23 (br s, 1H), 2.39 (s, 3H), 3.09 (t, J = 7.0 Hz, 2H), 4.22–4.24 
(m, 1H), 5.12 (dt, J = 10.4, 1.3 Hz, 1H), 5.26 (dt, J = 17.2, 1.4 Hz, 1H), 5.89 (m, 1H), 7.24 
(d, J = 7.9 Hz, 2H), 7.86 (d, J = 8.2 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  21.8, 31.1, 
34.4, 72.4, 115.0, 128.4, 129.4, 134.5, 140.9, 144.0, 200.4; HRMS (ESI) m/z calcd for 
C13H17O2 [M + H]
+ 
205.1229, found 205.1200. Ketone 44d was also obtained in 27% yield 
(27.0 mg, 0.143 mmol). 
 
 
1-(4-Fluorophenyl)hex-5-en-1-one (44e).
198 
Following the general procedure H, a 
solution of 5-bromo-1-pentene (1.14 mL, 9.66 mmol, 1.2 equiv) in THF (8 mL) was added 
drop wise to a stirring suspension of magnesium turnings (235 mg, 9.66 mmol, 1.2 equiv) 
and one small crystal of iodine in THF (7 mL) under argon atmosphere. After refluxing 
gently for 1 h, the reaction mixture was cooled to 0 C and treated with a solution of 4-
fluorobenzaldehyde (1.00 g, 8.05 mmol, 1.0 equiv) in THF (5 mL). The reaction mixture 
was then stirred at rt for 2 h. The aqueous work-up afforded the crude alcohol (1.75 g) as a 
yellow oil, which was used for the next oxidation step without further purification.  
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To a stirring solution of crude alcohol (1.75 g) in CH2Cl2 (50 mL) was added PCC 
(3.47 g, 16.1 mmol, 2 equiv) and the reaction mixture was stirred at rt for 2 h. The reaction 
mixture was filtered through Celite, rinsing with several portions of CH2Cl2, and the filtrate 
was concentrated under reduced pressure. Purification by chromatography on a silica gel 
(1% EtOAc/hexanes) afforded 1.25 g (6.51 mmol, 81% yield over 2 steps) of the 
corresponding ketone 44e as a colorless oil. Ketone 44e: Rf = 0.71 (15% EtOAc/hexanes); 
IR (neat) 1684, 1229 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.78 (m, 2H), 2.06–2.12 (m, 2H), 
2.88 (t, J = 7.3 Hz, 2H), 4.91–5.01 (m, 2H), 5.75 (m, 1H), 7.01–7.07 (m, 2H), 7.89–7.94 
(m, 2H); 
13
C NMR (100 MHz, CDCl3)  23.2, 33.1, 37.5, 115.3, 115.6 (d, J = 86.9 Hz, 2C), 
130.64 (d, J = 36.7 Hz, 2C), 133.53 (d, J = 11.8 Hz, 1C), 138.0, 165.6 (d, J = 1010.8 Hz, 
1C), 196.4; HRMS (EI) m/z calcd for C12H14OF [M + H]
+ 
193.1029, found 193.1021. 
 
 
(2R,3S)-rel-2-Cyclohexyl-3-(4-fluorophenyl)-3-(pent-4′-en-1′-yl)-1,2-oxaziridine 
(cis-42eb) and (2S,3S)-rel-2-Cyclohexyl-3-(4-fluorophenyl)-3-(pent-4′-en-1′-yl)-1,2-
oxaziridine (trans-42eb). Following the general procedure G, 1-(4-fluorophenyl)hex-5-en-
1-one 44e (0.500 g, 2.60 mmol, 1.0 equiv), cyclohexylamine 45b (0.446 mL, 3.90 mmol, 
1.5 equiv), PTSA (24.7 mg, 0.130 mmol, 0.050 equiv), and activated 5 Å molecular sieves 
(3.50 g) in toluene (30 mL) was refluxed for 60 h, followed by oxidation with m-CPBA 
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(0.539 g, 3.12 mmol, 1.2 equiv) in CH2Cl2 (20 mL). Purification by chromatography on a 
silica gel (0.5–0.7% EtOAc/hexanes) afforded a mixture of oxaziridine diastereomers cis-
42eb and trans-42eb and starting ketone 44e, followed by the mixture of cis-42eb and 
trans-42eb as yellow oils (0.617 g, 2.13 mmol, 82% yield; cis-42eb:trans-42eb = ca. 2:1 by 
1
H NMR). An analytical sample of the major diastereomer cis-42eb accompanied with 12% 
of the minor diastereomer trans-42eb was obtained for characterization during this 
purification. Major diastereomer cis-42eb: Rf = 0.67 (5% EtOAc/hexanes, run thrice);
 
IR 
(neat) 2931, 1510 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.74–0.85 (m, 1H), 0.98–1.18 (m, 
2H), 1.18–1.29 (m, 3H), 1.40–1.52 (m, 3H), 1.53–1.59 (m, 1H), 1.65–1.75 (m, 3H), 1.83–
1.87 (m, 1H), 1.93–2.07 (m, 2H), 2.33 (m, 1H), 4.88–4.95 (m, 2H), 5.69 (m, 1H), 7.04–
7.10 (m, 2H), 7.36–7.41 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  23.2, 24.11, 24.18, 25.8, 
28.6, 31.7, 33.7, 38.0, 60.9, 87.2, 115.0, 115.3 (d, J = 85.8 Hz, 2C), 129.65 (d, J = 32.3 Hz, 
2C), 131.2 (d, J = 13.0 Hz, 1C), 138.3, 162.9 (d, J = 985.8 Hz, 1C); HRMS (ESI) m/z calcd 
for C18H25FNO [M + H]
+ 
290.1920, found 290.1887.  
Minor diastereomer trans-42eb: Rf = 0.62 (5% EtOAc/hexanes, run thrice);
 1
H NMR 
(400 MHz, CDCl3; diagnostic peaks only)  2.26 (m, 1H), 2.56 (m, 1H); 
13
C NMR (100 
MHz, CDCl3; diagnostic peaks only)  29.3, 61.3, 85.2. 
 
 
1-(4-Fluorophenyl)-4-hydroxyhex-5-en-1-one (43e; Table 19, entry 3). Following 
the general procedure I, [Cu(PPh3)Cl]4 (50.0 mg, 0.0346 mmol, 0.050 equiv) in THF (12 
mL) was reacted with a solution of oxaziridine diastereomers 42eb (200 mg, 0.692 mmol, 
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1.0 equiv; cis:trans = ca. 88:12) in THF (8 mL). The reaction mixture was refluxed for 1 h. 
Purification by chromatography on a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 
98.7:1.0:0.3) afforded 72.0 mg (0.346 mmol, 50% yield) of the allylic alcohol 43e as a 
colorless oil. Allylic alcohol 43e: Rf = 0.34 (25% EtOAc/hexanes); IR (neat) 3411, 1681, 
1596 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.88–1.97 (m, 1H), 2.00–2.08 (m, 1H), 2.05 (d, J 
= 4.4 Hz, 1H), 3.09 (t, J = 7.0 Hz, 2H), 4.21–4.26 (m, 1H), 5.13 (dt, J = 10.4, 1.3 Hz, 1H), 
5.26 (dt, J = 17.2, 1.4 Hz, 1H), 5.90 (m, 1H), 7.09–7.14 (m, 2H), 7.97–8.02 (m, 2H); 
13
C 
NMR (100 MHz, CDCl3)  30.9, 34.4, 72.3, 115.1, 115.8 (d, J = 87.0 Hz, 2C), 130.9 (d, J = 
36.8 Hz, 2C), 133.51 (d, J = 11.8 Hz, 1C), 140.8, 165.9 (d, J = 1012.8 Hz, 1C), 199.0; 
HRMS (ESI) m/z calcd for C12H14FO2 [M + H]
+ 
209.0978, found 209.0991. Ketone 44e 
was also obtained in 19% yield (25.0 mg, 0.130 mmol). 
 
 
Following the general procedure J, CuCl (2.56 mg, 0.0259 mmol, 0.050 equiv) and 
rac-BINAP (16.1 mg, 0.0259 mmol, 0.050 equiv) in THF (9 mL) was reacted with a 
solution of oxaziridine diastereomers 42eb (150 mg, 0.519 mmol, 1.0 equiv; cis:trans = ca. 
58:42) in THF (3 mL). The reaction mixture was refluxed for 1 h. Purification by 
chromatography on a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 98.7:1.0:0.3) 
afforded 71.0 mg (0.341 mmol, 66% yield) of 43e as a yellow oil and 17.0 mg (0.0885 
mmol, 17% yield) of 44e.  
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1-(Furan-2-yl)hex-5-en-1-one (44f).
199
 Following the general procedure H, a 
solution of 5-bromo-1-pentene (4.43 mL, 37.4 mmol, 1.2 equiv) in THF (25 mL) was added 
drop wise to a stirring suspension of magnesium turnings (0.910 g, 37.4 mmol, 1.2 equiv) 
and one small crystal of iodine in THF (25 mL). After refluxing gently for 1 h, the reaction 
mixture was cooled to 0 C and treated with a solution of 2-furaldehyde (3.00 g, 31.2 
mmol, 1.0 equiv) in THF (10 mL). The reaction mixture was then stirred at rt for 1 h. The 
aqueous work-up afforded the crude alcohol (5.24 g) as a brown oil, which was used for the 
next oxidation step without further purification.  
To a stirring solution of crude alcohol (5.24 g) in CH2Cl2 (125 mL) was added Celite 
(12.0 g) followed by PCC (13.4 g, 62.4 mmol, 2 equiv), and the reaction mixture was 
stirred at rt for 12 h. The reaction mixture was filtered through Celite, rinsing with several 
portions of CH2Cl2, and the filtrate was concentrated under reduced pressure. Purification 
by chromatography on a silica gel (3% EtOAc/hexanes) afforded 1.20 g (7.31 mmol, 23% 
yield over 2 steps) of the corresponding ketone 44f as a yellow oil. Rf = 0.47 (15% 
EtOAc/hexanes). 
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(2R,3S)-rel-2-Cyclohexyl-3-(furan-2-yl)-3-(pent-4′-en-1′-yl)-1,2-oxaziridine (cis-
42fb). Following the general procedure G, 1-(furan-2-yl)hex-5-en-1-one 44f (0.500 g, 3.04 
mmol, 1.0 equiv), cyclohexylamine 45b (0.523 mL, 4.57 mmol, 1.5 equiv), PTSA (28.9 
mg, 0.152 mmol, 0.050 equiv), and activated 5 Å molecular sieves (3.50 g) in toluene (30 
mL) was refluxed for 60 h, followed by oxidation with m-CPBA (0.631 g, 3.65 mmol, 1.2 
equiv) in CH2Cl2 (20 mL). Purification by chromatography on a silica gel (0.7–0.8% 
EtOAc/hexanes) afforded the oxaziridine cis-42fb as a yellow oil (0.100 g, 0.383 mmol, 
12% yield; sample contains some minor impurities). Oxaziridine diastereomer cis-42fb: Rf 
= 0.55 (10% EtOAc/hexanes);
 
IR (neat) 2931, 1451 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  
0.88–0.99 (m, 1H), 1.12–1.18 (m, 2H), 1.19–1.25 (m, 2H), 1.33–1.41 (m, 1H), 1.45–1.57 
(m, 3H), 1.58–1.64 (m, 1H), 1.72–1.80 (m, 2H), 1.87–1.91 (m, 1H), 2.01–2.10 (m, 3H), 
2.32 (m, 1H), 4.90–4.99 (m, 2H), 5.74 (m, 1H), 6.38–6.40 (m, 2H), 7.45 (m, 1H); 
13
C NMR 
(100 MHz, CDCl3)  23.2, 24.1, 24.4, 25.8, 28.6, 31.8, 33.7, 36.0, 61.4, 82.3, 110.3, 111.5, 
115.0, 138.4, 143.5, 149.1; HRMS (ESI) m/z calcd for C16H24NO2 [M + H]
+ 
262.1807, 
found 262.1796. 
 
 
1-(Furan-2-yl)-4-hydroxyhex-5-en-1-one (43f; Table 19, entry 4). Following the 
general procedure I, [Cu(PPh3)Cl]4 (41.5 mg, 0.0287 mmol, 0.050 equiv) in THF (10 mL) 
was reacted with a solution of oxaziridine cis-42fb (150 mg, 0.574 mmol, 1.0 equiv) in 
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THF (5 mL). The reaction mixture was refluxed for 1 h. Purification by chromatography on 
a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 98.6:1.0:0.4) afforded 53.0 mg (0.294 
mmol, 51% yield) of the allylic alcohol 43f as a pale yellow oil. Allylic alcohol 43f: Rf = 
0.11 (25% EtOAc/hexanes); IR (neat) 3420, 1666, 1467 cm
–1
; 
1
H NMR (400 MHz, CDCl3) 
 1.86–1.95 (m, 1H), 1.97–2.05 (m, 1H), 2.09 (br s, 1H), 2.97 (t, J = 7.1 Hz, 2H), 4.22 (m, 
1H), 5.12 (dt, J = 10.4, 1.3 Hz, 1H), 5.26 (dt, J = 17.2, 1.4 Hz, 1H), 5.88 (m, 1H), 6.51–
6.53 (m, 1H), 7.20 (dd, J = 3.5, 0.6 Hz, 1H), 7.57 (m, 1H); 
13
C NMR (100 MHz, CDCl3)  
30.8, 34.3, 72.3, 112.4, 115.2, 117.4, 140.7, 146.6, 152.8, 189.7; HRMS (ESI) m/z calcd for 
C10H13O3 [M + H]
+ 
181.0864, found 181.0867. Ketone 44f was also obtained in 15% yield 
(14.0 mg, 0.0853 mmol). 
 
 
1-(Naphthalen-2-yl)hex-5-en-1-one (44g). A solution of 2-acetonaphthone (5.00 g, 
29.3 mmol, 1.0 equiv), N,N-dimethylhydrazine (5.29 g, 88.1 mmol, 3.0 equiv), and PTSA 
(279 mg, 1.46 mmol, 0.050 equiv) in benzene (35 mL) was refluxed for 18 h under nitrogen 
atmosphere with removal of water by a Dean–Stark apparatus. The reaction mixture was 
concentrated under reduced pressure and the residue was cooled to 0 C. The yellow solid 
obtained was triturated with hexanes and filtered, washed with hexanes and dried under 
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vacuum to afford the corresponding hydrazone as a creamish-yellow solid (mp 47–50 C) 
in 99% yield (6.15 g, 29.0 mmol).  
To a cooled 1.0 M LDA solution (23.3 mL, 23.3 mmol, 1.1 equiv) in THF at 0 C 
under nitrogen atmosphere was added the solution of hydrazone (4.50 g, 21.2 mmol, 1.0 
equiv) in THF (35 mL) slowly over 25 min and was allowed to stir at 0 C for 5 h. The 
reaction mixture was then cooled to –78 C and a solution of 4-bromo-1-butene (3.43 g, 
25.4 mmol, 1.2 equiv) in THF (10 mL) was added slowly over 20 min. The reaction was 
warmed to rt and stirred for 36 h. The reaction mixture was concentrated under reduced 
pressure and the residue was diluted with ether (20 mL) and then treated with an ice-cold 
solution of dilute H2SO4 (20 mL) for 30 min to hydrolyze the hydrazone. The resulting 
solution was diluted with water and extracted with ether (2  20 mL) and the combined 
organic extracts were washed with water (2  20 mL) and brine (20 mL), dried over 
Na2SO4, and concentrated under reduced pressure. Purification by chromatography on a 
silica gel (4% EtOAc/hexanes) afforded the ketone 44g as a cream-colored solid in 65% 
yield (3.10 g, 13.8 mmol; 95% brsm). Ketone 44g: Rf = 0.74 (10% EtOAc/hexanes, run 
twice);
 
mp 36–37 C; IR (neat) 1678, 1624 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.91(p, J = 
7.3 Hz, 2H), 2.20 (q, J = 7.0 Hz, 2H), 3.08 (t, J = 7.3 Hz, 2H), 5.03 (d, J = 10.1 Hz, 1H), 
5.09 (d, J = 17.1 Hz, 1H), 5.86 (m, 1H), 7.51–7.59 (m, 2H), 7.83–7.87 (m, 2H), 7.94 (d, J = 
7.9 Hz, 1H), 8.02 (d, J = 8.6 Hz, 1H), 8.44 (s, 1H); 
13
C NMR (100 MHz, CDCl3)  23.5, 
33.3, 37.8, 115.4, 124.0, 126.8, 127.8, 128.42, 128.47, 129.62, 129.65, 132.6, 134.4, 135.6, 
138.1, 200.1; HRMS (ESI) m/z calcd for C16H17O [M + H]
+ 
225.1279, found 225.1263. 
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(2R,3S)-rel-2-Cyclohexyl-3-(naphthalen-2-yl)-3-(pent-4′-en-1′-yl)-1,2-oxaziridine 
(cis-42gb) and (2S,3S)-rel-2-Cyclohexyl-3-(naphthalen-2-yl)-3-(pent-4′-en-1′-yl)-1,2-
oxaziridine (trans-42gb). Following the general procedure G, 1-(naphthalen-2-yl)hex-5-
en-1-one 44g (0.500 g, 2.23 mmol, 1.0 equiv), cyclohexylamine 45b (0.382 mL, 3.34 
mmol, 1.5 equiv), PTSA (21.2 mg, 0.115 mmol, 0.050 equiv), and activated 5 Å molecular 
sieves (3.50 g) in toluene (25 mL) was refluxed for 60 h, followed by oxidation with m-
CPBA (0.461 g, 2.67 mmol, 1.2 equiv) in CH2Cl2 (20 mL). Purification by chromatography 
on a silica gel (0.6% EtOAc/hexanes) afforded a mixture of oxaziridine diastereomers cis-
42gb and trans-42gb and starting ketone 44g as a colorless oil. Subsequent purification by 
chromatography on a silica gel (0.5–1% EtOAc/hexanes) afforded a mixture of cis-42gb 
and trans-42gb, which were separated into 2 fractions containing enrichment from each 
diastereomer (0.641 g, 1.99 mmol, 89% yield; cis-42gb:trans-42gb = ca. 1:1). A pure 
sample of the first cis-42gb and the second diastereomer trans-42gb for characterization 
was obtained during this purification. First diastereomer cis-42gb: Rf = 0.51 (5% 
EtOAc/hexanes, run thrice);
 
IR (neat) 1449 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.66–0.77 
(m, 1H), 0.94–1.17 (m, 2H), 1.21–1.33 (m, 2H), 1.35–1.39 (m, 1H), 1.41–1.57 (m, 4H), 
1.67–1.71 (m, 1H), 1.76–1.84 (m, 2H), 1.88–1.92 (m, 1H), 1.95–2.08 (m, 2H), 2.48 (m, 
1H), 4.87–4.95 (m, 2H), 5.69 (m, 1H), 7.50–7.56 (m, 3H), 7.85–7.90 (m, 4H); 
13
C NMR 
(100 MHz, CDCl3)  23.3, 24.0, 24.1, 25.8, 28.7, 31.8, 33.8, 38.1, 60.9, 88.0, 115.0, 124.9, 
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126.72, 126.78, 127.6, 127.9, 128.1, 128.5, 132.80, 132.85, 133.4, 138.4; HRMS (ESI) m/z 
calcd for C22H28NO [M + H]
+ 
322.2171, found 322.2155.  
Second diastereomer trans-42gb: Rf = 0.51 (5% EtOAc/hexanes, run thrice);
 
IR (neat) 
1450 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.21–1.45 (m, 3H), 1.46–1.65 (m, 4H), 1.69–
1.72 (m, 1H), 1.79–1.89 (m, 3H), 2.04–2.19 (m, 4H), 2.44 (m, 1H), 2.67 (m, 1H), 4.95–
5.03 (m, 2H), 5.73 (m, 1H), 7.46–7.51 (m, 3H), 7.82–7.87 (m, 4H); 
13
C NMR (100 MHz, 
CDCl3)  24.3, 24.6, 24.8, 25.9, 29.0, 29.3, 32.1, 33.8, 61.3, 85.9, 115.4, 123.8, 125.4, 
126.3, 127.8, 128.37, 128.39, 133.2, 133.3, 137.3, 137.9; HRMS (ESI) m/z calcd for 
C22H28NO [M + H]
+ 
322.2171, found 322.2143. 
 
 
4-Hydroxy-1-(naphthalen-2-yl)hex-5-en-1-one (43g; Table 19, entries 5 and 6). 
Following the general procedure I, [Cu(PPh3)Cl]4 (33.7 mg, 0.0233 mmol, 0.045 equiv) in 
THF (10 mL) was reacted with a solution of oxaziridine diastereomers 42gb (164 mg, 
0.510 mmol, 1.0 equiv; cis:trans = ca. 90:10) in THF (5 mL). The reaction mixture was 
refluxed for 3 h. Purification by chromatography on a silica gel (100% CH2Cl2 to 
CH2Cl2:acetone:MeOH, 99.4:0.5:0.1) afforded 70.0 mg (0.291 mmol, 57% yield) of the 
allylic alcohol 43g as a creamish-orange solid. Allylic alcohol 43g: Rf = 0.15 (20% 
EtOAc/hexanes); mp 59–61 C; IR (neat) 3410, 1673 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  
1.96–2.05 (m, 1H), 2.07–2.15 (m, 1H), 2.21 (br s, 1H), 3.26 (t, J = 7.0 Hz, 2H), 4.29 (br s, 
1H), 5.15 (d, J = 10.4 Hz, 1H), 5.30 (d, J = 17.2 Hz, 1H), 5.94 (m, 1H), 7.52–7.61 (m, 2H), 
7.85–7.88 (m, 2H), 7.95 (d, J = 7.9 Hz, 1H), 8.03 (dd, J = 8.6, 1.5 Hz, 1H), 8.49 (s, 1H); 
13
C NMR (100 MHz, CDCl3)  31.1, 34.5, 72.4, 115.1, 124.0, 126.9, 127.9, 128.64, 128.66, 
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129.7, 129.9, 132.7, 134.4, 135.8, 140.9, 200.6; HRMS (ESI) m/z calcd for C16H17O2 [M + 
H]
+ 
241.1229, found 241.1224. Ketone 44g was also obtained in 19% yield (22.0 mg, 0.982 
mmol). 
 
 
Following the general procedure J, CuCl (1.46 mg, 0.0147 mmol, 0.050 equiv) and 
rac-BINAP (9.20 mg, 0.0147 mmol, 0.050 equiv) in THF (8 mL) was reacted with a 
solution of oxaziridine diastereomers 42gb (95.0 mg, 0.29 mmol, 1.0 equiv; cis:trans = ca. 
90:10) in THF (2 mL). The reaction mixture was refluxed for 1 h. Purification by 
chromatography on a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 98.7:1.0:0.3) 
afforded 33.0 mg (0.137 mmol, 46% yield; 57% brsm) of 43g as a yellow oil and 7.00 mg 
(0.0312 mmol, 11% yield) of 44g. 
 
 
Following the general procedure I, [Cu(PPh3)Cl]4 (33.7 mg, 0.0233 mmol, 0.042 
equiv) in THF (10 mL) was reacted with a solution of oxaziridine diastereomers 42gb (178 
mg, 0.553 mmol, 1.0 equiv; cis:trans = ca. 16:84, accompanied with 2.5% of 44g) in THF 
(5 mL). The reaction mixture was refluxed for 3 h. Purification by chromatography on a 
silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 99.2:0.5:0.3) afforded 55.0 mg (0.229 
mmol, 41% yield) of 43g as an orange oil and 25.0 mg (0.111 mmol, 20% corrected yield) 
of 44g. 
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Following the general procedure J, CuCl (1.30 mg, 0.0132 mmol, 0.050 equiv) and 
rac-BINAP (8.22 mg, 0.0132 mmol, 0.050 equiv) in THF (8 mL) was reacted with a 
solution of oxaziridine diastereomers 42gb (85.0 mg, 0.264 mmol, 1.0 equiv; cis:trans = ca. 
16:84, accompanied with 2.5% of 44g) in THF (2 mL). The reaction mixture was refluxed 
for 1 h. Purification by chromatography on a silica gel (100% CH2Cl2 to 
CH2Cl2:acetone:MeOH, 98.7:1.0:0.3) afforded 34.0 mg (0.141 mmol, 53% yield; 73% 
brsm) of 43g as a yellow oil and ca. 4.0 mg (ca. 6% corrected yield) of 44g.  
 
 
(E)-1,6-Diphenylhex-5-en-1-one (44h). To a solution of Grubbs II catalyst
200
 (0.195 
g, 0.229 mmol, 0.04 equiv) in CH2Cl2 (20 mL) at rt under argon atmosphere was added a 
solution containing the mixture of 1-phenylhex-5-en-1-one 44a (1.00 g, 5.74 mmol, 1.0 
equiv) and styrene (1.97 mL, 17.2 mmol, 3.0 equiv) in CH2Cl2 (5 mL), and the reaction 
mixture was stirred at 40 C for 4 h. The reaction mixture was concentrated under reduced 
pressure. Initial purification of crude residue by chromatography on a silica gel (0.5–0.6% 
EtOAc/hexanes) afforded a mixture of desired product 44h and (E)-1,5-diphenylpent-4-en-
1-one byproduct 44ha
201
 as a white solid (0.770 g, 3.08 mmol, 54% corrected yield for 44h 
by 
1
H NMR). Subsequent purification by chromatography on a silica gel (0.5% 
EtOAc/hexanes) followed by recrystallization from hexanes afforded a partial separation of 
the desired product 44h as a white crystals. Ketone 44h: Rf = 0.38 (5% EtOAc/hexanes); 
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mp 52–54 C; IR (neat) 1682, 1196 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.98 (m, 2H), 2.35 
(q, J = 6.9 Hz, 2H), 3.03 (t, J = 7.2 Hz, 2H), 6.23–6.30 (m, 1H), 6.46 (d, J = 15.8 Hz, 1H), 
7.24 (t, J = 7.1 Hz, 1H), 7.33 (t, J = 7.5 Hz, 2H), 7.39 (d, J = 7.3 Hz, 2H), 7.47 (t, J = 7.5 
Hz, 2H), 7.57 (t, J = 7.3 Hz, 1H), 8.00 (d, J = 7.2 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  
23.7, 32.4, 37.7, 126.0, 127.0, 128.0, 128.54, 128.59, 129.9, 130.7, 132.9, 137.0, 137.6, 
200.0; HRMS (ESI) m/z calcd for C18H19O [M + H]
+ 
251.1436, found 251.1424. 
 
 
(2R,3S,E)-rel-2-Cyclohexyl-3-phenyl-3-(5′-phenylpent-4′-en-1′-yl)-1,2-oxaziridine 
(cis-42hb) and (2S,3S,E)-rel-2-Cyclohexyl-3-phenyl-3-(5′-phenylpent-4′-en-1′-yl)-1,2-
oxaziridine (trans-42hb). Following the general procedure G, (E)-1,6-diphenylhex-5-en-1-
one 44h (0.400 g, 1.60 mmol, 1.0 equiv), cyclohexylamine 45b (0.274 mL, 2.40 mmol, 1.5 
equiv), PTSA (15.2 mg, 0.0800 mmol, 0.050 equiv), and activated 5 Å molecular sieves 
(3.0 g) in toluene (30 mL) was refluxed for 60 h, followed by oxidation with m-CPBA 
(0.331 g, 1.92 mmol, 1.2 equiv) in CH2Cl2 (15 mL). Purification by chromatography on a 
silica gel (0.5–0.6% EtOAc/hexanes) afforded a mixture of major cis-42hb and minor 
trans-42hb diastereomers as a colorless oil (0.500 g, 1.44 mmol, 90% yield; cis-
42hb:trans-42hb = ca. 60:40 by 
1
H NMR). Subsequent purification of a small amount of 
the mixture of cis-42hb and trans-42hb by preparative TLC developing 13 times with 2% 
EtOAc/hexanes afforded a single band. The top and bottom portions of the band were 
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scraped from the plate and eluted separately with 100% CH2Cl2 through a short bed of silica 
gel. Evaporation of solvents for the top portion of the band afforded an analytical sample of 
cis-42hb for characterization and the bottom portion of the band afforded the mixture of 
cis-42hb and trans-42hb. Major diastereomer cis-42hb: Rf = 0.46 (5% EtOAc/hexanes, run 
twice); IR (neat) 2930, 2855, 1447 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.73–0.84 (m, 1H), 
0.98–1.19 (m, 2H), 1.19–1.29 (m, 1H), 1.31–1.39 (m, 2H), 1.43–1.59 (m, 4H), 1.68–1.83 
(m, 3H), 1.85–1.89 (m, 1H), 2.12–2.22 (m, 2H), 2.42 (m, 1H), 6.07–6.14 (m, 1H), 6.30 (d, 
J = 15.8 Hz, 1H), 7.15–7.19 (m, 1H), 7.24–7.30 (m, 4H), 7.37–7.43 (m, 5H); 
13
C NMR 
(100 MHz, CDCl3)  23.7, 24.1, 24.2, 25.8, 28.6, 31.8, 33.0, 38.1, 61.0, 87.7, 126.1, 127.0, 
127.8, 128.2, 128.6, 128.8, 130.42, 130.44, 135.2, 137.8; HRMS (ESI) m/z calcd for 
C24H30NO [M + H]
+ 
348.2327, found 348.2357.  
From a mixture of cis-42hb and trans-42hb: Minor diastereomer trans-42hb: Rf = 
0.40 (5% EtOAc/hexanes, run twice);
 1
H NMR (400 MHz, CDCl3; diagnostic peaks only)  
2.36 (m, 1H), 2.61 (m, 1H); 
13
C NMR (100 MHz, CDCl3; diagnostic peaks only)  29.1, 
61.2, 85.8, 137.7, 139.9. 
 
 
(E)-4-Hydroxy-1,6-diphenylhex-5-en-1-one (43h; Table 19, entry 8). Following 
the general procedure I, [Cu(PPh3)Cl]4 (31.2 mg, 0.0216 mmol, 0.050 equiv) in THF (10 
mL) was reacted with a solution of oxaziridine diastereomers 42hb (150 mg, 0.432 mmol, 
1.0 equiv; cis:trans = 60:40) in THF (5 mL). Reaction mixture was refluxed for 1 h. 
Purification by chromatography on a silica gel (0–1% acetone/CH2Cl2) afforded 83.0 mg 
(0.312 mmol, 72% yield) of the allylic alcohol 43h as a creamish solid. Allylic alcohol 43h: 
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Rf = 0.32 (25% EtOAc/hexanes); mp 59–61 C; IR (neat) 3400, 1677 cm
–1
; 
1
H NMR (400 
MHz, CDCl3)  2.01–2.18 (m, 2H), 2.58 (d, J = 4.1 Hz, 1H), 3.16 (t, J = 7.0 Hz, 2H), 4.42 
(m, 1H), 6.25 (dd, J = 15.9, 6.3 Hz, 1H), 6.61 (d, J = 15.8 Hz, 1H), 7.21–7.26 (m, 1H), 
7.29–7.32 (m, 2H), 7.36–7.38 (m, 2H), 7.42–7.46 (m, 2H), 7.53–7.57 (m, 1H), 7.96–7.98 
(m, 2H); 
13
C NMR (100 MHz, CDCl3)  31.4, 34.5, 72.1, 126.6, 127.8, 128.2, 128.7, 130.5, 
132.1, 133.2, 136.7, 136.9, 200.7; HRMS (ESI) m/z calcd for C18H19O2 [M + H]
+ 
267.1385, 
found 267.1392. Ketone 44h was also obtained in 19% yield (21.0 mg, 0.0840 mmol). 
 
 
Following the general procedure J, CuCl (2.13 mg, 0.0216 mmol, 0.050 equiv) and 
rac-BINAP (13.4 mg, 0.0216 mmol, 0.050 equiv) in THF (12 mL) was reacted with a 
solution of oxaziridine diastereomers 42hb (150 mg, 0.432 mmol, 1.0 equiv; cis:trans = 
60:40) in THF (3 mL). The reaction mixture was refluxed for 1 h. Purification by 
chromatography on a silica gel (0–1% acetone/CH2Cl2) afforded 79.0 mg (0.296 mmol, 
69% yield) of 43h as a yellow solid. Ketone 44h was also obtained along with unidentified 
impurities. 
 
 
1,4-Diphenylbutan-1-one (44i). To a cooled 1.0 M LDA solution (15.6 mL, 15.6 
mmol, 1.1 equiv) in THF at 0 C under nitrogen atmosphere was added a solution of 
acetophenone N,N-dimethylhydrazone (2.30 g, 14.1 mmol, 1.0 equiv) in THF (15 mL) 
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slowly over 15 min and was allowed to stir at 0 C for 5 h. The reaction mixture was then 
cooled to –78 C and a solution of (2-bromoethyl)benzene (2.49 mL, 18.4 mmol, 1.3 equiv) 
in THF (5 mL) was added slowly over 10 min. The reaction was warmed to rt and stirred 
for 16 h. The reaction mixture was concentrated under reduced pressure and the residue 
was diluted with ether (15 mL), and then treated with an ice-cold solution of dilute H2SO4 
(15 mL) for 30 min to hydrolyze the hydrazone. The resulting solution was diluted with 
water and extracted with ether (2  15 mL), and the combined organic extracts were 
washed with water (2  15 mL) and brine (15 mL), dried over Na2SO4, and concentrated 
under reduced pressure. Purification by chromatography on a silica gel (0.25% 
EtOAc/hexanes) afforded the ketone 44i in 71% yield (2.26 g, 10.0 mmol) as an off-white 
crystal. Ketone 44i: Rf = 0.60 (5% EtOAc/hexanes, run twice); mp 54–56 C; IR (neat) 
1682 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  2.07–2.14 (m, 2H), 2.74 (t, J = 7.5 Hz, 2H), 2.99 
(t, J = 7.3 Hz, 2H), 7.19–7.24 (m, 3H), 7.29–7.33 (m, 2H), 7.43–7.48 (m, 2H), 7.53–7.58 
(m, 1H), 7.93–7.96 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  25.8, 35.3, 37.8, 126.1, 128.1, 
128.5, 128.6, 128.7, 133.1, 137.1, 141.8, 200.2; HRMS (ESI) m/z calcd for C16H16O [M]
+ 
224.1201, found 224.1195. 
 
 
(2R,3S)-rel-2-Cyclohexyl-3-phenyl-3-(3′-phenylpropyl)-1,2-oxaziridine (cis-47) 
and (2S,3S)-rel-2-Cyclohexyl-3-phenyl-3-(3′-phenylpropyl)-1,2-oxaziridine (trans-47). 
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Following the general procedure G, 1,4-diphenylbutan-1-one 44i (0.500 g, 2.23 mmol, 1.0 
equiv), cyclohexylamine 45b (0.382 mL, 3.34 mmol, 1.5 equiv), PTSA (21.2 mg, 0.111 
mmol, 0.050 equiv), and activated 5 Å molecular sieves (3.50 g) in toluene (30 mL) was 
refluxed for 60 h, followed by oxidation with m-CPBA (0.462 g, 2.67 mmol, 1.2 equiv) in 
CH2Cl2 (20 mL). Purification by chromatography on a silica gel (0.6% EtOAc/hexanes) 
afforded a mixture of oxaziridine diastereomers cis-47 and trans-47 as a colorless oil (0.610 
g, 1.90 mmol, 85% yield; cis-47:trans-47 = ca. 55:45). For a mixture of cis-47 and trans-
47: IR (neat) 2930, 1448 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.75–0.86 (m, 1H), 1.00–
1.21 (m, 2H), 1.21–1.36 (m, 5H), 1.46–1.62 (m, 6H), 1.65–1.78 (m, 7H), 1.79–1.90 (m, 
4H), 1.97–2.00 (m, 1H), 2.04–2.11 (m, 1H), 2.31 (m, 1H), 2.39 (m, 1H), 2.50–2.57 (m, 
2H), 2.59–2.65 (m, 2H), 2.66–2.74 (m, 1H), 7.08–7.12 (m, 4H), 7.14–7.20 (m, 2H), 7.21–
7.26 (m, 4H), 7.27–7.33 (m, 2H), 7.33–7.42 (m, 8H); 
13
C NMR (100 MHz, CDCl3)  24.13, 
24.19, 24.3, 24.6, 25.7, 25.93, 25.95, 27.1, 28.7, 29.2, 29.4, 31.8, 32.1, 35.93, 35.98, 38.2, 
60.9, 61.2, 85.7, 87.7, 125.9, 126.1, 126.2, 127.8, 128.2, 128.3, 128.4, 128.52, 128.55, 
128.58, 128.7, 135.4, 140.0, 141.7, 142.2; HRMS (ESI) m/z calcd for C22H28NO [M + H]
+ 
322.2171, found 322.2173.  
Major diastereomer cis-47: Rf = 0.43 (5% EtOAc/hexanes, run twice);
 1
H NMR (400 
MHz, CDCl3; diagnostic peaks in the mixture)  2.39 (m, 1H); 
13
C NMR (100 MHz, 
CDCl3; diagnostic peaks in the mixture)  38.2, 60.9, 87.7.  
Minor diastereomer trans-47: Rf = 0.40 (5% EtOAc/hexanes, run twice);
 1
H NMR 
(400 MHz, CDCl3; diagnostic peaks in the mixture)  2.31 (m, 1H); 
13
C NMR (100 MHz, 
CDCl3; diagnostic peaks in the mixture)  29.4, 61.2, 85.7. 
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4-Hydroxy-1,4-diphenylbutan-1-one (48; Scheme 47).
202
 Following the general 
procedure I, [Cu(PPh3)Cl]4 (33.7 mg, 0.0233 mmol, 0.050 equiv) in THF (10 mL) was 
reacted with a solution of oxaziridine diastereomers 47 (150 mg, 0.467 mmol, 1.0 equiv; 
cis:trans = ca. 55:45) in THF (5 mL). The reaction mixture was refluxed for 3 h. 
Purification by chromatography on a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 
99.3:0.5:0.2) afforded 57.0 mg (0.237 mmol, 51% yield) of the benzylic alcohol 48 as a 
white solid. Benzylic alcohol 48: Rf = 0.15 (15% EtOAc/hexanes); mp 94–96 C; IR (neat) 
3420, 1677 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  2.14–2.27 (m, 2H), 2.49 (d, J = 3.6 Hz, 
1H), 3.10 (t, J = 6.9 Hz, 2H), 4.83 (m, 1H), 7.26–7.29 (m, 1H), 7.32–7.39 (m, 4H), 7.42–
7.46 (m, 2H), 7.53–7.56 (m, 1H), 7.92–7.95 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  33.3, 
34.9, 73.8, 125.9, 127.7, 128.3, 128.71, 128.76, 133.2, 137.1, 144.6, 200.6; HRMS (ESI) 
m/z calcd for C16H17O2 [M + H]
+ 
241.1229, found 241.1220. Ketone 44i was also obtained 
in 21% yield (22.0 mg, 0.0982 mmol). 
 
 
Following the general procedure J, CuCl (1.54 mg, 0.0155 mmol, 0.050 equiv) and 
rac-BINAP (9.69 mg, 0.0155 mmol, 0.050 equiv) in THF (9 mL) was reacted with a 
solution of oxaziridine diastereomers 47 (100 mg, 0.311 mmol, 1.0 equiv; cis:trans = ca. 
55:45) in THF (3 mL). The reaction mixture was refluxed for 3 h. Purification by 
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chromatography on a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 98.8:1.0:0.2) 
afforded 33.0 mg (0.137 mmol, 44% yield) of 48 as a creamish-yellow solid and 11.0 mg 
(0.0491 mmol, 16% yield) of 44i. 
 
 
(2R,3S)-rel-2-Cyclohexyl-3-(hex-4′-yn-1′-yl)-3-phenyl-1,2-oxaziridine (cis-49) 
and (2S,3S)-rel-2-Cyclohexyl-3-(hex-4′-yn-1′-yl)-3-phenyl-1,2-oxaziridine (trans-49). 
Following the general procedure G, 1-phenylhept-5-yn-1-one 44j
203
 (0.500 g, 2.68 mmol, 
1.0 equiv), cyclohexylamine 45b (0.461 mL, 4.03 mmol, 1.5 equiv), PTSA (25.5 mg, 0.134 
mmol, 0.050 equiv), and activated 5 Å molecular sieves (3.50 g) in toluene (30 mL) was 
refluxed for 60 h, followed by oxidation with m-CPBA (0.556 g, 3.22 mmol, 1.2 equiv) in 
CH2Cl2 (20 mL). Purification by chromatography on a silica gel (0.6–0.8% 
EtOAc/hexanes) afforded a mixture of oxaziridine diastereomers cis-49 and trans-49 as a 
colorless oil (0.640 g, 2.27 mmol, 85% yield; cis-49:trans-49 = ca. 54:46 by 
1
H NMR). An 
analytical sample of the major diastereomer cis-49 accompanied with 8% of the minor 
diastereomer trans-49 was obtained for characterization during this purification. Major 
diastereomer cis-49: Rf = 0.59 (5% EtOAc/hexanes, run thrice);
 
IR (neat) 2931, 1447 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.72–0.83 (m, 1H), 0.96–1.17 (m, 2H), 1.18–1.27 (m, 1H), 
1.29–1.40 (m, 2H), 1.42–1.49 (m, 2H), 1.50–1.58 (m, 2H), 1.66–1.75 (m, 2H), 1.71 (t, J = 
298 
 
2.5 Hz, 3H), 1.80–1.88 (m, 2H), 2.07 (m, 2H), 2.41 (m, 1H), 7.34–7.41 (m, 5H); 
13
C NMR 
(100 MHz, CDCl3)  3.6, 18.9, 23.5, 24.0, 24.1, 25.8, 28.6, 31.7, 37.7, 60.9, 75.9, 78.7, 
87.4, 127.8, 128.2, 128.7, 135.2; HRMS (ESI) m/z calcd for C19H26NO [M + H]
+ 
284.2014, 
found 284.2032.  
Minor diastereomer trans-49: Rf = 0.47 (5% EtOAc/hexanes, run thrice);
 1
H NMR 
(400 MHz, CDCl3; diagnostic peaks only)  2.61 (m, 1H); 
13
C NMR (100 MHz, CDCl3; 
diagnostic peaks only)  29.3, 61.2, 76.3, 78.3, 85.4. 
 
 
4-Hydroxy-1-phenylhept-5-yn-1-one (50; Scheme 47). Following the general 
procedure I, [Cu(PPh3)Cl]4 (51.0 mg, 0.0353 mmol, 0.050 equiv) in THF (12 mL) was 
reacted with a solution of oxaziridine diastereomers 49 (200 mg, 0.706 mmol, 1.0 equiv; 
cis:trans = ca. 74:26) in THF (8 mL). The reaction mixture was refluxed for 1 h. 
Purification by chromatography on a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 
98.7:1.0:0.3) afforded 106 mg (0.524 mmol, 74% yield) of the propargylic alcohol 50 as a 
white crystals. Propargylic alcohol 50: Rf = 0.26 (25% EtOAc/hexanes); mp 78–80 C; IR 
(neat) 3405, 2232, 1678 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.82 (d, J = 2.1 Hz, 3H), 
2.06–2.19 (m, 2H), 2.46 (d, J = 5.2 Hz, 1H), 3.14–3.28 (m, 2H), 4.48–4.54 (m, 1H), 7.43–
7.47 (m, 2H), 7.53–7.58 (m, 1H), 7.97–8.00 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  3.7, 
32.1, 34.4, 62.0, 80.0, 81.7, 128.3, 128.7, 133.3, 137.0, 200.3; HRMS (ESI) m/z calcd for 
C13H15O2 [M + H]
+ 
203.1072, found 203.1051. Ketone 44j was also obtained in 25% yield 
(33.0 mg, 0.177 mmol). 
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Following the general procedure J, CuCl (2.36 mg, 0.0238 mmol, 0.050 equiv) and 
rac-BINAP (14.8 mg, 0.0238 mmol, 0.050 equiv) in THF (9 mL) was reacted with a 
solution of oxaziridine diastereomers 49 (0.135 g, 0.477 mmol, 1.0 equiv; cis:trans = ca. 
74:26) in THF (3 mL). The reaction mixture was refluxed for 1 h. Purification by 
chromatography on a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 98.7:1.0:0.3) 
afforded 72.0 mg (0.356 mmol, 75% yield) of 50 as a pale yellow crystals and 7.00 mg 
(0.0376 mmol, 8% yield) of 44j. 
 
 
4-Methyl-1-phenylpentan-1-one (44k).
204
 To a cooled 1.0 M LDA solution (6.45 
mL, 6.45 mmol, 1.1 equiv) in THF at 0 C under nitrogen atmosphere was added a solution 
of acetophenone N,N-dimethylhydrazone (0.950 g, 5.86 mmol, 1.0 equiv) in THF (10 mL) 
slowly over 15 min and was allowed to stir at 0 C for 5 h. The reaction mixture was then 
cooled to –78 C and a solution of 1-bromo-2-methylpropane (0.764 mL, 7.03 mmol, 1.2 
equiv) in THF (5 mL) was added slowly over 10 min. The reaction was warmed to rt and 
stirred for 16 h. The reaction mixture was concentrated under reduced pressure and the 
residue was diluted with ether (15 mL), and then treated with an ice-cold solution of dilute 
H2SO4 (10 mL) for 30 min to hydrolyze the hydrazone. The resulting solution was diluted 
with water and extracted with ether (2  15 mL), and the combined organic extracts were 
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washed with water (2  15 mL) and brine (15 mL), dried over Na2SO4, and concentrated 
under reduced pressure. Purification by chromatography on a silica gel (0.5% 
EtOAc/hexanes) afforded the ketone 44k as a colorless oil in 71% yield (0.730 g, 4.14 
mmol). Rf = 0.74 (5% EtOAc/hexanes, run twice).  
 
 
(2R,3S)-rel-2-Cyclohexyl-3-isopentyl-3-phenyl-1,2-oxaziridine (cis-51) and 
(2S,3S)-rel-2-Cyclohexyl-3-isopentyl-3-phenyl-1,2-oxaziridine (trans-51). Following the 
general procedure G, 4-methyl-1-phenylpentan-1-one 44k (0.500 g, 2.84 mmol, 1.0 equiv), 
cyclohexylamine 45b (0.487 mL, 4.26 mmol, 1.5 equiv), PTSA (27.0 mg, 0.142 mmol, 
0.050 equiv), and activated 5 Å molecular sieves (3.50 g) in toluene (30 mL) was refluxed 
for 60 h, followed by oxidation with m-CPBA (0.588 g, 3.40 mmol, 1.2 equiv) in CH2Cl2 
(20 mL) for 45 min. The reaction was warmed to rt before quenching with saturated 
Na2S2O3. Purification by chromatography on a silica gel (0.5% EtOAc/hexanes) afforded a 
partial separation of the major diastereomer cis-51 containing ca. 22% of starting ketone 
44k, followed by the mixture of major and the minor trans-51 diastereomers containing 
10% of 44k as a colorless oil (ca. 0.410 g, 1.50 mmol, 53% corrected yield; cis-51:trans-51 
= ca. 87:13 by 
1
H NMR). Major diastereomer cis-51 containing ca. 22% of 44k was used 
for the subsequent reaction. Major diastereomer (cis-51, contains ca. 22% of 44k): Rf = 
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0.75 (5% EtOAc/hexanes, run twice); IR (neat) 2930, 1448 cm
–1
; 
1
H NMR (400 MHz, 
CDCl3)  0.71–0.79 (m, 1H), 0.79 (d, J = 6.6 Hz, 6H), 0.96–1.01 (m, 1H), 1.01–1.17 (m, 
2H), 1.20–1.29 (m, 2H), 1.30–1.35 (m, 1H), 1.42–1.51 (m, 3H), 1.52–1.57 (m, 2H), 1.66–
1.75 (m, 3H), 1.84–1.88 (m, 1H), 2.35 (m, 1H), 7.33–7.42 (m, 5H); 
13
C NMR (100 MHz, 
CDCl3)  22.4, 22.6, 24.11, 24.16, 25.8, 28.1, 28.6, 31.7, 32.7, 36.6, 60.9, 88.0, 127.8, 
128.1, 128.6, 135.3; HRMS (ESI) m/z calcd for C18H28NO [M + H]
+ 
274.2171, found 
274.2163.  
From a mixture of cis-51 and trans-51 containing 10% of 44k: Minor diastereomer 
trans-51: Rf = 0.75 (5% EtOAc/hexanes, run twice);
 1
H NMR (400 MHz, CDCl3; diagnostic 
peaks only)  2.26 (m, 1H), 2.59 (m, 1H); 13C NMR (100 MHz, CDCl3; diagnostic peaks 
only)  61.2, 86.0. 
 
 
4-Hydroxy-4-methyl-1-phenylpentan-1-one (52a)
205
 and 4,4-Dimethyl-3,4-
dihydronaphthalen-1(2H)-one (52b; Scheme 47).
188
 Following the general procedure I, 
[Cu(PPh3)Cl]4 (23.7 mg, 0.0164 mmol, 0.050 equiv) in THF (7 mL) was reacted with a 
solution of oxaziridine cis-51 (90.0 mg, 0.329 mmol, 1.0 equiv; containing ca. 22% of 
ketone 44k) in THF (3 mL). The reaction mixture was refluxed for 2 h. Purification by 
chromatography on a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 98.7:1.0:0.3) 
afforded ca. 19.0 mg (0.108 mmol, ca. 33% corrected yield) of 44k, 8.00 mg (0.0459 mmol, 
14% yield) of compound 52b as a pale yellow oil (Rf = 0.71 (25% EtOAc/hexanes)), and 
12.0 mg of tertiary alcohol 52a containing an unidentified impurities. Alcohol 52a 
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containing the impurities was further purified by chromatography on a silica gel 
(CH2Cl2:Et3N, 99.9:0.1% to CH2Cl2:acetone:Et3N, 97.4:2.5:0.1) to afford 10.0 mg (0.0520 
mmol, 16% yield) of 52a as a pale yellow oil (Rf = 0.18 (25% EtOAc/hexanes)).  
 
 
1-Phenylhept-6-en-1-one (44l).
196
 To a cooled 1.0 M LDA solution (13.5 mL, 13.5 
mmol, 1.1 equiv) in THF at 0 C under nitrogen atmosphere was added the solution of 
hydrazone (2.00 g, 12.3 mmol, 1.0 equiv) in THF (15 mL) slowly over 15 min and was 
allowed to stir at 0 C for 5 h. The reaction mixture was then cooled to –78 C and a 
solution of 5-bromo-1-pentene (1.75 mL, 14.8 mmol, 1.2 equiv) in THF (5 mL) was added 
slowly over 10 min. The reaction was warmed to rt and stirred for 18 h. The reaction 
mixture was concentrated under reduced pressure and the residue was diluted with ether (20 
mL), and then treated with an ice-cold solution of dilute H2SO4 (15 mL) for 30 min to 
hydrolyze the hydrazone. The resulting solution was diluted with water and extracted with 
ether (2  20 mL), and the combined organic extracts were washed with water (2  20 mL) 
and brine (20 mL), dried over Na2SO4, and concentrated under reduced pressure. 
Purification by chromatography on a silica gel (0.7–0.8% EtOAc/hexanes) afforded the 
ketone 44l as a colorless oil in 92% yield (2.13 g, 11.3 mmol). Rf = 0.52 (5% 
EtOAc/hexanes, run twice). 
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(2R,3S)-rel-2-Cyclohexyl-3-(hex-5′-en-1′-yl)-3-phenyl-1,2-oxaziridine (cis-53) and 
(2S,3S)-rel-2-Cyclohexyl-3-(hex-5′-en-1′-yl)-3-phenyl-1,2-oxaziridine (trans-53). 
Following the general procedure G, 1-phenylhept-6-en-1-one 44l (0.500 g, 2.65 mmol, 1.0 
equiv), cyclohexylamine 45b (0.456 mL, 3.98 mmol, 1.5 equiv), PTSA (25.2 mg, 0.132 
mmol, 0.050 equiv), and activated 5 Å molecular sieves (3.50 g) in toluene (30 mL) was 
refluxed for 60 h, followed by oxidation with m-CPBA (0.550 g, 3.19 mmol, 1.2 equiv) in 
CH2Cl2 (20 mL). Purification by chromatography on a silica gel (0.6–0.7% 
EtOAc/hexanes) afforded a mixture of oxaziridine diastereomers cis-53 and trans-53 along 
with the partial separation of major diastereomer cis-53 as colorless oils (0.720 g, 2.54 
mmol, 96% yield; cis-53:trans-53 = ca. 57:43 by 
1
H NMR). Major diastereomer cis-53: Rf 
= 0.52 (5% EtOAc/hexanes, run twice);
 
IR (neat) 1640, 1448 cm
–1
; 
1
H NMR (400 MHz, 
CDCl3)  0.72–0.83 (m, 1H), 0.97–1.16 (m, 2H), 1.16–1.28 (m, 2H), 1.29–1.40 (m, 4H), 
1.42–1.51 (m, 2H), 1.52–1.58 (m, 1H), 1.67–1.76 (m, 3H), 1.84–1.88 (m, 1H), 1.93–1.98 
(m, 2H), 2.33–2.40 (m, 1H), 4.85–4.95 (m, 2H), 5.71 (m, 1H), 7.34–7.42 (m, 5H); 
13
C 
NMR (100 MHz, CDCl3)  23.5, 24.1, 24.2, 25.8, 28.6, 29.0, 31.8, 33.7, 38.5, 60.9, 87.8, 
114.5, 127.8, 128.2, 128.7, 135.3, 138.9; HRMS (ESI) m/z calcd for C19H28NO [M + H]
+ 
286.2170, found 286.2163. 
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From a mixture of cis-53 and trans-53: Minor diastereomer trans-53: Rf = 0.45 (5% 
EtOAc/hexanes, run twice);
 1
H NMR (400 MHz, CDCl3; diagnostic peaks only)  2.59 (m, 
1H); 
13
C NMR (100 MHz, CDCl3; diagnostic peaks only)  29.6, 61.3, 85.8. 
 
 
5-Hydroxy-1-phenylhept-6-en-1-one (54a), 4-Hydroxy-1-phenylhept-6-en-1-one 
(54b),
206
 and N-Cyclohexylbenzamide (54c; Scheme 48).
207
 Following the general 
procedure I, [Cu(PPh3)Cl]4 (38.0 mg, 0.0263 mmol, 0.050 equiv) in THF (10 mL) was 
reacted with a solution of oxaziridine cis-53 (150 mg, 0.526 mmol, 1.0 equiv) in THF (5 
mL). The reaction mixture was refluxed for 1 h. Purification by chromatography on a silica 
gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 98.6:1.0:0.4) afforded ca. 35.0 mg (0.186 
mmol, ca. 35% yield) of a slightly impure 44l as a colorless oil, 15.0 mg (0.0738 mmol, 
14% yield) of amide 54c as a white solid (Rf = 0.46 (25% EtOAc/hexanes)), and ca. 21.0 
mg (0.102 mmol, ca. 16% yield for 54a and ca. 3% yield for 54b by 
1
H NMR) of a slightly 
impure mixture of allylic alcohol 54a and homoallylic alcohol 54b as a pale yellow oil. 
Further purification of the mixture of 54a and 54b by preparative TLC developing two 
times with 7% EtOAc/hexanes gave two bands corresponding to 54a and 54b, which were 
scraped from the plate and eluted with 1% MeOH/CH2Cl2 through a Pasteur pipette 
containing a cotton plug. Evaporation of solvents afforded analytical samples of 54a and 
54b as colorless oils for characterization. Allylic alcohol 54a: Rf = 0.26 (25% 
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EtOAc/hexanes); IR (neat) 3403, 1679 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  1.60–1.65 (m, 
2H), 1.74 (br s, 1H), 1.80–1.90 (m, 2H), 3.02 (t, J = 7.4 Hz, 2H), 4.15 (q, J = 6.3 Hz, 1H), 
5.12 (dt, J = 10.4, 1.3 Hz, 1H), 5.25 (dt, J = 17.2, 1.4 Hz, 1H), 5.88 (m, 1H), 7.44–7.47 (m, 
2H), 7.54–7.57 (m, 1H), 7.95–7.97 (m, 2H); 
13
C NMR (125 MHz, CDCl3)  20.1, 36.6, 
38.4, 73.0, 115.0, 128.2, 128.8, 133.2, 137.1, 141.1, 200.4; HRMS (ESI) m/z calcd for 
C13H17O2 [M + H]
+ 
205.1229, found 205.1237.  
Homoallylic alcohol 54b (sample obtained contains some minor impurities): Rf = 
0.36 (25% EtOAc/hexanes); IR (neat) 3439, 1683 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  
1.80–1.87 (m, 1H), 1.95 (br s, 1H), 1.98–2.04 (m, 1H), 2.20–2.26 (m, 1H), 2.32–2.38 (m, 
1H), 3.11–3.22 (m, 2H), 3.74 (m, 1H), 5.14–5.18 (m, 2H), 5.80–5.88 (m, 1H), 7.44–7.48 
(m, 2H), 7.54–7.58 (m, 1H), 7.97–7.99 (m, 2H); 
13
C NMR (125 MHz, CDCl3)  30.9, 35.1, 
42.5, 70.3, 118.6, 128.3, 128.8, 133.3, 134.7, 137.0, 200.8; HRMS (ESI) m/z calcd for 
C13H17O2 [M + H]
+ 
205.1229, found 205.1227.  
 
 
Following the general procedure J, CuCl (4.33 mg, 0.0438 mmol, 0.050 equiv) and 
rac-BINAP (27.3 mg, 0.0438 mmol, 0.050 equiv) in THF (15 mL) was reacted with a 
solution of oxaziridine diastereomers 53 (0.250 g, 0.877 mmol, 1.0 equiv; cis:trans = ca. 
72:28) in THF (5 mL). The reaction mixture was refluxed for 1 h. Purification by 
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chromatography on a silica gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 98.6:1.0:0.4) 
afforded a mixture of unreacted oxaziridine diastereomers 53 and ketone 44l (for 
oxaziridine diastereomers 53: 26.0 mg recovered, ca. 10% corrected yield, Z:E = ca. 65:35 
by 
1
H NMR; for ketone 44l: 39.0 mg, ca. 24% corrected yield by 
1
H NMR), and an impure 
mixture of allylic alcohol 54a and homoallylic alcohol 54b. Further purification of the 
impure mixture of 54a and 54b by preparative TLC developing two times with 20% 
EtOAc/hexanes afforded two bands, one containing a mixture of 54a and 54b and other 
containing a mixture of 54a and an unidentified byproduct, which were scraped from the 
plate and eluted with a solvent system of CH2Cl2:acetone:MeOH, 96:2:2 separately through 
a short bed of silica gel. Evaporation of solvents afforded a mixture of 54a and 54b and an 
impure sample of 54a as a pale yellow oil (for 54a: ca. 8.5 mg. 0.042 mmol, ca. 5% 
corrected yield by 
1
H NMR; for 54b: ca. 3.0 mg. 0.015 mmol, ca. 2% corrected yield by 
1
H 
NMR).  
 
 
Dec-9-en-5-one (44m).
208
 Following the general procedure H, a solution of 5-bromo-
1-pentene (2.47 mL, 20.8 mmol, 1.2 equiv) in THF (10 mL) was added drop wise to a 
stirring suspension of magnesium turnings (0.508 g, 20.8 mmol, 1.2 equiv) and two small 
crystals of iodine in THF (10 mL). After refluxing gently for 20 min, the reaction mixture 
was cooled to 0 C and treated with a solution of valeraldehyde (1.50 g, 17.4 mmol, 1.0 
equiv) in THF (5 mL). The reaction mixture was then stirred at rt for 1 h. The aqueous 
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work-up afforded the crude alcohol (3.05 g) as colorless oil, which was used for the next 
oxidation step without further purification.  
To a stirring solution of crude alcohol (3.05 g) in CH2Cl2 (50 mL) was added Celite 
(6.0 g) followed by PCC (5.63 g, 26.1 mmol, 1.5 equiv), and the reaction mixture was 
stirred at rt for 2 h. The reaction mixture was filtered through Celite, rinsing with several 
portions of ether, and the filtrate was concentrated under reduced pressure. Purification by 
chromatography on a silica gel (0.5–1% EtOAc/hexanes) afforded 2.44 g (15.8 mmol, 91% 
yield over 2 steps) of the corresponding ketone 44m as a yellow oil. Rf = 0.57 (10% 
EtOAc/hexanes). 
 
 
(E)-10-Phenyldec-9-en-5-one (44n). To a solution of Grubbs II catalyst (0.264 g, 
0.311 mmol, 0.04 equiv) in CH2Cl2 (28 mL) at rt under argon atmosphere was added a 
solution containing a mixture of dec-9-en-5-one 44m (1.20 g, 7.79 mmol, 1.0 equiv) and 
styrene (2.67 mL, 23.3 mmol, 3.0 equiv) in CH2Cl2 (7 mL), and the reaction mixture was 
stirred at 40 °C for 4.5 h. The reaction mixture was concentrated under reduced pressure. 
Initial purification of crude residue by chromatography on a silica gel (0.4% 
EtOAc/hexanes) afforded the mixture of desired product 44n and byproduct (E)-1-
phenylnon-1-en-5-one 44na as a colorless oil (0.728 g, 3.16 mmol, 41% corrected yield for 
44n by 
1
H NMR). Subsequent purification of the mixture of 44n and 44na (dissolved in 
DMSO) was carried out using the preparative HPLC. The product was purified in multiple 
batches. All the fractions containing the product were evaporated to dryness and the residue 
was diluted with ether (100 mL). The organic layer was washed with water (35 mL), dried 
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over Na2SO4, and concentrated. Pale yellow oil obtained was passed through a short bed of 
a silica gel using 100% CH2Cl2 to afford 480 mg of 44n as a colorless oil. Ketone 44n: Rf = 
0.30 (5% EtOAc/hexanes); IR (neat) 2931, 1710 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.91 
(t, J = 7.3 Hz, 3H), 1.26–1.35 (m, 2H), 1.52–1.59 (m, 2H), 1.77 (m, 2H), 2.22 (dq, J = 7.5, 
1.2 Hz, 2H), 2.38 (t, J = 7.4 Hz, 2H), 2.44 (t, J = 7.3 Hz, 2H), 6.14–6.21 (m, 1H), 6.39 (d, J 
= 15.8 Hz, 1H), 7.18–7.22 (m, 1H), 7.27–7.31 (m, 2H), 7.33–7.36 (m, 2H); 
13
C NMR (100 
MHz, CDCl3)  13.9, 22.4, 23.3, 26.0, 32.4, 41.9, 42.6, 126.0, 127.0, 128.5, 129.9, 130.6, 
137.6, 211.0; HRMS (ESI) m/z calcd for C16H23O [M + H]
+ 
231.1749, found 231.1750. 
 
 
(2S,3R,E)-rel-3-Butyl-2-cyclohexyl-3-(5′-phenylpent-4′-en-1′-yl)-1,2-oxaziridine 
(cis-55) and (2R,3R,E)-rel-3-Butyl-2-cyclohexyl-3-(5′-phenylpent-4′-en-1′-yl)-1,2-
oxaziridine (trans-55). Following the general procedure G, (E)-10-phenyldec-9-en-5-one 
44n (0.450 g, 1.95 mmol, 1.0 equiv), cyclohexylamine 45b (0.335 mL, 2.93 mmol, 1.5 
equiv), PTSA (18.6 mg, 0.0978 mmol, 0.050 equiv), and activated 5 Å molecular sieves 
(3.50 g) in toluene (35 mL) was refluxed for 60 h, followed by oxidation with m-CPBA 
(0.405 g, 2.34 mmol, 1.2 equiv) in CH2Cl2 (20 mL). Purification by chromatography on a 
silica gel (0.4–0.6% EtOAc/hexanes) afforded a mixture of oxaziridine diastereomers cis-
55 and trans-55 as a pale yellow oil (0.449 g, 1.37 mmol, 70% yield; cis-55:trans-55 = ca. 
56:44 by 
1
H NMR). For the mixture of cis-55 and trans-55: Rf = 0.51 (5% EtOAc/hexanes, 
309 
 
run thrice); IR (neat) 2929, 2856, 1449 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.89–0.96 (m, 
7H), 1.21–1.28 (m, 6H), 1.31–1.37 (m, 6H), 1.39–1.45 (m, 3H), 1.46–1.57 (m, 8H), 1.63–
1.66 (m, 3H), 1.68–1.74 (m, 3H), 1.74–1.82 (m, 4H), 1.83–1.87 (m, 2H), 1.89–1.95 (m, 
4H), 2.20–2.32 (m, 4H), 2.33–2.41 (m, 2H), 6.19 (m, 1H), 6.23 (m, 1H), 6.39 (d, J = 16.2 
Hz, 1H), 6.43 (d, J = 16.0 Hz, 1H), 7.17–7.23 (m, 2H), 7.27–7.31 (m, 4H), 7.32–7.36 (m, 
4H); 
13
C NMR (100 MHz, CDCl3)  14.13, 14.19, 23.0, 23.2, 24.35, 24.37, 24.4, 24.5, 24.6, 
25.2, 25.9, 26.8, 27.5, 27.6, 27.9, 29.2, 29.3, 32.14, 32.16, 33.2, 36.3, 36.6, 60.44, 60.48, 
85.90, 85.97, 126.1, 127.0, 127.1, 128.62, 128.67, 129.9, 130.42, 130.45, 130.8, 137.7, 
137.8; HRMS (ESI) m/z calcd for C22H34NO [M + H]
+ 
328.2640, found 328.2635. 
 
 
(E)-8-Hydroxy-10-phenyldec-9-en-5-one (56; Scheme 49). Following the general 
procedure I, [Cu(PPh3)Cl]4 (26.5 mg, 0.0183 mmol, 0.050 equiv) in THF (9 mL) was 
reacted with a solution of oxaziridine diastereomers 55 (120 mg, 0.366 mmol, 1.0 equiv; 
cis:trans = 58:42) in THF (3 mL). The reaction mixture was refluxed for 1 h. Purification 
by chromatography on a silica gel twice (0–1% acetone/CH2Cl2) afforded the allylic 
alcohol 56 as a pale yellow oil containing ca. 10% of two unidentified byproducts (58.0 mg, 
0.235 mmol, 64% corrected yield by 
1
H NMR). Allylic alcohol 56: Rf = 0.30 (25% 
EtOAc/hexanes); IR (neat) 3405, 1705 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.88 (t, J = 7.3 
Hz, 3H), 1.24–1.33 (m, 2H), 1.50–1.57 (m, 2H), 1.83–1.97 (m, 2H), 2.38–2.43 (m, 3H), 
2.57 (t, J = 6.9 Hz, 2H), 4.31 (m, 1H), 6.18 (dd, J = 15.9, 6.3 Hz, 1H), 6.57 (d, J = 15.9 Hz, 
1H), 7.21–7.25 (m, 1H), 7.28–7.32 (m, 2H), 7.35–7.37 (m, 2H); 
13
C NMR (100 MHz, 
CDCl3)  14.0, 22.4, 26.1, 30.9, 38.6, 42.8, 72.1, 126.6, 127.8, 128.7, 130.4, 132.0, 136.7, 
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212.0; HRMS (ESI) m/z calcd for C16H23O2 [M + H]
+ 
247.1698, found 247.1699. Ketone 
44n was observed in trace amounts by 
1
H NMR in a mixture of unidentified impurities.  
 
 
Following the general procedure J, CuCl (1.81 mg, 0.0183 mmol, 0.050 equiv) and 
rac-BINAP (11.3 mg, 0.0183 mmol, 0.050 equiv) in THF (9 mL) was reacted with a 
solution of oxaziridine diastereomers 55 (120 mg, 0.366 mmol, 1.0 equiv; cis:trans = 58:42) 
in THF (3 mL). The reaction mixture was refluxed for 1 h. Purification by chromatography 
on a silica gel (0–1% acetone/CH2Cl2) afforded 56 as a yellow oil containing ca. 11% of 
two unidentified byproducts (62.0 mg, 0.252 mmol, 69% corrected yield by 
1
H NMR). 
Ketone 44n was observed in trace amounts by 
1
H NMR in a mixture of unidentified 
impurities.   
 
 
1-Cyclohexylhex-5-en-1-one (44o).
209
 Following the general procedure H, a solution 
of 5-bromo-1-pentene (1.90 mL, 16.0 mmol, 1.2 equiv) in THF (10 mL) was added drop 
wise to a stirring suspension of magnesium turnings (0.390 g, 16.0 mmol, 1.2 equiv) and 
two small crystals of iodine in THF (10 mL). After refluxing gently for 20 min, the reaction 
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mixture was cooled to 0 C and treated with a solution of cyclohexane carboxaldehyde 
(1.50 g, 13.3 mmol, 1.0 equiv) in THF (5 mL). The reaction mixture was then stirred at rt 
for 1 h. The aqueous work-up afforded the crude alcohol (2.31 g) as colorless oil, which 
was used for the next oxidation step without further purification.  
To a stirring solution of crude alcohol (2.31 g) in CH2Cl2 (70 mL) was added Celite 
(6.0 g) followed by PCC (5.76 g, 26.7 mmol, 2.0 equiv), and the reaction mixture was 
stirred at rt for 75 min. The reaction mixture was filtered through Celite, rinsing with 
several portions of CH2Cl2, and the filtrate was concentrated under reduced pressure. 
Purification by chromatography on a silica gel (1% EtOAc/hexanes) afforded 1.68 g (9.33 
mmol, 70% yield over 2 steps) of the corresponding ketone 44o as a colorless oil. Rf = 0.62 
(10% EtOAc/hexanes). 
 
 
(2R,3S)-rel-2,3-Dicyclohexyl-3-(pent-4′-en-1′-yl)-1,2-oxaziridine (cis-57) and 
(2S,3S)-rel-2,3-Dicyclohexyl-3-(pent-4′-en-1′-yl)-1,2-oxaziridine (trans-57). Following 
the general procedure G, 1-cyclohexylhex-5-en-1-one 44o (0.500 g, 2.77 mmol, 1.0 equiv), 
cyclohexylamine 45b (0.476 mL, 4.16 mmol, 1.5 equiv), PTSA (26.3 mg, 0.138 mmol, 
0.050 equiv), and activated 5 Å molecular sieves (3.50 g) in toluene (30 mL) was refluxed 
for 60 h, followed by oxidation with m-CPBA (0.573 g, 3.32 mmol, 1.2 equiv) in CH2Cl2 
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(20 mL) for 45 min. Purification by chromatography on a silica gel (0.5% EtOAc/hexanes) 
afforded a mixture of oxaziridine diastereomers cis-57 and trans-57 and ketone 44o as a 
colorless oil. The ketone 44o was removed from the mixture by vacuum distillation at ca. 
65–67 C and the mixture of two diastereomers cis-57 and trans-57 along with some 
decomposition products were left in the flask as an orange-colored residue. This residue 
was further purified by chromatography on a silica gel (2% ether/hexanes) to afford a 
mixture of cis-57 and trans-57 as a colorless oil (0.340 g, 1.22 mmol, 44% yield; ratio of 
two oxaziridine diastereomers = ca. 79:21 by 
1
H NMR, unassigned). For the major 
diastereomer in a mixture of cis-57 and trans-57: Rf = 0.68 (5% EtOAc/hexanes, run 
twice); IR (neat) 2927, 2853, 1450, cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.00–1.32 (m, 
8H), 1.39–1.50 (m, 3H), 1.51–1.64 (m, 6H), 1.69–1.82 (m, 7H), 1.85–1.90 (m, 1H ), 2.05–
2.10 (m, 2H), 2.17–2.24 (m, 1H), 4.95–5.05 (m, 2H), 5.73–5.83 (m, 1H); 
13
C NMR (100 
MHz, CDCl3)  24.3, 24.5, 25.2, 25.94, 25.99, 26.3, 26.4, 26.8, 28.1, 29.2, 32.0, 34.1, 44.7, 
60.3, 87.4, 115.2, 138.2; HRMS (ESI) m/z calcd for C18H32NO [M + H]
+ 
278.2484, found 
278.2475. 
 
 
N-Cyclohexylhex-5-enamide (58; Scheme 49). Following the general procedure I, 
[Cu(PPh3)Cl]4 (13.0 mg, 0.00902 mmol, 0.050 equiv) in THF (5 mL) was reacted with a 
solution of oxaziridine diastereomers cis-57 and trans-57 (50.0 mg, 0.180 mmol, 1.0 equiv; 
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ratio of two diastereomers = ca. 79:21, unassigned) in THF (2 mL). The reaction mixture 
was refluxed for 1 h. Purification by chromatography on a silica gel (100% CH2Cl2 to 
CH2Cl2:acetone:MeOH, 98.7:1.0:0.3) afforded 26.0 mg (0.133 mmol, 74% yield) of the 
amide 58 as a white solid instead of the allylic alcohol. Amide 58: Rf = 0.27 (25% 
EtOAc/hexanes); mp 57–59 C; IR (neat) 3284, 1638, 1546 cm
–1
; 
1
H NMR (400 MHz, 
CDCl3)  1.04–1.19 (m, 3H), 1.30–1.41 (m, 2H), 1.58–1.64 (m, 1H), 1.66–1.76 (m, 4H), 
1.88–1.92 (m, 2H), 2.05–2.14 (m, 4H), 3.76 (m, 1H), 4.95–5.04 (m, 2H), 5.28 (br s, 1H), 
5.77 (m, 1H); 
13
C NMR (100 MHz, CDCl3)  25.06, 25.08, 25.7, 33.3, 33.4, 36.3, 48.2, 
115.4, 138.2, 171.9; HRMS (ESI) m/z calcd for C12H22NO [M + H]
+ 
196.1701, found 
196.1702. Ketone 44o was not recovered. 
 
 
Oct-7-en-3-one (44p).
210
 Following the general procedure H, a solution of 5-bromo-
1-pentene (3.67 mL, 31.0 mmol, 1.2 equiv) in THF (10 mL) was added drop wise to a 
stirring suspension of magnesium turnings (0.753 g, 31.0 mmol, 1.2 equiv) and two small 
crystals of iodine in THF (10 mL). After refluxing gently for 20 min, the reaction mixture 
was cooled to 0 C and treated with a solution of propionaldehyde (1.50 g, 25.8 mmol, 1.0 
equiv) in THF (5 mL). The reaction mixture was then stirred at rt for 1 h. The aqueous 
work-up afforded the crude alcohol (3.10 g) as a pale yellow oil, which was used for the 
next oxidation step without further purification.  
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To a stirring solution of crude alcohol (3.10 g) in CH2Cl2 (50 mL) was added Celite 
(5.0 g) followed by PCC (8.35 g, 38.7 mmol, 1.5 equiv), and the reaction mixture was 
stirred at rt for 1.5 h. The reaction mixture was filtered through Celite, rinsing with several 
portions of ether, and the filtrate was concentrated under reduced pressure. Purification by 
chromatography on a silica gel (3% ether/hexanes) afforded 1.50 g (11.9 mmol, 46% yield 
over 2 steps) of the corresponding ketone 44p as a yellow oil (significant amount of 44p 
was lost during concentration and drying due to its volatile nature). Ketone 44p: Rf = 0.47 
(10% EtOAc/hexanes); IR (neat) 1713, 1375 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.98 (t, J 
= 7.3 Hz, 3H), 1.62 (p, J = 7.4 Hz, 2H), 2.00 (q, J = 7.1 Hz, 2H), 2.33–2.38 (m, 4H), 4.89–
4.97 (m, 2H), 5.70 (m, 1H); 
13
C NMR (100 MHz, CDCl3)  7.9, 23.0, 33.2, 36.0, 41.5, 
115.2, 138.1, 211.5; HRMS (ESI) m/z calcd for C8H15O [M + H]
+ 
127.1123, found 
127.1149. 
 
 
(2S,3R)-rel-2-Cyclohexyl-3-ethyl-3-(pent-4′-en-1′-yl)-1,2-oxaziridine (cis-59) and 
(2R,3R)-rel-2-Cyclohexyl-3-ethyl-3-(pent-4′-en-1′-yl)-1,2-oxaziridine (trans-59). 
Following the general procedure G, oct-7-en-3-one 44p (0.500 g, 3.97 mmol, 1.0 equiv), 
cyclohexylamine 45b (0.680 mL, 5.95 mmol, 1.5 equiv), PTSA (37.7 mg, 0.198 mmol, 
0.050 equiv), and activated 5 Å molecular sieves (3.50 g) in toluene (35 mL) was refluxed 
for 60 h, followed by oxidation with m-CPBA (0.820 g, 4.76 mmol, 1.2 equiv) in CH2Cl2 
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(25 mL). Purification by chromatography on a silica gel (0.5–1.0% EtOAc/hexanes) 
afforded partial separations of oxaziridine diastereomers trans-59 and cis-59 as colorless 
oils and the remaining was obtained as a mixture of trans-59 and cis-59 (0.570 g, 2.56 
mmol, 64% yield; cis-59:trans-59 = ca. 46:54 by 
1
H NMR). Minor diastereomer cis-59 
(contains ca. 5% of trans-59): Rf = 0.58 (5% EtOAc/hexanes);
 
IR (neat) 2931, 1451, 1389 
cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.93 (t, J = 7.6 Hz, 3H), 1.16–1.39 (complex, 4H), 
1.42–1.52 (complex, 2H), 1.56–1.67 (complex, 4H), 1.70–1.92 (complex, 6H), 2.04–2.19 
(m, 2H), 2.32 (tt, J = 10.4, 3.9 Hz, 1H), 4.97–5.06 (m, 2H), 5.80 (m, 1H); 
13
C NMR (100 
MHz, CDCl3)  8.8, 24.4, 24.6, 24.7, 25.9, 27.0, 29.3, 29.8, 32.2, 34.0, 60.4, 86.6, 115.4, 
138.1; HRMS (ESI) m/z calcd for C14H26NO [M + H]
+ 
224.2014, found 224.1996.  
Major diastereomer trans-59: Rf = 0.68 (5% EtOAc/hexanes);
 
IR (neat) 2931, 1451, 
1384 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.08 (t, J = 7.6 Hz, 3H), 1.18–1.28 (complex, 
2H), 1.28–1.53 (complex, 7H), 1.61–1.93 (complex, 7H), 2.01–2.11 (m, 2H), 2.35 (tt, J = 
10.5, 3.9 Hz, 1H), 4.93–5.02 (m, 2H), 5.78 (m, 1H); 
13
C NMR (100 MHz, CDCl3)  9.7, 
21.2, 23.9, 24.4, 24.6, 26.0, 29.4, 32.2, 34.0, 35.6, 60.5, 86.6, 115.0, 138.5; HRMS (ESI) 
m/z calcd for C14H26NO [M + H]
+ 
224.2014, found 224.2013. 
 
 
6-Hydroxyoct-7-en-3-one (60; Scheme 50). Following the general procedure I, 
[Cu(PPh3)Cl]4 (32.4 mg, 0.0224 mmol, 0.050 equiv) in THF (8 mL) was reacted with a 
solution of oxaziridine diastereomer trans-59 (100 mg, 0.448 mmol, 1.0 equiv) in THF (2 
mL). The reaction mixture was refluxed for 1 h. Purification by chromatography on a silica 
gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 98.8:1.0:0.2) afforded a small amount (ca. 25 
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mg) of supposedly impure product 60 as a pale yellow volatile oil. 
1
H NMR showed 
characteristic peaks of product. However, the volatile nature of the product and the 
presence of ca. 25–35% of inseparable unidentified impurities/byproducts made further 
purification of the impure product unfeasible. Thus, analytical sample of pure product 60 
was not obtained for complete spectroscopic analysis. Impure allylic alcohol 60 (contains 
ca. 25–35% of unidentified impurities/byproducts; most of the product peaks were 
overlapping with byproducts peaks): Rf = 0.23 (25% EtOAc/hexanes); 
1
H NMR (400 MHz, 
CDCl3)  1.04 (t, J = 7.3 Hz, 3H), 1.70–1.81 (m, 2H, complete overlap with byproducts 
peaks), 2.17 (br d, J = 3.9 Hz, 1H), 2.44 (q, J = 7.3 Hz, 2H), 2.54 (t, J = 7.0 Hz, 2H), 4.13 
(m, 1H), 5.10 (dt, J = 10.4, 1.4 Hz, 1H), 5.23 (dt, J = 17.2, 1.4 Hz, 1H), 5.83 (m, 1H). 
 
 
Following the general procedure J, CuCl (2.88 mg, 0.0291 mmol, 0.050 equiv) and 
rac-BINAP (18.1 mg, 0.0291 mmol, 0.050 equiv) in THF (8 mL) was reacted with a 
solution of oxaziridine diastereomer cis-59 (130 mg, 0.583 mmol, 1.0 equiv) in THF (2 
mL). The reaction mixture was refluxed for 1 h. Purification by chromatography on a silica 
gel (100% CH2Cl2 to CH2Cl2:acetone:MeOH, 98.8:1.0:0.2) afforded a small amount of 
supposedly impure product 60 as a pale yellow volatile oil. 
1
H NMR showed characteristic 
peaks of product, which matched with that obtained from the reaction with [Cu(PPh3)Cl]4 
as mentioned above. Subsequent attempt to purify the impure product by preparative TLC 
was unsuccessful. Again, pure allylic alcohol 60 was not obtained for complete 
spectroscopic analysis.  
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(2R,3S)-rel-3-Methyl-3-phenyl-2-(4′-phenylbutyl)-1,2-oxaziridine (cis-61) and 
(2S,3S)-rel-3-Methyl-3-phenyl-2-(4′-phenylbutyl)-1,2-oxaziridine (trans-61). Following 
the general procedure G, acetophenone (0.500 g, 4.16 mmol, 1.0 equiv), 4-
phenylbutylamine 45e (0.986 mL, 6.24 mmol, 1.5 equiv), PTSA (39.6 mg, 0.208 mmol, 
0.050 equiv), and activated 5 Å molecular sieves (3.50 g) in toluene (35 mL) was refluxed 
for 60 h, followed by oxidation with m-CPBA (0.861 g, 4.99 mmol, 1.2 equiv) in CH2Cl2 
(25 mL). Purification by chromatography on a silica gel (0.6–0.7% EtOAc/hexanes) 
afforded oxaziridine diastereomer trans-61 with an inseparable impurity, followed by 
impure cis-61 containing small amounts of trans-61 and acetophenone as colorless oils (ca. 
1.07 g, 4.01 mmol, 96% corrected yield; cis-61:trans-61 = ca. 67:33 by 
1
H NMR). 
Subsequent purification of a small amount of impure trans-61 twice by preparative TLC 
developing two and seven times with 3% EtOAc/hexanes afforded a band corresponding to 
trans-61, which was scraped from the plate and eluted with 50% ether/hexanes through a 
short bed of silica gel. Evaporation of solvents afforded a slightly impure analytical sample 
of trans-61 as a colorless oil for characterization. Similar purification of a small amount of 
impure cis-61 containing small amounts of trans-61 and acetophenone by preparative TLC 
developing four times with 3% EtOAc/hexanes afforded a band corresponding to cis-61, 
which was scraped from the plate and eluted with 50% ether/hexanes through a short bed of 
silica gel. Evaporation of solvents afforded a slightly impure analytical sample of cis-61 as 
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a colorless oil for characterization. Major diastereomer cis-61: Rf = 0.45 (5% 
EtOAc/hexanes, run twice);
 
IR (neat) 2931, 1450, 1338 cm
–1
; 
1
H NMR (400 MHz, CDCl3) 
 1.56–1.67 (complex, 4H), 1.78 (s, 3H), 2.16–2.23 (m, 1H), 2.41–2.47 (m, 1H), 2.54–2.57 
(m, 2H), 7.12–7.18 (m, 3H), 7.24–7.27 (m, 2H), 7.39 (s, 5H); 
13
C NMR (100 MHz, CDCl3) 
 25.6, 28.0, 29.2, 35.8, 55.5, 84.8, 125.9, 127.3, 128.40, 128.42, 128.6, 128.9, 136.4, 
142.4; HRMS (ESI) m/z calcd for C18H22NO [M + H]
+ 
268.1701, found 268.1693.  
Minor diastereomer trans-61: Rf = 0.55 (5% EtOAc/hexanes, run twice);
 
IR (neat) 
2937, 1452, 1289 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.76–1.84 (complex, 4H), 1.92 (s, 
3H), 2.67–2.70 (m, 2H), 2.85–2.91 (m, 1H), 3.00–3.07 (m, 1H), 7.17–7.21 (m, 3H), 7.26–
7.31 (m, 2H), 7.32–7.38 (m, 3H), 7.43–7.46 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  16.2, 
28.3, 29.4, 35.9, 54.7, 81.3, 125.9, 126.2 (2C), 128.5 (4C), 128.6 (2C), 128.8, 140.7, 142.4; 
HRMS (ESI) m/z calcd for C18H22NO [M + H]
+ 
268.1701, found 268.1684. 
 
 
4-Amino-1-phenylbutan-1-ol (62; Scheme 51). Following the general procedure J, 
CuCl (2.77 mg, 0.0280 mmol, 0.050 equiv) and rac-BINAP (17.4 mg, 0.0280 mmol, 0.050 
equiv) in THF (12 mL) was reacted with a solution of oxaziridine diastereomer cis-61 (150 
mg, 0.561 mmol, 1.0 equiv) in THF (3 mL). The reaction mixture was refluxed for 1 h. 
Purification by chromatography on a silica gel (0–5% MeOH/CH2Cl2) afforded 
acetophenone (eluted out at 100% CH2Cl2) in ca. 59% yield (ca. 40 mg). Desired amino 
alcohol product 62 could not be obtained during this purification.  
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(E)-1-Phenylocta-1,7-dien-3-one (44q).
211
 Following the general procedure H, a 
solution of 5-bromo-1-pentene (1.61 mL, 13.6 mmol, 1.2 equiv) in THF (10 mL) was added 
drop wise to a stirring suspension of magnesium turnings (0.331 g, 13.6 mmol, 1.2 equiv) 
and two small crystals of iodine in THF (10 mL). After refluxing gently for 20 min, the 
reaction mixture was cooled to 0 C and treated with a solution of trans-cinnamaldehyde 
(1.43 g, 11.3 mmol, 1.0 equiv) in THF (5 mL). The reaction mixture was then stirred at rt 
for 1 h. The aqueous work-up afforded the crude alcohol (2.50 g) as a pale yellow oil, 
which was used for the next oxidation step without further purification.  
To a stirring solution of crude alcohol (2.50 g) in CH2Cl2 (50 mL) was added Celite 
(5.0 g) followed by PCC (4.89 g, 22.7 mmol, 2 equiv), and the reaction mixture was stirred 
at rt for 2 h. The reaction mixture was filtered through Celite, rinsing with several portions 
of CH2Cl2, and the filtrate was concentrated under reduced pressure. Purification by 
chromatography on a silica gel (1.0–1.5% EtOAc/hexanes) afforded impure enone 44q. 
Subsequent purification of impure enone 44q by chromatography on a silica gel (0.5–2.0% 
EtOAc/hexanes) afforded a small amount of impure enone followed by pure enone 44q as a 
pale yellow oil (1.00 g, 5.00 mmol, 44% corrected yield over 2 steps by 
1
H NMR). Enone 
44q: Rf = 0.56 (10% EtOAc/hexanes); IR (neat) 1689, 1663, 1610, 1450 cm
–1
; 
1
H NMR 
(400 MHz, CDCl3)  1.79 (m, 2H), 2.13 (m, 2H), 2.67 (t, J = 7.4 Hz, 2H), 4.98–5.08 (m, 
2H), 5.81 (m, 1H), 6.74 (d, J = 16.2 Hz, 1H), 7.38–7.39 (m, 3H), 7.53–7.57 (m, 3H); 
13
C 
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NMR (100 MHz, CDCl3)  23.5, 33.3, 40.2, 115.4, 126.4, 128.4, 129.1, 130.6, 134.7, 
138.2, 142.5, 200.4; HRMS (ESI) m/z calcd for C14H17O [M + H]
+ 
201.1279, found 
201.1263. 
 
 
(2S,3S)-rel-2-Cyclohexyl-3-phenyl-1,2-oxaziridine (trans-63; Scheme 52).
185,191
 
Following the general procedure G, (E)-1-phenylocta-1,7-dien-3-one 44q (0.500 g, 2.50 
mmol, 1.0 equiv), cyclohexylamine 45b (0.428 mL, 3.75 mmol, 1.5 equiv), PTSA (23.8 
mg, 0.125 mmol, 0.050 equiv), and activated 5 Å molecular sieves (3.50 g) in toluene (35 
mL) was refluxed for 60 h, followed by oxidation with m-CPBA (0.517 g, 3.00 mmol, 1.2 
equiv) in CH2Cl2 (20 mL). Purification by chromatography on a silica gel (0.4% 
EtOAc/hexanes) afforded impure oxaziridine trans-63 as a yellow oil (0.185 g, 0.911 
mmol, 36% corrected yield; ratio of trans-63:unidentified byproducts = ca. 84:16 by 
1
H 
NMR) instead of the desired cis- and trans-oxaziridine diastereomers (shown in the box). A 
small amount of the impure oxaziridine trans-63 was further purified by preparative TLC 
developing two times with 3% EtOAc/hexanes. The band corresponding to pure product 
was scraped from the plate and eluted with 50% ether/hexanes through a short bed of silica 
gel. Evaporation of solvents afforded an analytical sample of trans-63 as a colorless oil for 
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characterization. Oxaziridine diastereomer trans-63: Rf = 0.69 (5% EtOAc/hexanes, run 
twice); IR (neat) 2930, 2857, 1451, 873 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.21–1.34 
(complex, 3H), 1.40–1.50 (m, 1H), 1.54–1.66 (complex, 2H), 1.70–1.75 (m, 1H), 1.79–1.86 
(complex, 2H), 2.04–2.12 (complex, 2H), 4.54 (s, 1H), 7.36–7.41 (m, 3H), 7.41–7.45 (m, 
2H); 
13
C NMR (100 MHz, CDCl3)  24.3, 24.7, 25.9, 29.4, 31.8, 70.4, 80.0, 127.6, 128.7, 
130.1, 135.4; HRMS (ESI) m/z calcd for C13H18NO [M + H]
+ 
204.1388, found 204.1380. 
 
 
(E)-8-Methoxy-10-phenyldec-9-en-5-one (64; Scheme 54). To a solution of (E)-8-
hydroxy-10-phenyldec-9-en-5-one 56 (20.0 mg, 0.0813 mmol, 1.0 equiv) in MeOH (1 mL) 
in an open flask at rt was added two small drops of concentrated HCl (37%) and the 
reaction mixture was stirred for 30 min. The reaction mixture was concentrated and the 
residue obtained was purified by chromatography on a silica gel (100% CH2Cl2) to afford 
18.0 mg (0.0692 mmol, 85% yield) of the allylic ether 64 as a pale yellow oil. Allylic ether 
64: Rf = 0.62 (25% EtOAc/hexanes); IR (neat) 1712, 1364, 1108, 1086 cm
–1
; 
1
H NMR (400 
MHz, CDCl3)  0.89 (t, J = 7.3 Hz, 3H), 1.29 (m, 2H), 1.54 (m, 2H), 1.84–1.97 (m, 2H), 
2.39 (t, J = 7.5 Hz, 2H), 2.51 (t, J = 7.2 Hz, 2H), 3.30 (s, 3H), 3.73 (q, J = 6.8 Hz, 1H), 6.02 
(dd, J = 16.0, 7.8 Hz, 1H), 6.53 (d, J = 15.9 Hz, 1H), 7.23–7.27 (m, 1H), 7.31–7.34 (m, 
2H), 7.38–7.40 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  14.1, 22.6, 26.2, 29.7, 38.5, 42.9, 
56.5, 81.7, 126.7, 128.0, 128.8, 129.9, 132.7, 136.6, 211.1; HRMS (ESI) m/z calcd for 
C17H25O2 [M + H]
+ 
261.1855, found 261.1832. 
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Procedure for the Radical-Trapping Experiment with TEMPO (Scheme 46)  
 
 4-Hydroxy-1-phenylhex-5-en-1-one (43a), 1-Phenyl-4-((2,2,6,6-tetramethyl-
piperidin-1-yl)oxy)hex-5-en-1-one (46a), trans-1-Phenyl-6-((2,2,6,6-tetramethylpiperi-
din-1-yl)oxy)hex-4-en-1-one (trans-46b), and cis-1-Phenyl-6-((2,2,6,6-tetramethyl-
piperidin-1-yl)oxy)hex-4-en-1-one (cis-46c). A flame-dried two-necked round bottom 
flask equipped with a reflux condenser was charged with CuCl (1.82 mg, 0.0184 mmol, 
0.050 equiv) and THF (8 mL) under an argon atmosphere. The solution was degassed with 
argon and allowed to reflux for 30 min. A solution of TEMPO in THF (1 mL) followed by 
a solution of oxaziridine diastereomers 42ab (100 mg, 0.369 mmol, 1.0 equiv; cis:trans = 
1:1) in THF (3 mL) was added slowly by syringe to the resulting solution, and refluxing 
was continued for 1 h. The solvent was removed under reduced pressure and the crude 
mixture was purified by chromatography on a silica gel (100% CH2Cl2 to 
CH2Cl2:acetone:MeOH, 98.9:1.0:0.1 to 98.7:1.0:0.3) to afford 9.00 mg (0.0517 mmol, 14% 
yield) of 44a, 45.0 mg of a mixture containing three radical-trapped products (46a, 46b, 
and 46c), and 16.0 mg (0.0842 mmol, 23% yield) of the allylic alcohol 43a as an orange oil. 
Further purification of the mixture of 46a, 46b, and 46c by chromatography on a silica gel 
(0.6–1.2% EtOAc/hexanes) afforded the internal radical-trapped product 46a as a colorless 
oil (23.6 mg, 0.0717 mmol, 19% yield) and the mixture of terminal radical-trapped 
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products (trans-46b and cis-46c) as a colorless oil (21.4 mg, 0.0650 mmol, 18% yield, 
46b:46c = ca. 62:38). Internal radical-trapped product 46a: Rf = 0.36 (5% EtOAc/hexanes); 
IR (neat) 1686, 1360 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.07–1.18 (m, 12H), 1.27–1.30 
(m, 1H), 1.43–150 (m, 5H), 1.91–2.00 (m, 1H), 2.09–2.18 (m, 1H), 3.01 (t, J = 7.6 Hz, 2H), 
4.24 (m, 1H), 5.08–5.13 (m, 2H), 5.85 (m, 1H), 7.43–7.47 (m, 2H), 7.53–7.57 (m, 1H), 
7.94–7.97 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  17.4, 20.60, 20.67, 28.8, 34.4, 34.6, 
35.2, 40.4, 59.4, 60.3, 84.8, 116.4, 128.2, 128.7, 133.0, 137.2, 140.6, 200.3; HRMS (ESI) 
m/z calcd for C21H32NO2 [M + H]
+
 330.2433, found 330.2443.  
Terminal radical-trapped products (trans-46b and cis-46c): Rf = 0.30 (5% 
EtOAc/hexanes); IR (neat) 1686, 1358 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  1.08–1.17 (m, 
24H), 1.29–1.32 (m, 2H, trans), 1.42–1.45 (m, 8H), 1.50–1.59 (m, 2H, cis), 2.46–2.53 (m, 
4H), 3.02–3.10 (m, 4H), 4.22 (dd, J = 6.0, 1.1 Hz, 2H, trans), 4.36 (d, J = 5.2 Hz, 2H, cis), 
5.55–5.66 (m, 3H), 5.72–5.80 (m, 1H), 7.43–7.47 (m, 4H), 7.53–7.57 (m, 2H), 7.93–7.97 
(m, 4H); 
13
C NMR for trans (100 MHz, CDCl3)  17.3, 20.4, 27.1, 33.22, 38.2, 39.8, 59.8, 
78.2, 126.9, 128.2, 128.7, 132.0, 133.2, 137.1, 199.7; 
13
C NMR for cis (100 MHz, CDCl3)  
17.3, 20.3, 22.8, 33.29, 38.7, 39.85, 59.84, 73.4, 126.7, 128.2, 128.7, 131.1, 133.2, 137.0, 
199.5; HRMS (ESI) for trans m/z calcd for C21H32NO2 [M + H]
+
 330.2433, found 
330.2439; HRMS (ESI) for cis m/z calcd for C21H32NO2 [M + H]
+
 330.2433, found 
330.2445.  
 
The trans and cis configuration were assigned based on NOESY signal observed 
between Ha′ and Hb′ for trans-radical-trapped product 46b and between Ha and Hb for cis-
radical-trapped product 46c. 
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All oxaziridine stereostructures were assigned according to well-  
established chemical shift trends.
151b,161f,170a,181-182
   
Table S26. Assignment of Oxaziridine Diastereomers Based on 
1
H and 
13
C NMR
 
Shifts 
compd 
no. 
compd structure 
1
H NMR (ppm)
 13
C NMR (ppm) 
1′-H 2′-H 3-C 1′-C 1′′-C 
 
42aa 
 
2.99 1.48 88.4 62.8 37.9 
42aa′ 
 
– 1.14 – – – 
42aa′′ 
 
– 1.62 – – – 
42ba 
 
3.01 1.47 88.2 62.7 37.9 
42ba′ 
 
3.09 1.15 88.5 61.4 37.8 
42ca 
 
2.99 1.48 88.6 62.8 38.1 
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compd 
no. 
compd structure 
1
H NMR (ppm) 
13
C NMR (ppm)
 
1′-H 2′-H 3-C 1′-C 1′′-C 
42ca′ 
 
3.19 – 87.8 61.7 – 
42ca′′ 
 
3.82 – 85.8 62.9 – 
 
cis-42ab 
 
2.36 – 87.7 61.0 38.1 
trans-
42ab 
 
2.29 – 85.8 61.3 29.1 
cis-42bb 
 
2.31 – 87.5 60.7 38.1 
trans-
42bb 
 
2.28 – 85.4 61.4 29.2 
cis-42cb 
 
2.35 – 87.8 60.9 38.3 
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compd 
no. 
compd structure 
1
H NMR (ppm) 
13
C NMR (ppm) 
1′-H 2′-H 3-C 1′-C 1′′-C 
trans-
42cb 
 
2.26 – 85.9 61.2 29.4 
cis-42db 
 
– – 87.6 60.7 38.1 
trans-
42db 
  
– – 85.6 61.2 29.2 
cis-42eb 
 
2.33 – 87.2 60.9 38.0 
trans-
42eb 
 
2.26 – 85.2 61.3 29.3 
cis-42fb 
 
2.32 – 82.3 61.4 36.0 
cis-42gb 
 
2.48 – 88.0 60.9 38.1 
trans-
42gb 
 
2.44 – 85.9 61.3 29.3 
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compd 
no. 
compd structure 
1
H NMR (ppm) 
13
C NMR (ppm) 
1′-H 2′-H 3-C 1′-C 1′′-C 
cis-42hb 
 
2.42 – 87.7 61.0 38.1 
trans-
42hb 
 
2.36 – 85.8 61.2 29.1 
cis-47 
 
2.39 – 87.7 60.9 38.2 
trans-47 
 
2.31 – 85.7 61.2 29.4 
cis-49 
 
2.41 – 87.4 60.9 37.7 
trans-49 
 
- – 85.4 61.2 29.3 
cis-53 
 
2.33–
2.40 
– 87.8 60.9 38.5 
trans-53 
 
– – 85.8 61.3 29.6 
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Chapter 3 
Synthesis and Cytotoxic Evaluation of Withalongolide A Analogues 
 
3.1   Introduction 
Classically defined withanolides are a group of naturally occurring C28 steroidal 
lactones assembled on an ergostane skeleton with either a C-22,26 -lactone ring or a C-
23,26 -lactone ring (Figure 21). Most of the withanolides are highly oxygenated members 
of the Solanaceae family, which includes genera such as Acnistus, Datura, Jaborosa, 
Lycium, Physalis, Vassobia, and Withania.
212
 Structurally complex and diverse 
withanolides with a C-17 -lactone side chain, as shown in Figure 21, can be further 
classified into withanolides with an unmodified skeleton (e.g., withaferin A 66, 
withaperuvin B, and sominone) and those with a modified skeleton (e.g., withametelinone 
and physalin C).
212a,b
 The occurrence of unmodified withanolides is more common in 
nature.
212b,c
 Withanolides have attracted significant attention from several researchers as 
they exhibit numerous biological activities, including antimicrobial,
213
 antineoplastic,
214
 
anti-neurodegenerative,
215
 anti-inflammatory,
216
 immunomodulating, antioxidant, anti-
stress, cardiotonic, and insect antifeedant properties.
212a,b,217
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Figure 21. Representative examples of withanolides with a - and -lactone ring. 
 
Withaferin A 66 was the first withanolide isolated by Lavie from Withania somnifera 
in 1965 and has become an iconic example for the entire class since then.
212a,b,218
 
Withaferin A 66 is the most studied withanolide and possesses a wide range of 
pharmacological activities such as antitumor, antimicrobial, antioxidant, anti-inflammatory, 
protective, and antiangiogenic effects.
212a,b,214d,219
 The antitumor activity of 66 has been 
demonstrated both in vitro and in vivo against an array of tumor cells like breast, prostate, 
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lung, and head and neck squamous cell carcinoma (HNSCC).
212a,220
 Such promising 
antitumor activity results from targeting multiple signaling pathways such as HSP90 and 
NF-B, which may circumvent the development of resistance among cancer cells.219a,c,221 
The biological activities, especially the antitumor properties of 66 and other related 
unmodified withanolides, are thought to depend on the presence of structural features such 
as an ,-unsaturated ketone in ring A, a 5,6-epoxide in ring B, and a 17-oriented -
lactone ring.
212,222
 
 
 
Figure 22. Withalongolide A and its di- and triacetates. 
 
Recently, Timmermann and co-workers reported the isolation, structures, and 
cytotoxic activities of 14 new withanolides (named as withalongolides) from Physalis 
longifolia Nutt. (Solanaceae).
223
 These withalongolides feature the presence of a rare C-19 
hydroxy group. Withalongolide A (67, Figure 22; cf. 66 in Figure 21), a 19-
hydroxywithaferin A, was the major withanolide isolated from the crude plant extract. 
Despite much structural similarity to 66, withalongolide A 67 showed considerably 
decreased potency against the carcinoma and melanoma cell lines tested compared to 66. 
However, the semisynthetic derivatives withalongolide A 4,27-diacetate 72 (IC50 = 0.098 
M) and withalongolide A 4,19,27-triacetate 73 (IC50 = 0.067 M) (Figure 22) showed 
improved potency and selectivity against the melanoma cell line B16F10 over both the 
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parent compound 67 (IC50 ≥ 10 M) and 66 (IC50 = 0.29 M).
223
 This led us to initiate a 
study to examine preliminary SAR for analogues of compound 67.
224
  
 
3.2   Results and Discussions  
Semisynthesis 
As previous authors have asserted the importance of 2-ene-1-one, a 5,6-epoxide, 
and a 17-oriented -lactone for the antitumor activity of 66,212,222 we accordingly sought 
to minimize modifications at these positions. Moreover, since the di- and tri-acetate of 67 
displayed significant selectivity against melanoma cell line B16F10 with potency in the 
nanomolar range, we first focused on examining the effects of modifying the free hydroxyl 
group of 67. 
Accordingly, we prepared a series of aliphatic esters of 67 (Scheme 46). After slight 
modifications of the standard acetylation procedures, it was possible to isolate mono- (68–
70) and diacetylated analogues 71 and 72
223a
 from the same reaction along with some 
recovered 67 (acetic anhydride was added in two portions; see the Experimental Section for 
details). Triacetate 73
223a
 and withalongolide A 4,19,27-propionate 74 were obtained by 
treating 67 with appropriate anhydrides in the presence of pyridine and a catalytic amount 
of DMAP. On the other hand, reactions of 67 with both 2-chloroacetyl chloride and 
trifluoroacetic anhydride in pyridine led to complex mixtures and decomposition (Scheme 
56a,b). 
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Scheme 55. Synthesis of Acetylated and Propionylated Analogues of Withalongolide A 
67
a
 
 
a
Reagents and conditions: (a) For 68–72: (MeCO)2O, pyridine, rt, 73% combined yield; (b) for 73: 
(MeCO)2O, pyridine, DMAP, rt, 99%; (c) for 74: (EtCO)2O, pyridine, DMAP, rt, 99%. 
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Scheme 56. Unsuccessful Synthesis of Haloacetylated and Benzoylated Analogues 
 
The second series of analogues entailed the synthesis of acetates and aromatic esters 
in assorted combinations along with carbamates. An initial attempt to make benzoylated 
analogues of 67 with benzoyl chloride (BzCl, PhCOCl) under typical acylation conditions 
(pyridine and DMAP) resulted in an incomplete reaction and the formation of a complex 
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mixture (Scheme 56c). Gratifyingly, the reaction of 67 with p-chlorobenzoyl chloride in the 
presence of triethylamine (Et3N) and DMAP afforded a mixture of p-chlorobenzoylated 
analogues from which mono- (75), di- (76 and 77), and tri-p-chlorobenzoate ester 78 were 
isolated (Scheme 57).
225
 The free C-19 hydroxyl group of 77 was further acetylated with 
acetic anhydride to afford compound 79 (Scheme 57).  
 
Scheme 57. Synthesis of para-Chlorobenzoylated Analogues of Withalongolide A 67 
 
 
Carbamoylation only occurred at the C-4 hydroxyl even after treating 67 with excess 
dimethylcarbamoyl chloride, to afford monosubstituted dimethylcarbamate analogue 80 
(Scheme 58). Subsequent acetylation of the remaining two hydroxyl groups with acetic 
anhydride delivered compound 81 in good yield (Scheme 58). 
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Scheme 58. Synthesis of Carbamate Analogues of Withalongolide A 67 
 
 
An effort to make carbonate analogues from phenylchloroformate under similar 
conditions that were employed for the synthesis of p-chlorobenzoylated analogues was 
unsuccessful. A multitude of products was obtained, some of which seemed to be unstable 
during preparative TLC purification (Scheme 59). However, it was possible to isolate a 
very small amount (ca. 2–3 mg) of impure samples of compounds 82 and 83 (Scheme 59; 
shown in the box). Compound 82 might have presumably formed from the nucleophilic 
substitution on the C-27 carbonate by a chlorine atom generated in situ from phenyl 
chloroformate.  
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Scheme 59. Failed Attempt for the Synthesis of Carbonate Analogues 
 
 
Selective and mild etherification reaction of C-27 hydroxyl of 67 with methyl iodide 
in the presence of silver oxide (Ag2O) resulted in an incomplete reaction and formation of 
more than two inseparable products (Scheme 60).
226
 This experiment was not pursued 
further due to nonselectivity of the etherification reaction and the difficulty of separating 
the putative ether products. 
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Scheme 60. Fruitless Efforts towards the Synthesis of C-27 Methyl Ether Analogue 84 
 
 
Jaborosalactones are withanolides isolated from Jaborosa species such as Jaborosa 
integrifolia and Jaborosa leucotricha. We synthetically prepared close derivatives of 
known jaborosalactones (see Figure 23) by chemically manipulating 73 as shown in 
Scheme 61. Thus, the palladium-catalyzed, formate-mediated reduction of triacetate 73 
afforded a mixture of jaborosalactone derivatives 85
227
 and 86
228
 through C-4 
deoxygenation of the acetate group.
229
 The structure of the diacetate analogue of 
jaborosalactone V 85 was confirmed by single-crystal X-ray diffraction analysis (Figure 
24).
227
 Compound 86, a C-19 acetate analogue of jaborosalactone B 27-acetate, was 
obtained via similar C-4 deoxygenation followed by subsequent epoxide ring-opening.
228
 
Analogue 87, a C-19 acetate derivative of jaborosalactone E 27-acetate, was obtained by 
epoxide ring-opening of compound 85 using HCl solution in ether.
230
 Besides being 
expected from a mechanistic perspective, the anti relationship of the C-5 chlorine and C-6 
hydroxyl groups was assigned based on NMR data comparison with the literature values for 
jaborosalactone E and similar compounds.
230-231
 Acetylation of a small amount of 
compound 87 showed a downfield shift of H-6 from  3.99 to 5.12 suggesting the presence 
of a hydroxyl group at C-6 (see the Experimental Section for details).
230
 The C-6 free 
hydroxyl group of compound 86 was further acetylated to provide triacetylated analogue 
88. 
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Figure 23. Chemical structures of jaborosalactones. 
 
Scheme 61. Synthesis of Jaborosalactone Derivatives from Triacetate 73
a
 
 
a
Reagents and conditions: (a) Pd(OAc)2, PPh3, HCO2NH4, dioxane, reflux, 50% combined yield; (b) 
HCl solution in ether, CH2Cl2, rt, 70%; (c) (MeCO)2O, pyridine, DMAP, rt, 87%. 
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Figure 24. Single-crystal X-ray structure of analogue 85. 
 
The ,-unsaturated ketone of withaferin A is a Michael acceptor.221d Therefore, we 
sought to modify the ,-unsaturated ketone in order to modulate its reactivity. Initial 
efforts were focused toward making analogues with a minimal modification by keeping this 
important enone functionality intact. Thus, we directed our attention toward the synthesis of 
-substituted aryl analogues of the ring A enone of 67. Compound 67 and its triacetate 
analogue 73 were subjected to -iodination conditions using iodine and DMAP to afford 
their corresponding -iodoenone analogues 89 and 90 (Scheme 62).232 However, an attempt 
to execute Suzuki cross-coupling of the -iodoenone moiety in 90 with 4-
acetylphenylboronic acid
233 
to obtain -aryl analogue 91 met with no success; only 
decomposition of 90 was observed (Scheme 63). 
 
Scheme 62. Synthesis of -Iodoenone Derivatives 
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Scheme 63. Failed Suzuki Cross-Coupling of 90 with 4-Acetylphenylboronic acid 
 
 
An additional analogue was prepared via ring-closing macrocyclization
234
 to afford a 
rare steroidal macrocycle (Scheme 64).
235
 Initial bis-acylation of withalongolide 
monoacetate 68 with 4-pentenoyl chloride in the presence of Et3N and DMAP afforded a 
complex mixture of products. Pleasingly, the bis-acylation reaction of 68 with 4-pentenoic 
anhydride in the presence of pyridine and DMAP afforded 92 in excellent yield. 
Subsequent ring-closing metathesis with Grubbs II catalyst exclusively afforded the 14-
membered macrocycle 93 with E-configuration.
236
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Scheme 64. Synthesis of Steroidal Macrocycle 93 from Withalongolide Monoacetate 
68
a
 
 
a
Reagents and conditions: (a) (H2C=CHCH2CH2CO)2O, pyridine, DMAP, rt, 92%; (b) Grubbs II 
catalyst, CH2Cl2, 37 °C, 87%. 
 
Other Attempted Analogue Syntheses 
The complexity of 67 and its vulnerability to various reaction conditions made 
syntheses of many designed analogues unfeasible. For example, preliminary efforts to 
transform the ,-unsaturated ketone of 67 into fused A-ring analogues 94 and 95 through 
Diels–Alder reaction of the 
2,3
-olefin with dienes, such as furan and Danishefsky′s diene, 
met with failure (Scheme 65). The Diels–Alder reaction of a small amount of 67 with furan 
under Lewis acid (YbCl3)
237
 conditions did not lead to the desired product 94. Likewise, the 
reaction of 67 with Danishefsky′s diene at elevated temperature afforded a complex 
mixture. 
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Scheme 65. Unsuccessful Diels–Alder Reaction of 67 with Dienes 
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Scheme 66. Failed Efforts toward the Epoxide Ring-Opening Reactions of 67 
 
 
With an intention to access additional analogues through selective epoxide ring-
opening reaction of 67 with various nucleophiles, an initial attempt was made to open the 
epoxide ring in 67 with cyclohexylamine 45b in the presence of lithium bromide (LiBr).
238
 
However, a mixture of inseparable products was observed from this reaction (Scheme 66a). 
1
H NMR and mass analysis of this mixture of inseparable products and a crude reaction 
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mixture suggests the presence of conjugate-addition product 96b in the mixture. Such 
conjugate addition of secondary amines to withaferin A has been reported.
239
 Similar 
epoxide ring-opening reaction of 67 with iodine (I2) in the presence of thiophenol 
(PhSH)
240
 provided a complex mixture of impurities/byproducts and unreacted 67 (Scheme 
66b). The possibility of the conjugate addition of thiophenol to enone also exists in this 
case. On the other hand, the Baylis–Hilman reaction of 67 with benzaldehyde in the 
presence of DMAP failed to give any product 98 (Scheme 67). 
 
Scheme 67. Unsuccessful Baylis–Hilman Reaction of 67 
 
 
Incorporation of fluorine into a molecule can have a dramatic effect on the 
pharmacokinetic properties of the molecule such as increase in lipophilicity.
241
 Also, the 
substitution of a hydrogen or hydroxyl group for a fluorine can have a dramatic effect on 
the potency of the compound through conformational changes.
241
 Hence, we tried to 
introduce fluorine in 67 either through epoxide ring-opening or nucleophilic fluorination of 
alcohols to obtain analogues 99 or 100, respectively (Scheme 68). The epoxide ring-
opening reaction of 67 with BF3∙OEt2 led to a complex mixture and an incomplete 
reaction.
242
 Similarly, the nucleophilic fluorination of hydroxyl groups in 67 with DAST 
led to a complex mixture.
243
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Scheme 68. Unsuccessful Attempts to Incorporate Fluorine in 67 
 
 
Oxidation of primary and secondary alcohols of 67 to aldehydes and ketone can 
provide a handle for additional chemical manipulations in order to access useful analogues 
(Scheme 69). Initially, we followed the reported allylic oxidation of C-4 alcohol with 
activated manganese(IV) oxide (MnO2)
244
 on withalongolide A 67 (Scheme 69a). 
Unfortunately, the reaction afforded a mixture of products from which a very small amount 
(ca. 1 mg) of an impure sample of 1,4-dione product 101 was obtained (
1
H NMR and mass 
analysis of the impure sample showed the presence of 101). The quantity of 101 was not 
enough to obtain complete spectroscopic data and determine the structure conclusively. 
Changing the oxidation conditions to manganese(III) acetate and DDQ
245
 showed no 
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apparent formation of 101 by TLC analysis (Scheme 69b). Using a harsh oxidant like PDC 
led to decomposition and formation of a complex mixture (Scheme 69c). 
 
Scheme 69. Unsuccessful Oxidation Reactions of 67 
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Cytotoxic Evaluation (carried out in the laboratory of Dr. Mark Cohen) 
All synthesized analogues of 67, along with 66 as a positive control were tested for 
their cytotoxic activity against four cancer cell lines: head and neck squamous cell 
carcinoma (HNSCC, JMAR), breast cancer cells (MDA-MB-231), melanoma (SKMEL-
28), and colon cancer cells (DRO81-1), in addition to normal fetal lung fibroblast (MRC-5) 
cells (Table 20). Compound 67 was less potent than 66, as previously reported.
223a
 
Acetylation of 67 resulted in more potent analogues with diacetates (71 and 72) and 
triacetate 73 exhibiting enhanced cytotoxic activity than the monoacetylated analogues (68, 
69, and 70). Notably, diacetate 72 was found to be selectively cytotoxic towards DRO81-1 
with an IC50 value of 0.0580 M.
223a
 The tripropionylated analogue 74 was also active with 
IC50 values in the range of 0.130–1.00 M. The increased cytotoxic potency of the di- and 
triacetate analogues of 67 could be due to increased lipophilicity leading to enhanced cell 
permeability.
225,246
 
Although the mono-p-chlorobenzoylated derivative 75 and C-19,27-dibenzoylated 
analogue 76 were active, the C-4,27-dibenzoylated analogue 77 and tribenzoylated 
compound 78 were not (Table 20). Compounds 80 and 81 exhibited higher cytotoxic 
activity than 67, with compound 81 displaying 3–5 times increased cytotoxicity against 
breast cancer and melanoma cells compared to 66. Compound 81 also demonstrated modest 
selectivity towards DRO81-1 cells with an IC50 value of 0.0865 M, similar to analogue 72.  
Jaborosalactone V diacetate 85 was found to be equipotent to 66, suggesting that C-4 
hydroxyl group is not crucial for activity (Table 20).
212b,c
 Compound 87, containing a 
5,6-chlorohydrin, was slightly less potent than the 5,6-epoxy analogue 85, with IC50 
values in the range of 0.800–2.16 M against melanoma and carcinoma cells. The cytotoxic 
activity was abolished in epoxide-lacking analogues 86 and 88.
212b,c
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Table 20. Cytotoxicity Activity (IC50 Values in M) of Withalongolide A Analogues 
against Five Cell Lines
a
 
compd JMAR 
MDA-MB-
231 
SKMEL-28 DRO81-1 MRC-5 
66 1.00 0.540 1.00 0.780 2.70 
67 3.10 1.50 1.60 1.70 5.30 
68 1.22 0.415 0.705 1.05 2.30 
69 3.06 1.15 1.23 0.780 1.80 
70 2.48 0.890 1.22 0.570 1.20 
71 0.515 0.205 0.230 0.155 0.490 
72 0.600 0.635 0.170 0.0580 0.295 
73 0.655 0.655 0.110 0.110 0.310 
74 1.00 0.365 0.285 0.130 0.615 
75 1.72 1.40 2.25 1.85 2.55 
76 4.64 2.62 1.11 1.90 2.35 
77 >10 >10 >10 >10 >10 
78 >10 >10 >10 >10 >10 
79 >10 >10 >10 >10 >10 
80 2.09 0.610 0.515 0.585 1.75 
81 0.970 0.175 0.205 0.0865 0.510 
85 1.22 0.790 0.710 1.10 2.05 
86 >10 >10 >10 >10 >10 
87 2.16 0.800 1.17 1.35 3.15 
88 >10 >10 >10 >10 >10 
89 >10 >10 9.11 5.25 9.10 
90 0.830 0.210 0.275 0.115 0.475 
92 1.44 0.625 0.470 0.580 0.865 
93 0.965 0.245 0.205 0.225 0.360 
 a
Analogues 77, 78, 79, 86, and 88 were inactive with IC50 ≥ 10 M for all 
cell lines tested. 
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Even though the 2-iodoenone analogue 90 displayed comparable cytotoxicity to its 
parent compound 73, compound 89 showed very weak activity compared to 67 (Table 20). 
Interestingly, macrocycle 93 exhibited increased potency compared to its acyclic analogue 
92 across all cell lines tested with IC50 values in the range of 0.205–0.965 M.
234
 Most of 
the active analogues were moderately selective towards cancer cells compared to normal 
fibroblast cells. 
 
3.3   Conclusions 
Our initial goal to synthesize complex and varied derivatives of withalongolide A 67 
proved challenging as the highly oxygenated, intricate steroidal framework was vulnerable 
to various chemistries. This prevented us from attaining the synthesis of several designed 
analogues. However, in our efforts to contribute toward the development of anticancer-
related therapeutics, we accessed a series of cytotoxic agents based on the natural product 
67 through the developed chemistry. Overall, we prepared 20 new semisynthetic analogues 
of this fascinating class of cytotoxic agents and evaluated their cytotoxic activity. Many of 
these analogues were more potent than the parent compound and the SAR profile was in 
good agreement with those previously reported for withanolides having similar 
structures.
212,225
 The selectivity of analogues 72 and 81 towards colon cancer cells 
(DRO81-1) is intriguing and further efforts are underway to study these analogues as 
potential anticancer agents. 
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3.4   Experimental Section  
General Information. All reactions were performed under nitrogen atmosphere 
either in capped vials or oven-dried glassware. All chemicals were used as received from 
commercial source without further purification. Commercial anhydrous pyridine was used. 
Methylene chloride, ACN, and THF were dried by passage through neutral alumina 
columns using a commercial solvent purification system prior to use. TLC was performed 
using commercial glass-backed silica plates (250 microns) with an organic binder. 
Preparative TLC was carried out using glass-backed TLC plates (silica gel GF with UV 254 
nm, 1000 microns). Pasteur pipette with a cotton plug or SPE phase separator tabless (6 
mL) was used for filtration/elution during preparative TLC purification. Visualization was 
accomplished with UV light and Seebach’s stain or aqueous KMnO4 by heating. Flash 
chromatography was either carried out on a standard grade silica gel (40–63 m particle 
size, 230  400 mesh) with compressed nitrogen as a source of positive pressure or on a 
CombiFlash Rf system using a 4 g normal-phase silica flash column. IR spectra were 
acquired as thin films or solids. All NMR spectra (
1
H, 
13
C, APT, COSY, HSQC, HMBC, 
and NOESY) were recorded on either a 400 MHz or a 500 MHz with a dual carbon/proton 
cryoprobe instrument. All NMR samples were recorded in CDCl3 that was passed through 
basic alumina. Chemical shifts are reported in parts per million (ppm) and are referenced to 
the center line of the solvent ( 7.26 ppm for 1H NMR and  77.23 ppm for 13C NMR). 
Coupling constants are given in Hertz (Hz). HRMS data were collected with a LCT Premier 
time-of-flight mass spectrometer and an electrospray ion source. Reaction mixtures were 
concentrated under nitrogen gas using a sample concentrator. Melting points were 
determined in open capillary tubes either using a semi-automated or an automated melting 
point apparatus, were taken on solids rather than crystals, and were uncorrected. Single-
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crystal X-ray analyses were performed using Cu K radiation ( = 1.54178 Å) with either 
Bruker APEX2 or Platinum 135 CCD detector. X-rays were provided by a Bruker 
MicroStar microfocus rotating anode equipped with Helios multilayer optics. 
 
Cytotoxicity Assay. Cell viability was determined by a colorimetric CellTiter96
® 
AQueous 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) cell proliferation assay (Promega) to manufacturer′s specifications. In 
brief, each compound was dissolved in DMSO and serially diluted in media. Cells were 
seeded in 90 L of media in 96-well microtiter plates at 1  103 cells/well save for MRC5 
(3  10
3 
cells/well) and incubated overnight. Treatment was carried out in triplicate by the 
addition of 10 μL/well of the serial dilutions for a final drug concentration range of 0.039–
10 M plus control and incubated for 72 hours. 20 L of MTS reagent was added to each 
well, incubated at 37 C for approximately 1.5 hours, and then read at a wavelength of 490 
nm on a BioTek Synergy 2 plate reader. Values were normalized to media alone for the 
lower limit and untreated cells for the upper limit.   
 
Cell Culture. The colon cancer cell line DRO81-1 was a gift from Dr. G. Juillard 
(University of California, Los Angeles, CA) and was propagated in Roswell Park Memorial 
Institute media (RPMI 1640) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS), 1% L-glutamine, 1% penicillin/streptomycin, 1X Hyclone MEM-vitamin solution, 
1X MEM non-essential amino acid solution, and 0.11 mg/mL sodium pyruvate. The 
HNSCC cell lines JMAR was a gift from Dr. Jeffrey Myers (University of Texas, M.D. 
Anderson Cancer Center, Houston, TX). The breast cancer cell line MDA-MB-231 along 
with the human melanoma cell line SKMEL-28 and the fetal fibroblast cell line MRC-5 
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were purchased via ATCC (Manassas, VA). JMAR and MRC5 cell lines were propagated 
with Dulbecco′s Modified Eagle′s Media (DMEM) and supplemented with 10% heat-
inactivated fetal bovine serum, 1% L-glutamine, 1% penicillin/streptomycin, 1X MEM-
vitamin solution, and 1X MEM non-essential amino acid solution. The remaining cell lines 
were grown in similar DMEM but with 5% heat-inactivated FBS. All cell lines were 
expanded in T-75 flasks and incubated in a humidified environment containing 5% CO2 at 
37 C. Cells were harvested for the cytotoxicity assay when they were approximately 80% 
confluent. 
 
Experimental Procedures 
The extraction and isolation of withalongolide A 67 is already described.
223
 
Synthesized compounds were named based on the nomenclature system used for 
withanolides in the literature.
212a,b,225,231a,247
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(4S,20S,22R)-27-Acetyloxy-4,19-dihydroxy-5,6-epoxy-1-oxowitha-2,24-
dienolide (withalongolide A 27-acetate 68), (4S,20S,22R)-19-Acetyloxy-4,27-
dihydroxy-5,6-epoxy-1-oxowitha-2,24-dienolide (withalongolide A 19-acetate 69), 
(4S,20S,22R)-4-Acetyloxy-19,27-dihydroxy-5,6-epoxy-1-oxowitha-2,24-dienolide 
(withalongolide A 4-acetate 70), (4S,20S,22R)-19,27-Diacetyloxy-4-hydroxy-5,6-
epoxy-1-oxowitha-2,24-dienolide (withalongolide A 19,27-diacetate 71), and 
(4S,20S,22R)-4,27-Diacetyloxy-19-hydroxy-5,6-epoxy-1-oxowitha-2,24-dienolide 
(withalongolide A 4,27-diacetate 72; Scheme 55).
223a
 To a vial flushed with nitrogen gas 
at rt was added withalongolide A 67 (60.0 mg, 0.123 mmol, 1.0 equiv), pyridine (0.40 mL), 
and acetic anhydride (13.8 mg, 0.135 mmol, 1.1 equiv). The vial was capped and the 
reaction mixture was stirred at rt for 2 h after which an additional amount of acetic 
anhydride (13.8 mg, 0.135 mmol, 1.1 equiv) was added and stirring was continued for 
another 1 h. The reaction mixture was quenched with ethanol and volatile residues were 
removed under reduced pressure. The crude pale yellow residue obtained was dissolved in 
CH2Cl2 and was subjected to preparative TLC purification developing four times with 3% 
MeOH/CH2Cl2. Bands corresponding to products were scraped from the plate and eluted 
with 6% MeOH/CH2Cl2 through a Pasteur pipette containing a cotton plug. Evaporation of 
solvents under reduced pressure provided impure products, which were further subjected to 
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similar but separate preparative TLC purifications developing two to four times with 2.5% 
MeOH/CH2Cl2 for each product. Subsequent evaporation of solvents afforded 68 (16.0 mg, 
25%; colorless solid), 69 (5.0 mg, 8%; colorless oil), 70 (8.0 mg, 12%; colorless solid), 71 
(8.0 mg, 11%; colorless oil), and 72 (12.0 mg, 17%; pale yellow solid). Withalongolide A 
67 (10.0 mg, 17%) was recovered during the initial preparative TLC purification. 
Withalongolide A 27-acetate 68: Rf = 0.37 (4% MeOH/CH2Cl2, run twice); mp 184–
188 C; IR (neat) 3330 (br), 2940, 1736, 1706, 1677, 1380, 1232, 1026, 910, 729 cm
–1
; 
1
H 
NMR (500 MHz, CDCl3)  0.67 (s, 3H), 0.84–1.00 (m, 3H), 0.97 (d, J = 6.7 Hz, 3H), 1.02–
1.16 (m, 3H), 1.29–1.44 (m, 3H), 1.49–1.56 (m, 1H), 1.58–1.71 (m, 2H), 1.77 (br s, 1H), 
1.92–2.02 (m, 4H), 2.04 (s, 3H), 2.05 (s, 3H), 2.18–2.22 (m, 1H), 2.50 (dd, J = 17.7, 13.3 
Hz, 1H), 3.25 (s, 1H), 3.64 (d, J = 6.0 Hz, 1H), 3.77 (d, J = 9.7 Hz, 1H), 4.32 (d, J = 9.7 
Hz, 1H), 4.38 (dt, J = 13.2, 3.4 Hz, 1H), 4.84 (1/2 AB, J = 11.8 Hz, 1H), 4.88 (1/2 AB, J = 
11.9 Hz, 1H), 6.23 (d, J = 10.0 Hz, 1H), 7.01 (dd, J = 10.0, 6.0 Hz, 1H); 
13
C NMR (125 
MHz, CDCl3)  11.8, 13.5, 20.8, 21.1, 22.2, 24.3, 27.4, 30.2, 30.5, 31.2, 38.9, 39.7, 42.6, 
44.0, 52.0, 54.3, 56.8, 58.1, 61.7, 62.00, 62.01, 68.4, 78.3, 122.0, 133.0, 145.3, 157.2, 
165.5, 171.1, 200.2; HRMS (ESI) m/z calcd for C30H40O8Na [M + Na]
+ 
551.2621, found 
551.2625.  
Withalongolide A 19-acetate 69: Rf = 0.40 (4% MeOH/CH2Cl2, run twice); IR (neat) 
3444 (br), 2939, 1736, 1687, 1396, 1233, 1042, 913, 733 cm
–1
; 
1
H NMR (500 MHz, 
CDCl3)  0.73 (s, 3H), 0.86–0.92 (m, 1H), 1.00 (d, J = 6.6 Hz, 3H), 0.98–1.03 (m, 1H), 
1.05–1.17 (m, 3H), 1.26–1.39 (m, 2H), 1.52–1.71 (m, 4H), 1.95–2.02 (m, 4H), 2.03 (s, 3H), 
2.08 (s, 3H), 2.16–2.21 (m, 1H), 2.49 (dd, J = 17.3, 13.5 Hz, 1H), 2.85 (br s, 1H), 3.15 (s, 
1H), 3.49 (br s, 1H), 3.71 (d, J = 6.0 Hz, 1H), 4.21 (d, J = 10.9 Hz, 1H), 4.32–4.43 (m, 3H), 
5.04 (d, J = 11.0 Hz, 1H), 6.23 (d, J = 10.0 Hz, 1H), 7.05 (dd, J = 10.0, 6.0 Hz, 1H); 
13
C 
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NMR (125 MHz, CDCl3)  11.8, 13.5, 20.2, 21.2, 22.3, 24.4, 27.4, 30.0, 30.7, 31.1, 38.9, 
39.6, 42.7, 44.4, 51.4, 52.0, 56.7, 57.6, 60.7, 61.4, 64.2, 69.4, 78.8, 125.9, 132.4, 144.8, 
152.9, 167.1, 170.6, 198.4; HRMS (ESI) m/z calcd for C30H40O8Na [M + Na]
+ 
551.2621, 
found 551.2629.  
Withalongolide A 4-acetate 70: Rf = 0.47 (4% MeOH/CH2Cl2, run twice); mp 185–
189 C; IR (neat) 3524 (br), 2940, 1743, 1696, 1686, 1396, 1229, 1018, 916, 731 cm
–1
; 
1
H 
NMR (500 MHz, CDCl3)  0.75 (s, 3H), 0.82–0.96 (m, 2H), 1.00 (d, J = 6.6 Hz, 3H), 1.04–
1.18 (m, 3H), 1.27–1.41 (m, 2H), 1.57–1.70 (m, 2H), 1.82–1.91 (m, 2H), 1.95–2.02 (m, 
4H), 2.02 (s, 3H), 2.09 (s, 3H), 2.16–2.21 (m, 1H), 2.48 (dd, J = 17.3, 13.5 Hz, 1H), 2.87 
(dd, J = 10.0, 2.8 Hz, 2H), 3.22 (s, 1H), 4.10 (t, J = 10.9 Hz, 1H), 4.32–4.43 (m, 4H), 4.75 
(d, J = 6.0 Hz, 1H), 6.24 (d, J = 9.9 Hz, 1H), 7.03 (dd, J = 9.9, 6.0 Hz, 1H); 
13
C NMR (125 
MHz, CDCl3)  11.9, 13.5, 20.2, 21.0, 21.9, 24.3, 27.5, 30.0, 30.4, 31.4, 38.9, 39.7, 43.0, 
44.6, 52.0, 52.2, 57.0, 57.6, 59.8, 61.1, 65.6, 71.7, 78.9, 125.9, 134.4, 140.1, 152.9, 167.1, 
170.0, 198.8; HRMS (ESI) m/z calcd for C30H40O8Na [M + Na]
+ 
551.2621, found 551.2620.  
Withalongolide A 19,27-diacetate 71: Rf = 0.57 (4% MeOH/CH2Cl2, run twice); IR 
(neat) 3448 (br), 2940, 1736, 1710, 1678, 1380, 1232, 1033, 915, 732 cm
–1
; 
1
H NMR (500 
MHz, CDCl3)  0.73 (s, 3H), 0.86–0.93 (m, 1H), 1.00 (d, J = 6.6 Hz, 3H), 0.99–1.19 (m, 
4H), 1.26–1.40 (m, 2H), 1.52–1.73 (m, 4H), 1.96–2.03 (m, 4H), 2.05 (s, 3H), 2.06 (s, 3H), 
2.08 (s, 3H), 2.16–2.21 (m, 1H), 2.51 (dd, J = 17.6, 13.3 Hz, 1H), 3.15 (s, 1H), 3.49 (d, J = 
4.9 Hz, 1H), 3.70 (t, J = 5.2 Hz, 1H), 4.21 (d, J = 10.9 Hz, 1H), 4.40 (dt, J = 13.2, 3.4 Hz, 
1H), 4.86 (1/2 AB, J = 11.8 Hz, 1H), 4.89 (1/2 AB, J = 11.8 Hz, 1H), 5.04 (d, J = 11.0 Hz, 
1H), 6.23 (d, J = 10.0 Hz, 1H), 7.05 (dd, J = 10.0, 6.0 Hz, 1H); 
13
C NMR (125 MHz, 
CDCl3)  11.8, 13.5, 20.8, 21.1, 21.2, 22.3, 24.3, 27.4, 30.3, 30.7, 31.1, 38.9, 39.6, 42.7, 
44.4, 51.4, 52.0, 56.7, 58.2, 60.7, 61.4, 64.2, 69.4, 78.3, 122.1, 132.3, 144.8, 157.1, 165.4, 
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170.6, 171.1, 198.4; HRMS (ESI) m/z calcd for C32H42O9Na [M + Na]
+ 
593.2727, found 
593.2726.  
Withalongolide A 4,27-diacetate 72: Rf = 0.70 (4% MeOH/CH2Cl2, run twice); mp 
202–205 C. 
 
 
(4S,20S,22R)-4,19,27-Triacetyloxy-5,6-epoxy-1-oxowitha-2,24-dienolide 
(withalongolide A 4,19,27-triacetate 73; Scheme 55).
223a
 A solution of withalongolide A 
67 (300 mg, 0.617 mmol, 1.0 equiv), pyridine (3.0 mL), acetic anhydride (3.0 mL), and 
DMAP (15.1 mg, 0.123 mmol, 0.2 equiv) was stirred at rt under argon atmosphere for 2 h. 
The reaction mixture was quenched with ethanol and volatile residues were removed under 
reduced pressure. The crude yellow oil was purified by chromatography on a silica gel 
(1.0% MeOH/CH2Cl2) and the semisolid residue obtained was triturated with a 
hexanes:ether mixture. Vacuum filtration and drying afforded 73 as a creamish solid (375 
mg, 99%). Withalongolide A 4,19,27-triacetate 73: Rf = 0.71 (4% MeOH/CH2Cl2, run 
twice). 
 
 
 
 
 
357 
 
 
(4S,20S,22R)-4,19,27-Tripropionyloxy-5,6-epoxy-1-oxowitha-2,24-dienolide 
(withalongolide A 4,19,27-tripropionate 74; Scheme 55). A solution of withalongolide A 
67 (4.5 mg, 0.00926 mmol, 1.0 equiv), pyridine (0.050 mL), propionic anhydride (0.020 
mL), and a small pellet of DMAP (ca. 1–2 mg) was stirred at rt under nitrogen atmosphere 
for 2 h. The reaction mixture was quenched with ethanol and volatile residues were 
removed under reduced pressure. The crude pale yellow residue obtained was purified by 
preparative TLC developing two times with 2% MeOH/CH2Cl2. The band corresponding to 
the product was scraped from the plate and eluted with 5% MeOH/CH2Cl2 through a phase 
separator tabless. Evaporation of solvents afforded 74 as a colorless semisolid (6.0 mg, 
99%). Withalongolide A 4,19,27-tripropionate 74: Rf = 0.38 (2% MeOH/CH2Cl2); IR (neat) 
2978, 2942, 1736, 1710, 1677, 1462, 1349, 1179, 1082, 731 cm
–1
; 
1
H NMR (500 MHz, 
CDCl3)  0.74 (s, 3H), 0.85–0.92 (m, 1H), 1.00 (d, J = 6.7 Hz, 3H), 1.01–1.06 (m, 1H), 
1.08–1.19 (m, 11H), 1.23–1.28 (m, 2H), 1.35–1.42 (m, 1H), 1.60–1.73 (m, 3H), 1.78–1.85 
(m, 1H), 1.97–2.03 (m, 4H), 2.07 (s, 3H), 2.13–2.17 (m, 1H), 2.29–2.47 (m, 6H), 2.51 (dd, 
J = 17.8, 13.4 Hz, 1H), 3.13 (s, 1H), 4.36–4.42 (m, 2H), 4.81 (d, J = 5.9 Hz, 1H), 4.87 (1/2 
AB, J = 11.8 Hz, 1H), 4.90 (1/2 AB, J = 11.9 Hz, 1H), 5.10 (d, J = 11.6 Hz, 1H), 6.23 (d, J 
= 9.9 Hz, 1H), 7.02 (dd, J = 9.9, 5.9 Hz, 1H); 
13
C NMR (125 MHz, CDCl3)  9.1, 9.21, 
9.28, 11.8, 13.5, 20.8, 22.5, 24.4, 27.50, 27.54, 27.6, 27.9, 30.3, 30.9, 31.0, 39.0, 39.6, 42.9, 
44.9, 51.1, 52.0, 56.6, 58.1, 59.1, 59.5, 64.4, 71.1, 78.3, 122.2, 133.4, 141.1, 157.0, 165.4, 
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173.9, 174.0, 174.5, 198.4; HRMS (ESI) m/z calcd for C37H51O10 [M + H]
+ 
655.3482, found 
655.3494. 
 
 
(4S,20S,22R)-4-p-Chlorobenzoyloxy-19,27-dihydroxy-5,6-epoxy-1-oxowitha-
2,24-dienolide (withalongolide A 4-p-chlorobenzoate 75), (4S,20S,22R)-19,27-Di-p-
chlorobenzoyloxy-4-hydroxy-5,6-epoxy-1-oxowitha-2,24-dienolide (withalongolide 
A 19,27-di-p-chlorobenzoate 76), (4S,20S,22R)-4,27-Di-p-chlorobenzoyloxy-19-
hydroxy-5,6-epoxy-1-oxowitha-2,24-dienolide (withalongolide A 4,27-di-p-
chlorobenzoate 77), and (4S,20S,22R)-4,19,27-Tri-p-chlorobenzoyloxy-5,6-epoxy-
1-oxowitha-2,24-dienolide (withalongolide A 4,19,27-tri-p-chlorobenzoate 78; Scheme 
57). To a solution of withalongolide A 67 (60.0 mg, 0.123 mmol, 1.0 equiv), Et3N (0.50 
mL), and DMAP (15.1 mg, 0.123 mmol, 1.0 equiv) in CH2Cl2 (2.0 mL) at rt under nitrogen 
atmosphere was added p-chlorobenzoyl chloride (32.3 mg, 0.185 mmol, 1.5 equiv), and the 
reaction mixture was stirred for 0.5 h after which an additional amount of p-chlorobenzoyl 
chloride (10.8 mg, 0.0617 mmol, 0.5 equiv) was added and stirring was continued for 
another 0.5 h. Volatile residues were removed under reduced pressure. The crude pale 
yellow residue obtained was dissolved in 4% MeOH/CH2Cl2 and was subjected to 
preparative TLC purification developing one time with 2% MeOH/CH2Cl2. Bands 
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corresponding to products were scraped from the plate and eluted with 5% MeOH/CH2Cl2 
through a Pasteur pipette containing a cotton plug. Evaporation of solvents provided impure 
products 75, 76, 77, and 78. Impure products (75, 76, and 78) were further subjected to 
separate preparative TLC purifications developing one time (for 78) to six times (for 75 and 
76) with 1% MeOH/CH2Cl2 for each product. Bands corresponding to products were 
scraped from the plate and eluted with 27% MeOH/CH2Cl2 through a Pasteur pipette 
containing a cotton plug. Subsequent evaporation of solvents afforded 75 (7.7 mg, 10%; 
colorless solid), 76 (5.0 mg, 5%; off-white semisolid), and 78 (11.0 mg, 10%; off-white 
solid). Impure product 77 was triturated with ether twice to remove grease impurities. The 
ether layers were decanted to afford a sample of pure 77 as a colorless solid after drying 
under vacuum (48.0 mg, 51%). Withalongolide A 4-p-chlorobenzoate 75: Rf = 0.37 (2% 
MeOH/CH2Cl2); mp >250 C (dec.); IR (neat) 3587, 3541, 2933, 2869, 1719, 1706, 1684, 
1593, 1397, 1266, 1092, 1012, 907, 759 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  0.77 (s, 3H), 
0.86–0.92 (m, 1H), 0.97–1.06 (m, 1H), 1.01 (d, J = 6.6 Hz, 3H), 1.08–1.19 (m, 3H), 1.32–
1.42 (m, 2H), 1.58–1.71 (m, 2H), 1.85–1.93 (m, 2H), 1.95–2.03 (m, 4H), 2.03 (s, 3H), 
2.19–2.24 (m, 1H), 2.50 (dd, J = 17.3, 13.5 Hz, 1H), 2.85 (br s, 1H), 2.92 (dd, J = 10.2, 2.4 
Hz, 1H), 3.31 (s, 1H), 4.18 (t, J = 10.9 Hz, 1H), 4.32–4.41 (m, 2H), 4.42 (dt, J = 13.3, 3.4 
Hz, 1H), 4.52 (dd, J = 11.5, 1.8 Hz, 1H), 5.04 (d, J = 6.0 Hz, 1H), 6.30 (d, J = 9.9 Hz, 1H), 
7.13 (dd, J = 9.8, 6.0 Hz, 1H), 7.41–7.44 (m, 2H), 7.90–7.93 (m, 2H); 
13
C NMR (125 MHz, 
CDCl3)  12.0, 13.5, 20.2, 22.1, 24.3, 27.5, 30.0, 30.4, 31.5, 39.0, 39.7, 43.1, 44.7, 52.0, 
52.4, 57.0, 57.7, 60.0, 61.2, 65.7, 72.3, 78.9, 125.9, 127.6, 129.3, 131.4, 134.7, 140.0, 
140.4, 152.9, 165.1, 167.2, 198.9; HRMS (ESI) m/z calcd for C35H42ClO8 [M + H]
+ 
625.2568, found 625.2565.  
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Withalongolide A 19,27-di-p-chlorobenzoate 76: Rf = 0.40 (2% MeOH/CH2Cl2); IR 
(neat) 3468, 2924, 2861, 1702, 1670, 1594, 1270, 1104, 1014, 908, 729 cm
–1
; 
1
H NMR 
(500 MHz, CDCl3)  0.72 (s, 3H), 0.90–0.96 (m, 1H), 1.01 (d, J = 6.6 Hz, 3H), 1.07–1.21 
(m, 4H), 1.25–1.41 (m, 3H), 1.59–1.71 (m, 3H), 2.00–2.06 (m, 3H), 2.10–2.18 (m, 2H), 
2.13 (s, 3H), 2.55 (dd, J = 17.7, 13.3 Hz, 1H), 3.15 (s, 1H), 3.31 (br s, 1H), 3.79 (d, J = 5.8 
Hz, 1H), 4.41 (dt, J = 13.2, 3.4 Hz, 1H), 4.65 (d, J = 11.5 Hz, 1H), 5.13 (s, 2H), 5.16 (d, J = 
11.5 Hz, 1H), 6.24 (d, J = 10.0 Hz, 1H), 7.04 (dd, J = 10.0, 5.8 Hz, 1H), 7.37–7.42 (m, 4H), 
7.94–7.99 (m, 4H); 
13
C NMR (125 MHz, CDCl3)  11.9, 13.5, 20.9, 23.0, 24.3, 27.4, 30.4, 
30.9, 31.0, 39.0, 39.6, 42.8, 44.7, 51.2, 52.1, 56.6, 58.8, 60.6, 61.8, 65.4, 69.6, 78.3, 122.1, 
128.61, 128.64, 128.9, 129.0, 131.32, 131.36, 132.0, 139.7, 139.8, 144.2, 157.4, 165.4, 
165.8, 166.0, 198.7; HRMS (ESI) m/z calcd for C42H45Cl2O9 [M + H]
+ 
763.2441, found 
763.2443.  
Withalongolide A 4,27-di-p-chlorobenzoate 77: Rf = 0.65 (2% MeOH/CH2Cl2); mp 
>250 C; IR (neat) 3573, 2968, 2941, 1710, 1673, 1591, 1398, 1263, 1080, 1047, 1013, 
906, 757, 727 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  0.76 (s, 3H), 0.85–0.91 (m, 1H), 0.99–
1.04 (m, 1H), 1.01 (d, J = 6.6 Hz, 3H), 1.06–1.18 (m, 3H), 1.31–1.42 (m, 2H), 1.57–1.72 
(m, 2H), 1.84–1.92 (m, 2H), 1.97–2.06 (m, 4H), 2.12 (s, 3H), 2.18–2.22 (m, 1H), 2.54 (dd, 
J = 17.7, 13.3 Hz, 1H), 2.92 (dd, J = 10.4, 3.0 Hz, 1H), 3.31 (s, 1H), 4.17 (t, J = 11.0 Hz, 
1H), 4.41 (dt, J = 13.2, 3.4 Hz, 1H), 4.51 (dd, J = 11.6, 3.0 Hz, 1H), 5.03 (d, J = 6.0 Hz, 
1H), 5.12 (s, 2H), 6.29 (d, J = 9.9 Hz, 1H), 7.12 (dd, J = 9.9, 6.0 Hz, 1H), 7.36–7.39 (m, 
2H), 7.40–7.42 (m, 2H), 7.89–7.92 (m, 2H), 7.93–7.95 (m, 2H); 
13
C NMR (125 MHz, 
CDCl3)  11.9, 13.5, 20.9, 22.0, 24.3, 27.5, 30.36, 30.39, 31.4, 38.9, 39.6, 43.0, 44.6, 52.0, 
52.3, 56.9, 58.8, 60.0, 61.1, 65.6, 72.2, 78.4, 122.0, 127.5, 128.6, 128.8, 129.2, 131.31, 
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131.34, 134.6, 139.6, 139.9, 140.3, 157.4, 165.0, 165.3, 165.7, 198.8; HRMS (ESI) m/z 
calcd for C42H45Cl2O9 [M + H]
+ 
763.2441, found 763.2417.  
Withalongolide A 4,19,27-tri-p-chlorobenzoate 78: Rf = 0.87 (2% MeOH/CH2Cl2); IR 
(neat) 2942, 1715, 1678, 1593, 1400, 1268, 1091, 1014, 758 cm
–1
; 
1
H NMR (500 MHz, 
CDCl3)  0.63 (s, 3H), 0.92–0.98 (m, 1H), 0.99 (d, J = 6.6 Hz, 3H), 1.07–1.22 (m, 3H), 
1.26–1.38 (m, 3H), 1.57–1.73 (m, 3H), 1.80–1.87 (m, 1H), 1.96–2.06 (m, 3H), 2.11–2.16 
(m, 1H), 2.13 (s, 3H), 2.19–2.23 (m, 1H), 2.54 (dd, J = 17.7, 13.3 Hz, 1H), 3.30 (d, J = 1.5 
Hz, 1H), 4.41 (dt, J = 13.1, 3.4 Hz, 1H), 4.89 (d, J = 11.7 Hz, 1H), 5.04 (d, J = 11.8 Hz, 
1H), 5.13 (s, 2H), 5.15 (d, J = 5.7 Hz, 1H), 6.32 (d, J = 10.0 Hz, 1H), 7.13 (dd, J = 10.0, 5.7 
Hz, 1H), 7.29–7.32 (m, 2H), 7.34–7.40 (m, 4H), 7.86–7.89 (m, 2H), 7.93–7.96 (m, 4H); 
13
C 
NMR (125 MHz, CDCl3)  11.8, 13.5, 20.9, 23.4, 24.4, 27.4, 30.3, 30.9, 31.1, 38.9, 39.6, 
42.8, 44.9, 51.3, 52.1, 56.3, 58.8, 59.5, 59.9, 65.7, 71.7, 78.3, 122.1, 127.5, 128.5, 128.6, 
128.8, 128.9, 129.0, 131.2, 131.3, 131.4, 133.3, 139.6, 139.8, 140.2, 141.0, 157.4, 165.4, 
165.80, 165.85, 198.5; HRMS (ESI) m/z calcd for C49H48Cl3O10 [M + H]
+ 
901.2313, found 
901.2291.  
 
 
(4S,20S,22R)-19-Acetyloxy-4,27-di-p-chlorobenzoyloxy-5,6-epoxy-1-oxo-
witha-2,24-dienolide (withalongolide A 19-acetyloxy-4,27-di-p-chlorobenzoate 79; 
Scheme 57). To a solution of withalongolide A 4,27-di-p-chlorobenzoate 77 (15.0 mg, 
0.0196 mmol, 1.0 equiv), Et3N (0.10 mL), and DMAP (ca. 1.0 mg) in CH2Cl2 (0.30 mL) at 
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rt under nitrogen atmosphere was added acetic anhydride (0.10 mL), and the reaction 
mixture was stirred for 0.5 h. The reaction mixture was quenched with ethanol and volatile 
residues were removed under reduced pressure. The crude pale yellow residue obtained was 
purified by preparative TLC developing three times with 1% MeOH/CH2Cl2. The band 
corresponding to the product was scraped from the plate and eluted with 5% MeOH/CH2Cl2 
through a Pasteur pipette containing a cotton plug. Evaporation of solvents afforded 79 as 
an off-white solid (15.1 mg, 95%). Withalongolide A 19-acetate-4,27-di-p-chlorobenzoate 
79: Rf = 0.50 (1% MeOH/CH2Cl2, run twice); IR (neat) 2944, 2869, 1717, 1680, 1593, 
1400, 1268, 1092, 759 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.77 (s, 3H), 0.87–0.94 (m, 
1H), 0.98–1.20 (m, 4H), 1.02 (d, J = 6.6 Hz, 3H), 1.26–1.43 (m, 2H), 1.62–1.73 (m, 3H), 
1.86 (m, 1H), 2.01–2.07 (m, 1H), 2.03 (s, 6H), 2.13 (s, 3H), 2.16–2.21 (m, 1H), 2.55 (dd, J 
= 17.7, 13.3 Hz, 1H), 3.20 (s, 1H), 4.42 (dt, J = 13.1, 3.3 Hz, 1H), 4.48 (d, J = 11.7 Hz, 
1H), 4.97 (d, J = 5.9 Hz, 1H), 5.13 (s, 2H), 5.23 (d, J = 11.7 Hz, 1H), 6.28 (d, J = 9.9 Hz, 
1H), 7.16 (dd, J = 9.9, 5.9 Hz, 1H), 7.37–7.40 (m, 2H), 7.41–7.44 (m, 2H), 7.93–7.97 (m, 
2H), 8.02–8.05 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  11.7, 13.5, 20.9, 21.3, 22.3, 24.4, 
27.5, 30.4, 30.9, 31.0, 39.0, 39.6, 42.9, 45.0, 51.0, 52.0, 56.5, 58.8, 59.1, 59.5, 64.5, 72.5, 
78.4, 122.1, 127.7, 128.6, 128.8, 129.1, 131.3, 131.6, 133.7, 139.6, 140.2, 140.9, 157.3, 
165.3, 165.4, 165.7, 170.7, 198.1; HRMS (ESI) m/z calcd for C44H47Cl2O10 [M + H]
+ 
805.2546, found 805.2542. 
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(4S,20S,22R)-4-N,N-Dimethylcarbamoyloxy-19,27-dihydroxy-5,6-epoxy-1-
oxowitha-2,24-dienolide (withalongolide A 4-dimethylcarbamate 80) and 
(4S,20S,22R)-19,27-Diacetyloxy-4-N,N-dimethylcarbamoyloxy-5,6-epoxy-1-oxo-
witha-2,24-dienolide (withalongolide A 19,27-diacetyloxy-4-dimethylcarbamate 81; 
Scheme 58). To a solution of withalongolide A 67 (18.0 mg, 0.0370 mmol, 1.0 equiv), 
Et3N (0.10 mL), and a small pellet of DMAP (ca. 1–2 mg) in CH2Cl2 (0.40 mL) at 0 C 
under nitrogen atmosphere was added dimethylcarbamoyl chloride (0.10 mL). The ice-bath 
was removed and the reaction mixture was stirred at rt for 20 min. The reaction mixture 
was concentrated and the crude residue obtained was purified twice by preparative TLC 
developing two to three times with 3% MeOH/CH2Cl2. The band corresponding to the 
product was scraped from the plate and eluted with 10% MeOH/CH2Cl2 through a Pasteur 
pipette containing a cotton plug. Evaporation of solvents afforded 80 as a colorless oil (15.0 
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mg, 73%). Withalongolide A 4-dimethylcarbamate 80: Rf = 0.34 (3% MeOH/CH2Cl2); IR 
(neat) 3511, 2940, 2869, 1698, 1396, 1183, 1048, 909, 730 cm
–1
; 
1
H NMR (500 MHz, 
CDCl3)  0.75 (s, 3H), 0.83–0.89 (m, 1H), 0.94–1.00 (m, 1H), 1.00 (d, J = 6.6 Hz, 3H), 
1.04–1.18 (m, 3H), 1.24–1.40 (m, 2H), 1.57–1.69 (m, 2H), 1.82–1.91 (m, 2H), 1.95–2.02 
(m, 4H), 2.02 (s, 3H), 2.15–2.20 (m, 1H), 2.48 (dd, J = 17.4, 13.6 Hz, 1H), 2.88–2.96 (m, 
2H), 2.89 (s, 3H), 2.91 (s, 3H), 3.24 (s, 1H), 4.10 (t, J = 11.0 Hz, 1H), 4.31–4.43 (m, 4H), 
4.73 (d, J = 5.9 Hz, 1H), 6.21 (d, J = 9.9 Hz, 1H), 7.07 (dd, J = 9.9, 6.0 Hz, 1H); 
13
C NMR 
(125 MHz, CDCl3)  11.9, 13.5, 20.2, 22.1, 24.3, 27.4, 30.0, 30.4, 31.5, 36.3, 36.9, 38.9, 
39.7, 43.0, 44.6, 52.0, 52.1, 56.9, 57.6, 59.9, 61.4, 65.6, 72.2, 78.9, 125.8, 133.8, 141.5, 
152.9, 155.4, 167.1, 199.2; HRMS (ESI) m/z calcd for C31H44NO8 [M + H]
+ 
558.3067, 
found 558.3035. 
A solution of withalongolide A 4-dimethylcarbamate 80 (7.50 mg, 0.0134 mmol, 1.0 
equiv), pyridine (0.30 mL), acetic anhydride (0.30 mL), and a small pellet of DMAP (ca. 1–
2 mg) was stirred at rt under nitrogen atmosphere for 1 h. The reaction mixture was 
concentrated and then quenched with ethanol. The volatile residues were removed under 
reduced pressure. The pale yellow residue obtained was purified twice by preparative TLC 
developing two times with 2% MeOH/CH2Cl2. The band corresponding to the product was 
scraped from the plate and eluted with 5% MeOH/CH2Cl2 through a phase separator 
tabless. Evaporation of solvents afforded 81 as a colorless waxy solid (6.0 mg, 70%). 
Withalongolide A 19,27-diacetyloxy-4-dimethylcarbamate 81: Rf = 0.35 (2% 
MeOH/CH2Cl2, run twice); IR (neat) 2940, 2869, 1738, 1705, 1396, 1229, 1181, 1044, 917, 
731 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  0.76 (s, 3H), 0.86–0.92 (m, 1H), 0.98–1.04 (m, 
1H), 1.00 (d, J = 6.6 Hz, 3H), 1.06–1.19 (m, 3H), 1.23–1.28 (m, 2H), 1.35–1.42 (m, 1H), 
1.60–1.73 (m, 3H), 1.85–1.92 (m, 1H), 1.98–2.04 (m, 3H), 2.05 (s, 3H), 2.07 (s, 6H), 2.14–
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2.18 (m, 1H), 2.52 (dd, J = 17.7, 13.3 Hz, 1H), 2.90 (s, 3H), 2.96 (s, 3H), 3.13 (s, 1H), 4.41 
(dt, J = 13.2, 3.4 Hz, 1H), 4.44 (d, J = 11.8 Hz, 1H), 4.68 (d, J = 5.9 Hz, 1H), 4.86 (1/2 AB, 
J = 11.8 Hz, 1H), 4.90 (1/2 AB, J = 11.9 Hz, 1H), 5.11 (d, J = 11.7 Hz, 1H), 6.21 (d, J = 
9.9 Hz, 1H), 7.12 (dd, J = 9.9, 5.9 Hz, 1H); 
13
C NMR (125 MHz, CDCl3)  11.7, 13.5, 20.8, 
21.1, 21.3, 22.2, 24.5, 27.5, 30.3, 30.9, 31.1, 36.4, 37.0, 39.0, 39.6, 42.9, 44.9, 50.7, 52.0, 
56.5, 58.2, 58.9, 59.7, 64.8, 72.4, 78.3, 122.1, 132.8, 142.6, 155.6, 157.1, 165.5, 170.7, 
171.1, 198.4; HRMS (ESI) m/z calcd for C35H48NO10 [M + H]
+ 
642.3278, found 642.3259. 
 
 
(4S,20S,22R)-27-Chloro-19-hydroxy-5,6-epoxy-1-oxowitha-2,24-dienolide-4-
phenyl carbonate (withalongolide A 27-chloro-19-hydroxy-4-phenyl carbonate 82) and 
(4S,20S,22R)-4,27-Dihydroxy-5,6-epoxy-1-oxowitha-2,24-dienolide-19-phenyl 
carbonate (withalongolide A 4,27-dihydroxy-19-phenyl carbonate 83; Scheme 59). To 
a solution of withalongolide A 67 (60.0 mg, 0.123 mmol, 1.0 equiv) and Et3N (0.50 mL) in 
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CH2Cl2 (2.0 mL) at rt under nitrogen atmosphere was added phenylchloroformate (38.6 mg, 
0.247 mmol, 2.0 equiv), and the reaction mixture was stirred for 1 h (multitude of spots 
observed by TLC). Volatile residues were removed under reduced pressure. The crude 
residue obtained was dissolved in CH2Cl2 and was purified by preparative TLC purification 
developing two times with 2% MeOH/CH2Cl2. Two broad bands (band A and band B) 
comprising of a multitude of overlapping bands were scraped from the plate and eluted 
separately with 7% MeOH/CH2Cl2 through a Pasteur pipette containing a cotton plug. Band 
A containing multiple bands was subjected twice to preparative TLC purification 
developing three and four times with 1% MeOH/CH2Cl2 and three times with 100% 
CH2Cl2. The band corresponding to compound 82 was scraped from the plate and eluted 
with 5% MeOH/CH2Cl2 through a Pasteur pipette containing a cotton plug. Evaporation of 
solvents provided an impure sample of 82 as a colorless oil (ca. 3.2 mg, ca. 4% corrected 
yield; contains ca. 20% of unidentified impurities by 
1
H NMR). Similarly, band B 
containing multiple bands was also subjected twice to preparative TLC purification 
developing two times with 1% MeOH/CH2Cl2 and four and nine times with 2% 
MeOH/CH2Cl2. The band corresponding to compound 83 was scraped from the plate and 
eluted with 6% MeOH/CH2Cl2 through a Pasteur pipette containing a cotton plug. 
Evaporation of solvents provided an impure sample of 83 as a colorless oil (ca. 2.2 mg, ca. 
3% corrected yield; contains ca. 25% of unidentified impurities by 
1
H NMR). 
Withalongolide A 27-chloro-19-hydroxy-4-phenyl carbonate 82: IR (neat) 3548, 2944, 
1764, 1709, 1681, 1396, 1244, 1209, 1050, 731 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  0.77 
(s, 3H), 0.84–0.90 (m, 1H), 0.95–1.01 (m, 1H), 1.01 (d, J = 6.7 Hz, 3H), 1.05–1.21 (m, 
3H), 1.29–1.44 (m, 2H), 1.60–1.70 (m, 2H), 1.84–1.95 (m, 2H), 1.99–2.05 (m, 4H), 2.10 (s, 
3H), 2.19–2.24 (m, 1H), 2.54 (dd, J = 17.8, 13.3 Hz, 1H), 2.76 (d, J = 8.2 Hz, 1H), 3.29 (s, 
1H), 4.09 (t, J = 10.8 Hz, 1H), 4.32–4.45 (m, 4H), 4.76 (d, J = 6.0 Hz, 1H), 6.34 (d, J = 9.9 
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Hz, 1H), 7.10 (dd, J = 9.9, 6.0 Hz, 1H), 7.15–7.18 (m, 2H), 7.24–7.28 (m, 1H), 7.37–7.40 
(m, 2H); 
13
C NMR (125 MHz, CDCl3)  12.0, 13.6, 20.8, 22.0, 24.4, 27.6, 30.3, 30.5, 31.5, 
37.4, 39.0, 39.8, 43.1, 44.7, 52.1, 52.3, 57.0, 60.1, 61.1, 65.6, 75.6, 78.5, 121.1, 124.3, 
126.6, 129.8, 135.5, 138.9, 151.2, 153.1, 156.4, 164.9, 198.6; HRMS (ESI) m/z calcd for 
C35H42
35
ClO8 [M + H]
+ 
625.2568, found 625.2474; for C35H42
37
ClO8 [M + H + 2]
+ 
627.2539, found 627.2462 (chlorine isotopes were observed in mass).  
Withalongolide A 4,27-dihydroxy-19-phenyl carbonate 83: IR (neat) 3452, 2939, 
1761, 1685, 1396, 1240, 1211, 1023, 730 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  0.74 (s, 3H), 
0.86–0.94 (m, 1H), 1.01 (d, J = 6.7 Hz, 3H), 1.04–1.21 (m, 4H), 1.30–1.43 (m, 2H), 1.54–
1.74 (m, 6H), 1.95–2.06 (m, 4H), 2.03 (s, 3H), 2.22–2.26 (m, 1H), 2.50 (dd, J = 17.3, 13.7 
Hz, 1H), 3.20 (s, 1H), 3.76 (d, J = 6.1 Hz, 1H), 4.33–4.47 (m, 4H), 5.19 (d, J = 10.8 Hz, 
1H), 6.27 (d, J = 10.0 Hz, 1H), 7.08 (dd, J = 10.0, 6.1 Hz, 1H), 7.19–7.21 (m, 2H), 7.23–
7.26 (m, 1H), 7.36–7.40 (m, 2H); 
13
C NMR (125 MHz, CDCl3)  11.9, 13.6, 20.2, 22.3, 
24.4, 27.5, 30.1, 30.8, 31.1, 39.0, 39.7, 42.8, 44.5, 51.7, 52.1, 56.9, 57.7, 60.6, 61.4, 68.4, 
69.7, 78.9, 121.3, 125.9, 126.4, 129.7, 132.6, 144.8, 151.2, 152.9, 153.6, 167.2, 198.1; 
HRMS (ESI) m/z calcd for C35H43O9 [M + H]
+ 
607.2907, found 607.2864.  
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(20S,22R)-19,27-Diacetyloxy-5,6-epoxy-1-oxowitha-2,24-dienolide 
(jaborosalactone V 19,27-diacetate 85) and (20S,22R)-19,27-Diacetyloxy-6-hydroxy-
1-oxowitha-2,4,24-trienolide (jaborosalactone B 19,27-diacetate 86; Scheme 61). 
Following a modification of a reported protocol,
229,248
 to a solution of withalongolide A 
4,19,27-triacetate 73 (40.0 mg, 0.0652 mmol, 1.0 equiv) in 1,4-dioxane (1.5 mL) at rt under 
nitrogen atmosphere was added palladium acetate (ca. 1.5 mg, 0.00652 mmol, 0.10 equiv), 
triphenyl phosphine (3.4 mg, 0.0130 mmol, 0.20 equiv), and ammonium formate (12.3 mg, 
0.195 mmol, 3.0 equiv). The reaction mixture was heated at 100 C for 1 h in a sealed vial. 
The reaction mixture was concentrated and the residue obtained was purified twice by 
preparative TLC developing eight to ten times with 1.5% MeOH/CH2Cl2. Bands 
corresponding to products were scraped from the plate and eluted with 5% MeOH/CH2Cl2 
through a phase separator tabless. Evaporation of solvents afforded 86 as a pale yellow 
amorphous solid (9.5 mg, 26%) and 85 after recrystallization from EtOAc as colorless 
crystals (8.8 mg, 24%). Crystals of 85 were used for X-ray diffraction analysis (Table S27). 
Jaborosalactone V 19,27-diacetate 85: Rf = 0.57 (2% MeOH/CH2Cl2, run three times); mp 
172–174 C; IR (neat) 2924, 2853, 1734, 1711, 1673, 1377, 1235, 1034, 970 cm
–1
; 
1
H 
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NMR (500 MHz, CDCl3)  0.70 (s, 3H), 0.86–0.92 (m, 1H), 0.98 (d, J = 6.6 Hz, 3H), 1.02–
1.18 (m, 4H), 1.30–1.47 (m, 3H), 1.49–1.71 (m, 4H), 1.90–2.01 (m, 3H), 2.02 (s, 3H), 2.05 
(s, 3H), 2.06 (s, 3H), 2.07–2.10 (m, 1H), 2.13–2.17 (m, 1H), 2.51 (dd, J = 17.8, 13.3 Hz, 
1H), 3.05 (s, 1H), 3.18 (dt, J = 18.0, 2.5 Hz, 1H), 4.25 (d, J = 10.2 Hz, 1H), 4.39 (dt, J = 
13.2, 3.4 Hz, 1H), 4.74 (d, J = 10.2 Hz, 1H), 4.86 (1/2 AB, J = 11.8 Hz, 1H), 4.89 (1/2 AB, 
J = 11.8 Hz, 1H), 6.10 (dd, J = 10.1, 2.7 Hz, 1H), 6.92 (m, 1H); 
13
C NMR (125 MHz, 
CDCl3)  11.8, 13.5, 20.8, 21.1, 21.2, 22.7, 24.3, 27.4, 30.3, 30.5, 31.5, 35.3, 38.9, 39.8, 
42.7, 44.4, 52.0, 52.1, 56.6, 58.2, 59.9, 62.3, 65.7, 78.3, 122.0, 129.9, 145.2, 157.1, 165.4, 
170.5, 171.1, 199.8; HRMS (ESI) m/z calcd for C32H43O8 [M + H]
+ 
555.2958, found 
555.2971.  
 
Table S27. Selected Crystallographic and Refinement Parameters for Jaborosalactone 
V 19,27-Diacetate 85 
Compound Jaborosalactone V 19,27-diacetate 85 
CCDC deposition number 972242 
Empirical formula C36H50O10 (C32H42O8 + CH3COOCH2CH3) 
Formula wt. 642.76 
Temperature 100(2) K 
Crystal color Colorless 
Crystal system Monoclinic 
Crystal size (mm
3
) 0.28  0.14  0.11 
Space group P21 
a [Å] 11.9047(4) 
b [Å] 12.2331(4) 
c [Å] 12.3943(4) 
 [deg] 90 
[deg] 108.5560(10) 
 [deg] 90 
Z 2 
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Compound Jaborosalactone V 19,27-diacetate 85 
Volume [Å
3
] 1711.16(10) 
Dcalc [Mg/m
3
] 1.247 
F (000) 692 
Absorption coefficient  [mm–1] 0.737 
Theta range for data collection 3.76 to 69.25 
Range h –14<=h<=14 
Range k –11<=k<=13 
Range l –14<=l<=14 
Reflections collected 15605 
Independent reflections 4775 
Rint 0.0171 
Data / Restraints / Parameters 4775 / 1 / 578 
Final R indices [I>2(I)] 0.0431 
wR2 0.1169 
Absolute structure parameter –0.02(18) 
Goodness-of-fit on F
2
 1.049 
R-factor (%) 4.31 
Largest diff. peak and hole (eÅ
–3
) 0.684 and –0.525 
 
Jaborosalactone B 19,27-diacetate 86: Rf = 0.34 (2% MeOH/CH2Cl2, run three times); 
IR (neat) 3461, 2937, 2873, 1735, 1710, 1660, 1631, 1376, 1236, 1044 cm
–1
; 
1
H NMR (500 
MHz, CDCl3)  0.77 (s, 3H), 0.90–0.95 (m, 1H), 0.96–1.01 (m, 1H), 0.99 (d, J = 6.6 Hz, 
3H), 1.04–1.17 (m, 2H), 1.19–1.28 (m, 1H), 1.34–1.53 (m, 2H), 1.56–1.71 (m, 2H), 1.90–
1.94 (m, 1H), 1.90 (s, 3H), 1.97–2.03 (m, 3H), 2.03–2.12 (m, 3H), 2.04 (s, 3H), 2.05 (s, 
3H), 2.50 (dd, J = 17.7, 13.3 Hz, 1H), 2.87 (br s, 1H), 4.39 (dt, J = 13.2, 3.4 Hz, 1H), 4.63 
(t, J = 2.7 Hz, 1H), 4.75 (d, J = 9.7 Hz, 1H), 4.85 (1/2 AB, J = 11.8 Hz, 1H), 4.89 (1/2 AB, 
J = 11.8 Hz, 1H), 5.18 (d, J = 9.7 Hz, 1H), 6.09 (d, J = 9.6 Hz, 1H), 6.28 (d, J = 5.9 Hz, 
1H), 6.96 (dd, J = 9.7, 6.0 Hz, 1H); 
13
C NMR (125 MHz, CDCl3)  12.1, 13.4, 20.8, 21.0, 
21.1, 24.4, 27.5, 30.3, 31.7, 38.9, 39.7, 41.3, 42.9, 50.2, 51.9, 56.5, 58.1, 58.2, 67.8, 74.0, 
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78.3, 120.0, 122.0, 127.0, 140.4, 155.0, 157.1, 165.4, 171.1, 171.4, 202.2; HRMS (ESI) m/z 
calcd for C32H43O8 [M + H]
+ 
555.2958, found 555.2924. 
 
 
(20S,22R)-5-Chloro-19,27-diacetyloxy-6-hydroxy-1-oxowitha-2,24-dienolide 
(jaborosalactone E 19,27-diacetate 87; Scheme 61). To a solution of jaborosalactone V 
19,27-diacetate 85 (4.0 mg, 0.00721 mmol, 1.0 equiv) in CH2Cl2 (0.10 mL) under nitrogen 
atmosphere was added a 2.0 M HCl solution in diethyl ether (0.50 mL) and the reaction 
mixture was stirred at rt for 1 h. The reaction mixture was concentrated and the pale yellow 
residue obtained was purified twice by preparative TLC developing one to two times with 
2% MeOH/CH2Cl2. The band corresponding to the product was scraped from the plate and 
eluted with 5% MeOH/CH2Cl2 through a phase separator tabless. Evaporation of solvents 
afforded 87 as a colorless semisolid (3.0 mg, 70%). Jaborosalactone E 19,27-diacetate 87: 
Rf = 0.35 (2% MeOH/CH2Cl2, run twice); IR (neat) 3449, 2934, 2873, 1739, 1696, 1381, 
1237, 1031, 731 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  0.74 (s, 3H), 1.02 (d, J = 6.6 Hz, 3H), 
1.10–1.19 (m, 3H), 1.22–1.30 (m, 1H), 1.34–1.39 (m, 2H), 1.57–1.81 (m, 4H), 1.94 (br s, 
1H), 1.96–1.99 (m, 1H), 1.97 (s, 3H), 2.00–2.06 (m, 4H), 2.06 (s, 3H), 2.08 (s, 3H), 2.28–
2.31 (m, 1H), 2.51–2.58 (m, 2H), 3.60 (dt, J = 20.5, 2.6 Hz, 1H), 3.99 (s, 1H), 4.40–4.50 
(m, 3H), 4.87 (1/2 AB, J = 11.8 Hz, 1H), 4.90 (1/2 AB, J = 11.8 Hz, 1H), 6.01 (dd, J = 
10.2, 1.9 Hz, 1H), 6.62 (ddd, J = 10.2, 4.8, 2.3 Hz, 1H); 
13
C NMR (125 MHz, CDCl3)  
12.5, 13.4, 20.8, 21.1, 21.3, 23.4, 24.3, 27.4, 30.3, 30.4, 33.3, 37.9, 39.0, 40.1, 41.6, 43.3, 
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52.2, 55.3, 55.6, 58.2, 63.6, 73.7, 77.4, 78.4, 122.0, 129.2, 140.5, 157.3, 165.5, 170.6, 
171.1, 197.4; HRMS (ESI) m/z calcd for C32H44ClO8 [M + H]
+ 
591.2725, found 591.2737. 
In order to confirm the structure of 87, an acetylation reaction on a small amount of 
87 was carried out. The presence of acetyl group was confirmed by 
1
H NMR and HRMS 
analysis of the acetylated compound 87a. However, the quantity of sample obtained for 87a 
was not enough for complete spectroscopic analysis in order to obtain good quality data. 
 
 
(20S,22R)-5-Chloro-6,19,27-triacetyloxy-1-oxowitha-2,24-dienolide 
(jaborosalactone E 6,19,27-triacetate 87a). To a solution of jaborosalactone E 19,27-
diacetate 87 (ca. 1.1 mg, 0.0019 mmol, 1.0 equiv) and DMAP (ca. 1.0 mg) in pyridine (0.05 
mL) was added acetic anhydride (0.01 mL), and the reaction mixture was stirred at rt under 
nitrogen atmosphere for 2 h (messy reaction by TLC). The reaction mixture was 
concentrated and the residue obtained was quenched with ethanol. The solution was again 
concentrated and the residue was purified by preparative TLC developing two times with 
2% MeOH/CH2Cl2. Bands corresponding to 87a and 88 (vide infra) were scraped from the 
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plate and eluted separately with 5% MeOH/CH2Cl2 through a phase separator tabless. 
Evaporation of solvents afforded a slightly impure sample of 87a (ca. 0.1 mg) and a slightly 
impure sample of 88 (ca. 0.2 mg) as colorless oils. Jaborosalactone E 6,19,27-triacetate 
87a: Rf = 0.70 (3% MeOH/CH2Cl2, run twice); 
1
H NMR (500 MHz, CDCl3)  0.75 (s, 3H), 
1.02 (d, J = 6.7 Hz, 3H), 1.10–1.30 (complex, 6H), 1.33–1.40 (m, 2H), 1.58–1.72 (m, 3H), 
1.93–1.97 (m, 1H), 1.98 (m, 3H), 1.99–2.04 (m, 2H), 2.05–2.07 (m, 1H), 2.06 (s, 3H), 2.09 
(br s, 3H), 2.18 (s, 3H), 2.32–2.35 (m, 1H), 2.51–2.62 (m, 2H), 3.14 (dt, J = 20.4, 2.6 Hz, 
1H), 4.40–4.46 (m, 3H), 4.87 (1/2 AB, J = 11.8 Hz, 1H), 4.91 (1/2 AB, J = 11.9 Hz, 1H), 
5.12 (m, 1H), 6.03 (dd, J = 10.3, 1.9 Hz, 1H), 6.58 (ddd, J = 10.3, 4.8, 2.3 Hz, 1H); HRMS 
(ESI) m/z calcd for C34H46ClO9 [M + H]
+ 
633.2830, found 633.2791.  
1
H and 
13
C NMR data for 88 obtained from this experiment (acetylation reaction of 
87) matched with the NMR data for 88 obtained from the experiment shown below 
(acetylation reaction of 86).   
 
 
(20S,22R)-6,19,27-Triacetyloxy-1-oxowitha-2,4,24-trienolide (jaborosalactone B 
6,19,27-triacetate 88; Scheme 61). A solution of jaborosalactone B 19,27-diacetate 86 (4.5 
mg, 0.00811 mmol, 1.0 equiv), pyridine (0.050 mL), acetic anhydride (0.050 mL), and a 
small pellet of DMAP (ca. 1–2 mg) was stirred at rt under nitrogen atmosphere for 1.5 h. 
The reaction mixture was quenched with ethanol and volatile residues were removed under 
reduced pressure. The crude pale yellow residue obtained was purified by preparative TLC 
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developing two times with 3% MeOH/CH2Cl2. The band corresponding to the product was 
scraped from the plate and eluted with 5% MeOH/CH2Cl2 through a phase separator 
tabless. Evaporation of solvents afforded 88 as an off-white solid (4.2 mg, 87%). 
Jaborosalactone B 6,19,27-triacetate 88: Rf = 0.19 (2% MeOH/CH2Cl2); mp 239–243 C; 
IR (neat) 2940, 2869, 1739, 1712, 1664, 1635, 1371, 1247, 1025, 730 cm
–1
; 
1
H NMR (500 
MHz, CDCl3)  0.80 (s, 3H), 0.92–0.97 (m, 1H), 0.99 (d, J = 6.6 Hz, 3H), 1.00–1.09 (m, 
2H), 1.12–1.30 (m, 4H), 1.36–1.50 (m, 2H), 1.55–1.62 (m, 1H), 1.65–1.73 (m, 1H), 1.79–
1.83 (m, 1H), 1.86 (s, 3H), 1.89–1.96 (m, 1H), 1.97 (s, 3H), 1.99–2.03 (m, 2H), 2.05 (s, 
3H), 2.06 (s, 3H), 2.06–2.10 (m, 1H), 2.50 (dd, J = 17.7, 13.3 Hz, 1H), 4.40 (dt, J = 13.2, 
3.4 Hz, 1H), 4.71 (1/2 AB, J = 9.8 Hz, 1H), 4.77 (1/2 AB, J = 9.8 Hz, 1H), 4.86 (1/2 AB, J 
= 11.8 Hz, 1H), 4.89 (1/2 AB, J = 11.9 Hz, 1H), 5.56 (m, 1H), 6.12 (d, J = 9.6 Hz, 1H), 
6.44 (d, J = 6.0 Hz, 1H), 7.00 (dd, J = 9.7, 6.0 Hz, 1H); 
13
C NMR (125 MHz, CDCl3)  
12.3, 13.5, 20.82, 20.83, 21.0, 21.1, 21.4, 24.4, 27.5, 30.3, 32.6, 38.91, 38.96, 39.5, 42.9, 
49.7, 51.8, 56.4, 57.4, 58.2, 66.7, 75.0, 78.3, 122.14, 122.19, 127.1, 140.4, 150.0, 157.0, 
165.4, 170.3, 170.9, 171.1, 201.5; HRMS (ESI) m/z calcd for C34H45O9 [M + H]
+ 
597.3064, 
found 597.3058. 
 
 
(4S,20S,22R)-2-Iodo-4,19,27-trihydroxy-5,6-epoxy-1-oxowitha-2,24-dienolide 
(2-iodowithalong-olide A 89; Scheme 62). To a suspension of withalongolide A 67 (15.0 
mg, 0.0308 mmol, 1.0 equiv) in CH2Cl2 (1.0 mL) was added DMAP (3.8 mg, 0.0308 mmol, 
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1.0 equiv) and iodine (11.7 mg, 0.0462 mmol, 1.5 equiv), and the reaction mixture was 
stirred at rt under nitrogen atmosphere for 1 h. The crude reddish-brown reaction mixture 
was initially purified by preparative TLC developing four times with 3% MeOH/CH2Cl2. 
Broad brownish band corresponding to the product was scraped from the plate and eluted 
with 5% MeOH/CH2Cl2. The brown-colored elution was treated with few drops of 
saturated aqueous solution of Na2S2O3 until faint yellow. The solvents were evaporated 
under reduced pressure and the pale yellow residue obtained was purified by preparative 
TLC developing three times with 3% MeOH/CH2Cl2 and two times with 30% 
EtOAc/CH2Cl2. The band corresponding to the product was scraped from the plate and 
eluted with 5% MeOH/CH2Cl2 through a phase separator tabless. Evaporation of solvents 
afforded 89 as an off-white semisolid (7.5 mg, 40%). 2-Iodowithalongolide A 89: Rf = 0.44 
(4% MeOH/CH2Cl2, run twice); IR (neat) 3337 (br), 2941, 2920, 1686, 1397, 1044, 909, 
732 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  0.67 (s, 3H), 0.87–0.94 (m, 2H), 0.98 (d, J = 6.6 
Hz, 3H), 1.01–1.17 (m, 3H), 1.32–1.43 (m, 3H), 1.47–1.55 (m, 1H), 1.60–1.71 (m, 4H), 
1.83–1.87 (m, 1H), 1.94–2.01 (m, 3H), 2.03 (s, 3H), 2.20–2.25 (m, 1H), 2.48 (dd, J = 17.4, 
13.6 Hz, 1H), 2.87 (br s, 1H), 3.26 (s, 1H), 3.55 (d, J = 6.6 Hz, 1H), 3.79 (d, J = 9.6 Hz, 
1H), 4.32–4.42 (m, 4H), 7.75 (d, J = 6.6 Hz, 1H); 
13
C NMR (125 MHz, CDCl3)  11.8, 
13.5, 20.2, 22.0, 24.3, 27.4, 30.0, 30.4, 31.0, 38.9, 39.5, 42.6, 44.2, 51.9, 55.2, 56.7, 57.6, 
61.2, 61.6, 62.1, 70.8, 78.8, 107.5, 125.8, 153.0, 154.4, 167.1, 193.9; HRMS (ESI) m/z 
calcd for C28H41INO7 [M + NH4]
+ 
630.1928, found 630.1932. 
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(4S,20S,22R)-2-Iodo-4,19,27-triacetyloxy-5,6-epoxy-1-oxowitha-2,24-
dienolide (2-iodowithalong-olide A 4,19,27-triacetate 90; Scheme 62). To a solution of 
withalongolide A 4,19,27-triacetate 73 (20.0 mg, 0.0326 mmol, 1.0 equiv) in CH2Cl2 (1.0 
mL) was added DMAP (4.0 mg, 0.0326 mmol, 1.0 equiv) and iodine (12.4 mg, 0.0489 
mmol, 1.5 equiv), and the reaction mixture was stirred at rt under nitrogen atmosphere for 1 
h. The reaction mixture was quenched with few drops of saturated aqueous solution of 
Na2S2O3 until colorless and CH2Cl2 layer was separated. The aqueous phase was extracted 
with CH2Cl2 twice and the combined organic layers were dried over Na2SO4 and 
concentrated. The crude pale yellow residue obtained was purified by preparative TLC 
developing three times with 2% MeOH/CH2Cl2. The band corresponding to the product 
was scraped from the plate and eluted with 5% MeOH/CH2Cl2 through a phase separator 
tabless. Evaporation of solvents afforded 90 as an off-white waxy solid (17.0 mg, 71%). 2-
Iodowithalongolide A 4,19,27-triacetate 90: Rf = 0.21 (1% MeOH/CH2Cl2, run twice); IR 
(neat) 3337 (br), 2943, 2869, 1735, 1704, 1365, 1223, 1022, 911, 728 cm
–1
; 
1
H NMR (500 
MHz, CDCl3)  0.73 (s, 3H), 0.86–1.00 (m, 2H), 0.99 (d, J = 6.6 Hz, 3H), 1.06–1.19 (m, 
3H), 1.28–1.42 (m, 2H), 1.56–1.78 (m, 4H), 1.83–1.86 (m, 1H), 1.98–2.02 (m, 3H), 2.04 (s, 
3H), 2.06 (s, 3H), 2.07 (s, 3H), 2.11 (s, 3H), 2.16–2.20 (m, 1H), 2.51 (dd, J = 17.7, 13.3 Hz, 
1H), 3.14 (s, 1H), 4.36–4.41 (m, 2H), 4.66 (d, J = 6.5 Hz, 1H), 4.85 (1/2 AB, J = 11.8 Hz, 
1H), 4.89 (1/2 AB, J = 11.9 Hz, 1H), 5.05 (d, J = 11.5 Hz, 1H), 7.71 (d, J = 6.5 Hz, 1H); 
13
C NMR (125 MHz, CDCl3)  11.7, 13.5, 20.8, 20.9, 21.1, 21.3, 22.1, 24.3, 27.4, 30.2, 
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30.6, 30.7, 38.9, 39.4, 42.8, 45.1, 51.8, 51.9, 56.6, 58.1, 58.9, 59.0, 64.0, 72.8, 78.3, 108.2, 
122.0, 149.1, 157.1, 165.4, 170.2, 170.5, 171.0, 192.5; HRMS (ESI) m/z calcd for 
C34H44IO10 [M + H]
+ 
739.1979, found 739.1989. 
 
 
(4S,20S,22R)-27-Acetyloxy-4,19-di-pent-4-enoyloxy-5,6-epoxy-1-oxowitha-
2,24-dienolide (withalongolide A 27-acetyloxy-4,19-di-pent-4-enoate 92; Scheme 64). 
A solution of withalongolide A 27-acetate 68 (9.0 mg, 0.0170 mmol, 1.0 equiv), pyridine 
(0.10 mL), 4-pentenoic anhydride (0.020 mL), and a small pellet of DMAP (ca. 1–2 mg) 
was stirred at rt under nitrogen atmosphere for 1.5 h. The reaction mixture was quenched 
with ethanol and volatile residues were removed under reduced pressure. The crude pale 
yellow residue obtained was purified by preparative TLC developing two times with 2% 
MeOH/CH2Cl2. The band corresponding to the product was scraped from the plate and 
eluted with 5% MeOH/CH2Cl2 through a phase separator tabless. Evaporation of solvents 
afforded 92 as a pale yellow oil (10.8 mg, 92%). Withalongolide A 27-acetyloxy-4,19-di-
pent-4-enoate 92: Rf = 0.56 (2% MeOH/CH2Cl2, run twice) or Rf = 0.21 (1% 
MeOH/CH2Cl2, run three times); IR (neat) 2941, 1736, 1712, 1676, 1639, 1381, 1232, 
1161, 915 cm
–1
; 
1
H NMR (500 MHz, CDCl3)  0.74 (s, 3H), 0.88 (m, 1H), 1.00 (d, J = 6.6 
Hz, 3H), 1.00–1.19 (m, 4H), 1.26 (m, 1H), 1.38 (m, 1H), 1.57–1.72 (m, 2H), 1.79 (tt, J = 
11.1, 5.5 Hz, 1H), 1.97–2.03 (m, 4H), 2.05 (s, 3H), 2.06 (s, 3H), 2.15 (ddd, J = 15.1, 4.0, 
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2.5 Hz, 1H), 2.34–2.54 (m, 10H), 3.13 (s, 1H), 4.36 (d, J = 11.6 Hz, 1H), 4.40 (m, 1H), 
4.82 (d, J = 5.9 Hz, 1H), 4.86 (1/2 AB, J = 11.8 Hz, 1H), 4.89 (1/2 AB, J = 11.9 Hz, 1H), 
4.97–5.09 (m, 5H), 5.74–5.87 (m, 2H), 6.22 (d, J = 10.0 Hz, 1H), 7.00 (dd, J = 9.9, 5.9 Hz, 
1H); 
13
C NMR (125 MHz, CDCl3)  11.8, 13.5, 20.8, 21.1, 22.5, 24.4, 27.4, 28.8, 28.9, 
30.3, 30.9, 31.0, 33.3, 33.8, 38.9, 39.6, 42.8, 44.8, 51.1, 52.0, 56.6, 58.2, 59.2, 59.4, 64.5, 
71.1, 78.3, 115.7, 115.9, 122.0, 133.4, 136.4, 136.8, 141.0, 157.1, 165.4, 171.1, 172.5, 
172.6, 198.3; HRMS (ESI) m/z calcd for C40H53O10 [M + H]
+ 
693.3639, found 693.3630. 
 
 
(4S,20S,22R)-27-Acetyloxy-4,19-cyclo-(E)-oct-4-enedioyloxy-5,6-epoxy-1-
oxowitha-2,24-dienolide (withalongolide A 27-acetyloxy-4,19-cyclo-(E)-oct-4-
enedioate 93; Scheme 64). Following a modification of a reported protocol,
236
 to a solution 
of withalongolide A 27-acetyloxy-4,19-di-pent-4-enoate 92 (6.6 mg, 0.00952 mmol, 1.0 
equiv) in anhydrous CH2Cl2 (0.50 mL) at rt under nitrogen atmosphere was added Grubbs 
2
nd
 generation catalyst (ca. 0.4 mg, 0.000476 mmol, 0.050 equiv) and the reaction mixture 
was gently refluxed with stirring at 37 C for 2 h. The reaction mixture was concentrated 
and the crude brownish residue obtained was purified by preparative TLC developing four 
times with 1.5% MeOH/CH2Cl2. The band corresponding to the product was scraped from 
the plate and eluted with 5% MeOH/CH2Cl2 through a phase separator tabless. Evaporation 
of solvents afforded 93 as a colorless oil (5.5 mg, 87%). Withalongolide A 27-acetyloxy-
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4,19-cyclo-(E)-oct-4-enedioate 93: Rf = 0.15 (1% MeOH/CH2Cl2, run three times); IR 
(neat) 2933, 1736, 1712, 1676, 1339, 1240, 1157, 1132, 1025, 975 cm
–1
; 
1
H NMR (500 
MHz, CDCl3)  0.69 (s, 3H), 0.91 (m, 1H), 1.00 (d, J = 6.6 Hz, 3H), 1.07–1.41 (m, 6H), 
1.51–1.58 (m, 1H), 1.60–1.72 (m, 2H), 1.88 (qd, J = 11.2, 3.4 Hz, 1H), 1.96–2.04 (m, 3H), 
2.05 (s, 3H), 2.07 (s, 3H), 2.11–2.18 (m, 3H), 2.25 (m, 1H), 2.33–2.43 (m, 3H), 2.46–2.62 
(m, 4H), 3.24 (d, J = 2.6 Hz, 1H), 4.20 (d, J = 11.5 Hz, 1H), 4.41 (dt, J = 13.2, 3.3 Hz, 1H), 
4.69 (d, J = 11.5 Hz, 1H), 4.86 (1/2 AB, J = 11.8 Hz, 1H), 4.90 (1/2 AB, J = 11.8 Hz, 1H), 
5.16 (d, J = 5.7 Hz, 1H), 5.53 (ddd, J = 15.0, 7.6, 3.9 Hz, 1H), 5.85 (ddd, J = 15.1, 9.7, 5.2 
Hz, 1H), 6.21 (d, J = 10.0 Hz, 1H), 6.84 (dd, J = 10.0, 5.7 Hz, 1H); 
13
C NMR (125 MHz, 
CDCl3)  11.6, 13.5, 20.8, 21.1, 23.8, 24.5, 27.4, 27.8, 29.6, 30.2, 31.3, 31.5, 34.4, 36.4, 
39.0, 39.6, 42.8, 45.4, 51.5, 52.1, 55.9, 58.2, 59.6, 59.8, 66.8, 69.8, 78.4, 122.0, 129.4, 
129.8, 132.8, 141.2, 157.2, 165.5, 171.1, 172.9, 173.2, 200.0; HRMS (ESI) m/z calcd for 
C38H49O10 [M + H]
+ 
665.3326, found 665.3290. 
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Chapter 4 
Isolation of a Novel Minor Withanolide, Withalongolide O  
from Physalis longifolia 
 
4.1   Introduction 
As discussed in the previous chapter, withanolides are classified as modified 
ergostane-type C28 steroidal lactones, present mainly in 25 genera of the Solanaceae 
family, which includes Acnistus, Datura, Dunalia, Jaborosa, Nicandra, Physalis, and 
Withania.
212b,c,249
 Approximately 770 withanolides, exhibiting more than 22 different 
carbon frameworks, have been reported over the past five decades.
212c
 Among them, the 
classically-defined withanolides or the so-called unmodified withanolides, boasting a four-
ring steroid nucleus and a nine-carbon side chain featuring a lactone moiety, are the most 
abundant forms discovered in nature. Within this category alone, nearly 550 compounds 
were reported thus far in the literature. Furthermore, unmodified withanolides that display 
the most promising antiproliferative characteristics contain an ,-unsaturated ketone in 
ring A, a 5,6-epoxide or a 5-chloro-6-hydroxy functionality in ring B, and a 17-
oriented -lactone ring; e.g. withaferin A 66 (Figure 25).212c  
Recently, Timmermann and Cohen explored the antiproliferative potential of 
compounds present in several members of the Solanaceae: Physalis longifolia Nutt.,
223a
 
Vassobia breviflora (Sendtn.) Hunz,
220
 and Withania somnifera (L.) Dunal.
250
 Each extract, 
fraction, and isolated compound from the three genera were evaluated via a series of 
selected cell lines that probed epithelial tumor response, specifically the HNSCC cell lines 
(JMAR and MDA-1986) and melanoma cell lines (B16F10 and SKMEL-28), coupled with 
the toxicity gauging non-malignant fetal lung fibroblast cell line (MRC-5). This work by 
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Timmermann and Cohen resulted in the isolation, characterization, and cytotoxic evaluation 
of 35 withanolides.
220,223a,250
 Two of the most promising semisynthetic withanolides, 
withalongolide A 4,19,27-triacetate 73 and withalongolide B 4,19-diacetate 102a (Figure 
25) showed IC50 values less than 1 M against all the cells tested. These two compounds 
were synthesized from two rare 19-OH withanolides, withalongolide A 67 and B 102 
(Figure 25), which originated from the aerial parts of Physalis longifolia.
220,223a,250
  
To effectively probe the SAR of these analogues and in order to fulfill the 
requirements of an in vivo biological activity study in a full-term animal tumorigenesis 
model, a re-isolation of gram quantities of 67 and 102 was warranted. We also needed 
sufficient quantity of 66 to prepare a semisynthetic withanolide possessing all the essential 
structural features to maximize the antiproliferative potency. In the course of this work, a 
minor withanolide was discovered while isolating 66 and details of these endeavors are 
described here. 
 
 
Figure 25. Structures of cytotoxic withanolides. 
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4.2   Results and Discussions 
Isolation of Withaferin A 66 and Withalongolide O 103 
Timmermann and co-workers carried out the extraction of 2.97 kg of dried aerial 
parts of P. longifolia with CH2Cl2/MeOH (1:1).
251
 The extract obtained was suspended in 
water and subsequently partitioned with hexane, EtOAc, and n-BuOH, respectively. 
Subsequent purifications of the resulting EtOAc-soluble fraction afforded major 
withanolides, withalongolide A 67 (1.8 g, ca. 0.06% yield), withalongolide B 102 (0.5 g, 
ca. 0.017% yield), and withaferin A 66 (1.5 g, ca. 0.05% yield), respectively. Two new 
minor withanolides, withalongolide O 103 (7.0 mg) and withalongolide P 104 (20 mg) were 
also obtained during this purification process (Figure 26).
251
  
 
 
Figure 26. Two novel minor withanolides. 
 
As mentioned above, during the purification of the EtOAc-soluble fraction by 
Timmermann group, 3.2 g of crude withaferin A 66 was obtained. Prof. Timmermann 
provided us with 1.52 g of crude 66 to isolate pure 66. Our goal was to prepare a putative 
withanolide 105 through semisynthesis from 66 (see Figure 27). Semisynthetic withanolide 
105 bears structural resemblance to withanolide C and jaborosalactone E (Figure 27).
231b
 
The rationale for the synthesis of 105 was:
212c
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(1) An unmodified withanolide skeleton with a 17-oriented -lactone ring shows a more 
potent cytotoxic activity than withanolides featuring a modified skeleton (see Chapter 
3, Figure 21). 
(2) The presence of an ,-unsaturated ketone in ring A is presumed to be an important 
requirement for possessing the cytotoxic activity. 
(3) The presence of a 5,6-epoxide or a 5-chloro-6-hydroxy functionality in ring B is 
also presumed to be necessary. In most cases, the presence of the 5-chloro-6-
hydroxy functionality showed an increased in cytotoxic potency than the 5,6-
epoxide, when similar pairs of withanolides were compared. 
(4) The hydroxyl groups at C-4, 7, 11, 12, 14, 15, 16, 17, 18, 19, 20, 23, 24, and 27 do 
not contribute to the antiproliferative activity and in some cases, the presence of such 
hydroxyl groups diminish the potency. Acetylated derivatives of some of these 
hydroxyl groups such as C-4, 7, 19, and 27 have been reported to enhance the 
cytotoxic activity significantly.
223a,224,251
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Figure 27. Structure of target semisynthetic withanolide 105 and its related natural 
withanolides. 
 
The purification of crude withaferin A 66 is summarized in the following flow chart 
(Figure 28; see the Experimental Section for details). CombiFlash purification of 1.52 g of 
crude 66 (0–10% MeOH/CH2Cl2) afforded impure 66 and mixtures of polar compounds 
were collected as different fractions. Further purification by charcoal treatment and 
preparative TLC gave 0.471 g of pure 66. TLC analysis of fractions A and B indicated the 
presence of a limited number of unidentified products, which were amenable to further 
purification processes. Multiple preparative TLC purifications of fractions A and B resulted 
in the isolation of several individual bands, which still contained mixtures of unidentified 
compounds. Among them, one band containing compound 103 from fraction B (see Figure 
26) was interesting as 
1
H NMR displayed characteristic peaks of a withanolide and was 
obtained in sufficient purity for further spectroscopic analysis. Polar fractions C–E 
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contained complex mixtures of unidentified products and were not subjected to further 
purification. 
 
 
Figure 28. Purification flow chart for crude withaferin A 66. 
 
The molecular formula of compound 103 was determined to be C28H38O6 by HRMS. 
The 
1
H NMR spectrum (in CDCl3) of 103 (Table 21) displayed characteristic signals for 
five methyl groups at H 0.70 (s, 3H), 0.99 (d, J = 6.6 Hz, 3H), 1.41 (s, 3H), 1.87 (s, 3H), 
and 1.93 (s, 3H). The 
13
C NMR (APT) and HSQC spectra of 103 (Table 21) showed 28 
carbons differentiated as five CH3, five CH2, eleven CH (including two olefins at C 141.7 
and 132.8, and four oxygenated carbon at C 78.5, 73.3, 69.6, and 65.6), and seven C 
(including one ketone carbonyl at C 201.6, one ester carbonyl at C 167.3, two olefins at C 
149.2 and 122.2, and one oxygenated carbon at C 68.2). Detailed comparison of the 
1
H and 
13
C NMR spectroscopic data of 103 with those of the two previously isolated isomers,
223a
 
withaferin A 66 and withalongolide B 102, indicated that 103 contained the same A ring 
with a 
2
-1-oxo-4-hydroxy functionality as 66. The NMR data of 103 also suggested 
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identical substituent patterns in C and D rings as 66. The arrangement of substituents on the 
-lactone side chain of 103 was similar to that observed for 102. This pointed out the 
obvious difference in the substitution pattern for the B ring. The distinct substituent pattern 
observed among 103, 102, and 66 was the presence of an oxygenated methine (C 73.3, 
CH) in 103 and an oxygenated methylene in 102 (C-19: C 62.1, CH2) and 66 (C-27: C 
57.7, CH2),
223a
 which implies that 103 was either a 27-deoxy-7-hydroxy derivative of 66 or 
a 19-deoxy-7-hydroxy derivative of 102. Moreover, the comparison of the 
13
C NMR data of 
103 and 66 showed relatively high-frequency shifts for C-6 (C 65.6 in 103 and C 62.7 in 
66) and C-8 (C 38.8 in 103 and C 29.9 in 66) in compound 103.
223a
 Analysis of the COSY 
and HSQC correlations showed a fragment of C(Oepoxide)–CH(Oepoxide)–CH(OH)–CH–CH 
for ring B in 103 as compared to C(Oepoxide)–CH(Oepoxide)–CH2–CH–CH for ring B in 66, 
which further corroborated the existence of C-7 hydroxyl group. The HMBC correlations of 
H-6 (H 3.30) to C-4 (C 69.6), and H-4 (H 3.78) to C-5 (C 68.2) and C-6 (C 65.6) were 
also observed in 103 (Figure 29). The orientation of the hydroxyl group at C-7 was deduced 
as  due to the large coupling constant (J = 9.5 Hz) observed between H-7 and H-8252 
indicating a trans-diaxial relationship and a NOESY correlation observed between H-7 and 
H-14 (Figure 29).  
 
 
Figure 29. Key HMBC (HC) and NOESY (HH) correlations observed for 103. 
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Table 21. 
1
H (500 MHz) and 
13
C NMR (125 MHz) Data for Withalongolide O 103 and 
Withalongolide O Diacetate 106
a
 
position 
withalongolide O 103 withalongolide O diacetate 106 
H (J in Hz) C H (J in Hz) C 
1 – 201.6 – 200.5 
2 6.22, d (9.9) 132.8 6.21, d (9.8) 134.0 
3 6.93, dd (9.9, 5.9) 141.7 6.95, dd (9.8, 6.0) 139.8 
4 3.78, d (5.9) 69.6 4.62, d (6.0) 71.2 
5 – 68.2 – 64.6 
6 3.30, d (2.0) 65.6 3.29, d (2.0) 60.6 
7 3.57, m 73.3 4.81, dd (9.5, 2.0) 74.7 
8 1.43, m 38.8 1.71, m 34.6 
9 1.12, m 43.6 1.04, m 43.8 
10 – 47.2 – 47.5 
11 1.91, m; 1.46, m 27.4 1.58, m; 1.37, m 26.1 
12 1.94, m; 1.07, m 39.3 1.89, m; 0.99, m 39.1 
13 – 43.5 – 43.5 
14 1.09 m 55.7 1.00, m 55.2 
15 1.80, qd (16.0, 3.7); 1.47, m 22.3 1.70, m; 1.45, m 21.7 
16 1.70, m; 1.37, m 27.9 1.59, m; 1.30, m 27.8 
17 1.03, m 51.4 0.96, m 51.3 
18 0.70, s 11.8 0.65, s 11.8 
19 1.41, s 17.1 1.36, s 15.9 
20 1.96, m 39.0 1.90, m 38.9 
21 0.99, d (6.6) 13.7 0.93 d (6.6) 13.6 
22 4.36, dt (13.3, 3.4) 78.5 4.27, dt (13.3, 3.4) 78.4 
23 2.42, t (15.2); 1.90, m 29.8 2.35, t (15.1); 1.81, m 29.8 
24 – 149.2 – 149.2 
25 – 122.2 – 122.2 
26 – 167.3 – 167.2 
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position 
withalongolide O 103 withalongolide O diacetate 106 
H (J in Hz) C H (J in Hz) C 
27 1.87, s 12.7 1.81, s 12.7 
28 1.93, s 20.8 1.86, s 20.7 
4-OH 2.57, br s – – – 
4-OAc – – 1.99, s 20.9, 170.0 
7-OH 1.62, br s – – – 
7-OAc – – 2.03, s 21.7, 171.4 
a
Recorded in CDCl3 and  in ppm. Assignments were made on the basis of HSQC and 
1
H−
1
H 
COSY data. 
 
Compound 103 was recrystallized from EtOAc to afford colorless needle-like 
crystals, which were utilized for a single crystal X-ray diffraction analysis that eventually 
confirmed the structure of 103 as 27-deoxy-7-hydroxywithaferin A, and was named as 
withalongolide O (Figure 30). All of the material obtained was used to acquire 
spectroscopic, crystallographic, and biological data and to prepare an acetylated derivative 
106 (see Scheme 70); doing so unfortunately did not leave enough material for a melting 
point determination of 103. 
X-Ray diffraction analysis of 103 showed that the dihedral angles of H6–C6–C7–H7 
and H7–C7–C8–H8 were 57 and 166 respectively, which explains the observed small 
coupling constant of JH6,H7 = 2.0 Hz [equatorial (H-6)–axial (H-7) relationship] and the 
large coupling constant of JH7,H8 = 9.5 Hz (trans-diaxial relationship between H-7 and 
H-8). In our previous X-ray diffraction analyses of 66, 67, and 102,223a it was presented 
that the dihedral angles of H6–C6–C7–H7 and H6–C6–C7–H7 were both close to 57 
while those of H7–C7–C8–H8 and H7–C7–C8–H8 were within the range of 167–174 and 
50–59, respectively. These results are consistent with the small coupling constant of 
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approximately 2.0 Hz (JH6,H7 or JH6,H7), the medium coupling constant of 4.0 Hz 
(JH7,H8), and the large coupling constant of 14.5 Hz (JH7,H8) observed for withanolides 
66, 67, and 102. It is evident that, in withanolides with an ,-unsaturated ketone in the A 
ring and a 5,6-epoxy functionality (such as in 66, 67, 102, and 103), the small coupling 
constant between H-6 and H-7 (either H-7 or H-7) could not be used to propose the 
orientation of the functional group at C-7, but the large coupling constant between H-7 
and H-8 can be reliably employed for the determination of the  orientation of the C-7 
functional group due to the presence of the axially oriented H-8 in the four ring 
withanolide moiety.  
 
 
Figure 30. X-Ray ORTEP drawing of withalongolide O 103. 
 
Acetylation of 103 with acetic anhydride in pyridine yielded the 4,7-diacetate 
derivative 106 in quantitative yield (Scheme 70). This further confirmed the presence of 
hydroxyl groups at C-4 and C-7 by a downfield shift of H-4 (from H 3.78 in 103 to H 4.62 
in 106) and H-7 (from H 3.57 in 103 to H 4.81 in 106), and the disappearance of the 
signals of the labile protons of 4-OH (H 2.57, br s) and 7-OH (H 1.62, br s) in 103 (see 
Table 21). 
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Scheme 70. Acetylation of Withalongolide O 103 
 
 
The specific rotation of withalongolide O 103 was determined to be 101.5 (c 0.0886, 
EtOH). The UV–visible spectra in absolute ethanol were also obtained for both 
withalongolide O 103 and its diacetate 106 (Figure 31). The absorption maximums in 103 
and 106 were observed at 206 and 216 nm, respectively, which are characteristic of 
summation of absorptions of two isolated chromophores (,-unsaturated ketone in ring A 
and ,-unsaturated--lactone side chain).252a,253  
 
           
Figure 31. UV–visible spectra of 103 and 106. 
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Synthetic Approach towards Withanolide 105  
Having made the serendipitous discovery of the new withanolide 103 during the 
purification of 66, we focused our attention back on our original goal of synthesizing 
withanolide 105 from 66 (see Figure 27). Withanolide 105 could be synthesized from 66 in 
four steps as proposed in Scheme 71. The stepwise hydrogenation of 66 is known to give 
deoxydihydrowithaferin A 107.
218,254
 Tosylation of a C-4 hydroxyl group of compound 107 
would give tosylate 108, which upon treatment with alumina (Al2O3) would afford enone 
109. This tosylation-deoxygenation protocol to afford the ,-unstaurated ketone in ring A 
has been used for the conversion of 2,3-dihydro derivative of 4-hydroxywithanolide E 110 
to withanolide E 111 (Scheme 72).
255
 Lastly, there are literature precedents for the opening 
of the 5,6-epoxide ring in withanolides lacking 4-hydroxyl group with HCl solution in 
ether to provide 5-chloro-6-hydroxy derivative such as 105 (see Figure 27 and Scheme 
71).
224,230
  
 
 
 
 
 
 
 
 
 
 
 
392 
 
Scheme 71. Proposed Synthetic Route for 105 from 66 
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Scheme 72. Conversion of 2,3-Dihydro-4-hydroxywithanolide E into Withanolide E 
 
 
On the basis of above-mentioned precedents, the synthesis of 105 began with the 
initial hydrogenation step in the synthetic sequence (Scheme 73). Treatment of 66 with 
palladium on carbon (Pd/C) in the presence of H2 gave 107 in excellent yield via a 
dihydrowithaferin A intermediate 112. During the optimization of the hydrogenation 
reaction of 66, we found that short reaction times predominantly gave the hydrogenated 
product, dihydrowithaferin A 112, as a major product. However, running the same reaction 
for slightly longer period afforded complete conversion of 112 to 107 through 
hydrogenolysis. 
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Scheme 73. One-Pot Hydrogenation and Hydrogenolysis Reaction of 66 to 107 
 
 
With 107 in hand, several attempts were made to synthesize the corresponding 
tosylate 108 (Scheme 74). Initially, a small scale tosylation reaction of 66 was carried out 
with excess p-TsCl and pyridine following a reported protocol.
255
 To our surprise, only a 
trace amount of tosylate product 108 was detected from the mass analysis of a crude 
reaction mixture even after 72 h of stirring at room temperature. No product was observed 
when stronger bases such as Et3N and DMAP were used. Another small scale reaction (on a 
10 mg scale) employing excess amounts of p-TsCl, Et3N, 1-methylimidazole,
256
 and DBU 
at 40 °C led to some product formation as seemed evident by mass and 
1
H NMR analysis of 
a mixture. Unfortunately, running the tosylation reaction under similar conditions on a 150 
mg scale resulted in a complex mixture (Scheme 74). Attempts to isolate the desired 
product 108 from this complex mixture through multiple purification processes were 
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unsuccessful. During these trial experiments, all of the starting material 107 was exhausted, 
thus no further pursuits were made to complete the synthesis of 105.  
 
Scheme 74. Unsuccessful Attempts toward the Synthesis of Tosylate 108 from 107 
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Cytotoxic Evaluation (carried out in the laboratory of Dr. Mark Cohen) 
Withanolides 66, 67, 102, 103, and 106 were tested against the HNSCC (JMAR and 
MDA-1986), melanoma (B16F10 and SKMEL-28), and normal fetal lung fibroblast (MRC-
5) cells for their antiproliferative activities. As shown in Table 22, withanolides 66, 67, 
102, 103, and 106 exhibited cytotoxic effects against the cells tested with IC50 values in the 
range of 0.1512.5 M. As consistent with previous observations,212c,223a 103 and 106 
containing essential functionalities (the ,-unsaturated ketone in ring A, the 5,6-
epoxide in ring B, and the -lactone side chain) were active. The acetylated analogue 106 
showed increased cytotoxic activities against all cell lines tested compared to the parent 
compound 103. It is interesting to note that all three isomers, 66 (with a 27-hydroxyl 
group), 102 (with a 19-hydroxyl group), and 103 (with a 7-hydroxyl group), only differing 
in the position of their hydroxyl groups demonstrated potent cytotoxic activities. This 
observation not only revealed the significance of the above-mentioned functionalities, but 
also supported the hypothesis that the presence of a hydroxyl group at either C-27, C-19, or 
C-7 is not critically responsible for the observed antiproliferative activity.
212c
  
 
Table 22. Cytotoxicity IC50 of Withanolides (µM) against Five Cell Lines
a 
compound B16F10 SKMEL-28 JMAR MDA-1986 MRC-5 
withalongolide O 103 1.82  0.21 0.33  0.06 3.2  0.62 1.5  0.08 1.3  0.11 
withalongolide O diacetate 106 0.69  0.14 0.18  0.03 0.83  0.14 0.54  0.07 0.53  0.12 
withaferin A 66 0.27  0.04 3.5  0.15 1.5  0.23 0.86  0.25 0.32  0.06 
withalongolide A 67 11.6  0.19 5.6  0.60 5.1  0.23 3.10  0.46 12.1  0.42 
withalongolide B 102 0.26  0.07 3.3  0.48 0.25  0.14 1.7  0.08 0.38  0.03 
cisplatin (positive control) 1.4  0.35 1.7  0.32 1.5  0.41 1.9  0.58 9.1  0.25 
a
For cell lines used, see the text. 
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4.3   Conclusions 
A novel withanolide, withalongolide O 103, bearing a rare C-7 hydroxyl group was 
discovered during the isolation of withaferin A 66. The structure elucidation of 103 was 
carried out through extensive spectroscopic data interpretations and chemical methods 
(acetylation), and its structure was finally confirmed by single-crystal X-ray analysis. 
Efforts were made to synthesize withanolide 105 from 66 through semisynthesis; however, 
all attempts towards the tosylation reaction of C-4 hydroxyl of 107 were unsuccessful, 
eventually leading to its depletion. 
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4.4   Experimental Section 
General Information. All reactions were performed under nitrogen atmosphere 
either in capped vials or oven-dried glassware. All chemicals were used as received from 
commercial source without further purification. Commercial anhydrous pyridine was used. 
TLC was performed using commercial glass-backed silica plates (250 microns) with an 
organic binder. Preparative TLC was carried out using glass-backed TLC plates (silica gel 
GF with UV 254 nm, 1000 microns). Visualization was accomplished with UV light. Solid 
phase extraction (SPE) phase separator tabless (6 mL) was used for filtration/elution during 
preparative TLC purification. Flash chromatography was carried out on a CombiFlash Rf 
purification system using a 24 g normal-phase RediSep
 
silica flash column. IR spectra were 
acquired as thin films on a FTIR instrument. All NMR spectra (
1
H, 
13
C, APT, COSY, 
HSQC, HMBC, and NOESY) were recorded on a 500 MHz with a dual carbon/proton 
cryoprobe instrument. All NMR samples were recorded in CDCl3 that was passed through 
basic alumina. Chemical shifts are reported in parts per million (ppm) and are referenced to 
the center line of the solvent ( 7.26 ppm for 1H NMR and  77.23 ppm for 13C NMR). 
Coupling constants are given in Hertz (Hz). HRMS data were collected with a LCT Premier 
time-of-flight mass spectrometer and an electrospray ion source. Optical rotation was 
measured on a Rudolph RS Autopol IV automatic polarimeter. UV–visible spectrum was 
obtained on Agilent 8453 UV–Visible Spectrophotometer. Data was processed using 
Agilent UV–Visible Chemstation and Microsoft Excel. Single-crystal X-ray analyses were 
performed using Cu K radiation ( = 1.54178 Å) with either Bruker APEX2 or Platinum 
135 CCD detector. X-rays were provided by a Bruker MicroStar microfocus rotating anode 
equipped with Helios multilayer optics.   
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Cytotoxicity Assay. The cytotoxicity assays were performed as previously 
described.
220
 In general, ten concentrations ranging from 50 nM to 20 M were tested for 
each withanolide. Statistical analysis was carried out by one-way ANOVA on ranks test 
using GraphPad Prism 5 software. IC50 values were obtained from cell viability plots fitted 
with a sigmoidal dose-response function with variable slope using GraphPad Prism 5 
software. 
 
Experimental Procedures 
Isolation of Withaferin A 66 and Withalongolide O 103 (Figure 28). Purification 
of 1.52 g of crude 66 using a 24 g flash column on a CombiFlash Rf system (0–10% 
MeOH/CH2Cl2) afforded 600 mg of impure 66 (eluted out at 2% MeOH in CH2Cl2), 
followed by 140 mg of fraction A1 containing a mixture of impure 66 and other 
unidentified products (eluted out at 2–3% MeOH in CH2Cl2). Then, 35 mg of fraction A 
containing a mixture of other unidentified compounds eluted out at 3% MeOH in CH2Cl2, 
followed by 130 mg of fraction B containing a complex mixture of unidentified compounds 
(eluted out at 3–5% MeOH in CH2Cl2), and 500 mg of fraction C containing a complex 
mixture of polar unidentified products (eluted out at 5–10% MeOH in CH2Cl2). Finally, 
elution with 100% MeOH provided 35 mg of fraction D and 125 mg of fraction E.  
Treatment of 600 mg of impure 66 (greenish oily residue) with activated charcoal in 
hot CH2Cl2 followed by precipitation with ether afforded 460 mg of pure 66 as a creamish-
brown solid. Fraction A1 containing some impure 66 was purified twice by preparative 
TLC plate developing three times with 3% MeOH/CH2Cl2, three times with 20% 
EtOAc/CH2Cl2, and one time with 2% MeOH/CH2Cl2. The band corresponding to the 66 
was scraped from the plate and eluted with 5% MeOH/CH2Cl2 through a phase separator 
400 
 
tabless. Evaporation of solvents gave an additional 11 mg of pure 66 (overall yield of 66 = 
471 mg). 
Prep TLC purification of fraction A was unsuccessful and led to 21 mg of a mixture 
of unidentified compounds. Fraction B was purified by preparative TLC developing three 
times with 3% MeOH/CH2Cl2, one time with 20% EtOAc/CH2Cl2, and two times with 10% 
EtOAc/CH2Cl2. A mixture of overlapping low Rf bands was scraped from the plate and 
eluted with 10% MeOH/CH2Cl2 through a phase separator tabless. Evaporation of solvents 
gave 40 mg of a crude mixture containing 103. This crude mixture was re-purified by 
preparative TLC plate developing three times with 20% EtOAc in CH2Cl2 and one time 
with 2% MeOH in CH2Cl2. A high Rf band containing 103 and low Rf bands consisting of a 
mixture of unidentified products were scraped from the plate separately and eluted with 5% 
MeOH in CH2Cl2. Evaporation of solvents for the high Rf band gave 7.0 mg of sufficiently 
pure 103 as an off-white solid, which was recrystallized from EtOAC to afford a partially 
crystallized material as off-white crystals. Crystals of 103 were used for X-ray diffraction 
analysis (see Table S28). The mixture of unidentified products present in a low Rf bands 
were not purified further. Fractions C, D, and E containing complex mixtures of polar spots 
were not subjected to additional purification processes.  
(4S,20S,22R)-4,7-Dihydroxy-5,6-epoxy-1-oxowitha-2,24-dienolide 
(withalongolide O, 103). Rf = 0.26 (4% MeOH/CH2Cl2, run twice); [ ] 
   = 101.5 (c 
0.0886, EtOH); UV max (EtOH) nm = 206; IR (neat) 3419 (br), 2937, 1685, 1397, 1128, 
1034, 916, 732 cm
–1
; HRMS (ESI) m/z calcd for C28H39O6 [M + H]
+ 
471.2741, found 
471.2749. For 
1
H and 
13
C NMR data, see Table 21. For 1D and 2D NMR spectra, see 
below. 
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Table S28. Selected Crystallographic and Refinement Parameters for Withalongolide 
O 103 
Compound Withalongolide O 103 
CCDC deposition number 974653 
Empirical formula C32H46O8 (C28H38O6 + CH3COOCH2CH3) 
Formula wt. 558.69 
Temperature 100(2) K 
Crystal color Colorless 
Crystal system Monoclinic 
Crystal habit Triangular plate 
Crystal size (mm
3
) 0.34  0.26  0.09 
Space group P21 
a [Å] 10.8300(19) 
b [Å] 12.273(2) 
c [Å] 11.693(2) 
 [deg] 90 
[deg] 112.283(3) 
 [deg] 90 
Z 2 
Volume [Å
3
] 1438.0(4) 
Dcalc [Mg/m
3
] 1.290 
F (000) 604 
Absorption coefficient  [mm–1] 0.743 
Theta range for data collection 4.09 to 67.39 
Range h –12<=h<=12 
Range k –14<=k<=14 
Range l –13<=l<=12 
Reflections collected 15638 
Independent reflections 4754 
Rint 0.0235 
Data / Restraints / Parameters 4754 / 1 / 533 
Final R indices [I>2(I)] 0.0257 
wR2 0.0678 
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Compound Withalongolide O 103 
Absolute structure parameter 0.02(10) 
Goodness-of-fit on F
2
 1.031 
R-factor (%) 2.57 
Largest diff. peak and hole (eÅ
–3
) 0.190 and –0.154 
 
The HPLC purity of crude 66 and different fractions were deceptive as the HPLC 
chromatogram showed a number of overlapping and merged peaks. Thus, the actual content 
of 66 in the crude material was misleading in terms of percent purity. 
fractions HPLC purity of 66 
crude 66 85% 
fraction A 42% 
fraction B 29% 
fraction C 28% 
fractions D and E 0% 
 
 
 
Figure S5. Representative HPLC chromatograms for fractions A and C containing 66 
(peak (8) in chromatograms).  
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(4S,20S,22R)-4,7-Diacetyloxy-5,6-epoxy-1-oxowitha-2,24-dienolide 
(withalongolide O diacetate 106; Scheme 70). A solution of withalongolide O 103 (4.2 
mg, 0.0089 mmol, 1.0 equiv) and a small pellet of DMAP (ca. 1–2 mg) in pyridine (0.10 
mL) and acetic anhydride (0.10 mL) in a nitrogen-flushed vial was stirred at rt for 1.5 h. 
The reaction mixture was concentrated and then quenched with ethanol. The volatile 
residues were removed under reduced pressure. The pale yellow residue obtained was 
purified by preparative TLC developing two times with 2% MeOH/CH2Cl2. The band 
corresponding to the product was scraped from the plate and eluted with 5% MeOH/CH2Cl2 
through a phase separator tabless. Evaporation of solvents afforded 106 as a colorless waxy 
solid (4.9 mg, 99%). Withalongolide O diacetate 106: Rf = 0.84 (4% MeOH/CH2Cl2, run 
twice); UV max (EtOH) nm = 216; IR (neat) 2927, 1736, 1702, 1372, 1230, 1125, 1023, 
914, 731 cm
–1
; HRMS (ESI) m/z calcd for C32H43O8 [M + H]
+ 
555.2952, found 555.2944. 
For 
1
H and 
13
C NMR data, see Table 21. 
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(4S,20S,22R)-2,3-Dihydro-5,6-epoxy-4-hydroxy-1-oxowitha-24-enolide 
(deoxydihydrowithaferin A 107; Scheme 73).
218
 A flask containing a stirring suspension 
of withaferin A 66 (200 mg, 0.426 mmol, 1.0 equiv) and Pd/C (10% Pd basis; 20.0 mg) in 
ethanol was sealed with a septum and evacuated briefly under vacuum. The reaction flask 
was refilled with a hydrogen (H2) gas using a H2 balloon (atmospheric pressure) and the 
reaction mixture was allowed to stir at rt for 3.5 h (TLC analysis showed the presence of 
mostly dihydrowithaferin A 112 at 75 min and both 112 and 107 at 3.5 h). Since the 
reaction was progressing slowly, additional Pd/C (10.0 mg) was added and the old H2 
balloon was replaced with a new one. The reaction mixture was further strirred at rt for 1.5 
h (TLC analysis showed complete conversion to 107). The reaction mixture was 
concentrated and the suspension of resulting residue in CH2Cl2 was loaded on a silica gel in 
a 5 g sample cartridge. Purification using a 4 g flash column on a CombiFlash Rf system 
(0–1% MeOH/CH2Cl2) afforded 107 (eluted between 0.7–1% MeOH/CH2Cl2) as a 
colorless crystals in 95% yield (185 mg, 0.405 mmol). Rf = 0.62 (4% MeOH/CH2Cl2, run 
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twice); IR (neat) 3403, 1706, 1686, 1135 cm
–1
; 
1
H NMR (400 MHz, CDCl3)  0.63 (s, 3H), 
0.88–0.93 (m, 1H), 0.95 (d, J = 6.7 Hz, 3H), 1.02–1.15 (complex, 4H), 1.22–1.40 
(complex, 5H), 1.27 (s, 3H), 1.57–1.70 (m, 2H), 1.84 (s, 3H), 1.86–1.88 (m, 1H), 1.90 (s, 
3H), 1.90–2.03 (m, 3H), 2.04–2.12 (m, 1H), 2.17 (m, 1H), 2.39 (t, J = 15.3 Hz, 1H), 2.46–
2.63 (m, 2H), 2.75 (br s, 1H), 3.10 (s, 1H), 3.47 (t, J = 3.4 Hz, 1H), 4.32 (dt, J = 13.2, 3.4 
Hz, 1H); 
13
C NMR (100 MHz, CDCl3)  11.6, 12.6, 13.5, 15.5, 20.7, 21.5, 24.4, 26.4, 27.4, 
29.5, 29.7, 31.5, 31.8, 38.9, 39.2, 42.8, 43.2, 50.6, 52.1, 56.4, 58.9, 66.8, 72.9, 78.4, 122.1, 
149.2, 167.2, 211.6; HRMS (ESI) m/z calcd for C28H41O5 [M + H]
+ 
457.2954, found 
457.2973.  
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